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Abstract 
Introduction 
This dissertation investigates the current management of cancer pain with particular 
emphasis on the World Health Organization analgesic ladder. This was considered 
necessary because published studies examining the adequacy of cancer pain control 
have suggested that the efficacy of the WHO ladder may have been overestimated and 
because the place of morphine as the 1st line opioid at Step III of the ladder has been 
challenged. The dissertation also investigates whether an alternative approach might be 
superior and further explores the patient barriers to the use of opioids. 
Methods 
The studies incorporated within this dissertation include an observational pain study 
examining pain control in 242 patients under the care of specialist palliative care teams, 
a systematic review and meta-analysis of 4 trials investigating oxycodone in cancer- 
related pain, a pilot study for a randomised controlled trial of an experimental 2-step 
analgesic ladder versus the traditional 3-step approach and a qualitative study exploring 
patients' views and concerns when offered opioids for the treatment of pain caused by 
cancer. 
Results 
The observational study showed that pain was not well controlled for the majority 
(79.3%: C. I. 74.1% to 84.4%); the systematic review showed that there was no 
difference in efficacy and tolerability between oxycodone and morphine; and the 2-step 
trial showed that earlier use of Step III opioids within the novel 2-step approach might 
result in better pain control. However, the qualitative study showed that patients 
associate morphine and other Step III opioids with death and therefore they reject them 
as useful means of controlling pain. 
Conclusion 
Morphine and other opioids currently remain our best means of managing pain caused 
by cancer, but that both professionals and patients require ongoing education, so that 
we can break down the barriers that still inhibit their use. 
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Chapter 1: Introduction 
"The moment at which modern medicine typically states that "there is nothing 
more to be done", thus becomes the starting point for an emergent medicine of 
terminal care, central to which is the multi-faceted understanding of pain"' p. 733 
The management of pain due to cancer is perhaps one of the most important aspects of 
a palliative care physician's practice. This dissertation examines the pharmacological 
management of cancer pain, with emphasis on the World Health Organisation (WHO) 
analgesic ladder. 2 The introductory chapter will initially define the magnitude of the 
problem, discussing both the prevalence and consequences of cancer pain. The 
development of the analgesic ladder as an approach to be disseminated worldwide will 
be outlined and the evidence for its success reviewed. Factors associated with poor pain 
control will be discussed, along with a review of some alternative approaches to cancer 
pain described in the medical literature. The chapter will conclude with questions or 
issues raised about the current utility of the ladder, 20 years after it was first published. 
1.1 The prevalence of cancer pain 
Many different studies have attempted to estimate the burden of pain caused by cancer. 
These studies began to emerge in the 1980s, largely as a result of the efforts of John 
Bonica, the first President of the International Association for the Study of Pain, to 
highlight the clinical importance of pain management in all areas of medicine and to 
call for more epidemiological research in this previously neglected field 3° Initially 
studies attempted to both examine the prevalence of pain and to investigate whether 
prevalence rates differed according to disease site or stage. Daut and Cleeland5 
1 
examined data from 667 patients being seen at the University of Wisconsin hospital and 
found that pain was more frequently reported in patients with prostate or breast cancer 
compared to patients with cancer of the cervix or uterus and overall 33% of patients 
with metastatic disease had pain. A study of 208 ambulatory patients attending 
oncology outpatients at Albany Medical College in New York found an overall pain 
prevalence of 40%, but that this figure increased to 50% when considering those with 
metastatic disease particularly those with bone metastases. 6 Both these studies will have 
excluded patients who were unable to attend hospitals or clinics due to problems with 
pain and so may have under-estimated the problem. However, it is also possible that 
patients attending oncology centres are more likely to be those with difficult symptoms 
and so the pain prevalence may have been exaggerated. A later study attempted to 
eliminate such problems by trying to reach a broader group of patients by contacting a 
patient sample obtained from a cancer registry'. 536 of 591 patients approached, with 
lung, prostate, pancreas and cervical cancers agreed to an interview, the majority of 
which were conducted 6 months after initial diagnosis. 65% of these patients reported 
some degree of pain in the previous week. A review article by Kathy Foley in 1985 
summarised the results to date and suggested that 15% of patients without metastatic 
disease, 33% of those with metastatic disease and 60-90% of those with advanced 
disease will suffer cancer pain. 8 Goudas and colleagues9 conducted a more recent 
systematic review of studies investigating cancer pain prevalence, in an attempt to 
summarise their findings. This review retrieved 28 studies, almost half of which were 
conducted in the United States. Of the remaining studies, nine were conducted in 
Europe, one in Japan, one in South Africa and one in Taiwan. The authors report the 
wide range of settings, populations surveyed, populations recruited and methods used. 
Not surprisingly a wide range of prevalence rates was obtained. The lowest prevalence 
2 
figure was 14% recorded in a group of women with breast cancer post-mastectomy. 
The figure rises to as high as 73% recorded in a group of patients admitted to a 
specialty hospital for cancer in the United States. The authors were unable to synthesise 
the pain prevalence results from the individual studies retrieved, because of the 
heterogeneity of the studies, but conclude "that cancer pain is a substantial burden for 
the cancer patient" p. 189. The different populations assessed and differing research 
settings undoubtedly account for the wide range of prevalence rates reported. There are 
data which indicate that factors associated with higher pain prevalence rates include the 
nature of the primary tumour, the presence of metastatic disease, the presence of bone 
metastases and the stage of disease. 10 The wide variation in prevalence rates has not 
excited much discussion or evaluation and authors have tended to report broad figures 
rather than attempt to reconcile the different estimates. For example the rates often 
quoted through the literature are that 30-50% of patients undergoing active treatment 
for a solid tumour and 70-90% of patients with advanced disease will experience pain. '0 
It is not surprising then, that studies examining the prevalence of pain in populations 
referred to palliative care teams show higher prevalence rates, with pain often quoted as 
the commonest symptom at referral A large international study co-ordinated by the 
WHO Cancer and Palliative Care Unit in Genevan found an overall pain prevalence 
rate of 60% at time of referral to any palliative care service. This figure is similar to the 
overall prevalence rate found in an English survey, where pain was present in 64% of 
400 patients referred to three palliative care services in London. 12 The rates differed 
across each setting, with 75% of patients referred to outpatient facilities reporting pain, 
63% of patients referred to hospital support teams, 62% of patients referred to hospice 
units and 56% of patients referred to community teams. A limitation of prevalence 
studies is that they inform us about the proportion of patients experiencing pain of any 
3 
severity and as such may not allow an understanding of the complexity or severity of 
the problem. Some studies have attempted to estimate pain severity and it seems that 
when this is done, pain is shown to be a significant problem to the individual with high 
rates of moderate to severe pain being reported. The WHO study found that the 
majority (51%) of the patients with pain had experienced moderate or severe pain. " A 
multi-centre study co-ordinated by the European Association for Palliative Care found 
that 32% of patients reporting pain had at least moderate pain. 13 A large international 
study co-ordinated by the Cancer Task Force of the International Association for the 
Study of Pain also attempted to classify the differing types and characteristics of pain. '4 
They documented at least 22 different types of pain syndromes in 1095 patients. 
Twycross and colleagues conducted a survey of 111 patients in a palliative care service 
and showed that patients had a median of 3 pains. 15 Daut and Cleeland in their 1982 
study also showed that when pain was present and experienced at a moderate or severe 
level, it significantly interfered with patients' enjoyment of life and general activity. 5 
Pain due to cancer therefore represents a common, complex and challenging symptom 
for all involved in the care of patients with cancer and is probably the commonest 
symptom presented to palliative care professionals. 
1.2 The importance of good pain control 
Patients with pain have been shown to suffer more from other physical symptoms and 
are more likely to have low mood, greater anxiety and be more socially isolated. 16 
Grond and colleagues reported the association between increased pain intensity and 
insomnia, sweating, vomiting and reduced mobility in a prospective case series of 1635 
patients with cancer attending a pain relief clinic in Germany. '7 The prevalence rates of 
these other symptoms were greater in patients with very severe/maximal pain compared 
4 
to those with less pain (insomnia: 68% vs. 52%; sweating: 32% vs. 25%; vomiting: 
30% vs. 26% and reduced mobility: 12% vs. 8%). Strang and colleagues have shown in 
several studies that levels of anxiety and depression are greater in patients with pain 
and that there is also a correlation between the severity of these symptoms and the 
intensity of pain. '8 19 The studies by Strang confirmed the association with insomnia, 
but also demonstrated that social activities are reduced in patients with pain. The 
authors noted that all social activities listed in the questionnaire used for the study, 
including spending time on hobbies and seeing friends, were reduced if the patient 
experienced pain. This reduction in social activity and the effect on mood also led to an 
alteration in family roles because of reduced participation in activities. Patients with 
constant pain (as opposed to those who had some temporary relief from pain) were 
more likely to isolate themselves. Strang also highlights the acute and chronic nature of 
cancer pain and has demonstrated that because new pains often herald disease 
progression, the presence of uncontrolled pain leads to greater anxiety about the future 
for patients. Although Strang has conducted much of the work in this area, others have 
confirmed the association between pain and anxiety and depression°'24 and pain and 
insomnia. 25 Not only do these relationships between pain and other symptoms have an 
impact on quality of life 26 27 but they can also mean that exploring other psychosocial or 
spiritual issues or planning for a good death may be more difficult (my own 
observations). The importance of the psychosocial and existential components of pain 
were highlighted by Dame Cicely Saunders, when she introduced the concept of "total 
pain" illustrating pain as a multi-faceted experience, encompassing not only 
physiological characteristics, but having social, psychological and emotional 
components also. 28 However, she wrote in a letter to the BMJ in 196329 that "If physical 
symptoms are alleviated then mental pain is often lifted also"(p. 746), such was her 
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belief in the importance of pain control. Strang also believes that the physical pain is 
key and that impacting on pain scores will allow a reduction in the total pain 
experienced. 19 Further evidence to highlight the importance of pain control to patients 
is considered in a qualitative study investigating the concept of dignity in the terminally 
ill. 30 After conducting a series of semi-structured interviews with 50 patients, the 
authors found that one of the three major themes to arise was that of illness-related 
concerns, of which control of physical symptoms was a significant feature. When 
asked, "what does the term dignity mean to you? " several patients made reference to 
the control of pain. Conversely, poorly controlled pain was seen as a threat to dignity. 
There is a further societal consequence of unrelieved pain. Pain represents the symptom 
of cancer that is most feared by patients and their families. 31 This may in part be 
explained by the commonly held belief that it is an inevitable and untreatable symptom. 
First-hand experiences of poorly controlled cancer pain will only serve to promulgate 
this myth. Good pain control is not simply about reducing pain scores. Its aim is to 
allow the patient to function physically, socially and spiritually if desired, and 
ultimately achieve a dignified pain-free death. 
1.3 Management of cancer pain 
It is impossible to consider the management of cancer pain without reference to the 
WHO analgesic ladder, initially designed as a practical and simple method for the 
treatment of cancer pain. The two are inextricably linked, such has been the success of 
the WHO's Cancer Pain Relief document, 2 which contained the original version of the 
ladder and was the result of work done by professionals involved with the WHO 
Cancer Pain Relief Programme. The requirements at the outset of the WHO programme 
were to devise a method for managing cancer pain that was simple, inexpensive and 
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globally acceptable, in order to serve the developing as well as the developed world and 
then to disseminate it worldwide in an effort to provide freedom from cancer pain for 
all by the year 2000.32 The WHO ladder and approach to cancer pain relief has been 
remarkably successful and has become the worldwide standard for dealing with cancer 
pain. However, recent commentaries have questioned the continuing utility of the 
analgesic ladder and alternative models have been proposed. 3 The focus of this 
dissertation is the current utility of the ladder. However, in order to justify the 
questioning of the WHO ladder, it is necessary to describe its inception, subsequent 
field-testing and the literature describing its use in clinical practice. 
1.3.1 Before the ladder 
There was ample evidence that before the introduction of the analgesic ladder, cancer 
pain was poorly managed. Whilst some of this evidence was in the medical domain, 
with authors reporting the state of pain control in hospital settings, 34 a considerable 
amount of information about the poor state of cancer pain management is gained from 
the narratives of patients themselves. Throughout the 1960s and 1970s there was a 
growing literature written by patients and or their carers describing inadequate pain 
management, examples of which can be found in an article by Michelle Winslow, 
published in the Journal of Pain and Symptom Management in 2005.5 She describes 
how "By the 1970s, the published voice of the patient was becoming more challenging" 
(p. 29), mirroring the debates about personal freedom and autonomy that were taking 
place in wider society. All too often these narratives were critical of health 
professionals, who displayed attitudes towards analgesics that suggested prejudice 
against the use of opioids for moderate to severe pain (often referred to as strong 
opioids). Stories were told of reluctance to use morphine, with inappropriate use of 
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short-acting pethidine as an alternative, although some were advised that even 
injections of pethidine represented an "irrevocable step"(p. 26). This is perhaps not a 
surprise. The prevailing medical opinion at the time was that morphine and other so 
called "strong" opioids were drugs of dependence and addiction. A paper on the 
pharmacological management of cancer pain, 36 written in the Journal of the American 
Medical Association in 1941, claimed "the use of narcotics in terminal cancer is to be 
condemned if it can possibly be avoided", reflecting the concerns of doctors at that 
time. In 1952, the WHO Expert Committee on Drug Dependence saw opioids as a risk 
to public health, stating that "Morphine, and especially heroin, will always produce 
compulsive craving, dependence and addiction in any individual... Such drugs cause 
individual and sociological damage and must be rigidly controlled" (p. 46). 37 By the 
1960s, Britain was one of the only two countries not to have banned the use of 
diamorphine. So pain was viewed as an inevitable and almost untreatable consequence 
of cancer because opioids such as morphine, the essential treatment, risked greater 
harm to the individual in the form of tolerance and addiction. Fortunately, in the United 
Kingdom through the 1960s, Cicely Saunders and the hospice movement, along with 
others such as the Pain Relief Unit at Oxford, began to challenge this belief. Cicely 
Saunders, a doctor with both nursing and social work experience had begun to spend 
more time with patients with cancer pain in St. Joseph's hospice in Hackney and began 
studies investigating its management. She continued these with Dr Robert Twycross in 
St Christopher's hospice when it opened in 1967. The outcome of this research was 
essentially that oral morphine was just as effective as diamorphine, 38 (confirmed by 
pharmacokinetic data which showed that diamorphine was metabolised to morphine in 
the blood) and so presented a useful oral analgesic. They also showed that the extra 
ingredients in the Brompton cocktail (a common treatment for severe cancer pain) 
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consisting of various combinations of chlorpromazine, alcohol, cocaine along with 
diamorphine or morphine, could be omitted and morphine alone used in its place. This 
latter finding was confirmed by Melzack and Mount in Canada. 39 This simplified the 
treatment of cancer pain in Great Britain, allowing the use of oral morphine, instead of 
relying on diamorphine by injection. Along with the introduction of controlled-release 
morphine, this resulted in an increase in the use of morphine in cancer pain. 40 In 
addition, by following a cohort of 115 patients over 7 years, Twycross was also able to 
challenge the idea that tolerance to opioids was inevitable, by showing that most 
patients were able to reach a steady dose which did not vary for months. 1 An article on 
the history of the hospice movement' describes how keeping the voice and individuality 
of the patient central to her focus, Dame Cicely Saunders advocated the use of regular 
analgesia, to prevent pain returning, and to reduce the patient's reliance on the health 
professional. She stated "If pain is constantly allowed to occur, each time the patient 
had to ask for something to relieve it. Not only does he then make it worse by his fear 
and tension but he is reminded of his dependence upon the drugs and the person who 
gives them to him. " (p. 139)42 
At the same time, research into cancer pain control in the United States of America was 
progressing in a different way. Ray Houde, a doctor, Ada Rogers, a research nurse and 
Stanley Wallenstein, a psychologist, were together conducting analgesic studies with 
patients in Memorial Sloan Kettering's James Ewing Hospital. This housed a large 
population of New Yorkers, with advanced cancer, admitted when they were too sick to 
remain at home. Whilst the novel design of these studies were to become the future 
standard for analgesic trials, their original focus was not the relief of pain from cancer, 
but the quest for the "ideal" analgesic i. e. a drug that would be as effective as morphine 
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and diamorphine, but not addictive. The original studies served mainly to provide 
analgesic potency equivalence ratios by comparing the efficacy of one opioid versus 
another within the same patient. As a consequence these studies, a pain consultation 
service arose, and Dr. Kathy Foley was one of the first pain fellows. 
These two groups of researchers had had some opportunity to meet through the 1970s 
at both the International Association for the Study of Pain (IASP) conference in 
Florence in 1975 and the First International Symposium on Advanced Pain in Cancer in 
Venice in 1978. No consensus on the management of cancer pain was ever reached at 
these meetings, perhaps because of their differing research goals. 
1.3.2 The evolution of the ladder 
The impetus for reaching consensus came from the WHO itself, when, in 1982, the 
head of its Cancer Unit, Jan Stjemswärd, arranged an international meeting at the Villa 
d'Este on Lake Como, outside Milan. Stjernswärd had organized an international 
survey of cancer pain experiences in 1981 and the results showed that 29% of patients 
experiencing severe pain were receiving little or no relief. 43 Those attending the 
meeting included five experts in pain control, two of whom were Kathy Foley from 
Memorial Sloan-Kettering and Robert Twycross from St. Christopher's Hospice. 
Although the three of the other pain specialists present at the meeting also had 
experience in non-pharmacological pain-relieving interventions (John Bonica, Mark 
Swerdlow and Vittorio Ventafridda) it was recognised that what was required was a 
policy for cancer pain that was centred on drug use or a "global script"37 (guidelines 
which were simple and could be easily and cheaply disseminated into both the 
developing and developed world). Stjernswärd's vision was one of "a simple method 
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that an idiot like me can knows37 (p. 49) , but providing a simple diagrammatic 
algorithm for the management of cancer pain was also to serve as a legitimate 
framework for the provision of opioids for cancer pain control. Thus, the three-step 
ladder, which incorporated the approach of aspirin (or non-opioid analgesic) as first- 
line pharmacological management of cancer pain, progressing to codeine (termed 
"weak" opioid) and then to oral morphine (termed "strong" opioid) as pain progresses, 
evolved. The main principle of the approach was that the choice of analgesic was 
determined by pain severity and this was clarified in the 1996 version of the ladder, 44 
when the terms "weak" and "strong" were replaced by the phrases "opioids for mild to 
moderate pain" and opioids for moderate to severe pain" (Figure 1). 
Figure 1: Diagram of the ladder 
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At all three steps, the use of adjuvant drugs are recommended in order to treat the 
adverse effects of opioids, to enhance pain relief (e. g. steroids) and to treat concomitant 
psychological problems e. g. depression. Non-drug measures and drugs for 
neuropathic pain e. g. anti-depressants and anti-convulsants are also suggested, although 
not incorporated into the diagram. 
Emphasis was also placed on the regular administration of drugs and was framed by the 
maxim "by the clock and by the ladder". Robert Twycross had presented this approach 
at the Venice meeting in 1978, emphasising the need for the use of oral opioids to be 
dictated by pain severity and not life expectancy. However, at this stage the views of 
the U. S. and the U. K. were still opposing, with the Sloan-Kettering pain team 
considering parenteral morphine superior to oral and remaining concerned about 
regular use of opioids and the clinical importance of tolerance. The 1982 meeting 
forced a resolution of these two stances and resulted in the publication of the ladder 
within the booklet "WHO Draft Interim Guidelines Handbook on Relief of Cancer 
Pain". 45 
Another larger meeting of experts in the management of pain due to cancer convened 
by the WHO was held in Geneva in 1984, two years after the original meeting. Those 
present at this meeting were more multi-disciplinary and multi-professional and 
represented 15 different countries. Data were presented by Fumikazu Takeda, reporting 
his successful experience of the use of the ladder in Saitama, Japan, where 97% of 
patients achieved acceptable pain relief (defined as > 90% pain relief as reported by the 
patient) by following the 1982 guidelines. 6 Those attending this second meeting 
endorsed the analgesic ladder and the dissemination phase began simultaneously with 
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further field-testing of the guidelines. The publication of the WHO booklet, Cancer 
Pain Relief did not take place until 1986 however, two years later. This was in part due 
to continuing opposition to the use of morphine from some senior figures in the 
WHO, 37 with the chief of WHO publications suggesting the guidelines were an 
"attempt to spread morphine all over the world"(p. 52). Once published, the guidelines 
were translated into many languages and worldwide programmes began to teach the 
importance of cancer pain control 43 
1.3.3 Field test programme 
If Stjernswärd's aim of a method that was scientifically valid was to be realised, then 
the efficacy of ladder had to be tested. A multi-national project was co-ordinated by the 
WHO collaborating centre in Milan in conjunction with the WHO collaborating Centre 
for Biostatistics Evaluation at Harvard University in Boston. The aims of the project 
were to both test the utility of the ladder by measuring the extent to which centres 
around the world were able to comply with the recommendations and to validate the 
ladder by measuring its efficacy in the treatment of cancer pain. 
The project occurred in three phases. Phases I and II were designed to identify centres 
to assist with patient recruitment to the studies, with questionnaires sent out to 63 
possible centres in 29 countries, asking about the availability of drugs for pain relief 
(including the specific drugs available for use at each step), the use of non- 
pharmacological methods for pain relief and the personnel resources, facilities and 
continuing care networks available to each centre. In the initial years following the first 
publication of Cancer Pain Relief, 35 centres around the world were employed and 
completed questionnaires for phases I and II. Phase III consisted of two separate 
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studies. Centres without prior knowledge of the guidelines were chosen to submit data 
for Study 1, measuring the efficacy of usual or current cancer pain management 
practices. Centres already knowledgeable about the guidelines were enrolled into Study 
2, thereby testing the efficacy of the guidelines themselves. In total, 25 centres in 15 
countries submitted results to the WHO Collaborating Centres. The protocol for both 
phase III studies sent to each participating centre, was clear (Appendix 1). Patients with 
cancer pain were to be enrolled after an initial interview recording demographic data, 
cancer stage and estimated prognosis, Eastern Cooperative Group (ECOG) performance 
status and a description of the pain and treatment modalities used. Those centres 
involved in testing the guidelines were given a copy of the Interim Guidelines45 and 
instructions for their use. Patients were to be followed up at two weekly, then four 
weekly intervals until either lost to follow-up or death. Follow-up forms recorded an 
assessment of pain relief (a patient self-recorded linear analogue pain relief scale 
(Appendix 2)), pain intensity and duration, sleep hours, drug treatments for pain given 
since last form completed with the reason for any changes recorded, pain drug-related 
side effects and other pain relieving modalities. Although it appears that these initial 
studies were to be directly evaluated, to determine comparative efficacies of the new 
guidelines versus usual practice, by the time the field-testing was reported, this aim was 
noted to have been unrealistic. Differences existed between centres with regards to 
facilities and resources to the extent that the authors of the report47 state "it would have 
been incorrect to treat Studies I and II as two different experimental situations" (p. 455). 
The authors also report that it was "quite difficult to keep close feedback contacts with 
the participating centres" (p. 457) and that "the main drawbacks found ... were in pain 
evaluation and appropriateness of follow-ups" (p. 457). They state that the pain 
evaluation had to be withdrawn because it was not well understood or correctly used in 
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the majority of centres. These difficulties unfortunately led to high rates of excluded 
data, with 64% of Study I and 31% of Study II cases lost from the final analyses. In 
total, data from 110 patients and 261 patients were used for Study I and II respectively. 
Although the authors of the report write that it was not appropriate to compare the two 
studies, they then did so and claimed that there was a statistically significant difference 
between usual control of pain and the WHO guidelines in the percentage of patients 
with controlled pain at the fourth week follow-up period (48.5% of patients in Study I 
compared with 76% of patients in Study II; p=0.001) 47 No significant differences 
were found when comparing mean sleep hours or mean pain hours in the two studies. 
Perhaps one of the most significant findings from the Phase III studies was that the 
percentage of "strong" opioids used differed greatly in the two studies (51% of patients 
used strong opioids in Study II compared to only 15% of patients in Study I). The 
authors conclude that the superiority of the WHO guidelines was explained by this 
finding and that it was the use of strong opioids which explained the improved results 
(or the reluctance to use strong opioids which explained poor cancer pain control). 
1.3.4 Validation series 
Following the field-testing, numerous individual centres published the results of their 
studies in peer-reviewed journals, which acted as another means of dissemination of the 
guidelines, and further validated the use of strong opioids at Step III. The first of these 
papers was from the Milan Collaborating Centre itself, published in Cancer in 1986, 
reporting data collected from 1229 patients 48 This study is reported as being a 
retrospective study in the abstract, but the methods section describes a prospective 
method, employing nurses in both hospital and community settings to assist patients 
with recording pain scores. The authors suggest that the use of drugs alone provided 
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satisfactory analgesia in 79% of patients, but it seems that the definition of satisfactory 
analgesia was based on whether or not the patient required a neurolytic procedure. They 
comment that complete relief of pain was almost never achieved, but that pain could be 
maintained at a third of its pre-treatment level. They also reported on the need for 
management of side effects related to Step III opioids. In 1998, Walker and 
colleagues49 reported on 20 patients recruited to Study II from the Royal Marsden 
Hospital in London. Of the 20 recruited, 13 patients obtained adequate analgesia with 
drug treatment alone, achieving a fall in mean pain scores from 69mm at study entry to 
36mm at week 1 as measured by a 100mm visual analogue scale. 18 of the original 20 
patients eventually required Step III opioids during the study period. In nine of these 
patients opioid doses were able to remain stable during stable disease, over time periods 
that ranged from 4- 48 weeks. Seven patients provided long-term data, showing that 
long-term efficacy of the guidelines was good. Side effects were reported, but were 
managed aggressively and did not require cessation of treatment in any individual. In 
1990, Schug and colleagues50 reported the results from the Department of 
Anesthesiology at the University of Cologne, where 174 patients had been recruited. 
This retrospective study reported that about 90% of patients achieved acceptable pain 
relief (patient rated as either none, mild or moderate on a six-point verbal rating scale) 
and that this was maintained for the duration of the study (the study was continued until 
the death of the patient, change of therapy to parenteral medication or neurolytic 
procedure, or loss of contact). Over 50% of time for any patient was spent on Step III of 
the analgesic ladder. 
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1.3.5 Jaded and Browman systematic review 
In 1995, a systematic review51 of the series of studies conducted to validate the 
analgesic ladder was published in the Journal of the American Medical Association, 
and was critical of the methodology used to estimate the efficacy of the approach. The 
authors, Alejandro Jadad and George Browman were working at the Department of 
Clinical Epidemiology and Biostatistcs at McMaster University in Canada, the "home" 
of the emerging Evidence-Based Medicine paradigm. They used relatively novel 
critical appraisal and systematic review methodologies to assess the WHO ladder and 
validation studies. They stated that their reasons for doing so were that data emerging 
from recent large pain surveys still suggested that cancer patients around the world 
suffered inadequate pain control and that reasons proposed to explain this finding did 
not ever include the possibility that the ladder may not be effective. The authors 
conducted an exhaustive search and retrieved 14 case series studies, six of which were 
excluded because of either duplicate publication or insufficient reporting. The eight 
studies included in the review included the published data from the field-testing, 47 the 
published studies by Ventafridda, 48 Walker, 49 and Takeda, S2, a further Italian study 
translated from Tumori, 53 a paper published in the Philippine Journal of Surgical 
Specialties, 54 a paper reporting results from Argentina's WHO Cancer Pain Relief 
Programme55 and unpublished data from the Department of Anesthesiology at the 
University of Cologne, 56 detailing 10-year follow-up results from use of the ladder in 
2118 patients. Jadad and Browman describe the methodological limitations of the 
studies included in the review (short or variable follow-up periods, retrospective 
studies, small sample sizes and high exclusions or losses to follow-up) and are critical 
that no attempt was made by any study to try to compare the efficacy of the ladder with 
previous pain management approaches. One of their conclusions states "the evidence 
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provided cannot be used confidently to generate estimates of the effectiveness of the 
WHO ladder" (p. 1872) and that "what is still unknown is the proportion of patients for 
whom the ladder produces satisfactory results" (p. 1872). Letters in response to this 
article written by Marcus Reidenberg, 57 Robert Twycross58 and Vittorio Ventafridda 
with Jan Stjemswärd59 criticise the stance taken by the authors and point out that the 
ladder served not only as a pain management algorithm, but also as a political tool, 
facilitating the acceptance of opioid use. If this had been the sole aim of the ladder, then 
the validation studies have demonstrated by the overwhelming proportions of patients 
treated at Step III (the majority of whom received morphine) that the ladder has been 
successful. In addition, the WHO co-operated with the International Narcotics Control 
Board (INCB) an independent and quasi-judicial monitoring body for the 
implementation of the United Nations international drug control conventions, which 
collects data worldwide on opioid availability and consumption. 60 These data showed 
that in the 10 years following the introduction of Cancer Pain Relief, morphine 
consumption rose by 450% in Australia, Canada, Denmark, Iceland, Norway, Sweden, 
the United Kingdom and the United States, suggesting that more morphine was being 
used to manage pain caused by cancer. 61 The WHO booklet Cancer Pain Relief has 
since been widely disseminated and translated into 17 languages. By 1995,40 countries 
had developed national policies for reducing cancer pain 61 
1.3.6 Measuring the success of the ladder 
In spite of this, the worldwide applicability of the ladder has remained questionable. In 
1993,120 countries representing more than 80% of the world's population were 
consuming only 23% of the total morphine used in the world. Most morphine use 
worldwide (77%) continued to be located in the ten top countries listed above, 
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representing only 7% of the world's population. In addition, their effectiveness was 
also questionable. If the INCB data suggested that opioids were being used more often 
i. e. the guidelines were being followed in these countries and if the efficacy figures 
from the validation series were accurate, then 80-90% of patients with pain caused by 
cancer should have been experiencing a reduction in pain to a level that is tolerable and 
can allow them to function. Unfortunately, several large national pain studies conducted 
in some of these top ten countries have shown that this was not the case. The first of 
these, published in the New England Journal of Medicine in 1994 was a survey of pain 
and its treatment in outpatients with metastatic cancer. 62 1308 patients out of 1427 
approached, were recruited between October 1990 and September 1991 from the 
Eastern Cooperative Oncology Group cancer centres, community hospitals and clinics. 
871 of these 1308 patient had pain (pain prevalence = 67%). 62% of patients reporting 
pain rated their worst pain score as 5 or greater on an 11 point numerical rating scale, a 
score defined a priori by the authors as substantial pain, because patients reporting this 
score are more likely to also report significant functional impairment. 63 The second 
large study was a multicentre study of cancer pain conducted throughout France and 
reported in the BMJ in 1995 64 605 patients were recruited from 20 randomly selected 
sites within the five regions of France. Both inpatients and outpatients were recruited. 
Of the 325 patients reporting pain, 69% reported their worst pain in the past week as 5 
or greater. In 2000, the Scottish Clinical Resource and Audit Group of the Scottish 
Executive Health Department conducted a national cross-sectional survey of cancer 
pain control, conducted over 16 weeks. 65 Patients were recruited from different settings 
(acute hospitals, specialist palliative care units, community hospitals, patients' own 
homes and oncology centres). In total, 955 patients were recruited, of whom 646 had 
pain. Of these patients with pain, 49.7% had a worst pain score of 4 or greater, again 
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suggesting uncontrolled pain, or pain significantly interfering with function. A more 
recent one day pain prevalence study conducted in Norway, 66 in all hospitalised settings 
showed that 44% of patients with pain had a score of 5 or greater on a0- 10 visual 
analogue scale. All of these studies suggest that the analgesic ladder might not be as 
effective as the earlier evidence or studies propose. 
Several reasons for this are possible. The critical review by Jadad and Browmansl 
suggested that the analgesic ladder itself might not be as efficacious as the validation 
series had shown, the over-estimates of its success perhaps arising because of the poor 
methodological quality of the studies. Another possibility was that it was not being 
used correctly and that perhaps the use of morphine, although legitimised by the ladder, 
remained problematic because of previous cultural fears surrounding it or because of 
poorly tolerated or poorly managed opioid side effects that had perhaps been better 
managed in the validation studies. 
1.4 Problems with opioids: side effects 
At the original meeting in Milan in 1982, the experts agreed that the opioid of choice to 
be used at Step III was morphine. This was perhaps because it was available in oral 
formulations, and a certain aim of the ladder was to have a method that was easy to 
administer and oral administration would not rely on health professionals being 
available for each prescribed dose. It was also the opioid that had been used most in 
both the United Kingdom and the United States and Ray Houde had been unable to find 
a superior alternative in his comparison studies. In 2001, the European Association for 
Palliative Care endorsed the place of morphine as the "gold standard" opioid. 67 Since 
the introduction of the ladder, many different formulations of morphine have been 
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produced and marketed by pharmaceutical companies, all of which aim to improve the 
usefulness of morphine. Long-acting preparations (both 12-hourly and 24-hourly) were 
introduced in the early 1980s and their convenience encouraged the oral administration 
of morphine. However, one problem with morphine is its poor bioavailability, leading 
to an unpredictable dose-response relationship. Although all opioids require dose- 
titration to find the most effective dose for the individual patient with the least side 
effects, a very wide dose range exists for morphine because of its unpredictable but 
generally poor bioavailability. All opioids are associated with a wide range of side 
effects, some of which patients will become tolerant to (drowsiness and nausea) and 
some for which tolerance never develops (constipation). Side effects clearly represent a 
source of concern for patients and limit the use of these drugs. 68 In addition, opioid 
toxicity can result in sedation, hallucinations and an experience for the individual that 
may result in a loss of confidence with opioids. For this reason, when alternative 
opioids become available, it is important to consider their relative efficacy and 
tolerability compared to the "gold standard" morphine, to ensure its continued place as 
first line opioid at step III of the analgesic ladder. One such alternative, oxycodone was 
re-launched in 1996, having previously been used extensively in the United States as an 
opioid at Step II. Oxycodone has been in clinical use for almost a hundred years; its 
first recorded use being in Germany in 1917.9 In Canada, the United States and 
Australia it was used in combination with paracetamol or aspirin as a fixed dose 
combination drug, whereas in Finland it had been used as the main parenteral opioid for 
acute pain since the 1960s. Its use in the United Kingdom was restricted to rectal 
preparations. 0 Ada Rogers commented on the under-utilization of oxycodone in 1991 
at a time when single entity oxycodone had become available and highlighted this with 
a case report of successful use of oxycodone at a dose of 30mg every four hours, a dose 
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far greater than that which had been allowed by combination preparations. ' Glare and 
Walsh were amongst the first authors to systematically examine the use of single entity 
oxycodone in chronic cancer pain in 1992,72 and to subsequently call for its re- 
classification as an opioid for use at step III, when a dose-ranging study found it to be 
as efficacious as morphine. They suggested an equianalgesic ratio of 1: 1 morphine to 
oxycodone. The main pharmacokinetic difference between oxycodone and morphine is 
in oral bioavailability, which for oxycodone is about 60%-90%. 73 Subsequent studies 
investigated its pharmacokinetic profile and its utility in randomised controlled trials in 
comparison with other opioids. 74 77 However, only when oxycodone was made 
available in controlled release preparations in 1996 did it become suitable for use in 
chronic cancer pain. Shortly following its introduction and indeed even recently, some 
reviews suggested that it may have a more favourable side effect profile than oral 
morphine 78-80 and so should replace it as first line opioid. 81 Levy also makes the point 
that oxycodone may have less associated stigma than morphine. 9 Perhaps because of 
the suggestion of better tolerability and the alternative name, oxycodone has been used 
extensively since its introduction. Data from the International Narcotics Control Board 
suggest that it is being used widely, especially in the United States and the United 
Kingdom. (www. incb. org and www. doh. gov. uk), although some of the increase in use 
in the United States was perhaps because of its license for use in non-cancer pain. The 
yearly increase in prescriptions is greater than those seen for either fentanyl or 
hydromorphone; the other most commonly used alternative opioids. This may be in part 
because of evidence suggesting that neither of these drugs offer superiority over 
morphine. 82 83 Whilst it is no doubt useful to have another alternative to morphine 
available at Step III, because one of the options for managing persistent side effects due 
to morphine is opioid rotation 84(switching to an alternative opioid in the hope that a 
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better efficacy/side effect profile will result) it seems that an outstanding question about 
the superiority of oxycodone over morphine exists. If it is indeed better tolerated or 
more effective, then it should be considered as the drug of choice at Step III. 
1.5 Problems with opioids: myths and fears 
As previously stated, opioids for moderate to severe pain (morphine, oxycodone, 
fentanyl, hydromorphone and methadone) are the cornerstone of cancer pain 
management because of their place on the third step of the analgesic ladder. It is 
therefore unfortunate that incorrect fears exist which prevent their proper use and so 
threaten the utility of the ladder. Most of these myths and fears relate to the illegal use 
of opioids which characterizes them as drugs of abuse and addiction, hence dangerous 
and illicit. Because of this, they are often viewed as drugs to be avoided or delayed 
until absolutely necessary. Whilst anecdotal evidence of these fears is witnessed daily 
by professionals managing cancer pain, further evidence for their under-use is required 
if we are to argue that fears and myths about opioids contribute to poor pain 
management. This evidence can be found in studies examining either prescribing data 
or analgesic prescriptions at an individual level. Berger and colleagues85 used 
retrospective data from a large integrated health-insurance claims database in the 
United States to identify over 2000 patients with metastatic cancers and examine their 
pharmacy claims for the 12 months prior to death. Data were available to allow them to 
calculate the numbers of patients receiving both long- and short-acting opioids but also 
to calculate the number of days for which medication had been prescribed. They also 
conducted a sub-group analysis of patients with bone metastases (n=717) because these 
are a group of patients known to experience significant pain from their cancer. 86 The 
percentage of patients with and without bone metastases who had no pharmacy claims 
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for opioids over the entire 12-month period preceding death was 13.1% and 28.8% 
respectively. However, as "any opioid prescription" included opioids used at Step II of 
the ladder and would not necessarily reflect appropriate use of Step III opioids, the 
study also examined claims for prescriptions of long-acting opioids. 47% of patients 
with bone metastases and 77% of patients without, had no pharmacy claims for long- 
acting opioids in their final year of life. Although this study is limited by lacking any 
data on pain experienced by these patients, and is sponsored by a pharmaceutical 
company who manufacture two of the most commonly used long-acting opioids, these 
data suggest that opioids have either been under-prescribed, or that prescriptions have 
not been filled by the patients. 
Salvato and colleagues87 provide further evidence for insufficient prescribing by 
examining prescribing data from the Treviso district in Northern Italy (a country with 
strict opioid prescribing regulations) from 1993-2000. They used WHO 
methodological guidelines in order to ascertain whether or not opioid prescribing was 
satisfactory and simultaneously conducted a questionnaire survey of the prescribing 
attitudes of general practitioners. A sub-group of patients who died by the end of the 
data collection period and so were considered to be terminally ill outpatients were used 
to calculate the "adequacy" of opioid prescribing. This was done by calculating the 
expected "Defined Daily Doses" for this population and comparing it to the number of 
prescribed "Defined Daily Doses". The calculated "missing" Defined Daily Doses were 
then compared to the expected Defined Daily Doses and this ratio used to calculate the 
adequacy of opioid prescribing, which was found to be only 38%. The questionnaire 
data revealed high rates of anxiety about opioid side effects shown by the general 
practitioners, with 22.8% considering opioids shortened life expectancy. These factors 
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may at least partly explain the under-prescribing of opioids seen in the prescribing data. 
Zenz and colleagues88 examined prescribing patterns of German physicians (both 
general practitioners and specialists in internal medicine) when managing cancer pain 
and found that only 2% of 16,630 patients with a clear diagnosis of cancer (half of 
whom had documented metastases) had received a prescription for a Step III opioid. At 
the individual patient level, the two large studies in U. S. A. and France described 
previously62 64 which demonstrated high levels of uncontrolled pain, also demonstrated 
the under-use of Step III opioids. 42% of patients in the Eastern Cooperative study and 
51% of patients in the French study reporting uncontrolled pain had a negative pain 
management index. The pain management index is a simple calculation used to assess 
the suitability of pain relief medication. Pain is scored 0-3 (0 = no pain, 1= mild pain, 
2= moderate pain and 3= severe pain) for a patient, as is their medication according to 
the WHO ladder (0 = no pain relief, 1= simple analgesia, 2= Step II or opioids for mild 
to moderate pain and 3= Step III or opioids for moderate to severe pain). A negative 
pain management index suggests under-treatment of pain. Data does therefore exist to 
support the anecdotal experience that opioids are under-used and that this prevents 
good cancer pain control. 
Barriers to the proper use of opioids exist at several levels. At the institutional level, 
regulations intended to prevent diversion of opioids may interfere with their availability 
for medical use. We are fortunate in the United Kingdom, with relatively few 
regulations governing the prescribing of opioids. In other countries within Europe 
(Italy, Poland Portugal and parts of Spain) special forms must be obtained by the doctor 
in person from regional offices. In Austria, Germany, Portugal, Italy and Switzerland, 
prescription forms for Step III opioids must be completed in triplicate. There is some 
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evidence that these regulations inhibit the use of opioids for cancer pain, if only by 
causing a generally fearful attitude towards prescribing them. 89 A similar situation has 
arisen in the United States where illegal prescription misuse of OxyContin (sustained- 
release oxycodone) in the years after it was introduced for the management of chronic 
pain, resulted in severe restrictions placed by the Drug Enforcement Agency. These 
restrictions have resulted in high-profile legal cases against pain specialists, which have 
served as deterrents to prescribing Step III opioids for other doctors. This is in spite of 
Richard and Reidenberg9° demonstrating that there was little risk for a doctor to be 
subject to disciplinary action for prescribing opioids for pain if the medical record 
showed that a doctor-patient relationship existed and the doctor was treating a painful 
condition. 
Equally, there is much evidence that the attitudes and knowledge of the professionals 
managing cancer pain may represent another barrier to the appropriate use of opioids. 
Several studies from many different countries and cultures have confirmed that both 
doctors and nurses in all healthcare settings have concerns about prescribing opioids 
(Table 1). To provide a comprehensive literature review of these studies is beyond the 
scope of this dissertation, but the studies included in Table 1 demonstrate that 
professionals in many settings, cultures and countries have expressed concerns about 
prescribing opioids or have demonstrated inaccurate knowledge about their use. It is 
perhaps not surprising that those studies that used similar methods to allow direct 
comparison between professionals in separate countries demonstrate that professionals 
in countries with higher rates of opioid consumption seem to exhibit better knowledge 
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The ultimate barrier to opioids however, lies with the patients themselves. Several 
studies have documented poor adherence rates to opioid analgesics in cancer 
populations. Zeppetella103 and Kingsnorth and Wilkinson 104 have demonstrated in U. K. 
populations that adherence to opioid analgesics is not optimal with these drugs being 
the most likely drugs that patients will stop taking after discharge from inpatient 
palliative care units. Du Pen and colleagues'05 reported that during a randomised trial of 
a cancer pain management algorithm in the United States, (where patients were asked 
to complete daily pain diaries and had frequent monitoring from the research nurses), 
non- adherence rates for opioids (drug ordered / drug taken x 100) were 62-72% in both 
the intervention and control groups and this non-adherence negatively influenced worst 
pain scores. Adherence rates for adjuvant analgesics were better, with rates of 74 - 
84%. Within this paper the authors report that the "study nurses, working with patients 
in their homes, were continuously confronted with patients' refusal to take prescribed 
treatments even when pain was not well controlled and there were no side effects. Most 
often, when patients stopped taking prescribed medication they no longer discussed 
pain or its treatment with their physicians" (p. 368). Because of their inability to 
categorize or define the issues associated with adherence, the authors amended their 
subsequent trial phase to include a post-study qualitative interview with participants. 
These interviews were reported separately68 and are included in the review of 
qualitative literature on fears about opioids later in this chapter. Ferrell and 
colleagues'06 set out to examine the use of routine and breakthrough analgesics 
calculating adherence to both in a sample of 369 patients participating in a pain- 
education study. Prior to any intervention, only 55% of patients took the amount of 
regular analgesia prescribed, 38% took less than the amount prescribed and 7% took 
more. They also found that only 3% of patients took the actual amount of breakthrough 
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medication prescribed, 1% used their breakthrough more frequently than advised and 
96% took less. Whilst this study is lacking in any data describing the patients' pain it 
adds to the evidence that adherence and in particular adherence to opioid analgesics is 
an important factor in pain control. Miaskowski and colleagues107 found further 
evidence for poor adherence within a randomised trial of an educational intervention 
for pain management, when the range of adherence rates for the "around the clock" and 
"prn" opioid analgesics were 84.5-90.8% and 22.2-26.6% respectively. 
Many studies have confirmed that patients' fears of tolerance and addiction to opioid 
drugs are commonplace in both cancer and non-cancer populations and so may be two 
reasons for this non-adherence. Carlsson and colleagues'08 in 1997 sent a 27-item 
questionnaire to a random selection of 100 women admitted to the gynaecological 
oncology department at the University Hospital of Uppsala, Sweden and to a randomly 
selected group of 120 healthy women obtained from a Swedish population register. 
Similar numbers (86 and 87) replied from each group. Whilst approximately 80% in 
both groups thought that cancer pain could "almost always be controlled", and over 
90% in both groups thought that morphine was an effective treatment for cancer pain, 
40% of women in both groups thought that the problem with pain treatment was "the 
addiction caused by morphine". In both groups, those with less formal education were 
more likely to agree with this statement. Paice and colleagues'09 found high levels of 
concern about tolerance (56%) and addiction (39%) in a population of 200 patients with 
cancer. Patients with these concerns had greater pain scores than those without 
(difference in pain scores not given but p= <0.05). Other studies supporting these 
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Other potential factors impacting on cancer pain control, identified by reading the 
literature, include fear of side effects of pain medication, worries about distracting 
physicians from treating the underlying malignancy, fear that pain means disease 
progression, the belief that pain caused by cancer is inevitable and the belief that one 
must be a "good patient" and so not complain of uncontrolled symptoms. Some authors 
have tried to quantify all of these barriers in order to assess the degree to which they 
affect pain management. One of the most commonly used questionnaires is the Barriers 
Questionnaire' to (BQ), which was originally validated by Ward and colleagues in 1993. 
The questionnaire was designed to include the fears and beliefs mentioned above, with 
the aim of exploring the relationship between misconceptions about cancer pain and 
opioids with pain control and adequacy of analgesics used. In their original study, over 
70% of patients agreed that addiction was a problem, and over 50% agreed that 
tolerance was a concern. However, only scores related to addiction were correlated with 
any pain score as measured on the Brief Pain Inventory, correlating with pain on 
average (Pearson's correlation 0.26 p= <0.01). Summed BQ scores correlated with 
pain interference with function (Pearson's correlation 0.36 p= <0.01). However, higher 
scores for all individual factors were associated with under-medication (using less than 
adequate analgesia for the severity of their pain). The original barriers questionnaire 
was amended (shortened and updated) and then re-validated in 2002.115 BQ-II scores 
were found to be weakly correlated to least pain (r = 0.19, p= 0.01) and time spent in 
moderate to severe pain (r = 0.19, p= 0.01). The authors state that the BQ-II score was 
related to adequacy of analgesics being used by the study subjects, but the mean BQ-II 
scores were 1.42 for subjects using adequate analgesics and 1.7 for those not (p = 0.2). 
Not only is this result not statistically significant, but also we are not told what a 
clinically relevant difference in barrier scores might be. Lai and colleagues' 19 in Taiwan 
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felt that the original Barriers Questionnaire, which had been validated for use in Taiwan 
(BQT), was not sensitive enough as it did not mention opioids specifically. As part of 
the design phase for developing their own questionnaire, the Pain Opioid Analgesics 
Beliefs Scale (POABS-Ca), they attempted to address patient-derived concerns, in 
addition to literature and professional concerns, by conducting interviews with ten 
patients. This led to the inclusion of categories in the scale connecting opioids to a 
negative disease outcome (i. e. death from cancer) and suggesting that adults should 
endure as much pain as possible. The authors also commented that "The qualitative 
data provided a better understanding about these patients' beliefs about 
opioids. "(p. 378) The psychometric analyses showed that the scale was valid and 
reliable and in addition was clinically useful (only containing 10 questions). However, 
subsequent use of the POABS-CA in 194 in-patients with cancer recruited from four 
teaching hospitals did not find a relationship between the POABS-Ca and adherence to 
pain medication. 116 
Perhaps one of the reasons that correlation between barrier scores and pain scores were 
not consistently demonstrated is that a concern about a medication may not actually 
prevent the medication being taken. Thomason and colleagues 112 attempted to address 
this question in a study looking at patient self-reports of concerns and whether or not 
these acted as barriers to use of analgesics. Whilst concerns about addiction, tolerance 
and side effects related to opioids were present in 27%, 30% and 85% of the studied 
population, only 17%, 10% and 18% reported that these concerns prevented them from 
taking their medication. Another reason that barrier scores do not correlate with pain 
scores may be that the areas addressed in these questionnaires have been largely 
professional-derived, albeit after extensive literature searches. The questionnaires may 
34 
not actually reflect real concerns of patients. In addition, studies attempting to quantify 
the relationship between beliefs and behaviour are limited by the reliance on patients' 
self-reports of behaviour, which may not be accurate. They are also limited in that only 
two variables have been examined: pain scores and misconceptions about cancer pain 
and opioids and it is likely that other factors are involved in patients' decision-making 
when using analgesics for cancer pain. 
Perhaps because of this, others have employed qualitative methods in order to 
investigate the way in which concerns impact on behaviour or to explore how patients 
with cancer pain make their decisions to take opioid analgesics. Ersek and colleagues68 
reported the findings from the post-study interviews with patients undertaken after a 
randomised controlled trial of a pain management algorithm'05 (described previously). 
The authors had employed purposive sampling techniques to interview a combination 
of non-adherers and adherers and those experiencing both poor and adequate pain 
relief. The initial interviews asked patients to describe their decision-making processes 
when using pain relief, which was initially found to be too difficult a concept for them, 
so subsequent respondents were asked about factors that made it difficult for them to 
take their analgesics and factors that facilitated analgesic use. The commonest factor 
reported by 12/21 patients to negatively affect analgesic use was concern about side 
effects. Six of these 12 patients had personally experienced side effects and in three 
they had led to an increasing sense of fatalism or that they just had to "live with it 
[pain]" (p. 228). Five patients were concerned about tolerance but it was not clear how 
they acquired this belief (although one participant had been told by her physician that 
an increase in transdermal fentanyl could result in not being able to provide enough 
analgesia "at the end"). Coward and Wilkie120 interviewed 20 patients with cancer pain, 
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10 men and 10 women and asked them, amongst other questions, "how do you go about 
deciding to take your pain medications? " Nine of them said they took their medication 
as scheduled, but others talked about holding back on medication by using other 
manoeuvres to deal with pain, such as going to bed. Whilst fear of side effects and 
addiction were mentioned, others also described needing to know "what was going on" 
and the hope that anti-cancer treatments may have altered their pain. Pain severity and 
having a task that required completion were factors in deciding to take analgesics. 
Another qualitative study (part of a trial investigating a self-care intervention for the 
management of cancer pain) examined data gained from conversations between 
research nurses and study participants, which had been tape-recorded. 121 Content 
analysis of these conversations showed that fears over medication were just one aspect 
of obtaining good pain control and that even when patients had overcome their fears, 
managing pain at home was complex and included managing several symptoms 
simultaneously, accessing, processing and retaining information, accessing medication 
and managing new pains. Randall-David and colleagues122 confirmed the complexity of 
cancer pain management by patients, when they reported the findings from two focus 
groups held with patients with the aim of elucidating factors contributing to inadequate 
pain management. Factors preventing adequate pain management fell into four 
categories which included fear (of addiction and tolerance with pain medications, of 
side effects and of withholding of pain medication by family members). However, 
attitude, values and beliefs (about stoicism, the inevitability of pain and the stigma of 
so-called narcotics) structural barriers (access to a physician and pain being seen as an 
important symptom to discuss) and behaviours (withholding information about pain in 
order to be a "good patient") were other influences on obtaining good pain control. 
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Coyle, 123 using a narrative approach examining the lived experience of terminal cancer, 
provides us with perhaps the most illuminating information about patients' use of 
opioids for cancer pain. She conducted multiple interviews with seven persons with 
terminal cancer until they became cognitively impaired or too unwell to participate 
further and employed rigorous methods to analyse the data gathered. For these seven 
patients, opioids were seen as both a "blessing and a burden" (p. 304). They offered 
freedom from pain (the blessing) but also caused poorly controlled adverse effects (the 
burden). She describes how this changes as they became more unwell when she states, 
"without exception, however, as death drew near, patients saw the availability of potent 
opioid drugs as a blessing". She states that opioids become more acceptable as death 
becomes imminent, which seems to be because opioids were seen as a guarantor of a 
peaceful death and also perceived by some as a welcome means of hastening death. 
This finding, and the information from Lai and colleagues' 19 about opioids being 
associated with a negative disease outcome (meaning death) are the only two mentions 
in the recent literature about opioids and death, which has instead focused on tolerance, 
addiction and side effects. This is surprising given that the association of opioids with 
death and dying is mentioned in earlier literature. 124 It is possible that methods other 
than questionnaires are required to elicit sensitive information such as fear of death 
from patients. The change in perceptions of opioids when death approaches is clearly 
relevant for patients with pain related to cancer and is welcomed by their health 
professionals. But if palliative care is an approach that improves the quality of life of 
patients and their families facing the problems associated with life-threatening illness, 
as stated by the World Health Organization, then we cannot, and should not, wait until 
death is imminent to obtain good pain control. If fear of death is another obstacle to 
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good pain control we should try to understand why this is so and how it can be 
overcome. 
All of the patients involved in these qualitative studies had already commenced an 
opioid for moderate to severe pain and were reflecting on its use. No studies have been 
conducted with patients with cancer pain who are considering using morphine or other 
step three opioids for the first time. Little is known about this from the patients' point 
of view, yet this "step up", from the second to third step of the ladder may represent 
another important issue in obtaining pain control. If a patient or indeed their health 
professional is reluctant to consider opioids, then the availability of several other drugs 
at Step II may allow procrastination i. e. another Step II drug may be offered instead of 
morphine being commenced. 
1.6 The second to third step 
This is a particular issue when considering the ladder, because some authors have 
considered that the second step of the ladder i. e. the addition of an opioid for mild to 
moderate pain such as codeine or dextropropoxyphene (until recently) to a non-opioid, 
which has become ineffective for pain, has limited utility. 33 This second step created an 
artificial distinction between Step II and Step III opioids by using the terminology 
"weak" and "strong" which did not reflect their pharmacology, a fact best demonstrated 
by the history of the use of oxycodone, outlined in the previous section. Whilst the dose 
of oxycodone was limited by its use in fixed-dose combinations with paracetamol it 
was considered suitable for use at Step II only. However, once re-launched as a single 
entity formulations allowing dose titration, it has been widely used at Step III. The need 
for the second step of the ladder at its inception was a result of the necessity to have an 
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approach that was applicable worldwide and most of the world did not have Step III 
opioids. Perhaps it would have been unthinkable to move directly to an opioid for 
moderate to severe pain immediately as a non-opioid became effective, given the 
negative associations of morphine that prevailed at that time. 
In addition to the artificial pharmacological distinction made with having both Step II 
and Step III, there is an issue about the efficacy of adding fixed-dose opioids for mild to 
moderate pain to non-opioid analgesics when the latter have become ineffective. In 
1995, Eisenberg and colleagues125 published a meta-analysis of studies testing the 
efficacy and safety of non-steroidal anti-inflammatory drugs (non-opioid analgesics) in 
the management of pain caused by cancer. Their conclusions were that single or 
multiple doses of opioids for mild to moderate pain alone or in combination with non- 
opioid analgesics did not provide greater analgesia than NSAIDs alone. Other clinical 
studies have tended to support this finding. De Conno and colleagues126 demonstrated 
in an open study involving over 900 patients starting at Step II of the analgesic ladder, 
that after only two weeks, over 50% of patients had needed to increase to a Step III 
opioid because of lack of analgesic efficacy. Several authors have also demonstrated 
that using Step III opioids at lower initial doses than those routinely used, produces 
similar pain relief to using combinations of Step II opioids with a non-opioid, without 
compromising tolerability. 127-129 In particular, opioid-naive patients have been 
commenced on low-dose fentanyl patches (25mcg/hour), 130 131 low dose morphine 
(15mg in 24 hours) 132 and low dose oxycodone (10mg in 24 hours)'33 with good 
analgesic effect and without unacceptable toxicity or withdrawals due to side effects. 
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1.7 Alternative approaches 
A survey of the use of opioids by specialist palliative care teams in an area in the North 
of England134 showed two thirds of opioid naive patients were commenced directly to a 
Step III opioid, suggesting that some professionals had adopted a two-step approach to 
cancer pain management. Two randomised trials of alternative approaches have been 
attempted. 135 136 The first was a randomised trial of the WHO approach versus 
commencing Step III opioids directly. 135 Data on 92 patients were included in the final 
analyses from 100 enrolled. 48 patients were randomised to the WHO approach and 44 
were treated directly with Step III opioids. The choice and starting dose of each opioid 
was decided on a per patient basis and so were not reported in the paper. Patients were 
followed up until death, resulting in 503 weeks of treatment being analysed for the 
WHO arm and 467 weeks of treatment evaluated for the experimental approach. The 
pain scores were analysed as change in group means rather than individual differences 
and the authors suggest that because 48% of patients in the traditional approach were 
commenced on a Step III opioid by the end of the study period, the differences between 
the two approaches may have been diluted. However, in spite of this, a difference of 
approximately 7mm on a 0-100mm pain intensity rating scale was found between the 
two groups, favouring the experimental approach. Side effects were reported as 
absolute incidences of each side effect, (each mention by patients in their study diary 
was considered a single episode). Only the incidence of nausea was statistically 
significantly higher in the experimental arm but the numbers of episodes of vomiting 
did not differ between the two groups. However, the paper's discussion section, 
surprisingly concludes that the data support the fundamental assertions of the WHO 
guidelines, although they then state that the guidelines may need to be modified to take 
into account both disease outcomes and patient-centred outcomes. When Hanks and 
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colleagues137 challenged this discussion, the study authors suggested that because the 
patients included in the study were excluded from oncological treatment and had a short 
life expectancy, it would be wrong to generalise the results of the study to all patients 
with cancer (and thereby invalidate the WHO ladder). 
A second study by Maltoni and colleagues136 involved randomising patients to the 
traditional approach or to a two-step approach, omitting the second step of the ladder. 
Patients entering the trial had to have pain caused by cancer, have previously found a 
non-steroidal anti-inflammatory drug to be ineffective and have a pain score of 5-6 on a 
10 cm visual analogue scale. They were then randomised to either treatment with Step 
II drugs until these became ineffective, when step III treatment would be initiated 
(WHO approach) or directly to Step III drugs (experimental approach). Only 54 
patients had been recruited after 24 months, so the study was discontinued early 
because of poor accrual and was probably underpowered. In spite of this there was a 
trend for greater time spent with a pain score of 5 or less across all pains (worst, least 
average and now) in the experimental arm. The differences reached statistical 
significance for `worst' pain. 
1.8 Conclusions 
It seems from the literature that we should perhaps challenge the current status quo of 
cancer pain management or at least accept that there remain fundamental questions 
about the WHO analgesic ladder. Eminent researchers have raised methodological 
concerns about the studies which validated the use of the ladder, calling into question 
its efficacy. Alternative approaches have been tried in clinical studies with promising if 
not conclusive results and an alternative opioid has been launched which may be 
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superior to morphine. Lastly, we may not fully understand the reasons why patients are 
reluctant to consider using Step III opioids for cancer pain, a reluctance that impacts 
greatly on pain management. 
1.9 Outstanding questions 
1. Can we accept the estimates from the WHO validation series? 
Although it is widely taught that the proportion of patients in whom the ladder achieves 
good results is between 80 and 90%, it seems that there is growing evidence that these 
figures may be incorrect. The large pain prevalence studies conducted since the 
dissemination of the ladder certainly suggest that the proportion of patients with 
controlled pain is much lower, although reasons often given for the discrepancies are 
that the ladder is not being used appropriately, because of the problems associated with 
opioids. The alternative hypothesis stated by Jadad and Brownian in their review, is that 
the methodological quality of the validation studies was poor and the accuracy of the 
results is questionable. 
2. If we do accept the estimates from the WHO validation series, what are the 
reasons for pain prevalence surveys, conducted since its widespread dissemination 
consistently showing poor pain control? 
These pain prevalence studies have often found that patients have been under- 
medicated, or not receiving analgesics suitable for their pain. The reasons most 
commonly given for this are the fears and myths that prevent the proper use of opioids. 
Those fears most frequently cited in the recent literature are those of tolerance and 
addiction that both professionals and patients assume will occur with opioids for 
moderate to severe pain. However, earlier reviews suggested that patients associated 
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opioids with death. In order to fully address patients' fears when commencing opioids, 
we must know what these fears are. 
3. Is it too late to estimate the efficacy of the Ladder? 
Although it would now be impossible to compare the efficacy of the ladder against 
approaches to cancer pain relief used before its dissemination, it has proved possible to 
conduct trials of the 3-step approach against modifications of the ladder. Whilst neither 
of these trials conducted to date have clearly demonstrated superiority of the newer 
approaches, it seems that there is room to improve the 3-step ladder. An alternative 
approach should be tested in a clinical trial, which will provide information about the 
efficacy of both the traditional and the novel approaches. 
4. How do we measure efficacy? 
One of the criticisms of the validation series was that different outcome measures were 
used to measure pain control. Ventafridda used the proportion of patients requiring a 
neurolytic procedure, whilst others used pain scores. Many authors currently use a 
`worst' pain score of z5 to categorize poorly controlled pain, since Serlin and 
colleagues suggested that this score was associated with increased pain interference 
with function. As yet we do not know how patients define poorly controlled pain. 
5. Is morphine still the gold standard opioid? 
The position of morphine as the first-line opioid at the third step has remained 
unchallenged to date. The newer alternative, oxycodone has been suggested to be a 
superior opioid, with an improved side effect profile. Some studies examining its 
efficacy and side effect profile in comparison with morphine have proposed clinically 
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important differences in side effects but very few randomised controlled trials have 
been conducted. It may be possible to use techniques such as meta-analysis to obtain 
better estimates of comparative efficacy and tolerability in order to answer this 
important clinical question. 
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1.10 Aims of the dissertation 
The objectives of this dissertation were to answer the outstanding questions about the 
current validity and utility of the ladder, by the following studies: 
1. Can we accept the estimates from the WHO validation series? 
In order to clarify whether or not the WHO ladder is currently achieving its aim i. e. the 
relief of cancer pain I decided to measure pain control in a population of patients with 
cancer. In an attempt to control for the impact of professionals' fears around opioids, 
patients under the care of professionals experienced in the use of the ladder and skilled 
in the use of opioids for moderate to severe pain were studied. I conducted a multi- 
centre pain survey and recruited patients being seen by palliative care teams in the 
South West of England 
2. Is morphine still the gold standard opioid? 
In order to examine the comparative efficacy and tolerability of the alternative opioid 
oxycodone, to consider if it is superior to morphine and so should replace morphine as 
the opioid of choice at Step III, I conducted a systematic review of studies investigating 
oxycodone in the management of cancer pain. 
3. Is it too late to estimate the efficacy of the Ladder? 
Whilst it is impossible to conduct a trial comparing the WHO ladder to previous 
practice because the ladder has been adopted throughout the world, it is possible to 
conduct a randomised trial of the three-step ladder versus a new alternative approach, 
such as a two-step approach (where opioids for moderate to severe pain are commenced 
as soon as non-opioid analgesics are no longer sufficient). This is in fact the approach 
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suggested by Jadad and Brownian in their systematic review of the studies examining 
the efficacy of the ladder. Such a trial may be too difficult to conduct in a palliative 
care setting, because the majority of the patients seen by palliative care teams will 
already be using Step III opioids. Before a definitive study can be conducted, a pilot 
study examining the feasibility of recruitment and examining appropriate outcome 
measures is required. I therefore conducted a pilot study for a two-step ladder versus 
the three-step approach. 
4. If we do accept the estimates from the WHO validation series, why do pain 
prevalence surveys, conducted since its widespread dissemination, consistently 
show poor pain control? 
Previous pain surveys have shown that under-medication is a factor in uncontrolled 
pain. What is not known are the relative contributions of both patients' and doctors' 
fears of opioids, and the extent to which patients' fears of opioids are exacerbated by 
those of the professionals managing pain. In addition, if we are to consider an 
alternative approach, which would require earlier introduction of opioids in a patient's 
cancer journey (albeit perhaps only by a few weeks), we need to understand what this 
might mean to patients and whether or not they would consider such an approach 
acceptable. I conducted a nested qualitative study, exploring patients concerns when 
offered Step III opioids for the first time within the pilot study. 
5. How do we measure efficacy or whether or not pain is controlled (e. g. pain 
scores; function; requirement for a nerve block)? 
The analgesic ladder validation studies used different end-points for determining the 
efficacy of the ladder. However, deciding what is controlled pain is crucial if we are to 
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attempt to measure efficacy of pain management approaches as compared to drug-to- 
drug comparisons, where absolute pain scores can be used. The majority of pain 
surveys quote the work of Serlin and colleagues, which demonstrates that a Brief Pain 
Inventory worst pain score of >5 represents pain that is likely to interfere with function 
and so is uncontrolled pain. Very little work, however, has been conducted with 
patients themselves with cancer pain to clarify for research purposes what controlled 
pain or uncontrolled pain means to them. In order to begin to investigate this further, a 
single question "overall is your pain controlled? " was added to the multi-centre pain 
survey, in order to provide comparisons between responses to this question and worst 
pain scores obtained from the questionnaire. 
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Chapter 2: Methods 
2.1 A survey of cancer pain control by South West England 
Palliative Care Teams 
2.1.1 Study aims 
1. To define the prevalence of cancer pain in patients under the care of specialist 
palliative care teams in the South West of England. 
2. To determine the overall proportions of nociceptive, neuropathic and mixed 
pain types as recorded by the patient's palliative care doctor or nurse. 
3. To determine the percentage of patients with poorly controlled pain defined as a 
"worst' 'pain score of >5 on an 11-point numerical rating scale (pain which is likely to 
interfere with function). 
4. To examine the influence of demographic variables (age, sex, setting, time 
known to palliative care team and socio-economic deprivation) and clinical variables 
(ECOG performance status, primary tumour site, use of medication and frequency of 
breakthrough pain) on the proportion of patients experiencing a "worst" pain score of > 
5 on an 11-point numerical rating scale. 
5. To determine the proportion of patients requiring a rotation of opioid and prime 
indications for this practice. 
6. To determine the proportion of patients requiring anaesthetic procedures. 
7. To calculate the pain management index (PMI) for each patient to determine the 
extent to which his/her pain is appropriately managed. 
8. To compare the results of a single question; "Overall, is your pain controlled? " 
with the numerical rating scale measuring worst pain. 
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In order to explore the hypothesis that the WHO ladder may not be as efficacious or as 
applicable to routine clinical care as the validation series suggested, it seemed 
appropriate to attempt to measure the control of cancer pain in a group of patients being 
treated according to its principles. One of the reasons that the validation series may 
have over-estimated the efficacy of the WHO ladder is that the patients recruited to the 
validation series will have had better follow-up, more attention to side effects and were 
perhaps more likely to use the prescribed medication (better adherence rates) than those 
patients being treated in "real-world" clinical conditions. This phenomenon is well 
recognized and is a reason for continuing monitoring of health interventions after 
randomised controlled trials have shown efficacy. 138 The patients recruited to the 
validation series received regular follow-up. They were seen every two weeks initially 
and then every four weeks and were questioned about pain control and side effects from 
analgesic medication at each study visit. This is likely to be more intensive follow-up 
than is currently experienced by most patients with cancer pain and so in order to 
estimate the efficacy of the ladder in pragmatic or "real world" clinical settings, 
methods other than clinical trials must be used. It is also important to estimate pain 
control in community populations as well as in in-patient settings, to test the ease with 
which the WHO ladder can be followed by the patients themselves. 139 In order to 
achieve these goals, we conducted a cross-sectional survey of cancer pain control. 
2.1.2 Cross-sectional design 
A cross-sectional study is an observational study designed to measure the health 
experience of a population at a snapshot in time. 138 As the unit of such a study is the 
individual, it is possible to examine individual characteristics that might be associated 
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with the condition under investigation. In this study the aim was to investigate factors 
associated with poor pain control. 
Cross-sectional studies generally involve a geographically defined representative 
sample of the target population of interest (the target population is that to which the 
results will be extrapolated) (Figure 2). The sampling frame is that group of patients 
from whom the study patients will be drawn. The selected sample consists of those 
patients randomly selected to be approached about the study and the study sample 
consists of those patients who agree to participate. The response rate is measured by the 
proportion of the selected sample that actually participate. A high response rate is 
important to be confident that the results are not influenced by selection bias (selection 
bias occurs if the characteristics of those who participate in the study differ from those 
who don't). 
Figure 2: Recruitment to cross-sectional studies 
Target population 
(patients with cancer pain 
being seen by palliative care 
teams) 
Selected sample (patients 
being seen by palliative care 
teams on designated day) 
Study sample 






This study was designed to measure cancer pain control by a single group of 
professionals: palliative care professionals. There were two reasons for this. Firstly, I 
assumed that palliative care professionals have expertise in pain management and are 
familiar with the WHO ladder, so it was likely that the ladder would be applied 
appropriately for each patient with pain. Secondly, I assumed that because palliative 
care professionals are familiar with the use of Step III opioids, then the reluctance of 
professionals to commence morphine or an alternative opioid would not have an 
influence on the results obtained. I hoped that using a cross-sectional method would 
mean that results could be obtained efficiently, providing an estimate of pain 
prevalence for this group of patients and also provide an estimate of the percentage of 
patients for whom the WHO ladder was controlling their pain. 
2.1.3 Sample size calculation 
The sample prevalence obtained from a cross-sectional study could differ from the true 
population prevalence because (assuming no selection bias) it is dependent on sampling 
variation (i. e. which of the potentially eligible participants are included in the 
sample). 140 However, the precision of the prevalence estimate can be measured by 
calculating confidence intervals. The narrower the confidence intervals, the more likely 
it is that the estimate of uncontrolled pain prevalence obtained would approximate to 
the true population prevalence. 
The formula for calculating the standard error of a proportion (which allows the 
confidence intervals to be calculated) is: 
ý [P (1 p)/nl 
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where n= study population number. Hence the width of the confidence intervals 
depends on the sample size. 140 
If the approximate prevalence estimate is known, then it is possible to calculate the 
required sample size (the number of patients needed to be included in the study) in 
order to obtain narrow confidence intervals. If the true figure of patients whose pain is 
controlled using the WHO ladder is 80%, then it is possible to calculate the number of 
patients with pain required to be included in the study, in order to obtain this figure 
within confidence limits of between 75-85%. I performed this sample size calculation 
using Stata. 141250 completed questionnaires from patients with cancer pain would have 
80% power to obtain a result within these confidence intervals, at a level of statistical 
significance of 5%. In order to obtain this number of questionnaires, I estimated that 
with an approximate figure of 5% missing data, 20% failure to complete the 
questionnaire by the health professional, a suggested 20% refusal rate, and an overall 
pain prevalence of 64% in palliative care populations1° I needed to approach 
250* 1.05* 1.2* 1.2* 1.35 =510 subjects to achieve this sample size, but only required 
425 completed questionnaires from all patients, which should mean that 250 
questionnaires would be from patients with pain. 
2.1.4 Study documentation 
Documents prepared for the study included an information sheet written for the 
patients, explaining the reason for the study and why they had been asked to participate 
(Appendix 3). The purpose of the information sheet is to ensure that patients have 
access to sufficient information to allow them to give their valid informed consent to 
participate in a research study. In preparing the information sheet I followed the 
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guidance for researchers that is available on the Central Office for Research Ethics 
Committees website (www. corec. or2. uk). A consent form was also designed according 
to the COREC website template, (Appendix 4) which suggests that each patient not 
only signs the consent form, but that prior to this they are reminded of what they are 
giving their consent for and, if possible, write their initials in boxes placed alongside 
this information to show that they have understood it. The other documents developed 
were the patient and professional questionnaires designed to capture the information 
required to answer the survey questions. 
2.1.4.1 Patient questionnaire: Pain scale 
One of the issues in designing the patient questionnaire was deciding which pain scale 
to use. The original scale used to measure or rate the efficacy of pain control in the 
WHO ladder validation series was a patient self-rated pain relief tool, " which 
eventually had to be abandoned because of the difficulties experienced in its use. 
Several different pain scales have been validated for use in pain studies. They are either 
uni-dimensional i. e. measuring current pain severity only or multi-dimensional (either 
measuring more than one dimension of pain such as pain interference with function or 
measuring more than one pain severity e. g. pain now, pain worse, pain least and pain 
average). The commonly used single-dimension scales are the Visual Analogue Scale142 
which is a 100mm line anchored by "no pain" at the left side and "worst pain" on the 
right side. The patient is asked to place a mark on the line at a place that corresponds to 
their level of pain. The distance from the left anchor point to the mark represents the 
patient's pain score. The VAS has been shown to be valid and reliable and to be 
sensitive to change and so is often used in clinical trials. However, its ease of 
administration reduces with age and increases with experience of the administering 
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staff both of which were factors for this survey. 143 It was likely that patients from all 
age groups would be participating and the staff recruiting them would not necessarily 
have experience in the use of the VAS for research purposes. A further factor 
influencing the choice of scale is that the VAS requires a measurement to be taken by 
the investigator, making it more time-consuming and perhaps more open to error when 
entering the data into a database. A second, commonly used single dimension scale is 
the Numerical Rating Scale. '44 This consists of the numbers 0- 10 in a line, anchored 
by "No pain" at 0 and "Worst imaginable pain" at 10. Patients are asked to circle or 
mark the number that best describes their pain. Generally, the VAS and NRS can be 
considered equal in terms of validity and reliability and the choice of scale is usually 
determined by practical factors. 144 A report from the Expert Working Group of the 
European Association for Palliative Care suggested that the numerical rating scale was 
the easiest scale to apply and was associated with better compliance. 143 
The decision to use a worst pain score >5 as a score representing uncontrolled pain was 
for two reasons. One of the most commonly used multi-dimension scales in research 
studies is the Brief Pain Inventory (BPI) developed initially as the Wisconsin Brief Pain 
Questionnaire and subsequently modified to the BPI 145 This scale includes 
quantification of the extent to which pain interferes with general activity, mood, 
walking ability, normal work, relations with others, sleep and enjoyment of life with 
each factor being measured on separate numerical rating scales. The authors have done 
methodological work with the BPI and have been able to show that worst pain levels 
correlate best with pain interference 5 145 and that using a worst pain score of >5 as a 
cut-off point allows investigators to determine the proportion of patients in whom pain 
is significantly more likely to interfere with function or is "uncontrolled' 5 The second 
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reason was that the two large pain prevalence studies conducted in France64 and the 
United States62 and the Scottish pain survey65 all used a worst pain score of >5 to 
signify poorly controlled pain. 
Thus, for the purposes of this study, four separate numerical rating scales, asking about 
pain worst, least, on average and now were included in the questionnaire, to improve 
ease of administration, compliance, ease of handling the data and to allow comparisons 
with other cancer pain surveys. 
2.1.4.2 Patient questionnaire: design 
I attempted to keep the patient questionnaire as simple as possible, by limiting it to one 
side of A4 paper and asking clear questions (Appendix 5). The first three questions 
asked for demographic data (age, sex and postcode). Patients not wishing to participate 
in the survey were asked if it would be possible for the professional to collect age and 
sex data so that we could determine if this group varied in any important way from the 
study sample (i. e. an assessment of selection bias). The next question asked whether or 
not the patient experienced pain, or required painkillers. Patients not experiencing pain 
or using painkillers did not answer any further questions and were thanked for their 
participation. Those who did experience pain were asked to rate their pain at its current 
(pain now), least, worst and average levels over the past week. They were also asked 
about the presence and number of episodes of breakthrough pain. The final question 
asked "Overall is your pain controlled? " The reason for this final question was to 
compare the responses to this question with the scores from the validated "worst pain" 
numerical rating scale, but also to see if it is possible to develop a simple pain question 
that might be used in the consultation to differentiate between patients with well- 
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controlled and poorly controlled pain. I deliberately did not ask about satisfaction with 
pain control as patient satisfaction with pain relief has been shown to be influenced by 
measures other than pain scores. 146 
2.1.4.3 Piloting the questionnaire 
Once ethical approval was obtained, the original questionnaire was piloted at my own 
site (United Bristol Healthcare Trust) in order to ensure it was easy to understand, quick 
to complete and made sense to patients. Ten patients admitted to wards and seen in out- 
patients were asked to complete the questionnaire. All 10 patients found it 
straightforward and completed it in less than five minutes. A patient with impaired 
vision also managed to complete the questions with the assistance of a research nurse. 
However, it was noted that several patients scored their worst pain at 9 or greater, yet 
answered yes to the final question "overall is your pain controlled? " When asked about 
this, they all replied that although they experienced severe episodes of pain, they 
considered their pain to be controlled if the medication available for this pain ("as 
required" or breakthrough medication) worked. This piloting led to the addition of 
another two questions, asking about availability and effectiveness of breakthrough 
medication. The final questionnaire was piloted on a further five patients who again 
found it easy to complete. No further changes were made. 
2.1.4.4 Professional questionnaire 
The professional questionnaire was designed to capture information about the 
pharmacological management of the patient's pain along with information about the 
patient's cancer, performance status and the nature of the pain (Appendix 6). Questions 
were asked about other measures used to control pain including anti-cancer treatments 
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(radiotherapy and chemotherapy) and whether or not a nerve block had been tried. 
When opioids were used, information was obtained about the dose, route (including 
epidural and intra-thecal) and how many different opioids had been used (i. e. the 
number of opioid switches). A final question asked how long the patient had been 
known to the palliative care team. Each question was answered by ticking a box, apart 
from when including drug doses, which were to be written in full. Initially the 
professional questionnaire was designed to be on two sides of A4 paper only, for 
brevity. However, after amendments suggested by experienced clinical researchers, it 
was extended to a 4-sided booklet to make it easier to read and to include the 
instructions for professionals on the front page, so that these would be immediately 
accessible for all involved in recruiting patients. 
2.1.5 Measuring socioeconomic deprivation 
Socioeconomic deprivation was measured by matching the postcode for each patient to 
a Super Output Area (SOA) for which the Index of Multiple Deprivation (IMD 2004) 
score and quintile was known The IMD 2004 is a measure of multiple deprivations and 
is made up of seven domain indices: income, employment, health deprivation and 
disability, education, skills and training, barriers to housing and services, crime, and 
living environment. 
2.1.6 Data management 
Each individual question was given a number (1,2 etc. ) and if necessary sub-questions 
were labelled (e. g. la, lb etc. ) Each individual question also had codes assigned to 
responses (e. g. Yes = 1, No = 2). The results were entered into an Access database 
which had been designed for the study and was programmed to prevent errors by 
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setting limits and validation rules for each data point entered. In order to ensure 
maximum accuracy, all data entries were checked by a second person. 
2.1.7 Recruiting palliative care teams 
In order to achieve a sample size of 425 completed questionnaires (to obtain 250 
questionnaires from patients with pain), it was necessary to conduct a multi-centre 
study because it would not have been possible to recruit this number in a convenient 
time frame from a single centre. I invited all of the palliative care teams in the South 
West of England to participate in the survey because this is a group of professionals 
with whom the Department of Palliative Medicine already had some established 
educational links. Keeping the participating teams to a geographically defined area 
would also mean that the survey would be easier to facilitate as a single researcher. The 
names of both the lead nurse and consultant for each team were taken from the Hospice 
and Palliative Care Directory United Kingdom and Ireland 2004 and entered into an 
access database along with their contact details. In December 2004, the database was 
used to send a mail-merge letter to each nurse and lead consultant explaining the 
reasons for the survey and inviting them to participate (Appendix 7). A copy of the 
provisional patient information sheet and consent form were included, as well as a copy 
of both the patient and professional questionnaires. Comments were invited on all of 
these documents, as I felt that it was important to hear the views of the collaborators at 
this stage of the study. Clarification about the potential participants was required for 
one team, and amendments to both the patient and professional questionnaires were 
made after feedback from another. 
58 
2.1.8 Research governance 
In 2001, as a result of high profile research misconduct which had caused public 
distress, the Department of Health released a document called the Research Governance 
Framework for Health and Social Care, setting the standards for future research in 
health and social care. 147 Version 2 was released in 2005, defining the broad principles 
of good research governance that are key to ensuring that health and social care 
research is conducted to high scientific and ethical standards. The standards were to be 
understood by all those either engaged in research or hosting and managing research. 
They set out the processes to be followed for approval to be obtained for a research 
project and the care required to both protect patients and ensure confidentiality during 
health and social care research. This document, along with The Medicines for Human 
Use (Clinical Trials) Regulations 2004 that came into place in April 2004 has put in 
place standard processes which must be adhered to when conducting clinical research 
in the United Kingdom. 
2.1.8.1 Sponsorship arrangements 
Since April 2004 it has been a requirement that all research projects must have a 
sponsor. This role does not simply mean financial support, although it can incorporate 
this. The sponsor takes on the overall responsibility for ensuring the adequacy of the 
design and management of the study, including assessing the quality of the research and 
ensuring appropriate arrangements for conduct and monitoring of the research. 
Examples of organisations that can take on the role of sponsor include research councils 
and charities, universities and NHS trusts. Because this study was being conducted as 
part of a postgraduate degree under supervision provided by the University of Bristol, I 
applied to the University to request sponsorship for the study. This was facilitated by 
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the survey having already been peer-reviewed as a requirement of registering for a 
postgraduate degree. This was granted provisionally in January 2005, subject to 
satisfactory ethical and NHS trust research and development (R&D) approvals. 
2.1.8.2 Ethical approvals 
All research being conducted with NHS patients must have been considered by a 
research ethics committee and ethical approval granted. Since this was a multi-centre 
study, an application for ethical approval was made in March 2005 to the South West 
Multi-centre Research Ethics Committee (MREC), using the on-line Central Office for 
Research Ethics Committees (COREC) application form version 4.0 (Appendix 8). The 
initial MREC approval process resulted in additional documents (an invitation letter 
{Appendix 9) and consent form for each professional recruiting patients to the study 
(Appendix 10)) and alterations to the consent form. The committee also requested that 
a letter be sent to general practitioners of those patients recruited from either day-care 
or domiciliary settings, to inform them of the study. Approval for the study was given 
in May 2005 (Appendix 11). 
Each participating palliative care team involved required a named local investigator, so 
local ethical approvals were required from each Local Research Ethics Committee 
(LREC). This approval process required the completion of 25 separate Section Cs of 
the on-line COREC form and the final Site Specific Assessment was completed in 
September 2005, four months after approval from the MREC. 
Following this process, the data protection officer at Gloucestershire Hospitals NHS 
Foundation Trust was concerned that the collection of postcode data meant that the 
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questionnaires were not completely anonymous and that patients should be informed 
about this. These concerns were discussed with the administrator of the South West 
MREC who agreed that this had been overlooked during the original ethical review. 
The patient information sheet was therefore amended and a Notice of Substantial 
Amendment sent to the South West MREC to seek their approval for this amendment 
(Appendix 12). 
2.1.8.3 NHS R&D Approvals 
The Research Governance Framework for Health and Social Care meant that as well as 
obtaining ethical approval for each site it was also necessary to obtain local hospital 
trust R&D approval for those teams who would be recruiting from NHS trusts. The 
framework was meant to standardise the process of obtaining R&D approvals, and 
completion of the on-line COREC form facilitated completion of a Standard NHS R&D 
Application Form by cross-population of information to the R&D website. Not all of 
the trusts in the survey accepted the NHS Standard R&D form, so 15 different 
applications were made to NHS Trust R&D departments. The final R&D approval was 
obtained approximately seven months from the time of the original MREC application. 
2.1.8.4 Site visits 
In the month before each site was due to conduct the study, a visit was made to each 
recruiting centre, in order to meet the principal investigator and to speak to as many as 
possible of the professionals who would be recruiting patients to the survey. The 
Medicines for Human Use (Clinical Trials) Regulations 2004 state that it is good 
clinical practice for each participating site in a study to have an Investigator Site File 
(ISF) within which the essential information and documentation for the study can be 
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found. 30 site files were compiled, containing study contact numbers (Appendix 13), a 
copy of the instructions for principal investigators (Appendix 14), a subject recruitment 
record (Appendix 15), a staff signature log and delegation of tasks form (Appendix 16), 
the study protocol and copies of ethics and R&D applications and approvals. A copy of 
the trial sponsorship and insurance arrangements (Appendix 17), copies of all the 
information sheets, letters to GPs (Appendix 18) and questionnaires were also included 
along with a section to store copies of the signed professional and patient consent 
forms. The ISFs were given to the local principal investigator along with the actual 
study documents which had been grouped into "patient packs". Each "patient pack" 
contained all the necessary documents required to recruit a single patient to the study. 
This included the patient information sheet and consent form, a patient and professional 
questionnaire with matching study ID numbers (unique to each patient), an AS size 
envelope for the patient questionnaire and a larger A4 envelope in which the 
professional questionnaire, the consent form and the smaller envelope were to be 
placed. Both the envelopes were also marked with the same study ID number. It was 
hoped that this would mean that the recruitment of patients in their own homes by the 
community palliative care nurses would be simple, requiring only one pack to be taken 
into the house. 
The instructions were explained to all members of the teams present at the site visits. 
Any remaining questions were dealt with and arrangements made for return of the 
questionnaires. For centres recruiting large numbers of patients I decided to use a 
courier collection service. For those centres recruiting less than ten patients, the Royal 
Mai1TM registered delivery service was used. 
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2.1.9 Study process 
Each team designated one day during September that was convenient for them to 
conduct the study. All patients seen on that day were to be asked if they wished to read 
a patient information sheet and to consider participating in the study. If a patient 
declined to enter the study, the professional requested permission to collect 
demographic data, and if given, the patient consent form was completed appropriately. 
If the patient agreed to fully participate, they were asked to initial each of the boxes on 
the consent form and then to sign to confirm their consent. They were then given the 
questionnaire to complete. The instructions to the professional asked that if possible, 
the patient questionnaire would be completed independently of the healthcare 
professional who had recruited the patient to the study, in order that the patient could be 
honest about their pain scores. An informal carer or a volunteer in in-patient units could 
assist if necessary. The patient was then to place the questionnaire directly into the 
smaller envelope. 
The professionals were advised to complete the professional questionnaire at the same 
time as the patient completed theirs. All patients seen on the designated study day were 
to be asked about participation until all the patient packs had been used, however, the 
protocol stated that the professional should not approach any patient about the study if 
they did not consider it appropriate. It was thought likely that this would exclude 
patients who were actively dying or unduly distressed. 
2.1.10 Statistical analyses 
The percentage of patients experiencing pain due to their cancer was calculated. 
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2.1.10.1 Pain scores: 
Using only those patients who experienced pain, the percentage of patients with a 
"worst pain" score of _5 was computed. 
Patients with "worst" pain scores of <5 were compared with those with "worst" pain 
scores of >_ 5 using t-tests for continuous variables and chi-squared tests for categorical 
variables. 
Those reporting a numerical rating scale score of >5 for "worst" pain were compared 
with those answering "No" for the question "Overall is your pain controlled? " using the 
chi-squared statistic. 
2.1.10.2 Pain management 
The proportion of patients on each Step of the WHO ladder was calculated. 
The adequacy of pain treatment was assessed using the Pain Management Index 
(Introduction: 1.5). A PMI of -3 to -1 suggests a patient is undermedicated. A PMI of 0 
to 3 suggests a patient is adequately medicated. 
The proportions of patients who had received oncology treatments and adjuvants for 
pain was control were calculated. 
The proportion of patients who did not have any drug treatment for breakthrough pain 
was calculated. 
The proportion of patients requiring an opioid switch was calculated. 
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2.2 Oxycodone for cancer-related pain: meta-analysis of 
randomised controlled trials 
As stated previously, the re-launch of oxycodone in a formulation suitable for use in 
chronic pain has led to a great increase in its use. Whilst it was likely that the practice 
of opioid switching to relieve persistent side effects caused by other opioids84 would 
explain some of this increase in its use, anecdotal evidence from personal experience 
suggest that some professionals consider oxycodone to be a superior opioid to 
morphine and are using it as their first-choice opioid. This seems to be because there is 
some evidence from randomised controlled trials of its use in cancer pain that it might 
have fewer adverse effects than morphine. 75 76 Some authors have also suggested it is a 
superior opioid 79 81 However, the evidence base is relatively weak, with only a few 
published randomised controlled trials reporting data on side effects. 4 76 148 It was 
therefore appropriate to conduct a systematic review, with meta-analysis if possible, of 
the available evidence for oxycodone. If oxycodone is a better tolerated opioid than 
morphine then it would be worth evaluating whether it should replace morphine as the 
opioid of choice in guidelines such as those produced by the WHO and the EAPC. 
Secondly, if it is not superior, given its greater cost (www. bnf. org) it could be argued 
that it should not be considered a first line opioid in health systems where cost is a 
concern. 
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2.2.1 Reasons to conduct a systematic review 
A single study frequently fails to detect, or exclude with certainty, a modest, albeit 
clinically relevant difference in the effects of two therapies. 149 This is because many 
studies often lack the power to detect such a difference, due to insufficient patients 
being recruited. This is particularly relevant in cancer pain, where it is difficult to 
recruit large numbers of patients even to multi-centre trials '50151 and subsequently trials 
are underpowered or simply abandoned. 136 A meta-analytical approach, where data 
from patients in several trials evaluating the same drug are considered and used to 
obtain a weighted average of the results, offers an alternative to conducting large 
studies and so may offer a more practical way of answering an important question. 
Systematic reviews may also offer more evidence about the generalisability of the 
results, by investigating the extent to which differing trial or patient characteristics 
influence the overall treatment effect. 149 
2.2.2 Limitations of systematic reviews 
The main limitations of systematic reviews are that the validity of the results is 
dependant on the attempts to find suitable studies eligible for inclusion in the review 
and on the quality of those individual studies. This is because meta-analysis consists of 
calculating a weighted average of included studies, so if those studies are flawed 
because of poor quality, or if attempts to find studies are not comprehensive enough, 
then the results of the reviews may be biased. However, knowledge of the potential 
sources of bias in a review allows investigators to conduct a review which attempts to 
minimize bias, or at least attempts to assess the influence that any particular bias may 
have had on the outcome. 
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2.2.3 Quality of included studies 
In controlled trials, bias falls into four main categories: selection bias, performance 
bias, detection bias and attrition bias. 152 Selection bias has occurred if the intervention 
and control groups differ at baseline in any important way and during trial conduct is 
prevented by two separate events; the appropriate generation of allocation sequence and 
concealment of allocation from the investigators enrolling patients. Empirical studies 
have demonstrated that both of these but particularly concealment of allocation, if not 
conducted properly, will exaggerate treatment effects. 152 Performance bias occurs when 
the intervention and control groups are handled in a different way; ideally all additional 
treatments and follow-up care provided should be equal in all study groups. Attrition 
bias occurs when there are losses-to-follow-up or protocol deviations, as it is likely that 
lost-to-follow-up patients differ in some way from those remaining in the study. If 
possible, all patients randomised should be included in the final analyses but pain 
studies usually rely on continuous outcome variables such as pain scores and so it is not 
always possible to include all patients lost-to-follow-up. In these studies, the proportion 
of patients excluded from the analyses from each group should be made available for 
the reader. 
Different opinions exist about the measurement of trial quality within a systematic 
review. Some, such as the Pain, Palliative and Supportive Care (PAPaS) Review group 
of the Cochrane Collaboration, advocate the use of composite scales to measure quality, 
where information about several features of the trial are combined in a single score. 
This score can then be used to give additional weighting to each trial's contribution to 
the final estimate of treatment effect. Another approach, advocated by the Cochrane 
Statistical Methods Group suggests that each dimension of trial quality should be 
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considered individually. This is because composite scores tend to vary in both their 
composition, complexity and subsequently their overall indication about a trial's 
quality, and have also shown different results when used to perform sensitivity analyses 
for previous meta-analyses. 153 A further problem when deciding how to adjust for trial 
quality in a systematic review is that what is actually being considered is the quality of 
the reporting and not necessarily the quality of the trial conduct. 154 Relatively recent 
developments such as the CONSORT guidelines (www. consort-statement. org) have 
attempted to guide authors to give accurate reports of a trial's conduct but these 
guidelines were not available for studies reported before their publication. For this 
reason, the most appropriate approach seems to be to conduct sensitivity analyses that 
explore the associations between treatment effect and study characteristics using 
categorical data on individual components on trial quality. 153 
2.2.4 Other sources of bias in systematic reviews 
The methods of retrieval of studies for inclusion in a review are important if all studies 
relevant to the intervention of interest are to be obtained. It is well known that only a 
proportion of research findings that are presented at conferences or as abstracts will 
eventually be published in indexed peer-reviewed journals. 155 Studies with statistically- 
significant results are more likely to be published than those without and in fact this 
may be a more important factor in obtaining publication than the quality of the trial 
itself. 155 It is also known that a large proportion of trials submitted to licensing 
authorities remain unpublished and so it is particularly important to attempt to retrieve 
unpublished data held by pharmaceutical companies. However, if unpublished data are 
obtained, decisions must then be made about their inclusion in meta-analysis, since it is 
often not possible to assess the quality of these data. Data from some large studies have 
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been presented more than once in published papers and including duplicated data will 
bias overall treatment effects. Most of these sources of bias can be eliminated by a 
comprehensive literature search including databases and citation lists of review articles 
and attempts to retrieve unpublished data or papers published in languages other than 
English with a protocol stating unbiased pre-defined inclusion/exclusion criteria. 
2.2.5 Quality of systematic reviews 
The overall quality of a systematic review requires assessment by the reader, if reviews 
are to fulfil their potential of providing clinicians with a means of keeping up with the 
medical literature by summarising the accumulated research. A systematic review 
should provide a statistical aggregate of relevant studies which have been 
systematically identified, appraised and synthesised according to a pre-determined 
explicit methodology. A conference of epidemiologists and clinicians resulted in the 
dissemination of the QUORUM statement, which provides a tool for the conduct and 
reporting of systematic reviews. 156 The methods of the QUORUM statement were 
followed in both the conduct and subsequent publication of this review. 157 Ideally, in 
order to minimise any bias, a protocol should be written at the outset and adhered to as 
in any other research study and advice should be taken from clinicians with knowledge 
of the clinical problem and from experts in research synthesis. A further source of help 
in research methodology is the Cochrane Collaboration, an international organisation 
that aims to help people make well-informed decisions about health care by preparing, 
maintaining and promoting the accessibility of systematic reviews and by developing 
methods to be used in systematic reviews. 158 
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2.2.6 Review protocol 
With the help of Professor Matthias Eggar and Dr. Jonathan Sterne in the Department 
of Social Medicine, at the University of Bristol, a protocol was written, to define "a 
priori" those studies which would be considered for inclusion and the methods to be 
used to identify studies and extract data from the study reports. We also decided to 
conduct the review with assistance from the Pain, Palliative and Supportive (PaPAS) 
Care Group of the Cochrane Collaboration to ensure that the results would be made 
available to a wider audience. 
2.2.6.1 Identification of eligible studies 
The inclusion criteria are dependant on the question being considered, which for this 
review was the effectiveness and tolerability of oxycodone in the treatment of cancer 
pain. I therefore planned to include randomized controlled trials, comparing oxycodone 
with either placebo or an active analgesic drug, in patients with cancer-related pain in 
any treatment setting. All routes of drug administration and all formulations of 
oxycodone were to be considered. Only those studies reporting patient-assessed 
outcome measures were to be included. Studies comparing combination oxycodone 
preparations (e. g. fixed-dose oxycodone combined with paracetamol) were excluded. 
2.2.6.2 Search Strategy 
Along with Sylvia Bickley, the Trials Search Co-ordinator for the PaPAS Group, I 
designed a detailed search strategy to include all possible names for oxycodone in 
combination with appropriate MeSH headings for pain and cancer (Appendix 19): I 
searched the following electronic databases Cochrane Pain, Palliative and Supportive 
Care Register 2002; Cochrane Controlled Trials Register 2002: Cochrane Library 
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current issue; MEDLINE (1966 - 5/2002); EMBASE (1980 - 5/2002); CancerLit (1960 
- 5/2002); and CINAHL (1982 - 5/2002). In order to minimise the effects of 
publication bias and to retrieve any unpublished data, I also searched Dissertation 
Abstracts (2002) and SIGLE (2002). 1 hand-searched reference lists of any retrieved 
articles and other relevant literature such as pain or opioid reviews. I wrote to the 
manufacturers of oxycodone preparations (Napp Pharmaceuticals U. K. and Purdue 
Pharma U. S. A), to known oxycodone investigators and to experts in the field to request 
any unpublished data on oxycodone in cancer pain. I also made a request to subscribers 
of the journals Palliative Medicine, Journal of Pain and Symptom Management and 
Pain for data from unpublished trials or information about other trials I had not 
identified. I distributed flyers at a major opioid conference and a Palliative Medicine 
conference making requests for any information regarding unpublished data on 
oxycodone. The search strategy was repeated in April 2005. 
2.2.6.3 Selection of studies suitable for inclusion 
In order to avoid error in assessment of whether studies met the inclusion criteria, two 
separate researchers (myself and Dr. Andrew Davies) read the study abstracts obtained 
after conducting the original searches, and then completed a form stating whether or not 
the full study report should be retrieved. If it was not considered necessary to retrieve 
the full article, reasons for exclusion were noted on the form. A record of excluded 
studies was kept so that they could be entered into RevMan (systematic review software 
provided by the Cochrane Collaboration) and so could be made available to interested 
readers. 
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2.2.6.4 Data Extraction 
The full text versions of potentially eligible articles were then obtained and 
independently assessed for inclusion by myself and Dr. Davies. We initially screened 
for duplicate publications by reviewing study name, authors, location, study population, 
dates, and study design, and then by confirming with the study authors that each of the 
included reports did indeed represent a separate study. Other reasons for excluding a 
trial were recorded. For eligible trials, we independently extracted data from the article 
using a specifically designed data extraction form. This form recorded the following: 
publication details, patient population details, nature of pain if described, interventions, 
outcome measures used, analgesic (efficacy) results and adverse effects (tolerability) 
data. We also extracted data on reported methods of generation of the allocation 
sequence, concealment of allocation and the blinding of patients, clinicians and 
outcome assessors and whether or not analysis had been by intention to treat in each 
trial, in an attempt to assess the quality of the studies to be included in the review. 
2.2.7 Systematic review and meta-analysis 
Meta-analysis involves a 2-stage process whereby appropriate summary statistics are 
calculated for each included study and then these summary statistics are combined to 
provide a weighted average of the results, described as the pooled estimate of treatment 
effect. Continuous data are usually combined as a difference in means or as a 
standardized difference in means if a mixture of measurement scales has been used in 
the included studies. To obtain a standardized mean difference, each individual study 
mean difference is divided by its standard deviation (SD) to obtain a set of results 
standardized to a uniform scale (the size of treatment effect in each trial relative to the 
variability observed in that trial). '59 These data may then be combined using a fixed 
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effects model where the weight is calculated for each study according to the quantity of 
information it contains. If hetereogeneity between the individual study findings is 
demonstrated by statistical methods, then an estimate of the between study variation is 
also incorporated into the calculation of the common effect, using random effects meta- 
analysis. Generally the weights in a random effects model will be smaller and more 
similar to each other than the weights in a fixed effects analysis and the estimated 
treatment effect more likely to be conservative, with wider confidence intervals. The 
method to be used for meta-analysis therefore depends on the data type, the choice of 
summary statistic and the observed heterogeneity between the individual studies. The 
weighting of each study is related to the individual study variance, which is closely 
related to the sample size and it is for this reason that large studies often carry more 
weight. Meta-analysis is not therefore simply a combination of the data from all trials 
as if they represented a single large trial. 
For continuous outcomes, meta-analysis requires the number of participants and the 
mean response with its standard deviation for both intervention and control groups, in 
order that the summary statistics can be calculated. If appropriate, once the main meta- 
analysis has been conducted, further sensitivity analyses can be undertaken to ascertain 
the robustness of the data. An example of such a sensitivity analysis is when the meta- 
analysis is repeated after exclusion of poor quality trials. The more consistent the 
obtained summary statistic is with repeated analyses, the greater justification exists for 
expressing the effect of treatment in a single summary number. 
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2.2.7.1 Particular considerations for this meta-analysis: incorporation of crossover 
trials into a meta-analysis 
Most meta-analyses are of randomised controlled trials where patients are randomised 
to two different parallel treatment groups. However, a particular feature of the 
pharmacological treatment of chronic pain is that it fulfils the necessary criteria for 
crossover designs i. e. it is a chronic condition which doesn't alter greatly during a short 
study duration, it is subject to temporary relief during treatment and will recur after the 
withdrawal of treatment. 160 Crossover trials also require fewer patients to produce the 
same precision as a parallel group trial because each subject acts as their own control 
and within-subject variation is usually less than between-subject variation. This is 
frequently exploited when examining chronic pain caused by cancer because as stated 
previously, it is often difficult to recruit large numbers of patients to these trials. 
Particular issues when considering inclusion of crossover trials within systematic 
reviews and meta-analyses are around the quality of the reporting of the data, how 
much of the data to include and whether or not the results of crossover trials can be 
combined with results from parallel group studies. Although crossover trials are usually 
powered by sample size calculations which take into consideration their increased 
statistical power, their results are not always reported as within-subject treatment 
differences. Instead, the mean and its standard deviation for assessments after treatment 
and the mean and its standard deviation for assessments after placebo are often 
reported, as if the data were obtained from a parallel group trial. However, these data 
are unsuitable for inclusion in meta-analyses because they do not take account of the 
fact that the patients in a cross-over trial receive both treatments and hence the groups 
are not independent of one another; a requirement for meta-analysis. 161 Also, the effects 
of simply pooling the results from both periods may exaggerate the benefits of the more 
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successful treatment. 161 Authors of other systematic reviews have chosen to use the data 
from the first period only and use these data as if they had been obtained from a parallel 
group trial. However, these data are not always available, and if in fact they are, they 
may represent biased data, the authors having chosen to display these data because of a 
favourable treatment effect. In addition, the data obtained from the first period only 
may be underpowered to detect or exclude important differences. Ideally, the results 
from the paired analyses should be included in meta-analysis. This requires an estimate 
of the within-person comparison of treatments and its standard deviation (or standard 
error or confidence interval to allow calculation of the standard deviation). If the 
within-person correlation of scores is also known, then the study variance can be 
calculated and used to conduct the meta-analyses. 
2.2.8 Data retrieval 
The original trial reports did not contain sufficient data to allow meta-analysis, mainly 
because four of the included studies were crossover studies, where the authors provided 
mean pain scores for patients whilst on oxycodone in comparison with mean pain 
scores for patients whilst on control drug i. e. the results were reported as if from a 
parallel group trial. The parallel group trial also did not report mean differences in pain 
scores (e. g. the mean individual difference in pain scores comparing Day 1 with the last 
study day) but instead reported group mean pain scores. This problem has been 
encountered in other systematic reviews of opioids in cancer pain and the authors 
conducting these reviews have chosen to report the findings in a qualitative overview of 
results. 82162 A recent paper by Elbourne and colleagues161 suggested that this was usual 
practice in Cochrane reviews, with authors either choosing to omit the results from 
crossover trials or using other methods to include their data. However, a recently 
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conducted systematic review of opioids in breathlessness 163 had encountered similar 
difficulties with the reporting of trial outcomes and those involved also reported the 
methods used to counter these difficulties. 161 In order to try to replicate these methods, 
we contacted Napp Pharmaceuticals (the sponsor of the included studies) and the 
individual study authors to request further pain data from the trials. An initial request 
for individual patient data was granted by one of the authors, 75 but refused by Napp 
Pharmaceuticals. A second request was then made for summary statistics (the mean 
within-patient difference comparing each patients' pain scores on the last day of the 
control phase with the last day of the oxycodone phase and its standard deviation) in 
order that meta-analysis of these data could then be undertaken. This second request 
was granted six months later following several discussions with the owners of Purdue 
Pharma based in the United States, the parent company of Napp Pharmaceuticals in the 
U. K. After the initial analyses of the efficacy data, a request was made to Purdue 
Pharma via Napp Pharmaceuticals for individual patient data on the presence or 
absence of side effects recorded in the studies. These data were also eventually granted 
after a further six months. 
2.2.9 Consistency of results (testing for heterogeneity) 
The value of the overall estimate of treatment effect obtained by a meta-analysis is 
sometimes limited when the included studies have shown differing results. For this 
reason, attempts are usually made to establish the consistency of the results obtained 
from each study, particularly as this can then lead to an assessment of the 
generalisability of the overall result. A test for heterogeneity seeks to establish whether 
the results are genuinely different between studies (heterogenous) or whether they are 
actually the same (homogenous) but the differing results obtained have arisen by 
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chance due to sampling variation. The results of tests for heterogeneity are also used to 
determine which methods should be used to combine the study results (i. e. to use either 
the fixed or random effects methods as described above). Tests for heterogeneity such 
as Cochran's Q test are limited when dealing with a meta-analysis including only a 
small number of studies, whereas the J2 statistic is more sensitive because it provides a 
quantification of the inconsistency (and so can be used to determine the effect to which 
the inconsistency affects the conclusions of the meta-analysis). 164 The J2 statistic lies 
between 0 and 100% and represents the percentage of total variation across the studies 
that is due to heterogeneity rather than due to chance. It can also be quantified, with 
25%, 50% and 75% representing low, moderate and high heterogeneity respectively. 164 
2.2.10 Investigating heterogeneity 
Meta-analysis is a synthesis of data from several different clinical trials which often 
have encompassed a variety of different regimes, participants and outcomes. This 
clinical heterogeneity may mean that the results are incompatible because of observed 
statistical heterogeneity. However, it is not sufficient to simply assess the amount of 
heterogeneity. An exploration of the source of the heterogeneity using meta-regression 
methods allows an investigation into how the different trial or patient characteristics 
have influenced the treatment effects. '59 A certain degree of caution is required in the 
results obtained from meta-regression analyses since they are, in a way, comparable to 
the results of sub-group analyses of controlled trials. However, more confidence can be 
placed in results from meta-regression analyses if either indirect evidence or biological 
considerations support their findings. 
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2.2.11 Statistical methods used 
Since the statistical combination of the data from cross-over and parallel group trials is 
complex, the meta-analysis was conducted with help from epidemiologists at the 
Department of Social Medicine at the University of Bristol (Dr Richard Martin and 
Professor Jonathan Sterne). We analysed the mean within-person difference in pain 
scores recorded on the first study day and those recorded on the final day on each study 
drug (to ensure steady state had been reached). Different assessment scales were used 
to record pain scores in the trials so treatment effects were expressed as standardised 
weighted mean differences. 
To validly combine the results from the cross-over trials with the parallel group trial, 
the following parameters were estimated. For the parallel group trial, the standardised 
weighted mean difference was calculated using Glass's estimator159 (p. 291) and the 
standard error calculated according to equation 9 of Curtin and colleagues. 165 For cross- 
over studies, standardised weighted mean differences were estimated according to 
equation 11 of Curtin and colleagues, 165 by dividing the treatment effect by the 
between- plus within-subject standard deviation of the cross-over differences. To 
estimate the standard deviation of the cross-over differences a common between-period 
intra-class correlation coefficient of 0.2 was estimated using individual level data 
available only for the Heiskanen trial 75 Estimates of the variance of the cross-over 
effect sizes were then derived by equation 14 of Curtin and colleagues. 165 Since the 
trials used different control groups (morphine or hydromorphone), and there was 
evidence of between-trial heterogeneity, they were pooled using random effects meta- 
analysis. 159 We obtained data on the presence or absence of 16 common opioid-related 
side effects from the authors of each crossover trial and calculated the marginal odds 
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ratio estimate described by Becker and Balatgas160 to obtain odds ratios and their 
standard errors for the crossover trials. For each side effect, these odds ratios were 
combined with the corresponding odds ratio derived from the published report of the 
parallel group trial. 
2.2.11.1 Statistical Software 
Analyses were conducted using Stata version 8 (meta-analysis of pain outcomes) and 
RevMan version 4.2.7 (meta-analysis of side effects). Dr Martin and Professor Sterne 
conducted the meta-analysis of pain outcomes. I conducted the meta-analysis of side 
effects, under the supervision of Drs. Martin and Sterne. 
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2.3 The 2-step study: a pilot study for a randomised 
controlled trial of a two-step versus a three-step approach in 
the management of cancer-related pain 
Some have considered it impossible to conduct a randomised controlled trial of the 
WHO ladder166 despite Jadad and Browman51 considering this to be exactly the study 
required to assess its efficacy. It is likely that a trial of two different approaches (or 
ladders) to manage pain would need a different design from a trial comparing two 
analgesic drugs, but it seems important to attempt such a study in order to answer 
questions about the continuing efficacy of the ladder. 
2.3.1 Napp Pharmaceuticals Pilot 
Napp Pharmaceuticals began a pilot study for a trial of a two-step versus a three-step 
approach in September 2003 as a multi-national, multi-centre study, recruiting in both 
Spain and the United Kingdom. The Department of Palliative Medicine at the 
University of Bristol was one of the recruiting centres for this study and had been 
closely involved with the study design and protocol development. Several months into 
the trial, with 19 patients already recruited, Napp Pharmaceuticals withdrew their 
sponsorship, citing poor accrual rates. 
The Department of Palliative Medicine decided to apply for funds to continue the pilot 
study in three centres, Bristol, Nottingham and Edinburgh and for it to become the 
focus of this dissertation. This decision was coincident with new clinical trials 
regulations, the Medicines for Human Use (Clinical Trials) Regulations 2004, the aim 
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of which was to achieve improved and standardised conduct in clinical trials throughout 
the European Union. The pilot study protocol required alterations in order to comply 
with these new regulations, giving us the opportunity to improve its design. The most 
significant amendment to the protocol was the inclusion of a nested qualitative study 
aiming to explore the views or concerns of patients when being offered Step III opioids 
for the first time, described in Methods 2.4. Other modifications to the protocol 
included shortening the period of data collection for the primary outcome measure from 
eight weeks to four. This was to make use of information obtained from the original 
validation series, 48 56 which showed that the mean time spent at the second step of the 
WHO ladder was 28 days. Hence, any differences in the two approaches should be 
demonstrable within 28 days. Reducing the data collection period for the primary 
outcome measure would also minimise attrition, often a significant problem in studies 
in cancer pain. We also extended recruitment in Bristol to include local general 
practices. The other amendments were made to comply with the pharmacovigilance 
requirements of the new trial regulations. 
2.3.2 Change of sponsor 
Napp Pharmaceuticals had withdrawn their sponsorship of the trial, so an application 
was made to United Bristol Healthcare Trust to take on the role of sponsor (Appendix 
20). This involved obtaining an external peer review, which was conducted by 
Professor Henry McQuay, the Chair of the Palliative Care Clinical Studies 
Development Group of the National Cancer Research Institute. UBHT agreed to take 
on the role of study sponsor in August 2004. 
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2.3.3 EUDRACT Registration 
The new regulations state that any clinical trials must be registered on the European 
Database of Randomised Controlled Trials (EUDRACT) and obtain a EUDRACT 
number. This number is then used for all communications with either the regulatory 
authority (the Medicines for Human Use Regulatory Authority or MHRA) or the 
research ethics committees. The EUDRACT number 2004-004235-66 was obtained in 
October 2004. 
2.3.4 MHRA Authorisation (DDX to CTA) 
The new regulations state that any organisation involved in a study of an investigational 
medicinal product must hold a Clinical Trials Authorisation certificate in order to do so. 
The CTA replaced previous authorisations called the Doctors and Dentists Exemption 
(DDX: MLA 162 and MLA 163). All of these are regulated and issued by the MHRA. 
However, all trials already in progress holding a DDX when the regulations became 
statutory on May Vt 2004, simply had the DDX certificate for the trial transferred over 
to a CTA with no costs incurred. When the 2-step study had been under Napp 
sponsorship, a DDX had not been considered necessary because the study drugs were 
being used within licence. However, in view of the impending new regulations, I 
applied for a DDX (MLA 162 and 163) in the knowledge that this would then be 
converted into a CTA. This certificate was issued in June 2004 (Appendix 21). 
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2.3.5 Study approvals 
2.3.5.1 Ethical approval 
I completed a protocol amendment form (Appendix 22), available on the COREC 
website (www. corec. org. uk), stating the changes made to the study (the change of 
sponsor, protocol changes made to comply with the new regulations, the change in 
recruitment process and the addition of the qualitative component of the trial). This was 
reviewed by the South West MREC protocol amendment committee and ethical 
approval was given in October 2004 (Appendix 23). It was considered unlikely that the 
amendments gave rise to any particular site-specific issues, so separate approvals from 
local research ethics committees were not required for the recruiting centres. 
2.3.5.2 R&D approval from UBHT 
Although the study previously had trust approval from UBHT, the change of sponsor 
meant that I had to re-apply for trust R&D approval. This was granted in July 2004. 
2.3.5.3 R&D approvals at Nottingham and Edinburgh 
Both of the trusts involved at these sites requested copies of the protocol amendment 
form, the CTA and the letter confirming the new sponsorship agreement before R&D 
approval could be given. This was issued in Nottingham in March 2005 and in 
Edinburgh in October 2005. 
2.3.5.4 North Bristol Primary Care Trust approval 
In view of the changes being made to the protocol to allow recruitment to the study to 
take place from general practices throughout Bristol, we applied for North Bristol 
Primary Care Trust R&D approval which was granted in October 2004. The two 
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members of the research team were issued honorary contracts to allow us to visit and 
recruit patients in the community. 
2.3.6 Good clinical practice (GCP) 
The Medicines for Human Use (Clinical Trials) Regulations 2004 outline the standards 
to which clinical trials must be conducted in order to protect the trial subjects. These 
standards and principles are generally referred to as "good clinical practice". The 
research nurse and I undertook locally arranged training sessions in order that we were 
familiar with what constitutes good clinical practice. 
2.3.7 Application for research funding 
I co-ordinated a bid to Cancer Research UK (CRUK) via the Clinical Trials 
Applications and Awards Committee for funding for the study as a co-investigator with 
Professor Hanks, Dr Marie Fallon in Edinburgh and Dr. Andrew Wilcock in 
Nottingham. This was successful and £43000 was awarded to fund statistical support 
and salaries. 
2.3.8 Maximising recruitment 
This pilot study represented a challenge to recruitment for palliative care research 
teams, because of the need to recruit patients who are only at Step I of the ladder (i. e. 
using paracetamol or a non-steroidal anti-inflammatory drug for their pain control). The 
majority of patients being seen by palliative care professionals will have already 
commenced morphine or an alternative Step III opioid. 134 This trial therefore required 
cooperation from oncology and primary care colleagues. 
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2.3.8.1 Visits to general practice teams 
The research nurse and I both visited each practice prepared to recruit to the study in 
order to explain the aims and rationale of the study. Investigator Site Files were 
compiled for all practices so that each would have all the necessary study 
documentation as well as copies of the study approvals. During these visits, 
arrangements were agreed for obtaining prescriptions for medications during the study. 
A flow diagram of the recruitment process was agreed with each practice and a copy 
left in the ISF (Appendix 24). This flow diagram gave the necessary contact numbers 
for the research team. 
2.3.8.2 Recruitment within UBHT 
The research nurse and myself held regular meetings with the site-specific clinical 
nurse specialists, oncology outpatient and day-care nursing staff and the oncology ward 
doctors to remind them of the inclusion criteria for the study. We offered to see any 
patients with uncontrolled pain attending outpatients and irrespective of whether or not 
they entered the trial, advice was given on pain management. This meant that the 
research team was at times functioning as additional members of the hospital palliative 
care team, but this seemed necessary in order to gain access to an adequate number of 
patients, by encouraging other teams to refer to us. We screened the case-notes of 
patients attending the twice-weekly uro-oncology outpatient clinics and the notes of 
patients attending the Bristol Haematology and Oncology Centre day unit for 
pamidronate infusions (bisphosphonates are used in the treatment of bony metastases, 
which are often associated with pain) to assess eligibility for the study. 
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2.3.8.3 Recruitment from St. Peter's Hospice 
We were also able to use our links with our palliative care colleagues at St. Peter's 
Hospice to increase our accrual rate, by gaining access to patients with cancer pain 
attending day hospice and being visited by the hospice community clinical nurse 
specialists. 
2.3.8.4 Recruitment from other Edinburgh and Nottingham 
There were significant delays in recruiting from Edinburgh, mainly due to the length of 
time taken to obtain trust R&D approval, which was only granted in October 2005 
(over one year after the corresponding approval in Bristol). Recruitment in Nottingham 
was also slower than in Bristol, so the research nurse from Bristol visited to share ideas 
about maximising recruitment. 
2.3.9 My role 
Once the approvals had been obtained, and the study had commenced in the various 
settings I continued to act as study co-ordinator, dealing with enquiries from the 
recruiting teams in other sites. For the UBHT site I acted as study doctor and so was 
involved in the recruitment procedures and liaising with colleagues to promote the 
study. I provided supervision for the research nurse who was appointed to assist with 
recruitment and clinical management of patients within the study. 
2.3.10 Protocol 
The study was designed as an open, randomised, parallel group study. 30 participants 
were to be allocated in a ratio of 1: 1 to either the experimental two-step approach or the 
traditional three-step approach and followed up for 12-18 weeks. All patients were to 
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be managed by the research team although their own primary care team could make 
alterations to analgesic medication if necessary. 
2.3.10.1 Inclusion criteria 
" Patients aged 18 or over 
" Patients with a confirmed diagnosis of cancer 
" Patients with pain caused by their cancer, requiring (but not yet taking) Step II 
medication 
" Patients who are able to take oral medication 
" Patients willing to complete a patient diary 
" Patients willing and able to give their informed consent to take part in the study 
2.3.10.2 Exclusion criteria 
0 Patients who had used regular Step II analgesics in the two weeks before study 
entry 
" Patients who had used regular Step III opioid in the month before study entry. 
" Patients thought to be at an increased risk of the central nervous system 
depressant effects of the study medication 
" Patients with a history of depression or personality disorder which might lead to 
self-harm or admission to hospital 
" Patients with a known sensitivity to oxycodone or other opioids 
" Patients with a history of drug or alcohol abuse 
" Patients involved in research studies involving a new clinical entity 
" Patients scheduled to undergo cancer-related surgery 
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2.3.10.3 Randomisation 
Patients were sequentially allocated to treatment according to a pre-prepared 
randomisation schedule which had been produced in blocks of four, with separate 
blocks for each centre. Treatment allocations were concealed in opaque envelopes 
which were opened by the study doctor once the patient had given their written 
informed consent for the study and the research nurse had completed the screening and 
study entry documentation. For patients recruited in Edinburgh and Nottingham, a 
member of the research team or an administrator in Bristol confirmed treatment 
allocation by telephone. 
2.3.10.4 Study medication 
Patients randomised to the experimental two-step approach initially received 
OxyContinTM (modified-release oxycodone) 5mg twice daily with OxyNormTM 
(normal-release oxycodone) 5mg as required for breakthrough pain. These patients 
were also routinely prescribed laxatives to use regularly and titrate as necessary and 
anti-emetics to use if required. 
Patients randomised to the three-step approach were given co-codamol 30/500, two 
tablets four times a day with normal-release morphine sulphate solution to be used for 
breakthrough pain. These patients were commenced on sustained-release morphine 
sulphate tablets if their pain progressed and at this time would be given an anti-emetic 
and laxatives. 




Patients were telephoned at the end of the first week (by the research nurse) and seen 
every two weeks (by me or the research nurse), until week four, after which visits were 
conducted monthly. Throughout the study period, all patients were advised to contact 
the research team if they had problems with pain control or side effects during normal 
working hours. Participants in Bristol were given the contact number for the on-call 
U. B. H. T. Palliative Medicine physician to use out-of-hours. They were also advised 
that they could contact their own general practitioner if they wished. 
2.3.10.6 Study documentation 
Patients completed a daily pain diary asking them to rate their average pain for that day 
on a Box Scale 11 as below. 
0123456789 10 
They were also asked to record the number of doses of escape or breakthrough 
medication they had used and whether or not they had had any contact with a healthcare 
professional that day. 
At each study assessment visit they were asked to complete a Brief Pain Inventory pain 
assessment tool (Appendix 25) and information was obtained about side effects or other 
adverse events. 
2.3.10.7 Outcome measures 
The primary outcome measure was the percentage of time spent in the first four weeks 
of the study period with a BS-1 1 pain score of four or less (this is considered to 
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represent mild pain). 63 We also planned to examine the probability of patients in both 
approaches having controlled pain (< 4) on any given day using logistic regression. 
Secondary outcome measures included mean BS-11 pain scores, the time taken to reach 
stable pain control (defined as four or more days with a score of 4 or less), mean BPI 
pain intensity (worst, least, average and now) and pain interference scores recorded at 
each assessment visit. The number of adverse events in both groups was examined as 
well as adherence to medication and use of breakthrough medication in both groups. 
2.3.10.8 Statistical Methods 
The data for the primary and secondary outcome measures were examined using 
appropriate multivariable regression models (that is, linear or logistic for continuous 
and binary outcomes respectively). Models also included stratification variables and 
baseline pain score as covariates. The effects of other variables such as funder and 
weighting for the number of pain days' data provided per patient were investigated in 
the secondary analyses and reported as appropriate. For repeated measures data 
(individual patients may have provided up to 28 days of pain data), appropriate random 
effects (linear or logistic) regression models were used to take account of the 
hierarchical nature of the data. The time taken to achieve stable pain control was 
analysed as survival data using Cox's regression analysis. 
2.3.10.9 Imputations for missing data 
If an individual failed to provide 28 days of pain data, then imputations were made 
according to whether or not they were alive at censoring for the primary analysis only. 
If they were alive, it was assumed that they had a pain score of > 4. If dead, their data 
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remained missing. If only one value was missing in between two available data points, 
then the average of those two points was calculated and that value imputed. 
2.3.10.10 Safety 
Adverse events were recorded, graded and assigned causality using knowledge about 
expected or likely side effects caused by opioids. All serious adverse events were 
reported to the study sponsor. 
2.3.10.11 Monitoring 
The study sponsor, UBHT Research and Effectiveness Department was responsible for 
the monitoring of the study at UBHT. 
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2.4 A qualitative study to explore the views of patients 
considering morphine for relief of pain caused by cancer 
Patients have concerns when commencing opioids and in particular morphine. These 
concerns are likely to impact on their decisions when considering options for pain 
management. The two-step pilot study, discussed in the previous chapter, offered an 
opportunity to engage with patients with cancer pain when a Step III opioid was first 
offered for pain control, in order to explore these concerns. 
2.4.1 A nested qualitative study 
As stated previously (Introduction: 1.5), most research into patient "barriers" to cancer 
pain control, including fears about opioids, has employed quantitative methods to 
quantify or score the extent to which individuals are affected. "° 115 116 These studies 
have failed to show a clear relationship between barrier scores and pain scores, so it is 
possible we have not yet fully understood these fears, how they vary in different 
circumstances or how they influence pain control. 
Other authors have used qualitative methods to examine in greater depth patients' 
views on different classes of drugs. Benson and Britten167 explored patients' views 
about anti-hypertensive drugs and their reasons for adhering to drug regimens in spite 
of their reservations about these drugs. Grime168 used semi-structured interviews to 
explore the attitudes of patients to anti-depressant drugs in primary care settings and 
how behaviour was influenced by actual experience of taking anti-depressants. 
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Qualitative research has been described as "research that focuses on the experience and 
meanings of individuals or groups in order to analyse how and why people form 
associations with other people, with things and with their immediate environments". 169 
Clark, 170 in his paper describing what qualitative research can contribute to palliative 
care, states "qualitative research has the power to disrupt existing assumptions and to 
challenge what passes for knowledge". Using a method that did not make any 
assumptions, but instead used the experience of the individuals recruited to the trial, 
would allow better exploration of their associations with morphine, so I chose to use a 
qualitative method alongside the 2-step trial, a concurrent nested strategy. I did not plan 
to combine the data obtained, but thought it possible that data obtained from the 
qualitative component of the study might improve our understanding of the quantitative 
results and perhaps also provide information about the utility of the outcome measures 
in the 2-step trial and the acceptability of the approach to patients. 
2.4.2 Sampling strategy and recruitment of participants 
I obtained ethical approval to approach both those patients choosing to participate in the 
trial and also those who refused participation, thus interviewing those both willing and 
unwilling to accept the possibility of being randomised to a Step III opioid. The nesting 
of the qualitative study within the pain management trial would mean that I had the 
opportunity to interview patients similar to those seen in day-to-day practice, with a 
variety of social circumstances and disease variables to allow greater confidence in the 
generalisability of the findings. Where possible I conducted the interviews at the 
second-week study visit, or as soon as possible for those not recruited. 
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Twenty-nine patients were approached about the interview study and eighteen 
participated. Of these eighteen, twelve had also agreed to participate in the 2-step trial. 
Five patients who entered the 2-step trial did not participate because they died soon 
after study entry. Six other patients were approached about the interviews but did not 
take part; two died very quickly and four did not want to take part (Figure 3). 
Figure 3: Recruitment of participants into the interview study 
Given a patient information sheet for 2- 
step in Bristol 
N=29 
Entered trial Did not enter trial 
N=17 N=12 
Interviewed N= 12 Interviewed N=6 
Reasons not interviewed: Reasons not interviewed: 
Died N=5 Died N=2 
Refused N=0 Refused N=4 
2.4.3 In-depth interviews 
I decided to use in-depth interviews to explore patients' concerns about morphine and 
other Step III opioids. Using a mixture of open and closed questions would give an 
opportunity to develop discussion according to the issues the participants raised and 
would avoid me imposing my assumptions on them. In this way, concepts and theories 
are derived inductively from the interviews themselves and may be different from those 
predicted at the start of the research process. 171 1 conducted the interviews with the aid 
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of a topic guide (Appendix 26) in order that the same key areas were covered with each 
person. The first part of the interview was designed to introduce the topic and to ensure 
that the participant had sufficient information (Appendix 27) to give written informed 
consent (Appendix 28). I then asked the participants about the history of their cancer in 
order that the appropriate terminology for that person could be used for the remainder 
of the interview and to make them feel at ease with the interview process. They were 
then asked to describe their pain and how it impacted on their lives. The second stage 
of the interview focussed on the consultation at which opioids had been offered as a 
possible option for pain control and asked open questions about this, encouraging 
participants to discuss their thoughts and feelings at this time. This part of the 
interview was led by their responses. Further questions were asked to explore whether 
others in the participant's social network had an influence on their decisions regarding 
opioid analgesics. When all areas had been covered, the interview concluded with a 
rounding off question, which was usually "Was there anything else you wanted to ask 
or thought that I might ask you? " Throughout the interview clarification of meaning 
was sought and further probing questions were used in response to the conversation that 
was taking place. The topic guide was refined during the research process when the 
early participants raised further areas of interest, allowing these areas to be explored in 
subsequent interviews. 
2.4.4 Data recording 
The interviews were recorded using a cassette recorder with an external digital 
microphone. The recordings were professionally transcribed in full and I checked the 
transcripts for accuracy. I anonymised the transcripts and kept a record of pseudonyms. 
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2.4.5 Analysis 
I analysed the data with Dr. Rachael Gooberman-Hill, a social scientist from the 
Department of Social Medicine at the University of Bristol, in order to improve the 
reliability of the analysis. 171 We used the constant comparison method described by 
Glaser and Strauss. 172 Using this method ensures that any resulting theory emerges 
from and is grounded in the data and requires that data collection and data analysis are 
inter-related and are occurring in a cyclical, iterative process. 173 After the initial reading 
of an interview, sections of text were marked with codes by both of us independently 
and all data relevant to that particular code were identified. In the initial analysis phase 
there were several overlapping codes, derived in an attempt to capture as many of the 
nuances in the data as possible. These initial codes with their supporting data were then 
displayed in charts using the methods described by Tissier174 allowing similarly coded 
sections of texts from separate interviews to be compared. The codes were then 
discussed and refined by both of us into analytical themes, in order to summarise the 
phenomena under study for others. A further refinement and validation of the themes 
was sought by showing the charts generated by the first 13 interviews to a group of 
palliative care doctors and nurses during a journal club session. Throughout the 
analysis deviant cases were used to test and develop the themes. Once the final themes 
were decided upon, all of the data relevant to these themes were gathered in a 
descriptive account, along with a description of the participants and the impact of pain 
on their lives. This descriptive account "pulled together" all of the information obtained 
in the interviews and from it a model was developed in order to describe for others the 
relationships between the emergent themes. The interviews for trial participants and 
non-participants were analysed in a single group because initial analysis revealed that 
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there were no noteworthy differences between the two groups. Furthermore, both 
groups contained people who had commenced step III opioids by time of interview. 
2.4.6 Reflexivity 
It was possible that my dual role of interviewer and study doctor might have an impact 
on the in-depth interviews and also my analysis of them. '75 However, being aware of 
this meant that I took measures to minimise the risk of bias. When possible, the 2-step 
trial research nurse undertook the recruitment visit and the first week telephone call, 
minimising my contact with participants before the interview. I used impartial 
terminology during the interviews and encouraged participants to "tell me everything, 
even the bits you think I may not want to hear". The majority of the interviews were 
conducted in the participants' own homes. Rachael listened to the first interview as a 
check on style and I used the first read of all transcripts to monitor my technique. My 
influence on analysis is considered later in the discussion of the interviews. 
2.4.7 Quality 
In summary, I aimed to conduct the qualitative component of the study in as rigorous a 
manner as possible; maximising the generalisability of the findings by recruiting all 
respondents approached about the study and potentially offered Step III opioids; 
assuring reliability with the use of a topic guide so that all areas were covered with all 
informants and by collaborating with Rachael Gooberman-Hill so that the initial coding 
and refinement of coding was done by more than one person and in a transparent 
manner as described above. This collaboration also served as a safeguard that my role 
as a doctor did not overly influence the data generated in the interviews. 
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Chapter 3: Results 
3.1 A survey of cancer pain control by South West England 
Palliative Care Teams 
26 of the 32 palliative care teams approached participated in the study. Reasons for not 
participating at the outset included not having indemnity for research (1), censure of the 
questionnaire (1), lack of response (1) and no access to medical records, therefore 
unable to complete the professional questionnaires (1). Two further teams withdrew 
from the study after approvals had been obtained; one because of a change in personnel 
and one team citing insufficient time. 
3.1.1 Palliative care services recruited 
A mixture of hospital support teams and hospice services across the South West region 
were recruited. The teams involved covered inner-city areas, towns and rural 
populations. A total of 122 professionals were involved in the study, of whom the 
majority (95) were nurses. Patients from all settings were represented although there 
were very few outpatients (Table 3). 
3.1.2 Number of patients recruited 
A total of 298 patient questionnaires were returned. 286 patients completed the 
questionnaires in full and 12 patients provided demographic data only. 242 patients had 
pain, only eight less than the required sample size of 250. Most of the centres had over- 
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estimated the number of recruits they hoped to obtain. In general, if a lower number had 
been estimated, the more realistic that number was (Table 4). 
3.1.3 Patients declining to participate 
20 of the 26 participating teams provided data about the number of patients who 
declined the study outright. From these 20 teams, only 12 patients were shown to have 
declined, seven of whom came from one site. There was no obvious reason for this. 
Table 3: Numbers recruited from each setting 
Setting No. of patients recruited No. of patients with pain (%) 
Hospice IPU 72 68 (94.4) 
OP Clinic 99 (100.0) 
Day hospice 61 45 (73.8) 
Home 93 74 (79.6) 
Hospital 50 45(90.0) 
Total 285 241 (84%) 
data on setting missing for one patient 
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Table 4: Patients recruited per centre with numbers estimated 
Site 
number 









11 Hospital support team 6 10 60.0 
40 Hospice 18 20 90.0 
21 Hospital support team 7 15 46.7 
27 Hospice 14 45 31.1 
26 Hospice 13 45 28.9 
13 Hospital support team 3 10 30.0 
12 Day hospice 5 15 33.3 
34 Hospice 3 10 30.0 
35 Hospice 18 20 90.0 
18 Hospital support team 4 10 40.0 
17 Hospital support team 7 15 46.7 
and hospice 
36 Hospice 43 80 53.8 
30 Hospital support team 4 15 26.7 
29 Hospice 26 45 57.8 
10 Hospital support team 5 20 25.0 
15/16 Hospital support team 17 35 48.6 
and hospice 
19/20 Hospital support team 31 40 77.5 
and hospice 
22/23 Hospital support team 10 10 100 
and hospice 
24/25 Hospital support team 12 60 20.0 
and hospice 
28 Hospital support team 10 10 100 
31 Hospital IPU 5 15 33.3 
32 Hospice 12 10 120 
37 Hospital support team 5 15 33.3 
38/39 Hospice 20 33 60.6 
Total 298 603 49.4 
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3.1.4 Differences between patients providing pain data and patients 
providing demographic data only. 
There were no significant differences between those patients providing pain data and 
those providing only demographic data in terms of age, primary tumour site, ECOG 
scale or the setting from which they were recruited (Table 5) 
Table 5: Comparison between patients providing pain data and those providing 
demographic data 
Demographic Pain data P value 
data provided provided 
Age in years (mean) 67.0 67.7 
N 9 284 0.85 
Primary tumour 
site (%) 
Breast 10.0% 14.7% 
Colorectal 10.0% 15.4% 
Lung 20.0% 12.3% 
Upper GI 20.0% 11.6% 
Unknown 10 10.0% 2.8% 
Prostate 20.0% 19.6% 
Haematological 0.0% 3.8% 
Mesothelioma 0.0% 1.7% 
Head/neck 10.0% 2.5% 
Other 0.0% 15.4% 
N 10 285 0.62 
ECOG Scale* (%) 
0 18.2% 7.8% 
1 18.2% 45.4% 
2 45.4% 23.8% 
3 18.2% 17.4% 
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Demographic Pain data P value 
data provided provided 
4 0% 5.7% 
N 11 282 0.21 
Setting 
Hospice IPU 27.3% 25.3% 
O/P Clinic 0.0% 3.2% 
Day Hospice 18.2% 21.4% 
Home 27.3% 32.6% 
Hospital IPU 27.3% 17.5% 
N 11 285 0.89 
*ECOG Scale: O = normal activity; 1= symptoms but fully ambulatory; 2= 
symptomatic but in bed < 50% of the day; 3= needs to be in bed >50 % of the day but 
not bedridden; 4= unable to get out of bed 
3.1.5 Percentage of patients with uncontrolled pain (score of >_ 5) 
Of the 242 patients reporting pain, 79.3% (C. I. 74.1% to 84.4%) had a worst pain score 
of >_ 5 or uncontrolled pain. 
3.1.6 Demographic characteristics of those reporting worst pain scores 
of >_ 5 versus <5 
Those with uncontrolled pain were on average 4 years younger than those with 
controlled pain (p = 0.04) (Table 6). There was no evidence that sex, IMD quintile, 
setting, ECOG performance status, or primary tumour site influenced whether or not 
pain was controlled. There was some weak evidence that the length of time known to 
the palliative care team was a factor in pain control. There was a greater percentage of 
patients with controlled pain (87.8% vs. 78.4%) in those patients who had been known 
to palliative care teams for longer than one week. 
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Table 6: Demographic factors in those reporting pain scores of <5 and >5 
Worst pain <5 Worst pain >_ 5 p-value 
Mean age, yrs (SD) 70.7 (11.6) 66.7 (12.2) 0.04 
N 49 192 
Male (%) 49.0 42.0 
N 49 192 0.4 
IMD quintile (%) 
1 8.2 10.7 
2 12.2 18.3 
3 28.6 30.2 
4 40.8 29.0 
5 10.2 11.8 
N 49 
Setting (%) 
Hospice IPU 26.0 
O/P Clinic 6.0 

































Worst pain <5 Worst pain 5 p-value 
Lung 12.0 10.9 
Upper GI 8.0 13.6 
Unknown 1° 0.0 3.7 
Prostate 28.0 17.8 
Haematological 4.0 3.7 
Mesothelioma 4.0 1.6 
Head/neck 0.0 2.6 
Other 12.0 15.2 
N 49 192 0.34 
Time known to palliative care teams (%) 
< 24 hours 0.0 9.2 
> 24 hours but <1 
12.2 12.4 
week 
>1 week 87.8 78.4 
N 49 185 0.08 
IMD = Index of Multiple Deprivation 
*ECOG Scale: O = normal activity; 1= symptoms but fully ambulatory; 2= 
symptomatic but in bed < 50% of the day; 3= needs to be in bed >50 % of the 
day but not bedridden; 4= unable to get out of bed 
3.1.7 Mechanism of pain 
The most frequent pain mechanisms were thought to be nociceptive and mixed pain. 
Pure neuropathic pain or other causes of pain such as tenesmus were rare. Nociceptive 
pain was caused by bone, viscera and soft tissue in equal proportions of those with 
nociceptive pain. There was no evidence that the mechanism of the pain was associated 
with uncontrolled pain, but there was strong evidence that the presence of pain flares 
(or breakthrough pain) was associated with poor pain control as was the frequency of 
these flares (Table 7). 
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Table 7: Effect on pain scores of pain mechanism and pain flares 
Worst pain <5 Worst pain >5 p-value 
Mechanism of pain (%) 
Nociceptive 62.5 53.2 
Neuropathic 2 .12.7 
Mixed 31.3 41.0 
Other 4.2 1.1 
N 48 188 0.32 
Pain flares present (%) 59.2 87.5 
N 49 192 < 0.001 
Number of flares in those with pain flares (%) 
0-3 93.1 57.1 
4-6 6.9 32.1 
7-10 0.0 6.6 
>10 0.0 4.2 
N 29 168 0.003 
3.1.8 Opioid medication 
15% of patients were under-medicated according to their pain management index 
scores but this was not a factor contributing to poor pain control. Patients with a 
positive pain management index were more likely to have a worst pain score of < 5. 
This may simply be because worst pain score contributes to the pain management index 
score i. e. the lower the worst pain score, the more likely the PMI is to be positive if the 
patient is using Step III opioids. A greater percentage of patients with uncontrolled pain 
used medication for breakthrough pain (rescue medication). Amongst those who used 
rescue medication, it was effective in a greater proportion of patients with controlled 
105 
pain (p = 0.27). More patients with uncontrolled pain were using a Step III opioid for 
pain control (Table 8). 
Table 8: Effect of medication on pain control 
Worst pain <5 Worst pain 2: 5 p-value 
Adequately medicated (% yes) 84.0 81.6 
N 50 190 0.69 
Pain management index (%) 
-3 0.0 1.1 
-2 4.0 7.9 
-1 12.0 9.5 
0 16.0 51.6 
1 34.0 29.5 
2 26.0 0.5 
3 8.0 0.0 
N 50 190 <0.001 
Use rescue drugs (% yes) 71.1 85.7 
N 38 175 0.03 
Rescue drugs effective (% yes) 96.2 89.2 
N 26 148 0.27 
% of patients using a Step III 42.0 69.6 
opioid 
N 50 191 <0.001 
3.1.9 Use of drugs and other treatments for pain control 
The majority of the patients (66.5 %) were using a Step III opioid. Very few patients 
had had an anaesthetic procedure. The use of adjuvants was also less than expected 
(Table 9). 
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Table 9: Use of drugs and non-drug measures for pain control 
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Nerve block 1.6 
Epidural / intra-thecal 
2.9 
block 
Other non drug measures$ 10.7 
The commonest reasons for an opioid switch were inadequate analgesia (23.6%), 
inadequate analgesia plus side effects (29%), adequate analgesia but side effects (18.2) 
and change of route (21.8%). tThese included TENS, relaxation, massage and 
breathing exercises 
Other drugs used for the treatment of pain included anxiolytics (diazepam and 
lorazepam), anti-spasmodics (hyoscine butylbromide, glyceryl trinitrate and 
mebeverine), acid suppressing drugs (omeprazole and mucaine) anti-diarrhoeals and 
anti-thrombotics. 
3.1.10 Patients' views on pain control 
239 patients answered the final question about pain control (Table 10). Of these, 
contrary to the results from the worst pain score, only 34 (14.2%) felt that their pain 
was not controlled. Those who said that their pain was not controlled had higher "pain 
now" scores (difference = 2.8, CI 1.9 to 3.7; p=<0.001), higher "worst" pain scores 
(difference = 2.0, CI 1.1 to 3.0; p=<0.001), higher "least" pain scores (difference = 1.2, 
CI 0.45 to 1.9; p=0.02) and higher "on average" pain scores (difference = 2.1, CI 1.4 to 
2.9; p=<0.001). The factors influencing the response to this question were the 
frequency of pain flares and the effectiveness of rescue medication (Tables 11 and 12). 
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Table 10: Demographic factors in those reporting pain controlled or not controlled 
Pain controlled Pain not controlled p-value 
Mean age, yrs 
67.3 (12.1) 68 (11.9) 0.62 
(SD) 
N 205 
Male (%) 42.2 
N 204 








Hospice IPU 27.5 
O/P Clinic 2.9 








































Pain controlled Pain not controlled p-value 
Colorectal 18.1 11.8 
Lung 11.8 8.8 
Upper GI 12.3 11.8 
Unknown 1° 2.5 5.6 
Prostate 19.6 17.7 
Haematological 4.4 0.0 
Mesothelioma 2.5 0.0 
Head/neck 2.0 2.9 
Other 14.7 14.7 
N 204 34 
Time known to palliative care teams (%) 
<24hours 7.1 9.1 
> 24 hours but 
11.6 18.2 
<1 week 
>1 week 81.3 72.7 
N 198 33 
0.46 
0.49 
IMD = Index of multiple deprivation quintile (1 is the most deprived and 5 least 
deprived). 
*ECOG Scale: 0 = normal activity; 1= symptoms but fully ambulatory; 2= 
symptomatic but in bed < 50% of the day; 3= needs to be in bed >50 % of the day but 
not bedridden; 4= unable to get out of bed 
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Table 11: Effect of pain mechanism and pain flares on pain control question 
Pain controlled Pain not controlled p-value 
Mechanism of pain (%) 
Nociceptive 56.0 58.0 
Neuropathic 2.0 5.8 
Mixed 40.0 35.3 
Other 1) nnn A. v v. v 
N 200 34 0.46 
Pain flares present (%) 79.9 91.2 
N 204 34 0.12 
Number of flares in those with pain flares (%) 
0-3 68.7 25.8 
4-6 25.8 45.2 
7-10 3.1 19.4 
>10 2.5 9.7 
N 163 31 <0.0001 
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Table 12: Effect of medication on pain control question 
Pain controlled Pain not controlled p-value 
Adequately medicated (% yes) 83.7 76.5 
N 203 34 0.30 
Pain management index (%) 








Use rescue drugs (% yes) 
N 
Rescue drugs effective (% yes) 
N 








203 34 0.11 
84.9 74.2 
179 31 0.14 
96 52.2 
149 23 <0.0001 
63.7 70.6 
N 204 34 0.44 
32 out of the 34 patients stating that their pain was not controlled had a worst pain score 
of >5i. e. the negative predictive value of the question was 94.1%. However, 46/205 
patients stating that their pain was controlled had a pain score of ?5i. e. the positive 
predictive value was only 22.4%. 
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Table 13: Comparison of answers to the single question "Is your pain controlled? " 
with pain scores from a numerical rating scale 
"Is your pain controlled? " Worst pain <5 Worst pain >_ 5 Total 
Yes 46 159 205 
No 2 32 34 
Total 48 191 239 
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3.2 Oxycodone for cancer-related pain: meta-analysis of 
randomised controlled trials 
3.2.1 Search results 
The search strategy yielded 104 references. After an initial read of the abstracts by two 
reviewers, 25 were retrieved for a more detailed analysis (reasons for not retrieving all 
papers are given in Figure 4). Of these 25, a further 19 studies were excluded for the 
following reasons: no active drug or placebo control group (n = 7); no randomisation (n 
= 8); data previously published (we identified replication of efficacy data from two 
trials contained within papers reporting on the pharmacokinetic outcomes from these 
studies) (n = 2); studies comparing oxycodone in combination with paracetamol (n = 2). 
This meant 6 trials met the inclusion criteria (Figure 4). Of these, one was a single-dose 
study evaluating the analgesic potency and duration of action of intra-muscular 
oxycodone against intra-muscular morphine and codeine and was excluded from meta- 
analysis. Of the remaining five reports, there were: three crossover trials comparing 
oral oxycodone with oral morphine; one crossover trial comparing oral oxycodone with 
oral hydromorphone; and one parallel group trial comparing oral oxycodone and oral 
morphine (Table 14). 
After contacting study others or sponsors, individual patient data were obtained for the 
Heiskanen study. For the Bruera, Hagen and Mucci-LoRusso studies, we were 
provided with mean within-patient differences in pain scores (comparing the first and 
final study day) and an estimate of the standard deviation. Analysable data were 
unavailable for the Kalso study (which reported no statistically significant difference in 
visual analogue scale ratings between the morphine and oxycodone groups, but more 
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nausea with oral morphine) and the Beaver study (which demonstrated that 
intramuscular oxycodone was 0.68 times as potent as intramuscular morphine but had a 
slightly shorter duration of action). Thus four studies were included in the meta- 
analysis. 
Figure 4: Quorum Statement flow chart 
I Potentially relevant trials identified and screened I 
n= 104 
Trials excluded: not randomised controlled trial 
(n = 42); not cancer pain (n = 12); not a 
comparison with oxycodone (n = 24); and 
abstract not held by British Library (n =1) 
Retrieved for more detailed evaluation: 
n=25 
Trials excluded: no active drug or placebo 
control group (n = 7); no randomisation (n = 
8); data previously published (n = 2); studies 
comparing oxycodone in combination with 
paracetamol (n = 2) 
Potentially appropriate trials to be included in I 
meta-analysis: n=6 
Excluded from meta-analysis: single dose 
study (n = 1); crossover trial reporting pain 
outcomes as if parallel group trial & no 
further data suitable for synthesis obtained (n 
= 1) 
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3.2.2 Methodological quality of included studies 
Only one trial (Heiskanen) reported on the method of concealment of allocation to 
treatment (the randomisation code was kept by the hospital pharmacist), although 
information about whether or not restricted randomisation was used in generating the 
allocation sequence was not available in the trial report (Table 15). All of the trials used 
matched placebo tablets to blind both the patient and the clinician. No studies indicated 
whether or not analysis by intention-to-treat was undertaken. In all included trials, 
patients who withdrew from the study for any reason were excluded from the final 
analyses reported in the paper. The numbers who withdrew from each trial were as 
follows: Bruera (32 entered; 9 withdrawals); Hagen (44 entered, 13 withdrawals); 
Heiskanen (45 entered, 18 withdrawals); Mucci LoRusso (101 entered, 22 withdrawals) 
(Table 15). None of the publications reported on whether or not the outcome assessor 
was blind to treatment. Each trial reported that patients in both treatment groups had 
their opioids titrated in a similar manner until stable doses were obtained. The trials 
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3.2.3 Pain intensity scores 
3.2.3.1 Summary pain scores 
Table 16: Summary pain scores obtained from Napp 
Pharmaceuticals for included studies 








Hagen 25.21 27.68 -2.47 1.57 
Bruera 28.34 24.73 3.61 2.74 
Mucci- 19.56 19.98 -0.42 5.35 
LoRusso 
Heiskanen 0.88 0.73 0.15 0.18 
3.2.3.2 Pooled scores 
In pooled analyses, there was no evidence that mean pain scores differed between 
oxycodone and control groups (mean difference in standardised pain scores = 0.04; 
95% CI: -0.29 to 0.36; p =0.8) (Figure 5). There was evidence of heterogeneity 
between the study estimates (I2 = 62%, heterogeneity p=0.05). The pooled 
standardised difference in pain scores for the 3 studies that compared oxycodone with 
morphine was 0.20 (-0.04 to 0.44; I2 = 0%) and the standardised difference for the study 
that compared oxycodone with hydromorphone was -0.36 (-0.71 to 0.00) (p for 
difference in effect estimates = 0.1). Based on the pooled standardised differences we 
observed and the standard deviations observed in the individual trials, we estimate that 
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for oxycodone compared with morphine or hydromorphone, the pooled standardised 
differences represent only 2-3 mm on a 100mm visual analogue scale. 
Figure 5: Standardised weighted mean differences (95% confidence 
intervals) in pain intensity scores in patients with cancer, comparing 
oxycodone minus control in all four trials with analysable data. 
Helskannen (1997) 
Hagan (1997) 
Lo Russo (1 
Bruera (1998 
-0.6 -0.4 -0.2 0 0.2 0.4 0.6 
Favours oxycodone Favours control 
Standardised weighted mean difference (SWMD) 
SWMD (95% Cl) 
0.22 (-0.17,0.61) 




The results of other outcomes described in the included papers are detailed in Table 14. 
In summary, no differences in patient preference or quality of life were demonstrated, 
although the Heiskanen study suggested that night-time acceptability of morphine was 
better than oxycodone. As different measures were used and the results were not 
reported in sufficient detail, they could not be combined in meta-analyses. 
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3.2.4 Side effects 
The point estimates for the pooled odds ratios comparing oxycodone with control were 
0.75 (95% C. I. 0.51-1.1) for nausea and 0.72 (95% C. I. 0.49-1.06) for vomiting (Table 
17). There was no evidence for any differences between oxycodone and morphine in 
any of the side effects examined within the trials. There was substantial evidence of 
heterogeneity in estimates of the association of oxycodone with dry mouth and 
drowsiness (I2 = 73.7% and 71.4%, respectively). When the meta-analysis was 
repeated using only data from the trials with morphine as control, both pooled odds 
ratios favoured oxycodone (dry mouth: odds ratio = 0.56; 95% Cl: 0.38 to 0.83; 
drowsiness: odds ratio = 0.72; 95% CI 0.47 to 1.1). 
3.2.5 Adverse events 
Overall, the discontinuation rate due to adverse events was 13% (29/222) when data 
from all studies were combined; as many as 90% experienced opioid-related side 
effects in each trial (Table 18). Discontinuation rates due to adverse events were similar 
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3.3 The 2-step study: a pilot study for a randomised 
controlled trial of a two-step versus a three-step approach 
in the management of cancer-related pain 
3.3.1 Recruitment 
Recruitment re-commenced in December 2004 and closed at the end of November 
2005 in Bristol and at the end of February 2006 in Edinburgh and Nottingham. 20 
patients were recruited in total, 17 of whom were recruited from Bristol at a rate 
of 1-2 per month (Figure 6). 
Figure 6: Flow ofparticipants through the trial when funded by CR UK 
Assessed for eligibility n= 95 
Excluded n= 75 
Did not meet inclusion criteria 
(n = 59) 
Refused to participate 
(n = 14) 
Other reasons (n = 2) 
Randomised (n = 20) 
Allocated to 3-step approach 
(n = 11) 
Received allocated intervention 
(n = 11) 
Allocated to 2-step approach 
(n=9) 
Received allocated intervention 
(n=9) 
Lost from study (n = 3) 
Reasons (Died n= 3) 
Discontinued intervention (n = 
0) 
Analysed (n = 11) 
Excluded from analyses (n = 0) 
Lost from study (n = 4) 
Reasons (Died n= 2) 
Discontinued intervention (n = 2) 
Analysed (n= 8) 
Excluded from analyses (n = 1; 
no data provided beyond 
baseline) 
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Table 19: Bristol recruitment figures 
Setting Numbers Numbers 
approached recruited 












*Information about setting is missing on 6 patients 
Figure 7: Flow of participants through the trial when funded by Napp 
Assessed for eligibility n= 79 
Excluded n= 74 
Did not meet inclusion criteria 
(n = 64) 
Refused to participate 
(n = 9) 
Other reasons 
(n= 1) 
Randomised (n =18) 
Allocated to 3-step approach 
(n = 8) 
Received allocated intervention 
(n = 8) 
Allocated to 2-step approach 
(n= 10) 
Received allocated intervention 
(n= 10) 
Missing data (n = 4) 
Reasons (Died n=0; 
discontinued intervention n=2; 
other n= 2) 
Analysed (n = 7) 
Excluded from analyses (n = 1; 
no data provided beyond 
baseline) 
Missing data (n = 3) 
Reasons (Died n=0; 
discontinued intervention n= 3) 
Analysed (n= 10) 
Excluded from analyses (n = 0) 
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3.3.2 Extra contacts during the study period 
The mean number of extra contacts during the first four weeks of the study for the 
study participants recruited in Bristol was 3 (range 0- 9). The majority of these 
contacts were related to either pain control or adverse events. 
3.3.3 Attrition rates 
19 patients in the CRUK funded study provided data for the primary outcome 
measure. 17 patients in the Napp funded study provided data for the primary 
outcome measure. These 36 patients provided a total of 825 daily pain scores, the 
average number of observations per participant being 23 (out of a possible 28). 
The minimum number was 2 and the maximum was 28. 
3.3.4 Second step analgesics used 
A variety of second step analgesics were used for the 8 patients randomised to the 
3-step approach during the Napp sponsored study (Table 20). Only 1 of these 
patients had received a Step III opioid by the end of the 28 days. During the 
CRUK sponsored study, all 10 patients were initially given co-codamol 30/500. 
Only 3 of these patients remained on this at the end of the 28 days. Four patients 
had required a Step III opioid and the remaining three patients had died. 
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Table 20: Choice of second step analgesics during Napp sponsored study 
Patient ID Drug used Drug in use at 28 days 
00001 Paracetamol and codeine Step III opioid 
00009 Paracetamol and codeine NSAID 
00026 Dihydrocodeine Buprenorphine 
00044 Tramadol Tramadol 
00045 Tramadol Tramadol 
00046 Tramadol Tramadol 
00049 Paracetamol and codeine Paracetamol and codeine 
00081 Paracetamol and codeine Discontinued 
3.3.5 Descriptive statistics 
The following results considered the two studies as one and 19 patients were 
initially allocated to each group. Both groups had similar baseline pain scores at 
study entry (see table 21). There was no evidence of a difference in age (p = 0.3), 
sex (p = 0.2) or primary tumour (p = 0.6) between the two groups. 
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Table 21: Baseline characteristics of participants 
3-step approach 2-step approach 
(n=19) (n=19) 
Mean baseline pain score (SD) 4.8 (2.0) 5.2 (2.2) 
Age (yrs) 67.5 65.3 
Sex M=10 M=6 
Primary tumour Lung 23 
Breast 5 5 
Prostate 3 3 
Colon 3 3 
Gynaecological 0 3 
Bladder 1 0 
Unknown 1 1 
Haematological 2 0 
Sarcoma 1 1 
Stomach 1 0 
Mean number of days with pain data 21.1 (10.2) 22.3 (8.9) 
(SD) 
Stratum n= (%) BHOC 9 (50.0) 8 (44.4) 
Nottingham 1 (5.3) 0(0) 
Edinburgh 1 (5.3) 1 (5.3) 
Napp U. K. 1(5.3) 4(21.1) 
Napp Spain 7(36.8) 6(31.6) 
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3.3.6 Primary analyses 
The primary analyses were: 
i). To examine the difference in proportion of time in the first 28 days of the study 
that patients recorded a pain score of <_ 4, using linear regression models to adjust 
for the effects of stratum and baseline pain score. 
ii). To examine the probability of patients in both approaches having controlled 
pain (<_ 4) on any given day using logistic regression, taking into account the 
hierarchical nature of the data (up to 28 days of pain scores are clustered within an 
individual). 
Table 22: The proportion of time spent in the first 28 days of the study with a 
pain score of 4 or less 
Mean % of days with a Crude Adjusted Fully Fully Fully 
pain score of <_ 4 (SD) difference differencef adjusted adjusted adjusted p 
value* difference* 95% Cl* 
3-step 2-step 
approach approach 
59.8 (34.6) 70.6 (34.2) 10.8 16.6 16.9 -4.1 to 38.0 0.11 
f adjusting for stratum 
*adjusting for baseline pain scores and stratum 
These results favour the 2-step approach, showing a greater proportion of days 
with controlled pain in the 2-step approach but there is little statistical evidence to 
support them. The confidence intervals are wide and also consistent with a lesser 
proportion of controlled pain days in the 2-step approach. 
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Table 23: The odds of having controlled pain on any given day in the 2-step 
approach compared to the 3-step approach 
Odds Ratio (OR) for controlled pain on 
any given day on 2-step approach 
compared to 3-step approach 
Crude Adjusted- Fully adjusted* Fully adjusted 
OR OR OR 95% CI* 
Fully adjusted 
p value* 
1.7 3.3 2.7 0.7 to 10.5 0.15 
t adjusting for stratum 
*adjusting for baseline pain scores and stratum 
The fully adjusted model favoured the 2-step approach but there was little 
statistical evidence to support this finding and the confidence intervals were 
consistent with both a beneficial and detrimental effect of the 2-step approach. 
The effect of funder was also important when added to the regression models, 
showing a magnitude of effect of similar order to that of treatment (OR = 2.2; 
95% C. I. 0.5 to 8.9, p=0.29). 
3.3.6.1 Imputations for missing data 
Repeating the analyses with imputations for missing data did not alter the results 
for the primary outcome measures (data not shown). 
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3.3.6.2 Weighting according to the amount of data provided by each patient 
The difference in the proportion of days with controlled pain did not alter 
significantly when the data were weighted according to the methods described in 
the previous chapter, although the confidence intervals were narrower (difference 
in proportions, fully adjusted model = 18.7, C. I. -1.2 to 38.6; p=0.065). 
3.3.7 Secondary analyses 
3.3.7.1 Mean pain scores during the study period 
The overall mean pain score in participants randomised to the 3-step approach was 
4.0 (SD 1.9) and was 3.4 (SD 2.1) in the 2-step approach (Table 24). The fully 
adjusted difference indicates a lower mean pain score of 1.0 points in the 2-step 
approach. Whilst the 95% confidence interval is wide and includes the null, it is 
consistent with the possibility of a clinically significant lower mean pain score (- 
2.1) and excludes a clinically significant deleterious effect. 
Table 24: Mean pain scores for the first 28 days for the 2-step approach compared to 
3-step approach 
Mean daily pain 
score in first 28 
days (SD) 
3-step 2-step Unadjusted Adjusted Fully Fully Fully 
difference difference- adjusted* adjusted adjusted p 
difference 95% CI value 
4.0 3.4 -0.6 -0.9 -1.0 -2.1 to 0.1 0.07 
(1.9) (2.1) 
f adjusting for stratum 
*adjusting for baseline pain scores and stratum 
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The fully adjusted difference in mean pain scores did not alter when the regression 
coefficient was weighted for amount of data provided (i. e. number of days pain 
data were provided) by each patient (fully adjusted weighted mean difference =- 
1.2; 95% Cl = -2.2 to -0.2, p=0.02). 
3.3.7.2 Interaction by source of funding 
The difference in mean proportion of days with a score of <4 was 3.2 for the two- 
step minus the 3-step approach in the NAPP study, and was 24.2 in the CRUK 
study (i. e. a crude difference in effect-size between the two funding sources of 
21.0 [= 24.2-3.2]) (Table25). The difference in effect size observed in the CRUK 
funded study minus the NAPP study, adjusted for baseline pain score, was only 
8.0 (95% CI = -32.3 to 48.2) and there was no statistical evidence of interaction 
by 
source of funding (p for interaction = 0.69). The statistical power of the test for 
interaction is low, however, and must be interpreted with caution. 
Table 25: The proportion of time spent in the first 28 days of the study with a 
pain score of 4 or less by source of funding 
Source of Treatment Mean proportion of days Difference in mean 
funding with score of <_ 4 (SD) proportion of days with 
a score of <4 
NAPP 3-step 53.6 (30.9) 3.2 
2-step 56.8 (40.0) 
CRUK 3-step 63.7 (37.7) 24.2 
2-step 87.9 (13.5) 
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3.3.7.3 Time to stable pain control 
There was evidence that stable pain control was achieved more quickly in the 2- 
step approach (mean 7.1 days SD = 8.7) compared to the 3-step approach (mean 
10.8 days SD 9.8). This is demonstrated in the Kaplan-Meier curve below (Figure 
8). 
Figure 8: Kaplan Meier survival estimates by 2-step vs. 3-step approach 
0 
Proportion 






Kaplan-Meier survival estimates, by treatment 
I treatment =3 step treatment =2 step 
82.4% of patients in the 2-step approach achieved stable pain control compared to 
64.7% in the 3-step approach. However, the p value of 0.24 (derived from the chi- 
square statistic from a two by two table) was consistent with there being no 
difference between the 2 groups. In a Cox proportional hazards model (Table 26), 
the fully adjusted hazard of achieving stable pain control was 100% greater (95% 
CI = -20% to 360%) using the two-step versus the three-step approach. The p- 
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0 10 Days 20 30 
value provides only weak evidence, however, in support of this finding (Cox 
survival analysis p value = 0.12), which must therefore be interpreted with 
caution. 
Table 26: Hazard of achieving stable pain control on 2-step approach vs. 3- 
step approach 
Hazard ratio for achieving stable pain 
control on 2-step vs. 3-step approach 
Crude Adjusted ratio* Adjusted 95% Adjusted p- 
ratio CI* value* 
1.7 2.0 0.8 to 4.6 0.12 
'adjusting for baseline pain scores and stratum 
The graph below (Figure 9) demonstrates that Cox's hazards are proportional 
throughout the study, indicating that the key assumption of this method of survival 
analysis ("the proportional hazards assumption") is met. 
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Figure 9: Nelson Aalen estimates by 2-step vs. 3-step approach 




3.3.7.4 Brief Pain Inventory Scores 
All mean BPI scores at weeks 2 and 4 were averaged in order to compare the 
scores in the two approaches. All of these mean pain scores were less on the 2- 
step approach (tables 27-31 and figures 10-13). 
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0 10 Analysis time 
20 30 
treatment =3 step treatment =2 step 
Table 27: Mean BPI Least Pain Scores 
Mean BPI least pain score (SD) 
3-step 2-step 
Day 0 2.8 (2.8) 3.1 (2.5) 
Week2 2.3 (2.6) 2.0 (3.1) 
Week 4 2.1 (2.2) 0.9(l. 7) 
Figure 10: Mean BPI Least pain scores over time in the 2-step approach 
compared to the 3-step approach 





2 -Treatment = 3-step 




Day 0 Week 2 Week 4 
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Table 28: Mean BPI Worst Pain Scores 
Mean BPI worst pain score (SD) 
3-step 2-step 
Day 0 6.4 (2.6) 7.3(l. 5) 
Week2 4.8 (2.6) 3.6 (2.6) 
Week 4 3.8 (2.8) 2.1 (3.0) 
Figure 11: Mean BPI Worst pain scores over time in the 2-step approach 
compared to the 3-step approach 







to -Treatment = 3-step ö4 Treatment = 2-step 






Day 0 Week 2 Week 4 
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Table 29: Mean BPI Average Pain Scores 
Mean BPI average pain score (SD) 
3-step 2step 
Day 0 4.8 (2.0) 5.2 (2.2) 
Week2 3.8 (2.6) 2.9 (2.6) 
Week 4 2.8 (2.4) 1.7(2.0) 
Figure 12: Mean BPI Average pain scores over time in the 2-step approach 
compared to the 3-step approach 





-Treatment = 3-step 






Day 0 Week 2 Week 4 
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Table 30: Mean BPI Pain Now Scores 
Mean BPI pain now score (SD) 
3-step 2-step 
--------- - Day 0 4.6 (3.2) 3.6 (2.4) 
Week2 2.6 (2.9) 2.0 (2.9) 
Week 4 2.7 (2.9) 0.9(l. 5) 
Figure 13: Mean BPI pain Now scores over time in the 2-step approach 
compared to the 3-step approach 





Treatment = 3-step 3 







Day 0 Week 2 Week 4 
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Table 31: Differences in mean BPI scores comparing the 2-step vs. the 3-step 
approach 
Unadjusted Adjusted* Adjusted Adjusted p 
difference in difference in 95% CI value 
mean score mean score 
BPI pain -1.4 -2.3 -3.8 to -0.8 0.003 
worst 
BPI pain least -0.7 -1.1 -2.4 to 0.2 0.08 
BPI pain -1.0 -1.4 -2.7 to -0.2 0.03 
average 
BPI pain now -1.1 -1.5 -3.0 to 0.1 0.06 
BPI overall -0.9 -0.9 -2.9 to 1.1 0.4 
interference 
score 
* adjusted for baseline BPI scores and centre 
There was strong evidence in favour of the 2-step approach for the mean BPI pain 
worst scores (p = 0.003), the mean BPI pain least (p = 0.08), the mean BPI pain 
now (0.06) and the mean BPI on average score (p = 0.03). 
3.3.7.5 Adherence to medication 
There was a difference in adherence rates between the two approaches, in that 
analgesics were taken on 99.8% of days in the 2-step approach compared to 
89.7% of days in the 3-step approach (Table 32). This difference was not 
statistically significant however. 
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Table 32: % adherence to medication in the 2-step vs. 3-step approach 
Adherence to 
medication (SD) 
3-step 2-step Difference Adjusted* Adjusted Adjusted 
difference 95% CI p value 
89.7 (25.0) 99.8 (0.01) 10.1 8.2 -4.7 to 21.3 0.21 
*adjusted for baseline pain score and centre 
3.3.7.6 Use of escape medication 
The use of escape medication also varied between the approaches, with the crude 
difference showing a greater use of escape medication in the 2-step approach. 
However, when this difference was adjusted for baseline pain score and centre, 
there was a lesser use of escape medication in the 2-step approach. The confidence 
intervals were wide and consistent with no difference between the approaches 
(Table 33). 
Table 33: Use of escape medication in the 2-step vs. the 3-step approach 
Use of escape 
medicationt (SD) 
3-step 2-step Difference Adjusted* Adjusted Adjusted p 
difference 95% CI value 
0.43 (0.51) 0.54 (0.53) 0.11 -0.03 -0.34 to 0.3 0.85 
* adjusted for baseline pain score and centre 
t use of escape medication calculated by number of doses used divided by number of days data 
provided 
142 
3.3.8 Effect of adherence on the primary outcome measure 
In light of the higher adherence in the 2-step approach, the primary analyses were 
repeated, with adherence added as an additional covariant in the model. This 
allowed us to examine the effect of treatment on the percentage of time spent in 
controlled pain in the first 28 days or the odds of having controlled pain on any 
given day, independent of adherence. The 2-step approach resulted in mean 
difference of 17.6 percentage points (95% CI -4.4 to 39.6; p=0.11) a result 
similar to that obtained before adjusting for adherence. The odds of having 
controlled pain on any given day after adjusting for adherence were 2.74 (95% CI 
0.7 to 11.3; p=0.16) again similar to the results obtained previously. 
3.3.9 Adverse Events 
Overall the adverse event rate was low, so descriptive statistics only are shown 
below (Table 34). 
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Table 34: Adverse events in both approaches 
2-step approach (n = 19) 3-step approach (n = 19) 
Mean (SD) Range Mean (SD) Range 
Total adverse 2.5 (2.4) 0-9 2.1 (2.3) 0-9 
events 
Severe adverse 0.9 (1.0) 0-3 0.4 (0.6) 0-2 
events 
Severe adverse 0.3 (0.8) 0-3 0.05 (0.23) 0-1 
events related to 
study drugs 
3.3.10 Estimates of required sample sizes for definitive trial 
comparing a novel 2-step vs. the traditional 3-step approach 
Using the standard deviations of the proportion of time spent with a pain score of 
<4 in both arms of the pilot study, we have estimated the sample sizes required 
for a definitive study, using a minimum clinically important difference of 10% 
and a maximum likely difference of 25%. Two calculations have been conducted 
in order to define sample size for studies with 80% and 90% power to detect a 
difference (Table 35). 
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Table 35: Sample sizes required for a definitive study with both 80% and 







Power a Required 
sample size in 
each arm 
Mean % of Minimum 80% 0.05 186 
days with a 10% 90% 0.05 249 
pain score of Intermediate 15% 80% 0.05 83 
<4 (SD) 90% 0.05 111 
Maximum 80% 0.05 30 
25% 90% 0.05 40 
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3.4 A qualitative study to explore the views of patients 
considering morphine for relief of pain caused by cancer 
The following chapter describes the results from the qualitative component of the 
2-step trial. The characteristics of those interviewed will be described, including 
information about their primary cancer and its changing status at the time of 
recruitment, whether or not they had had previous contact with palliative care 
teams and the type of analgesic used at the time of the interview. The patients' 
own descriptions of the nature and impact of pain on their lives will follow, so that 
the description of the emergent themes can be read in the context of their pain 
experiences. The conformity of the interviews will be discussed as well as the way 
in which deviant case analysis validated the themes. Finally, the observed 
relationship between these themes will be explained and a model of the use of 
morphine and other Step III opioids in cancer pain proposed, informed by data 
gathered during both the 2-step trial and the interviews. 
3.4.1 Characteristics of the participants 
The eighteen participants ranged in age from 55 to 82 years. Nine were women. 
All of the participants lived with another person, usually a spouse, except one of 
the women who lived alone. Of the nine male participants, seven had advanced 
cancer of the prostate, one had cancer of the lung and one a cholangiocarcinoma. 
Four of the women had cancer of the breast, two had lung cancer, one a rare form 
of sarcoma and one cancer of the ovary. All of the participants had metastatic 
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disease. At the time of entry to the 2-step trial, three participants had received 
visits from a community palliative care nurse, but the others had not been 
introduced to palliative care teams. This was because they had previously been 
receiving life-prolonging treatment and so had not been thought to have required 
palliative care. Generally, their entry to the study was associated with either new 
evidence of disease progression, a new complication related to their cancer or the 
cessation of chemotherapy. These circumstances are significant in a patient's life, 
and often lead to a change in the focus of treatment from life-prolonging treatment 
to palliative care. 
The pseudonym, sex and age and analgesics at time of interview for each of the 
participants are detailed in Table 36. 
At the start of the interviews, all of the participants were asked to tell me about 
their pain, which was difficult for two of them. One could not because the 
interview was rushed since she very nervous about missing an oncology 
appointment. The other respondent had experienced a resolution of her pain since 
a change in chemotherapy and so did not have any pain at the time of the 
interview. The remaining 16 participants described how they had been struggling 
with pain and the pain experience, similar in all, seemed to be unrelated to the 
nature or cause of the pain. 
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Table 36: Characteristics of participants recruited to the interview study 
Entered 2-step trial 
Pseudonym Age Diagnosis Analgesics at time of interview 
Rupert 63 Ca prostate 
Regular cocodamol plus "as 
required morphine 
Patricia 68 Ca breast Oxycodone 
Andrew 80 Ca prostate Oxycodone 
Betty 69 Sarcoma Oxycodone 
Regular modified-release 
Jim 82 Ca prostate 
morphine 
Mary 58 Ca breast Paracetamol 
Paracetamol plus "as required" 
Vanessa 62 Ca breast 
morphine 
Tom 67 Ca prostate Oxycodone 
Karen 55 Ca breast Oxycodone 
Andy 57 Ca prostate Regular modified-release 
morphine 
Daisy 77 Ca lung Paracetamol plus "as required" 
morphine 
Gloria 66 Ca breast Cocodamol 
Did not enter 2-step trial 
Harvey 58 Ca prostate Regular normal-release morphine 
Ruth 62 Ca lung Regular co-codamol plus "as 
required morphine 
Henry 69 Ca prostate Cocodamol 
Joseph 69 Ca prostate Ibuprofen "as required" 
Philip 68 Cholangiocarcinoma Morphine "as required" 
Margaret 68 Ca ovary Nil 
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3.4.2 The impact of pain on the lives of the participants 
Pain resulted in reduced mobility (7/18 respondents) and functioning (11/18), at 
times causing the respondents to give up their jobs (2/18), driving (2/18) or other 
activities (6/18). When describing how the pain had limited his walking ability, 
Andrew said: 
I think the worst bit of it was when um ... when we went into Bristol to do 
some shopping, and I had to walk about 300 yards to the shops because I 
was out buying a new jacket, and I hadn't experienced pain like that for a 
long time. It was um - it took about quarter of an hour to get to the shop, I 
could only walk about 10 yards at a time. 
Ruth described how the limitation to her mobility was affecting her efforts to 
recuperate following chemotherapy. 
Well it's very demoralising.... Because, you know, I find um I have to lie 
down or um - and then I get it when I'm walking. . . and 
it comes on - 
sometimes it comes on when I'm walking, so I can't walk.... So it's - yeah 
and that annoys me when I want to be fit, you know.... So I find it's difficult 
in-between not overdoing it, and doing it. 
Mary describes a feature that was common to many of the participants, which was 
that the pain could affect all areas of life, simply by "slowing" her. 
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Um I'm a lot slower than I was... I mean obviously I don't -I mean I used to 
rush around here, there and everywhere, but now I've slowed down ... I think 
before I do things.. .1 don't do a lot of things that I used to do. 
Pain also led to difficulty sleeping (5/18) and a feeling of being out of control 
(2/18). One respondent described "unbearable" intermittent pain that made 
breathing difficult. Jim described how when he was in pain, he could not 
concentrate and how this resolved when he had used his painkillers and they had 
relieved the pain. Eight of the sixteen respondents described themselves as being 
depressed, miserable or low in mood as a result of their pain. Patricia seemed to 
believe that this change in mood affected her ability to "fight" the cancer when 
she said: 
And I think finally, um at the point where I met with you, I had then started 
to feel very low, very depressed, and I felt that I was losing the fight because 
I could not - all of a sudden the pain, I think, had finally got to me. 
Four of the respondents described the impact of suffering pain on their family life 
and how their families, observing them in pain, treated them differently. Harvey 
and Tom talked about the impact of uncontrolled pain on their wives and Gloria 
described how the pain affected her relationship with her husband. 
Yes it does affect my moods, yes. If it does come in the daytime, which it 
was before I was taking a lot of tablets, yes I was very nasty sometimes to 
my poor husband - he'll tell you. 
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Three participants talked about being unable to spend time with their 
grandchildren because of pain, including Patricia who said: 
When my grandson was here, or if I was going to them, I couldn't nurse him 
or play the usual things. Because the sternum, my sternum, the agony would 
last for something like two days. 
Perhaps because of the physical and social impact that the pain had wrought on 
these people's lives, they described it as a difficult symptom to deal with 
emotionally. Patricia talked about the pain being her biggest challenge, secondary 
even to dealing with either chemotherapy or her mastectomy. Jim told how he felt 
that he was being singled out to suffer and when experiencing pain would 
question why. 
It seemed that both the physical, emotional and social consequences of pain could 
be construed as loss for the participants. For some, reduced mobility or inability to 
drive resulted in a loss of independence. For some, their roles were threatened 
when they became unable to do household chores or other activities such as 
gardening. Others experienced a loss of self when treated differently by their 
families when they were in pain. Patricia seemed to sum up these losses when she 
said: 
But I just feel I've been robbed. 
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3.4.3 Emergent themes 
After analysis of all the interviews, the themes from the transcripts were identified 
within four major analytical categories. These were: 
" Anticipation of death 
0 Morphine as a last resort 
0 Role of the professional 
0 "I haven't got any choice" but to use morphine 
The subsequent part of this chapter will describe the themes within these 
categories and illustrate their meaning using the participants' own words. 
3.4.4 "You've got cancer, you're going to die": Anticipation of 
death 
One of the most striking themes to arise from the interviews was the extent to 
which the development or presence of pain related to cancer caused the 
participants to consider the extent of their disease. Contemplation of anticipated 
death then followed. This may have been in part explained by the frequent 
response of the oncologists when new pain was reported, which was to request 
further investigations to look for evidence of disease spread. For some, the 
original diagnosis of cancer or the news of its recurrence had been the result of 
investigations for pain, strengthening the association between pain and severity of 
disease. The anticipation of death also seemed to be aggravated by news of more 
extensive disease, or the change in goals of care (from life-prolonging treatments 
to a focus on quality and comfort) that many of the participants had experienced in 
the weeks preceding study entry. 
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For some, the presence of pain made them question whether or not their disease 
was more widespread than their doctors were aware. A few participants actually 
distrusted information they had been given by their oncologist about the extent of 
their disease. Mary was a bit hesitant to reveal this, as demonstrated by the pauses 
during the relevant part of the conversation. 
INTERVIEWER: And so as the pain has become a feature of the cancer, 
and as it has got worse, what are your thoughts then, what are you thinking 
then? 
MARY: I think that obviously the um cancer has got worse than it was.... 
But um they tell me no, but (pause) 
INTERVIEWER: Go on. 
MARY: What they tell you and what actually is happening is - can be 
sometimes two different things. I mean I think they tell you what you want 
to know. 
Not only the presence of pain, but also the need to take analgesics made several 
participants anxious that their anticipated death would be hastened. Tom clearly 
highlighted this fear when he said: 
Um I'd had a hard job to accept I'm going to die.... It's not easy for 
me... um because I still -I feel that there is something somewhere, you 
know, people do beat it, and I feel I can. But the more the painkillers have 
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to be increased, the kind of more it drags you down a bit, and you can see 
that the future is going to be harder, and you have to fight that much more. 
Generally the psychological impact of unrelieved or worsening pain was negative, 
because of its association with disease progression and death. As Mary said: 
The pain is niggling, and then it keeps reminding me, "You've got cancer, 
you're going to die. " 
3.4.5 "Surely I can't be that bad? ": Morphine as a last resort 
The overwhelming concern that the participants had about morphine was that it 
was a drug that was used when a person with cancer was thought to be imminently 
dying. The word used most commonly by the participants to describe this was 
"last"; either last resort (used most frequently), last minute, last stage (of the 
cancer), last ditch or last step. Because of this, some of the participants 
commented that they had been frightened at the first consultation when a drug 
described as being similar to morphine was considered a possibility for their pain. 
Margaret described her initial emotion as being one of fear when morphine was 
mentioned. 
Um well it did, in that it made me fearful. Because um I, rightly or wrongly, 
always associate morphine with the sort of top end of the scale of 
intervention, meaning the sort of the last resort almost. 
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Betty described a similar reaction and also made the link between cancer and 
death. 
Quite a reaction actually, because I've always um associated it with people 
really ill with cancer, and near the end of their life. 
Mary described how she saw morphine and death being linked. 
So morphine and pain and death, it's all in one to me. 
Vanessa spoke of how she thought that using morphine would mean that she was 
dying. 
No, but when you get to morphine you think the end is nigh, you know? 
Because morphine was seen by all the participants as a drug that was used when 
someone with cancer was thought to be dying, several said they considered using 
morphine meant that they were accepting that they were dying. Patricia described 
how she could not accept she was ill enough to need morphine. 
I'm not ready to take on the next step of the path of my, of the path of my 
life. You know, um I-I very much sometimes look at myself when I've 
got no pain, and I know that I look fine, and think they've got it wrong. 
Ruth also could not accept that she was ill enough to require morphine and when 
trying to explain why she was reluctant to use extra doses said: 
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Surely I can't be that bad? 
Three participants had refused the drug when it had been offered initially, as a 
means of trying to postpone death. Mary described her conversation with her 
oncologist when initially offered morphine. 
Well I said to him [her oncologist] then, "I won't take it. " And he said, 
"Why? " And I said, "Because I've got a thing about morphine. " And then 
he said, "Why? " And I said, "Because I think it's the last - the last stage of 
the cancer. When you have morphine. " 
Ruth tried to explain why she was reluctant to use "as required" doses of 
morphine, even though she had found it useful for her pain. 
Um no I-I think -I think I've more or less accepted now that it's. I think 
it's more to do with the fact that if I take quite a lot of this morphine then I- 
it just means I'm getting worse. And I don't want to get worse. Well I mean 
I know I'm going to get worse (laughs) but um it's a sort of puritanical thing 
you know. 
Gloria also spoke of morphine meaning progression of disease and death, because 
of her perception that the aim of treatment had altered to providing symptom relief 
but not modifying the cancer. 
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But as soon as I have to take morphine, I know it's coming closer to not 
being treatable, because all you want to do is just stop the pain, not treat the 
problem. 
She went on to confirm that using morphine would mean she had accepted her 
death as inevitable. 
GLORIA I'm 67 but I'm too young, I've got another - give me another ten 
years and I'll take the morphine if you like (laughs) 
INTERVIEWER: (laughs) Right. And if you were to use the morphine, 
would you feel you were then accepting that you might be dying? 
GLORIA: The inevitable yes. 
Those who had commenced morphine worried that others would interpret this as 
bad news. Mary had not been able to tell her children. 
But I did worry that um my children - certainly my daughter, my eldest 
daughter - might think if I'm on morphine that I am worse than I actually 
am.... Because that, to us, was the last minute drug. 
Ruth also spoke of her anxiety at informing her daughter that she had needed to 
use morphine because of the message she thought it might convey. 
It's like everything else has failed. 
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This final quote from Philip about the perception of morphine sums up what the 
other participants were saying. Morphine is seen to represent a terminal prognosis 
by patients and their families. It seemed as if the commencement of morphine 
represented a symbol for the commencement of the dying process. 
Yeah it does have this sort of reputation with morphine - oh it's almost sort 
of an explanation as to how bad things are. That if someone says they're on 
morphine you sort of - as a lay person - almost understand that he's not near 
the end, but he's not far away. And it's almost a painkiller which is used 
because it doesn't matter. It's going to clear the pain up, but you're sort of 
not going to be here in a year's time so if you get addicted it doesn't matter. 
It's there to give them a peaceful end. 
One of the participants, Andy, did not discuss associating morphine with death at 
all during the interview. However, once the microphone was switched off his wife 
mentioned that when she had gone to collect his first ever prescription of 
morphine, the pharmacist had personally handed her the tablets (which was not 
their normal practice) greeting her with the words "is he worse then? " During the 
subsequent discussion off-tape, Andy said that he had been very anxious when 
first offered morphine because he, like other participants, associated it with dying. 
This was difficult for him to articulate and he began to cry. He said the following 
words, which he was happy for me to quote: 
The three words that strike the fear of God into your average working class 
bloke are `morphine', `palliative' and `hospice'. 
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The association of morphine as a last resort was either informed or strengthened 
by the perceptions of both its side effects and the manner in which it is used. 
Whilst a knowledge of side effects came from some people's personal experience, 
the majority of the participants' knowledge came from hearing stories about or 
witnessing others, usually relatives or friends, who had taken morphine. 
3.4.5.1 "The morphine trail": Morphine in increasing doses 
Many of the participants described the way in which they considered morphine 
was given to people with cancer who were thought to be dying. They described 
increasing doses being given, not because of lack of effect, but as an inevitable 
consequence of having commenced morphine. Harvey called this "the morphine 
trail" and anticipated that he would require increasing doses when he said: 
And so I reckon I'm on the morphine trail and I'll just have to keep on 
increasing the dose. 
Karen also felt that dose increments were inevitable. 
Well I know they said it was a low form of morphine, but you always hear 
that when people are really in pain you give them morphine. Obviously I 
believe that morphine is probably the strongest painkiller, and obviously all 
they can do is keep piling the dose up. 
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Some developed this further; implying that morphine became the cause of death in 
patients because of the unavoidable dose increments. Jane had memories of her 
father's death. 
Well she [the research nurse] said I made a face. And I said, "Well it's 
because I associate it with death basically. " I remember my father who was 
on more and more morphine until he died. 
Betty also had memories of the use of morphine when her close relatives were 
dying. 
And um a bad experience that my father died of cancer, and father-in-law, 
and neighbour, and I used to see them having more and more, upping their 
dosage of morphine.... And come the end they just had it injected into 
them. 
Whilst recalling her memories of this time, she seemed to feel that her father-in- 
law had deteriorated quickly once he had commenced morphine, and when asked 
if she thought the morphine had caused his death, she agreed, as demonstrated in 
the following text. 
BETTY: Oh yeah, oh gosh yeah, yeah. Because um when he went in he didn't 
seem too bad actually when he was taken in, but within a few days 
INTERVIEWER: he'd died? 
BETTY: he'd died yeah. 
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INTERVIEWER: Right, and am I right that part of you felt that that was because 
of his morphine being increased? 
BETTY: Yeah, but then when you look at it there is so much pain anyway, 
nothing else could be done for them, and they were both in their eighties. 
Betty was not alone. However, those who discussed the use of morphine in 
increasing doses and its apparent hastening of death did not appear to judge it 
negatively or deem it unethical. Instead they described a tension between life and 
freedom from pain, and that the freedom from pain therefore justified the 
perceived shortening of life, as when Joseph states: 
It's a fine line, isn't it? 
It was interesting that it was also Joseph who was the only participant to associate 
morphine with malicious illegal killing. Although he discussed the tension 
between freedom from pain and pain relief when morphine was used at the end of 
life, he seemed to be talking about a different practice altogether when he said: 
Yes um I suppose it's only because um you have the feeling, and I don't 
really know why, but um you have the feeling it's er not a very nice drug, 
it's often used if someone is in er severe pain, or terminal, or something like 
that. ... Um somewhere in the back of my mind I tend to feel that doctors 
don't know what the correct dose of morphine is anyway. Er I may be 
wrong about that, but I have, in the back of my mind I have that feeling - 
and they just go on giving it, shall we say.... But if someone's terminal, 
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well you do of course hear of occasions when it's used um - what shall we 
say? - when um - in crime, in crime, shall we say. ... Morphine is used to 
dispose of someone. (laughs) Um you do hear about that. 
The perception that morphine is given in life-threatening doses seemed to further 
reinforce the belief that morphine was used only when someone was dying. It was 
as if the price to be paid for pain relief from morphine was so high, it would only 
be worth considering if death was likely to be soon, as the following words from 
Philip show: 
My association is that you're getting near the end when you're on morphine, 
and therefore you want a painkiller which is going to knock out the pain, 
you're not really bothered about anything else, you just want to actually get 
rid of the pain. And if they go a bit gaga well what can you expect, it's 
either-or. Either-or, you know, you're either not bad enough or you are bad 
enough, if you see what I mean. 
3.4.5.2 "Seeing them dying": Origins of the associations 
For most (11) of these participants, their associations with morphine were linked 
to previous experiences with relatives, usually older family members, at the time 
of their deaths. When asked where his associations with morphine came from, 
Tom said: 
All the information that I've got in my head has come from watching them, 
hearing about them and seeing them dying. 
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Participants carried memories, often from many years previously, of conversations 
with professionals about increasing doses of morphine or of seeing loved ones 
hallucinating or confused as a consequence of morphine. Vanessa remembered 
witnessing her grandmother hallucinate with morphine when she was a small 
child. 
Um it's strange how things stick in your mind, because I was only just four I 
think. And I went upstairs, and she [her grandmother] said, "There's a lady 
under the big floor. " And I've never forgotten that. And I came down and 
told my mother and my aunt, and they said, "She's delirious, it's the 
morphine. " 
Some like Ruth were even told by professionals that morphine, although being 
used as a comfort measure, was perhaps hastening death. 
No - well except of course it puts people out of their misery, I mean I was 
only too thankful. In fact when my father was dying we were asked if they 
could increase the dose although it probably would kill him. And we said 
yes. I mean we didn't want to put him through ... he was dying, and so we 
said yes, and of course they did. So for him I was only too thankful. 
One of the participants described how, 30 years previously, she had been given 
some morphine tablets for her father who had been dying of cancer. He had 
suffered uncontrolled pain as a consequence of his cancer, but was only given 
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morphine in his final hours. The tablets had been left for her to administer because 
she was a nursing student. Her father had died two hours after the first tablet had 
been given, leaving her with the belief that she had "just finished him off'. This 
experience was reinforced by practice that she witnessed as a nursing auxiliary in 
elderly care wards in hospitals, where syringe drivers containing morphine would 
be commenced routinely when someone was thought to be dying. 
Others mentioned conversations with friends and families or hearsay as the source 
of their associations. Mary remembered a conversation with the husband of her 
friend who had died recently, suggesting that her death would be soon because 
morphine had been commenced. 
No, they only went on morphine -I mean my friend that died of a brain 
tumour, her husband phoned up and said, "Oh she's being injected with 
morphine now, if you want to come and see her you'd better come and see 
her". 
Some also described the media as displaying negative images of morphine as a 
consequence of reporting news of drug addiction or reinforcing ideas of morphine 
as an end-of-life drug in fiction. Joseph could not remember any personal 
experience of seeing morphine used and could only cite the media (newspapers, 
television and radio) as sources of information when he said: 
No I think it's only what's built up through the years, possibly through the 
media, I would have thought. 
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3.4.5.3 Other associations with morphine 
Six of the participants with previous experience of opioids mentioned side effects 
as an association. Mary remembered previous painkillers causing constipation and 
making her feel more unwell than she did already. When asked if she felt 
comfortable using painkillers regularly she said that she had to use them in order 
to be able to get on with her life but that she didn't like taking painkillers. When 
asked to explain this she replied: 
Well I just - basically I just don't like taking tablets. I mean I just don't um 
-I am a bit scared of taking new tablets, messing up my stomach like, you 
know, making me constipated, making me ill, bad. 
Vanessa, who had witnessed her grandmother hallucinate with morphine had 
herself experienced hallucinations with morphine. When describing how 
morphine brought all her fears to the surface, which seemed to be its 
psychological impact on her, she immediately went on to explain her 
hallucinations, which she described as a "bad effect". 
INTERVIEWER: I was wondering if the morphine being offered as the 
treatment, to some extent reinforces what the pain makes you feel? 
RESPONDENT: Um frightened, yeah it does, yeah... it brings all my fears 
to the surface.... Yeah and also it actually has the bad effect on me that I 
hallucinate quite easily.... In the day um particularly, I can't explain it 
terribly well, but if I take it during the day, you know, it's a low dose sort of 
thing, I will doze, but it's not an ordinary doze, I sort of see faces and things. 
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Rupert spoke of his previous experiences of drowsiness and hallucinations when 
he had used morphine several months earlier for his pain caused by his cancer. 
During the trial remained extremely reluctant to consider either "as required" 
morphine or regular modified-release morphine. This was in spite of recording 
high daily pain scores and experiencing marked loss of function and social activity 
because of pain. 
Some of the participants associated morphine with unavoidable sedation. Gloria 
considered it to be deliberate sedation, again without a negative judgement of this 
practice. The intended "slowing" seemed to be considered an act of kindness as 
demonstrated by the following quote, where she says the intent is to "relax you": 
GLORIA: I should imagine they want to slow you down, isn't it, and make 
you tired? 
INTERVIEWER: Are you saying that's a side effect, or are you saying 
that's almost a deliberate effect? 
GLORIA: I think it's a bit of both. 
INTERVIEWER: OK tell me a bit more about that? 
GLORIA: Well because I've - I've sort of seen it. And um as soon as you 
have the morphine - and I also saw my young nephew as well I forgot him - 
as soon as they have the morphine then they're just sleeping all the time. 
INTERVIEWER: Right, but you think some of that is intentional? 
GLORIA: I-I- well I don't know, I can't say I do -I don't know. 
INTERVIEWER: You don't know. 
GLORIA: No. 
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INTERVIEWER: But there's a slight reservation? 
GLORIA: There's a slight reservation thinking that's what it's to do, to 
slow you down, to relax you. 
Again, there was a sense that these side effects were considered inevitable, the 
price that must be paid for pain relief. Gloria, who was trying to remain active in 
order to be able to look after her sick husband, described what she would have 
thought was ahead had she been randomised to oxycodone: 
INTERVIEWER: So if we had given you morphine, or something like it, 
would you have? 
GLORIA: I'd immediately have thought, "That's it, I've got to slow down 
and I can't do all what I want to do. " 
When asked what she would have done if she had been randomised to oxycodone, 
she said that she probably would not have taken it. 
Nine of the participants talked about addiction. Those who had a previous 
smoking habit themselves, or had witnessed their spouse's smoking habit found it 
easier to describe what they meant by addiction, usually in terms of "needing to 
keep taking morphine". Joseph's wife was currently trying to stop smoking and 
when asked what being addicted might mean he replied: 
I would imagine it meant that you, you know, you really had to use it, you 
had to keep on taking it, you know, you felt you had to keep on taking it ... 
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um even perhaps if the pain wasn't that bad, perhaps you would feel that um, 
"Well I'd better have some more, " I would think. 
He did then also comment that addiction might mean being "slowed down" and 
being "not too well". Joseph had mentioned addiction because when he had first 
been prescribed morphine for pain caused by a bone metastasis his surgeon 
seemed worried about it: 
And um I don't think he [the surgeon] was too keen on giving it to me, to be 
honest with you, because to begin with I um was taking three 50 ml, I 
believe, three teaspoons anyway, and he asked me to cut it down to one as 
quickly as I could.... And then he said he wouldn't like to see me on it for 
too long. And then I was taken off of it altogether, and I think, by then, I'd 
had some radiotherapy and some hormone treatment. Um he - he -I think 
he thought I- he might get a reaction from me when he suggested I used it. 
Because um he said, "It's alright, you won't become addicted to it. " So he 
must have thought that most patients thought you could get addicted to it - 
which I believe is correct, of course. But um I wasn't thinking that. 
For others addiction to morphine was more difficult to define and sometimes 
seemed to be confused with being given higher and higher doses. Betty raised 
addiction and drug addicts early in the interview. When asked if she had been 
anxious about becoming addicted, she seemed unable to say clearly what it might 
mean, but perhaps using more and more and therefore feeling weaker and weaker 
with shortened life as a consequence: 
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More and more and ... that would be the end of your life, yeah. 
Andy was asked how he would imagine he might behave if he was addicted to 
morphine and replied that he would see it as a downward spiral. When asked to 
clarify he said: 
Well there's sort of no getting out, once you've started on morphine and 
become addicted to it, it would be a hell of a job to get out of trouble and 
stop taking it - if that makes sense to you. 
When Tom mentioned addiction as an association of morphine, it was not seen to 
be a practical problem since he considered any remaining life would be short. 
Um not so much the addiction.... Because I think I had accepted that if I 
cannot beat this then the addiction um might be there, and it isn't going to 
matter if the road I'm on is one that's going to end, you know, relatively 
shortly. 
Harvey mentioned tolerance because he had read about it in the patient 
information leaflet. 
"Well I've been told that they have to increase the dose. And I always read 
the leaflets that come with the packet.... But it says that you become tolerant 
to it and you'll have to increase the dose" 
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Henry, perhaps because of his role as a city councillor, made the distinction 
between illicit drugs and morphine during the interview, when he said 
No well I've heard nothing negative about morphine. Now if they asked me 
to take cocaine or heroin or something, well then I would have been 
concerned.... But I haven't heard anything er untoward about morphine. 
Margaret did not think addiction to painkillers was the same thing as addiction to 
illicit drugs: 
Yes I think that um one can become addicted, if only if you're using them as 
a crutch, tablets. I mean you can talk about paracetamol, you see people 
who pop pills, paracetamol, aspirin or whatever, just um - and they can't do 
without them for some reason. It's the act of taking the pill, like smoking a 
cigarette, sometimes it's not so much that the pill is going to do them much 
more good, I think one becomes psychologically addicted, not necessarily 
dependent like if, you know, like someone had cocaine, you know, and 
becomes an addict, it's not the same thing. 
3.4.6 Role of the professional 
The role of the professional in pain management was referred to in some way by 
most of the participants. They referred frequently to three main areas: 
communication about pain, communication about opioids (especially the way in 
which they were offered to the participants) and trust in the professional. 
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3.4.6.1 Communication with the professional 
The manner in which consultations were conducted following reports of pain was 
important. The participants expressed a need to have their pain believed even if no 
obvious cause was found and the need for pain to be considered an important topic 
during the consultation. Patricia described how it had been a relief to have the 
research nurse sit down and listen to the story of her pain and resolve to do 
something about it. She felt that previously she had simply been offered various 
analgesics without explanation and that her pain had not been dealt with because 
no cause could be found. It was distressing to hear her say that she had been made 
to feel her pain was not real, as she does in the following words, describing the 
management of her pain at the oncology centre. 
Because they [the oncology team] are just mystified. They don't know what 
I'm saying, they don't understand my pain at all. And therefore it's made 
me feel that I'm not - that I'm lying.. . that makes me feel that I have been 
making a fuss about nothing. And I haven't made a fuss about nothing, I'm 
not like that. 
Andy, who had multiple bone metastases from his advanced prostate carcinoma 
also described similar experiences and he too noted the different reaction he 
perceived when he saw the "pain team" (palliative care team): 
Um yes I think the er - the pain team, they basically knew what I was telling 
them was the genuine article.... Sometimes you go to the doctor and say, 
"Well I'm getting this pain, " and they don't always necessarily tend to 
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believe you.... And the pain for me is real in my left - right knee, whether or 
not I'm imagining it, which I'm sure I'm not, but er it doesn't make any 
sense why I've got the pain. 
Participants also spoke of the need for the professional to be both confident and 
competent when discussing the use of opioids. Philip and his wife described the 
way the palliative care nurse dealt with his pain as being "wonderful". When 
asked to explain why, they spoke of her attitude to them when treating them as 
equals, her confidence in painkillers and her knowledge, as shown in the 
following exchange. 
INTERVIEWER: And how was she [the palliative care nurse] when she 
was discussing that? 
PHILIP: Oh she was very relaxed. It was obviously her field, I mean she 
was obviously well genned up on it, and she was talking to us both about it. 
It was, you know, as far as she was concerned I think it was a matter of 
that's what she's there for. 
This was different to the attitudes and knowledge of other professionals they had 
encountered dealing with his pain. 
Since some of the participants had commenced a Step III opioid by the time of the 
interviews, it was possible to explore what words used during the consultation had 
helped them to accept the prescription. Vanessa, amongst others, said that it had 
been useful to hear that they would be using a low dose of opioids and went on to 
172 
describe how an oncology nurse had persuaded her to use some morphine for the 
pain in her leg, which was later found to be due to a pathological fracture of her 
femur. 
INTERVIEWER: And what was it about the way she [the oncology nurse] 
said that to you? 
VANESSA: Well just that she said, "You are being silly. Dr. Thomas has 
told you that morphine is not dangerous in that sense, and it's a very mild 
dose, and people take it for all sorts of things, not just cancer. " 
Karen also noted that the language used when describing the trial drugs helped 
with her decision to enter: 
Um probably - because it was only a low dose I'm probably quite happy to 
take it. But I think if you would have told me, "We're putting you on this 
drug and there's quite a high dose of morphine in it, " I probably wouldn't 
have done it, I wouldn't have took it. 
When recruiting to the trial, we had been careful to inform potential participants 
that they could leave the trial, or stop trial drugs at any time, without it affecting 
their care, according to Good Clinical Practice guidelines. Betty was one of two 
interview participants who said they had found it reassuring to hear that if 
necessary, because of side effects or other reasons, the opioid could be 
discontinued and that this made the decision to commence the opioids easier. 
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No, no I thought yeah I'd give it a try.... And like um Dr. Sarah said that 
you can come off it, I didn't have to um stay on the trial if I wasn't happy 
with it.... So I thought yes give it a try, and it seems to be working fine. 
3.4.6.2 "It's your choice": Opioids offered as a choice 
Another way in which the language used by the professional influenced the use of 
opioids was in the offering of Step III opioids as a choice for the individual. 
Harvey mentioned the fact that when the morphine was offered to him by nursing 
staff in response to his reporting of pain in a hospital ward, he was told that it was 
his choice to use it or not. 
They actually don't say, "Mr. Smith, would you like to take the morphine? " 
They always say, "It's your choice. " 
He found this difficult, particularly as he had come to believe that he did not have 
a choice. If he wanted to be out of pain, he needed to use the morphine: 
INTERVIEWER: "And in relation to being offered morphine, and being told 
morphine is your choice, what do you think about being offered morphine as 
a choice rather than being...? " 
HARVEY: "Well I realise now that it isn't, I haven't got any choice. " 
The fact that he realised that morphine was necessary for pain control and yet 
offered as a choice, increased his suspicion of opioids and he said: 
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If it is my choice, what are they not telling me? 
Four of the respondents mentioned that when opioids were offered as a choice, 
then they did not use them. When later that choice was removed, they took them. 
In the following text, Karen describes how during the randomisation process, the 
opioids were "chosen for her" and this allowed her to use them. 
INTERVIEWER: Right, do you think it's better to have it offered as just, 
"This is the option"? 
KAREN: Yes I think that's the best way to do it. 
INTERVIEWER: Right, and why do you think that might be the best way? 
KAREN: Um because the choice wasn't up to me. 
INTERVIEWER: OK tell me more. 
KAREN: Um well the choice was, in the end, you know, they offered it and 
said what I was going to have.... And I just - because I chose that envelope, 
or that envelope was chosen for me, and because you said it was a low dose, 
I decided to go for it.... But if I was asked to say go onto morphine or 
something else, I probably - because of what I said at the beginning, I 
probably would have took the other option. 
3.4.6.3 "Advised to take it by the medical service": Trust in the professional 
It was clear that trust in a professional was also an important factor when 
considering whether or not to commence the opioid they offered. This was 
mentioned by eight of the participants. Harvey, who had said how mistrustful he 
was of professionals who offered him morphine as a choice, was eventually 
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persuaded to use it by a night-nurse during an admission to a urology ward. When 
asked why this particular nurse had convinced him to try using morphine, he said: 
Well she was just a human being, you know .... And you realised she had 
great experience.... You know, and she was just er -I mean I knew she was 
a very smart person, and that she knew what she was doing in everything she 
said.. . and you can't say that you know how to build a wall, or you 
know 
how to do this, or you know how to do that, but you get to know by looking, 
by watching and by listening, you get to know the person who is good at 
their job. 
Patricia commenced oxycodone within the 2-step trial having felt "listened to" 
and that the research nurse believed her pain. During the interview she mentioned 
that the first doctor who prescribed her morphine, which she did not use, was a 
general practitioner she did not know well: 
Yes definitely it made me feel, "Oh morphine, well this is something people 
take, you know, when things are really getting much more advanced and 
bad. And, you know, where am I? " You know, um and er I didn't have, at 
that time, any intention of taking it.... Because I felt that at the time he was a 
reasonably - although he'd been in the practice a long time, he was a 
reasonably new doctor to me. 
The importance of trust in the professional varied in degree. The two examples 
above show how trust or confidence in the professional allowed the individuals to 
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make their own decision to commence opioids. Those, such as Jim, who seemed 
to describe strong faith in health professionals, appears to have abdicated the 
responsibility for decision-making to the professional; Jim says: 
No, no I'd think to myself, "Well they're putting me onto something else 
which is a stronger drug to help me. "... And I just accepted that. I mean 
when I go to any doctor - well most doctors anyway - um ... I always go 
in 
there with the idea that um they know what they're doing. 
This trust allowed him to accept morphine, even though he had had negative 
information about morphine from other sources, as shown when he said: 
I mean over the years I've heard about it with all sorts of things. But um it 
didn't worry me because I was being advised to take it by the medical 
service. 
3.4.7 "I haven't got any choice" but to use morphine: factors 
influencing the decision to commence an opioid 
The majority of the participants had been prepared to enter the 2-step trial and so 
accept the possibility of randomisation to a Step III opioid. However, at least one 
of the 2-step trial participants said she would not have taken the oxycontin had she 
been randomised to the experimental arm. Eight of the participants had already 
commenced a regular opioid for moderate to severe pain by the time of the 
interview but we also witnessed several participants either resist our attempts to 
commence them on regular morphine during the trial or decide not to use extra 
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doses of "as required" morphine when experiencing poor pain control. This gave 
us an opportunity to explore the factors influencing the decision to commence 
opioids within the interviews. Some of the participants had been offered morphine 
previously and made references to these episodes, allowing us to gain more 
information about their decision-making. The role of the professional in this 
decision has been highlighted already. Other factors which seemed to influence 
the decision to commence regular opioids or indeed to take doses of "as required" 
medication included: 
9 concern about the effect of unrelieved pain on others 
" the severity of the pain 
3.4.7.1 Concern for others 
Those participants who described a lot of contact with their family, particularly 
with extended family such as grandchildren, were aware that others were 
distressed by witnessing their pain and some of their decisions were influenced by 
the wish to avoid this. Andy was very closely involved in the lives of his family 
all of whom lived nearby and he and his wife provided childcare for many of their 
grandchildren. He had initially felt very strongly that commencing Step III opioids 
was a negative step and was desperate to avoid using them, but in the following 
words described how his role in his family meant he took extra doses to relieve his 
pain. 
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I had to do something, although everything in me was saying, "No, no, 
no.... " But I realised I had to do it. I'm a father, I'm a granddad, I had to do 
something. 
He also spoke of the way in which his pain had an impact on his wife and how this 
affected his decisions: 
But at the end of the day I know - you know, my wife is having to live here 
with me, and if I am in pain, or ache like that, she's suffering as well.... So I 
take it.... So some of this I am doing for my family. 
Harvey also had noted the impact of his pain on his wife. He said that he had 
found the morphine to be beneficial for his pain, so accepted that he would need to 
keep using it in order that his wife did not need to witness his suffering, when he 
said: 
You see, because I've known what I'm like when the pains come back, life 
is so intolerable that I haven't got any choice, and I've had to find that out 
myself. 
When asked about influences on his decisions about painkillers, Rupert also talked 
of how improvements in his pain control would have benefits for all of his family: 
179 
So anything I do has obviously got to relate to them. So if I can make my 
life better, and it reflects on how I am with them, fine, I'll go with anything 
that -I think will benefit all of us. 
3.4.7.2 Severity of the pain 
Most of the participants mentioned that pain would have to be, or had been, severe 
before they would contemplate using morphine or other Step III opioids. 
I didn't really give it a thought. My main thought was for any sort of drug 
that would get rid of this bloody pain -I would have accepted anything. 
(laughs) (Andrew) 
Um I think at that stage I was so desperate with the pain I would have done 
anything. (Vanessa) 
I think the only difference is, then I was in severe pain and I was glad to get 
the pain relieved. (Joseph) 
I suppose it's if you're in pain you'll take anything that will make the pain 
go away ... To be honest I couldn't care less, 
if it stopped the pain. (Philip) 
It was as if severe pain then gave them permission to take opioids, or perhaps 
severe pain meant the benefits would outweigh the potential harms. Some of the 
participants mentioned they did not know how severe their pain was in 
comparison to others. This was important because their decision to commence 
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Step III opioids was being based on pain severity rather than an understanding of 
the analgesic ladder or a step-wise approach to pain management. Some 
questioned how they would know if their pain had become severe enough to merit 
opioids, although the majority described that their pain would have to be extreme 
before they would consider them, as demonstrated when Gloria says: 
I would have if like... like I said, I'm not that silly that I would like to sit in 
dreadful pain. Because if there's something to help the pain, then I would 
take it. But I'd have to be in excruciating pain to take it regularly. 
3.4.8 Dynamic associations 
It seemed the anticipation of death that was such a prominent feature of these 
interviews was perhaps what resulted in the overwhelming impression of 
morphine being "a last resort". This may have been exacerbated by the recent 
progression of disease or change in goals of care that participants had 
experienced. It was clear that they interpreted being offered morphine as a signal 
that they were entering the final stage of their disease. Betty explained that there 
was a difference between her husband having morphine for kidney stones and her 
being offered morphine when she was told she had metastases from a sarcoma: 
BETTY: And then on the other hand, my husband suffers with kidney 
stones.. . and when he's been really ill the doctor has either given him 
morphine injections or pethidine... but when - when er they said I had 
tumours, and then morphine, you think, "Oh my goodness it's - you know. 
INTERVIEWER: Oh my goodness what? 
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BETTY: (laughs) It must be pretty bad and er...... you know you sort of 
have more and more morphine and er that puts the end of your life, sort of 
thing, doesn't it? 
Some of the other respondents also mentioned that it was the presence of their 
cancer which meant they were frightened when offered morphine. When asked 
how it would feel if the next painkiller offered after paracetamol for cancer pain 
was morphine, Daisy answered "terrible", and went on to say: 
I feel morphine - it means they put you on morphine, and you've got cancer, 
it means you're going to die. 
The fear of morphine because of the presence of cancer was highlighted very 
clearly by Margaret, who discussed how she had felt very positive about having 
had a prophylactic oophorectomy some years previously, in order to prevent 
ovarian cancer. When given morphine post-operatively she was not concerned and 
certainly did not have the same reaction that she had experienced when being 
offered it after reacting badly to her first cycle of chemotherapy. Comparing her 
recent experience to that time she explained: 
But when - you know, these last few months I know I have been seriously 
ill, very seriously ill, and I think that was a completely different situation in 
which um I knew that there was a possible end, that there was not um - it 
wasn't - it was more distressing. It was er -I felt there wasn't much future, 
and you feel you're just being um - you're just being made comfortable 
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while you're still alive. Whereas before it was something to help me with 
the future, to prolong the future, so to speak. 
It seemed then that it was certainly the presence of their cancers and possibly the 
recent changing disease status that meant morphine was being interpreted as an 
unspoken terminal prognosis and therefore shunned as a rite of passage towards an 
inevitable death. However, some of the participants had accepted Step III opioids 
and six of the eight who had commenced either regular morphine or oxycodone 
spoke of the confidence in these drugs they had developed since using them. Andy 
spoke of having felt "forced into a corner" before he eventually commenced 
morphine, but having done so said he had "improved his quality of life by 85%" 
and that he was more comfortable with using it. 
Basically yeah. I daresay there probably are other options but um I'm quite 
happy to take it now. 
Two of the participants felt that they had more confidence about their pain control 
in the future. Daisy had not used regular morphine, but preferred to simply use "as 
required" oral morphine, but both she and her husband said: 
It's taken some of the hit and miss out of the future. 
Tom had initially felt that any painkillers were taking him "down a path he didn't 
want to go down", but when asked if that had changed after commencing regular 
oxycodone within the trial he said: 
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I don't feel it's the last step.... With the oxys.... I think this could take me 
through all that I have to pass through into the future. 
Patricia felt that she had been given back some control because her pain had been 
dealt with. 
Um since the programme that I've been on with you, with the painkillers, it 
has turned my life around because it's freed me up from this terrible pain. 
It also seemed that she no longer associated morphine with death: 
INTERVIEWER: But your main association with it then would be that it's a 
drug at the next stage? 
PATRICIA: Yes hmm, but I would say, for me, um that over the last 
fortnight my mind has changed dramatically (laughs). 
3.4.9 Uniformity of responses (data saturation) 
Whilst only 18 interviews were conducted because of the sampling strategy used 
and because of the frailty of the population being interviewed, no new themes 
arose after the first few interviews. Subsequent interviews were used to confirm 
and elucidate theories that had already arisen. 
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3.4.10 Deviant case analysis 
Almost all of the participants discussed either their disease progression or lack of 
response to chemotherapy with an awareness of their mortality, although the word 
death or dying was not always used. Only four did not say during the interviews 
that they associated morphine with death. On careful re-reading of these four 
interviews, it seems likely this is because these participants had been unable to 
fully acknowledge or discuss their death with professionals, either during the 
interviews or during the 2-step trial. It is possible therefore that these participants 
also associated morphine with death, but their inability to talk to me about their 
own death meant that they could not raise the subject during the interview. This 
was best demonstrated by Andy who had been described by his oncologist as 
being unable to talk openly about his prognosis. He did not mention death when 
talking about morphine during the interview but when the tape was turned off and 
his wife started to describe the episode with the pharmacist when the first 
prescription for morphine was dispensed, he began to talk about how frightening it 
was to be offered morphine because everyone saw it as a death sentence. I think 
these negative cases reinforce the "morphine as a last resort" theme. 
3.4.11 Relationship between the themes 
What is prominent from the interviews is the way that these themes are clearly all 
interrelated, with each having the ability to influence the other. If morphine 
representing death because of it being a "last resort" is central to the interviews, 
then the other themes are influenced by or can influence this central theme in 
some way (Figurel4). 
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Figure 14: The relationship between the themes 
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Central to the participants' experience is that cancer pain causes them to consider 
their anticipated death and causes them loss. This loss is either experienced as a 
physical symptom such as reduced walking ability or as a loss of role or self, for 
example when contact with family members is affected as a result of pain. It is 
likely that these losses then worsen the pain that is being experienced, because of 
the multi-dimensional nature of pain. 
For most patients, talking about uncontrolled pain in a consultation will result in 
Step III opioids being offered when appropriate. These interviews show that this 
provokes fear by reinforcing the anticipation of dying. This occurs because if a 
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patient associates morphine with death and is then offered morphine, they are 
more likely to assume that their health professional thinks they are close to death. 
Those patients who associate morphine with being "slowed" will also anticipate a 
further reduction in their function. Thus, for the patient, the offer of morphine for 
pain relief apparently threatens to reinforce the emotional and physical 
consequences of the pain itself. This may explain why the patient often rejects the 
initial suggestion of morphine or another Step III opioid for cancer pain. 
If, however, the consultation results in both the acceptance and use of Step III 
opioids then two scenarios are possible. If the opioid works and pain is better 
controlled, then the patient is no longer frequently reminded of their death. 
Improved function leads to more faith in Step III opioids as well as greater 
confidence for the future. This allows them to lose the association of morphine or 
other opioids as a "last resort", if only because they are still alive and possibly 
because they are more functionally able than they were before commencing 
morphine. 
However, the second possible scenario is that the opioid is commenced but causes 
side effects. These side effects may cause increased loss of function due to the 
neuro-toxic side effects of sedation or hallucinations or by making the patient feel 
less well because of other unpleasant symptoms such as constipation (a side effect 
that was anticipated by Mary). This may then increase the association of Step III 
opioids with loss of function and/or dying. Strengthening of these negative 
associations by personal experience of side effects is likely to lead to future 
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refusal of Step III opioids, as demonstrated by Rupert during the trial, when his 
previous experience of side effects prevented him from attaining pain control. 
So, for those patients who can no longer refuse morphine because of the severity 
of their pain or concern for others, a successful experience should allay their fears 
and dispel negative associations. However, a negative experience due to side 
effects is likely to prohibit either further dose increases or the use of "as required" 
doses for breakthrough pain or even lead to stopping the opioid. All of these result 
in uncontrolled pain. 
This dynamic relationship reinforces the importance of the role of the professional 
managing pain caused by cancer. During the interviews the participants told me 
ways in which negative associations had been confirmed by professionals and 
how perceived ambivalence towards Step III opioids (when offering them as a 
choice to the patient) reinforced the negative associations. They also told me how 
certain language used by professionals helped them to accept a prescription for a 
Step III opioid and that it was useful if the professional spoke confidently and 
positively about morphine and other opioids. They were more likely to accept a 
Step III opioid if they trusted the health professional, a trust that was earned by 
listening to and believing stories of pain. 
The overwhelming implication of these interviews is that we do not have to accept 
patients' fears or concerns about opioids as a reason for poor cancer pain control. 
This is particularly true if we consider that the professionals themselves appear to 
be a source of the negative associations. We have a better understanding now of 
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what these concerns are and we now need to consider how we address them, at 
both an individual and societal level. There are also implications for the way in 
which professionals offer morphine and monitor side effects. This will be dealt 
with in the discussion chapter of this dissertation. 
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Chapter 4: Discussion 
4.1 A survey of cancer pain control by South West 
England palliative care teams 
4.1.1 Patients recruited 
The numbers recruited to the pain survey show that relatively large sample sizes 
can be met in palliative care studies when multi-centre designs are used. However, 
as shown, this was a time-consuming process because of the research governance 
requirements. There has been debate in the literature about the perceived recent 
increase in bureaucracy and its likely impact on research output in the NHS. 176177 
Since this survey, changes have been made in order to assist researchers e. g. 
geographically linked R&D departments are now offering a streamlined R&D 
approval process, where only one application is made to a designated "lead" R&D 
department. In addition, some R&D departments are providing much more 
assistance with completion of the paperwork than was available before e. g. in 
obtaining key approval signatures from relevant personnel within hospital 
trusts. 178 
In this study, the numbers of patients recruited at each site was generally far less 
than the numbers anticipated by teams based on their normal daily workload. This, 
along with the very small numbers of refusals, possibly suggests that some gate 
keeping by the professionals recruiting to the study took place i. e. not all patients 
seen on the day were asked to participate. This may have been to comply with the 
protocol which stated that patients who were too distressed or not well enough 
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should not be asked about the survey. It is also possible that not as many patients 
were actually seen as was anticipated. On the day St. Peter's Hospice in Bristol 
were recruiting, several of the community nurses had their planned visits altered 
because of patients cancelling appointments due to unexpected hospital 
admissions. In future projects, the only way to be able to discern whether or not 
patients were being purposively selected would be to ask participating 
professionals to keep a log of all patients seen on the day and to note reasons for 
not approaching patients. However, this is likely to add to the documentation for a 
project and may be perceived as onerous by professionals trying to incorporate a 
research study into a normal working day. 
A high percentage (84.3%) of patients participating had pain. Pain prevalence was 
highest in the outpatient setting (100%), followed by in-patient hospice (94.4%) 
and hospital (88.2%) then home (78.7%) and was lowest in day hospice (73.8%). 
These high percentages may be further evidence of selection bias having taken 
place although they are in line with other pain prevalence studies in palliative care 
populations. 12 65 179 The majority of patients had nociceptive pain (57.2%) or 
mixed pain (38.4%). Only 2.4% were thought to have neuropathic pain only. 
Again this is in keeping with other studies. 14 
Patients were recruited to the study in equal numbers from all settings except that 
fewer patients were recruited from outpatient departments. This reflects palliative 
care practice, where community nurses see most outpatients in their own homes, 
rather than suggesting large groups of outpatients were missed. A wide range of 
primary tumours were represented and the majority (77%) of patients with pain 
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were ECOG performance status 0-2. Only 5.7% of patients had a performance 
status of 4 (unable to get out of bed), but this was in keeping with the protocol 
where professionals were advised not to approach any patients who were 
considered too unwell to participate. Although the numbers of patients providing 
demographic data only were small, there were no differences in patient 
characteristics between them and those providing pain data, so there was no 
statistical evidence of selection bias. It is likely that the results are generalisable to 
the wider palliative care population and in particular to those who are of good 
performance status. 
4.1.2 Control of pain 
79.3% of patients had poorly controlled pain, defined as a worst pain score of >_ 5. 
This was unexpectedly high and was worse than the results obtained from 
previous pain surveys using comparable methods. 62 64 65 Two pain surveys 
conducted in Israeli and American outpatients '80181 have reported similarly high 
levels of uncontrolled pain. Poor pain control was not associated with sex, ECOG 
performance status, setting or primary tumour site. Those with worst pain scores 
of >_ 5 were 4 years younger, but it is unlikely that this finding is clinically 
relevant. There was weak evidence that longer time known to the palliative care 
team was associated with better pain control. The most important factors related to 
pain control were the occurrence of and number of breakthrough pains. 87.5% of 
patients with worst pain scores of >_ 5 had pain flares, compared to 59.2% of those 
with worst pain scores of <5 (p =<0.001). Those with worst pain scores of z5 
also had more frequent episodes of pain flares (p = 0.003). It is impossible to 
know whether or not these pain flares represented transitory exacerbations of pain 
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in otherwise stable pain or whether they represented pain that was poorly 
managed. Those reporting pain flares had a higher mean pain on average score 
(difference = 2.3; 95% CI 1.1 to 3.3, p= <0.0001) and a higher mean pain now 
score (difference = 1.0; 95% CI 0.1 to 1.8, p=0.01) possibly suggesting the latter. 
One of the most interesting findings from the survey however, was the difference 
in proportion of patients with a research definition of uncontrolled pain and the 
proportion of patients who considered themselves to have uncontrolled pain. Only 
14.2% of patients considered that their pain was not controlled, compared to 
79.3% of patients who had a worst pain score of ? 5. This may simply suggest 
that the single question was not able to discriminate between good and poor pain 
control, perhaps because the expectations of patients are lower than that of their 
doctors. It was interesting to note that socioeconomic deprivation influenced the 
answer to this question, in that those in the most deprived areas were less likely to 
say that their pain was not controlled. 
The original evidence that a pain score of z5 represented pain that was likely to 
substantially interfere with function is usually quoted as Serlin and colleagues. 63 
They examined data accumulated from studies validating the Brief Pain Inventory 
in the United States, China, The Philippines and France and optimised cut-off 
points for grading worst pain scores as mild, moderate or severe, based on their 
impact on the mean pain interference score. The choice of worst pain score rather 
than pain now, pain on average or least pain was because pain worst had been 
shown previously to be more closely correlated to pain interference with 
functions Other authors have confirmed this findingl79 181 182 with correlation 
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coefficients ranging from 0.39 to 0.64. Serlin and colleagues concluded that the 
best "fit" for cut-off points for the numerical rating scale were 0-4 to represent 
mild pain, 5-6 to represent moderate pain and 7-10 to represent severe pain, on the 
basis of the correlation coefficients obtained with pain interference scores. 
However, although this paper is usually listed as the reference for a worst pain 
score of >_ 5 as representing a level at which pain significantly interferes with 
function, no such data are presented. This instead is found in an earlier paper5 and 
the table in that paper supporting this cut-off point is shown below. 
Figure 15: Table reproduced front Daut and Cleeland5 showing the difference 
in interference score between worst pain scores of <5 and worst pain scores of 
>_S 
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Daut and Cleeland5 argue that because there is a greater jump in the mean activity 
interference score and mean enjoyment interference score between a worst pain 
score of 4 (activity interference = 2.6, enjoyment interference 2.8) and a worst 
pain score of 5 (activity interference = 4.4, enjoyment interference 4.4) than 
between other scores, then worst pain scores of >_ 5 represent pain significantly 
likely to interfere with function and so proposed its use as a cut-off to represent 
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poor pain control. Potter and colleagues''s investigated this further using a sample 
of 93 adults with cancer and came to similar conclusions when comparing those 
with worst pain scores of <5 with those with worst pain scores of > 5.1 lowever, 
as can be seen from their data below, the mean interference scores in both groups 
are low and we still do not know whether the differences in interference scores 
reported are clinically important to patients. 
Figure 16: Table reproduced from Potter and colleagues ''8 showing the 
differences in interference scores between worst pain scores of< 5 and worst 
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A telephone survey183 asking the views of 287 randomly selected residents in 
Harris County, Texas about cut-off points to represent mild, moderate and severe 
pain on a 0-10 pain scale has confirmed that lay people describe similar figures to 
those obtained by Serlin and colleagues. However, our survey suggests that 
patients do not agree with the cut-off of ?5 for worst pain as a level that 
distinguishes controlled pain from uncontrolled pain. 
Whilst a great deal of methodological work has been conducted in order to 
validate pain scales for clinical trials and observational studies, very little work 
has examined what patients themselves see as the goals of pain management. 
Zelman and colleagues184 conducted 11 focus groups with 53 patients 
experiencing chronic pain due to low back pain, osteoarthritis and metastatic 
cancer. Patients discussed achieving "manageable" pain days, because they did 
not expect their pain to be completely relieved. Manageable days were those 
during which pain was sufficiently relieved to allow them to concentrate on 
something else, when they were able to accomplish something, engage socially, 
obtain night-time rest and have a more positive affect. Undesirable days were 
those when pain restricted function, side effects of medication "eclipsed" the gains 
in pain severity, or when they were socially withdrawn because of pain with 
negative emotional consequences. The participants all considered it unlikely that 
they could achieve a pain score of <5 without excessive side effects from pain 
medication and were generally critical of the use of pain scales in chronic pain. 
Further work would seem to be required with patients themselves, in order to 
explore the best way of measuring good pain control in cancer pain. 
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When initially piloting the patient questionnaire, several patients reported worst 
pain scores of 8- 10, but answered that their pain was controlled. When 
questioned about this, they replied that when they had breakthrough pain, they 
took their breakthrough medication and it worked, and they perceived this to be 
controlled pain. This was confirmed within the survey results. 11/17 patients who 
said their rescue medication was not effective answered "no" to the single 
question, compared to 6/17 patients who answered "yes". 
The presence of pain flares was not associated with responses to the single 
question, however the frequency of the flares was. As the frequency increased, so 
did the proportion of patients answering "no" to the single question (p = <0.0001). 
It seems likely then, given that frequency of breakthrough pain was a mediator of 
both an answer "no" to the single question and a worst pain score of >5, that 
control of breakthrough pain is crucial to pain control. Other studies have found 
high prevalence rates of breakthrough pain in cancer settings 185-187 and 
demonstrated that breakthrough pain is often difficult to predict, or if it is 
predictable (when it is often referred to as incident pain because it is provoked by 
particular incidents such as weight-bearing) it is usually difficult to treat because 
of its short duration. Zeppetella and O'Doherty188 conducted a prospective survey 
of breakthrough pain in hospice patients and found that both the presence of 
breakthrough pain and its frequency predicted dissatisfaction with pain control. 
One of the pharmacological problems in the treatment of breakthrough pain is the 
rate of onset of analgesia from oral medication. A large proportion of 
breakthrough pains last less than 30 minutes, 188 189 but analgesia can take up to 40 
minutes when the oral route is employed and can last for several hours, leading to 
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side effects (sedation in particular). Newer formulations of opioids with a quicker 
onset of action such as oral transmucosal fentanyl citrate (OTFC) are becoming 
more common, but are not without their own difficulties e. g. the transmucosal 
route is sometimes difficult to use in the presence of xerostomia. Another 
difficulty in the treatment of breakthrough pain is that there is no agreed 
consensus for the dose of opioid that should be used. In the UK, guidelines 
suggest using l/6 `h of the patient's total 24 hour opioid dose. North American 
papers suggest 10-15% of the usual 24-hour dose, but data from the initial trials 
investigating the use of OTFC190 suggest that a rigid schedule is not appropriate 
and as Portenoy and Hagen189 amongst others suggest, breakthrough analgesia 
should be titrated to effect. Other treatment modalities such as radiotherapy or 
interventional procedures are often necessary to manage breakthrough pain and 
30% of patients in this survey had received radiotherapy for pain control. 
4.1.3 Use of drugs/other treatments 
It was reassuring that only 15% of patients had a negative Pain Management 
Index and that this was not associated with poor pain control as it has been in 
other studies. 62 64 The percentage of patients taking a Step III opioid for pain 
control (66.5%) was expected. 56 Just over half of patients were taking morphine 
(52%), with fentanyl (22%) and oxycodone (20%) the other two most frequently 
used opioids. Only 4% of patients were being given diamorphine for pain control, 
but this probably reflects the national shortage of this drug when the survey was 
conducted. No patients in this survey were taking methadone for pain relief. 
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The use of adjuvants was less than anticipated. Less than 20% of patients were 
prescribed either steroids or anti-depressants, and less than 10% were prescribed 
anti-convulsants. This is lower than in other studies191 but higher than in others. '92 
Klepstad and colleagues13 found regional differences in the use of adjuvants 
between 21 European countries participating in a cross-sectional survey. These 
differences may be explained by regional access to medications, but if not, suggest 
the WHO ladder is not used in the same manner by all professionals treating 
cancer pain, as was originally intended. 9.9% of patients were using 
bisphosphonates for pain relief, but this probably reflects the limited data 
supporting their use in pain relief from bone metastases. 193 What cannot be 
assessed in this survey however is adherence to treatment which has been shown 
to be a significant mediator of worst pain. 105 
It seemed that very little use was made of interventional techniques in the survey 
population. Linklater and colleagues' 94 reported similar rates after conducting an 
audit of their own practice of interventional techniques. However, following a 
regular weekly session with an anaesthetist specialising in pain management their 
epidural rate increased from 1.9% to 5.4%. Very few units responding to their 
questionnaire about the use of anaesthetic services had formal links with 
anaesthetic colleagues, and most were satisfied with informal "as required" input. 
Informal links may mean that we are not always aware of what our anaesthetic 
colleagues can offer and patients' pain management options are limited as a 
consequence. This may be of particular relevance to the control of breakthrough 
pain where pharmacological management is currently limited. 
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4.1.4 Implications of the results: achieving desired sample sizes 
One of the most promising results of the survey was that the sample size was 
almost achieved and so the estimates for the proportion of patients with poor pain 
control were obtained within narrow confidence intervals, improving their 
authority. Fostering research links with geographically connected teams seems to 
be a suitable way forward for achieving numbers required in other studies and will 
hopefully be facilitated by recent developments within NHS R&D departments. 
4.1.5 Implications of the results: pain control 
These data suggest that we cannot be confident in the estimate of 80% of patients 
achieving adequate pain control with use of the WHO ladder. The discrepancy 
may have arisen because of the methodology of the validation studies, with short 
follow-up in the studies leading to an overestimation of its success. Alternatively, 
it may suggest that the 80% figure can only be applied to patients with low 
complexity of needs and hence not those seen currently by palliative care teams. 
Repeating this survey across oncology inpatient, outpatient and day unit settings 
would allow us to assess this by comparing the proportion of patients with a worst 
pain score of z5 in all groups. However, when others have conducted surveys 
across all settings, the figure of 80% has not been verified 62 64 65 The high 
percentage of patients with poorly controlled pain also seems to be contrary to the 
results obtained in both arms of the 2-step trial, where in the first 28 days, patients 
recorded a score of 4 or less on approximately 60% of days in the 3-step approach 
and 71% of days in the 2-step approach. This apparent difference may simply be 
explained by the use of "average" pain scores as an outcome measure in the 2-step 
trial and not "worst" pain scores. The difference may also reflect the intense pain 
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monitoring and frequent patient-professional interactions that took place during 
the 2-step trial, that are unlikely to be replicated in usual practice. A definitive 2- 
step trial should perhaps include a follow-on phase, where recruits continue to 
monitor daily pain scores, side effects and use of breakthrough analgesics, but 
with less contact with the research team. This might allow the continuing efficacy 
of both approaches during more "usual care" circumstances to be measured. 
4.1.6 Implications of the results: clinician versus patient desirable 
outcomes for pain control 
The most unequivocal finding from this survey was that the patients themselves 
did not agree with a research definition of poor pain control. Whilst there is 
clearly a positive correlation between worst pain scores and pain interference with 
function it is possible the evidence for the cut off of a worst pain score of >_ 5 is 
perhaps not sufficiently robust. Whilst pain scores are necessary in order to 
compare two approaches or two different analgesics, it certainly seems that we 
should seek the views of patients about how to measure good pain control for 
observational studies on cancer pain. 
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4.2 Oxycodone for cancer-related pain: meta-analysis of 
randomised controlled trials 
4.2.1 General findings 
One of the most significant findings from this review was the lack of high-quality 
evidence available for synthesis in the meta-analysis. Only six studies were 
retrieved, and only four studies provided analysable data, representing 160 
patients in total. The trials were of short duration, lasting between 10 and 20 days. 
Both of these reflect the difficulties of conducting clinical trials in this group of 
patients150151 where high attrition rates lead to pragmatic studies of short duration 
in order to minimise the losses to follow-up. 
4.2.2 Effectiveness of oxycodone 
The 95% confidence limits for the effect of oxycodone versus morphine are 
narrow. The upper limit of the confidence interval is consistent with a difference 
of only 6 mm on a 100mm visual analogue scale and the lower limit is consistent 
with a difference of 0.5 mm. For oxycodone versus hydromorphone the 
equivalent figures are 0 and 6 mm. These differences are much lower than those 
that are suggested to be meaningful to patients (a change of 20mm on a 0-10 pain 
intensity scale195) Therefore, in spite of the small number of studies we can 
exclude any clinically important differences in effectiveness between oxycodone 
and morphine and oxycodone and hydromorphone. 
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4.2.3 Tolerability of oxycodone 
In view of the short trial durations, data on longer-term tolerability is not 
available, but the results demonstrate that there is no evidence of a difference in 
the tolerability of oxycodone and either hydromorphone or morphine. These 
studies provide adverse event data for dose titration phases of Step III opioids, 
which is important information for clinicians managing patients with cancer pain. 
It means that they can inform patients of the likelihood of experiencing early side 
effects and also reinforces the need for appropriate management of these side 
effects. The percentage of patients experiencing side effects and discontinuing 
treatment due to adverse events in the studies included in this review was 
considerable and in line with discontinuation rates from other studies of opioids in 
both cancer and non-cancer populations. 83 196-198 As the presence of side effects is 
one of the reasons patients are unwilling to continue or increase doses of pain 
relief medication68 these findings re-emphasise the need for active questioning 
about, and aggressive management of, opioid related side effects. 
Clinical experience suggests that the side effect profile of opioids does change 
with time, in that patients tend to develop tolerance to the sedation, nausea and 
respiratory depressant effects of opioids'99 but few studies are ever long enough to 
measure actual rates of continuing side effects. A comprehensive systematic 
review by Chou and colleagues197 could not find any evidence to prove one 
controlled-release opioid had superiority over another in the chronic pain setting. 
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4.2.4 Trial quality 
The study reports did not allow us to be confident about the internal validity of the 
trials. Only the Heiskanen trial reported an attempt to conceal treatment 
allocation, stating that the hospital pharmacist held the codes for treatment 
allocation. However, inadequate concealment of treatment allocation is usually 
associated with an exaggeration of treatment effect, 152 and so would not explain 
the absence of differences between oxycodone and control group that we found in 
our meta-analysis. In each of the included studies, patients who withdrew for any 
reason were not included in the final analyses comparing pain scores between 
oxycodone and control (Table 15). Attrition bias might further threaten the 
validity of the individual studies, but the discontinuation rates due to adverse 
events were similar for both oxycodone and control groups in all studies, so it is 
unlikely that it has influenced the results of our meta-analysis. Each trial reported 
that patients in both treatment groups had their opioids titrated in a similar manner 
until stable doses were obtained so there was no evidence of performance bias. 
4.2.5 Generalisability 
The studies recruited mainly from hospital communities, with pain from a variety 
of cancers, so it is likely that the patient population is representative of patients 
with cancer-related pain and that the findings can be generalised to this patient 
group. It is unclear whether or not the findings are relevant to other pain 
management settings. Three recently published systematic reviews196-198 have 
demonstrated the effectiveness of opioids for pain management in the chronic, 
non-cancer pain population. Chou and colleagues, 197 in a systematic review of the 
comparative efficacy and safety of long-acting oral opioids for chronic non-cancer 
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pain did not retrieve any papers directly comparing oxycodone with other opioids 
in these patients. Eisenberg and colleagues, 196 in a systematic review of opioids in 
neuropathic pain, did not retrieve any papers that compared one opioid with 
another. The Kalso systematic review198 only included trials comparing opioids 
with placebo, so no data were retrieved on direct comparisons of one opioid with 
another. All of these reviews confirmed the efficacy of opioids in a variety of 
chronic pain conditions and demonstrated that adverse effects are as common as in 
cancer populations, but no studies comparing oxycodone with other Step III 
opioids have been conducted in patients with non-cancer pain. 
4.2.6 Implications for practice 
Morphine, in both normal-release and modified-release formulations, has been the 
first-line opioid in the United Kingdom for the management of moderate to severe 
cancer pain. In this review, we did not find any important differences between 
oxycodone and morphine. Oxycodone is almost four-times more expensive than 
morphine in the UK and there is less general experience of its use. This is likely to 
be the case worldwide also, apart from perhaps the United States, where it remains 
more expensive but has been used more widely. Thus, there is no reason to 
challenge the recommendation to use morphine as a first-line agent for cancer 
pain. However, there is a need for larger trials of longer duration designed to 
obtain comparative efficacy and adverse event data for Step III opioids in both 
cancer and non-cancer populations. 
There is no reason to assume that any one opioid should be superior to another at a 
population level, but one Step III opioid may be a better option than another at the 
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level of the individual patient. 200 Riley and colleagues201 have conducted a 
prospective study investigating the characteristics of patients who require a switch 
from morphine. Although this study has limitations (there were no `a priori' 
guidelines for deciding when to switch opioid and no information about any 
measures taken to control side effects other than the opioid switch was given in 
their paper) some genetic factors emerged as possible predictors of those patients 
who might need an alternative to morphine. 202 The information obtained in this 
review confirms the place of oxycodone as a suitable alternative to morphine in 
those individuals who become intolerant to morphine. 
The increase in prescribing of oxycodone that was highlighted in the introduction 
may be explained by some professionals believing that oxycodone is a superior 
alternative to morphine after the experience of seeing an individual patient's side 
effects disappear following a switch from morphine to oxycodone. Anecdote is a 
powerful factor in our treatment choices but as palliative care professionals, we 
should educate our generalist colleagues that a successful opioid switch for an 
individual does not confer superiority to the alternative opioid used at a population 
level. It is likely that though that for some, oxycodone may remain a first line 
opioid by virtue of the fact that it is not called morphine. 
4.2.7 Conclusion 
It is important to be clear about the value of this meta-analysis. Our original aim 
was to display the accumulated evidence to date on which current prescribing 
patterns are based, highlighting both its strengths and limitations. The systematic 
retrieval, assessment and presentation of results of trials are crucial if clinical 
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practice is to meet the aim of being evidence-based. The combination of studies in 
a Forest plot and meta-analysis has a number of aims, not just restricted to the 
final pooled estimate: a) presentation of the results of all the included studies in 
one figure with easily accessible study-specific effect sizes and their confidence 
intervals; b) assessment of whether the results are heterogeneous (we found e= 
62%, heterogeneity p=0.05); c) meta-regression allows sources of heterogeneity 
to be investigated (we demonstrated that the type of control may be a source of 
heterogeneity; p for difference in effect estimates = 0.1). If the results are 
consistent with each other (we showed that when studies were stratified by type of 
control group, they were), the final pooled estimates provide an appropriate 
summary statistic, on which to make (in combination with a critical analysis of the 
quality of the papers, clinical heterogeneity etc. ) evidence-based, systematically 
obtained conclusions. Our conclusion would be that there is no current evidence to 
support the use oxycodone as a first line Step III opioid for all, but that for some 
patients who are intolerant to morphine, oxycodone is a good alternative. 
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4.3 The 2-step study: a pilot study for a randomised 
controlled trial of a two-step versus a three-step approach 
in the management of cancer-related pain 
This section of the discussion chapter will consider the results of the 2-step trial 
and in particular consider factors relating to the feasibility and design of a 
definitive study to compare a 2-step approach versus the traditional 3-step 
approach. The results will be compared with the validation series studies and also 
with other trials comparing alternative approaches to the 3-step ladder. 
4.3.1 Feasibility: trial recruitment 
One of the most interesting findings from the recruitment figures in the CRUK 
pilot study was the difference in recruitment rates between the three centres 
involved. Whilst this may be in part related to the length of time the study was 
open in each centre, this is clearly not the only explanation. Recruitment in Bristol 
was at a rate of 1-2 patients per month. Oncology and palliative care colleagues 
from within hospital, hospice and community settings referred patients for the 
trial. Having ethical approval to visit and recruit patients in their homes 
undoubtedly facilitated recruitment of these patients, if only for pragmatic reasons 
such as the notorious difficulty of parking at Bristol Haematology and Oncology 
Centre (BHOC). It is unlikely that all of the patients we recruited in their homes 
would have entered the pilot study if they had been asked to attend the BHOC. 
Another difference between recruitment at Bristol, Edinburgh and Nottingham 
was that the research team at Bristol was dedicated almost exclusively to the 2- 
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step study. This meant that they were able to regularly screen patients' notes prior 
to key oncology clinics which served two purposes: it helped identify potential 
recruits but also raised colleagues' awareness of the study. Having a trial- 
dedicated palliative care research team also meant that we were available to 
provide pain consultations at short notice, even if a patient was eventually 
considered ineligible for the trial. Assisting colleagues with difficult pain 
problems seemed to increase the likelihood that they would remember the trial in 
the future. Another factor that may have been relevant to the differing accrual 
rates was that we raised the issue of fear of opioids early in the recruitment 
process with patients in Bristol, in order to mitigate its impact on trial refusals. 
This approach was suggested to us by the Quartet (Qualitative Research to 
Improve Recruitment to Randomised Controlled Trials) study group at the 
Department of Social Medicine in Bristol. It seemed that these key differences 
between the centres could explain the recruitment rates observed and means that a 
definitive study should apply for funds to have dedicated personnel at each 
recruiting site. 
It was disappointing that no patients were recruited from primary care settings. 
Only two potential recruits were identified from the eight participating practices 
but neither entered. One was ineligible because of drug sensitivities and the 
second declined after reading the patient information sheet. The research 
governance process and the visits to individual practices had been extremely time- 
consuming during the set-up of the trial, and this did not seem to have been an 
efficient use of time or resources. We have been unable to explore reasons for this 
since only one of the participating practices has replied to recent email 
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correspondence about the trial. The definitive study could still consider 
participation from community settings, with the trial team having honorary 
primary care trust contracts, but it seems more likely that community palliative 
care teams will refer patients than primary care teams. 
4.3.2 Design: use of diaries 
The patient assessment booklet or diary seemed a useful tool with which to record 
pain data. Minimal data were required, which means that notation was less 
onerous for the patient and this possibly increased compliance with its use. 203 
Those who wished to write more could do so. In fact, some patients continued to 
use a pain diary after they had completed the trial in order to keep a record of their 
pain control. 
4.3.3 Design: additional contacts 
The recruits in Bristol had an average of 3 extra contacts with the study team 
during the first 28 days. The majority of these were telephone contacts and were 
related to pain control or adverse events. A definitive study should incorporate 
these additional visits into the study design. 
4.3.4 Design: attrition and missing data 
Patients provided a mean of around 21 days of pain scores in the first 28 days of 
the study. When each day's pain score was considered, 825 data points from 37 
patients were obtained. The majority (55%) of patients recruited to the CRUK 
study completed all 28 days as did 61% of patients recruited to the Napp study. 
This compares favourably with rates quoted in a systematic review204 of attrition 
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in palliative care studies of between 34-80%. It seems then that a study period of 
28 days is appropriate, since this will result in about 21 days of pain scores per 
individual and a significant proportion of patients will complete the study. 
4.3.5 Design: utility of the outcome measures 
The percentage of days when each individual recorded a pain score of 4 or less 
seemed to have the ability to detect a difference between the two approaches, but 
it is difficult to know what difference in percentage points would be clinically 
meaningful to patients. It seems appropriate to consider using a pain score of <4 
as a cut off point for a definitive study comparing two approaches to pain 
management, since several studies including those asking patients themselves 
have confirmed that this represents "mild" pain. 
63 183 205 This might seem to 
contradict arguments used against this cut-off point in the pain survey discussion 
(4.1.5) but the crucial difference is that a definitive trial would be comparing the 
difference in the percentage of time a patient records "mild" pain between the two 
approaches, rather than the difference in pain "control" between the two 
approaches. 
4.3.6 Design: difference in Napp and CRUK studies 
The mean proportions of time with a pain score of _5 
4 were 53.6 (3-step approach) 
vs. 56.8 (2-step approach) in the Napp study and 63.7 (3-step approach) vs. 87.9 
(2-step approach) in the CRUK study. This means the difference between the two 
approaches was 24.2 percentage points in the CRUK study vs. 3.2 percentage 
points in the Napp study. Thus, the overall proportion of days with a score of <4 
was lower in the Napp study as well as the difference in proportions. Although the 
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test for interaction between the funders was not significant, it is unlikely that that 
the test had sufficient power to detect a difference. These differences may be 
explained by the observed regional differences in pain management and the fact 
that many different teams were recruiting to the Napp study compared to the 
CRUK study. If a definitive study is not to be confounded by such differences, 
then the use of analgesics will need to be controlled within the protocol and the 
number of personnel recruiting should be limited. This means requesting a 
research grant to concentrate the study on fewer sites, but with sufficient 
manpower at each site e. g. a half-time dedicated trial nurse. This should allow a 
difference between the approaches to be detected if a difference exists. 
4.3.7 Pain results 
The results show that pain scores were <4 for the majority of the time in both 
arms of the trial. This suggests that pain was mild for the majority of the time in 
both approaches and is somewhat at odds with the findings from the pain survey, 
although this might have been due to the different pain scores being recorded 
(average vs. worst). Pain control was possibly better in the study than it might 
have been in usual practice though, a finding that has been observed repeatedly in 
other research studies and is referred to as the Hawthorne effect206 and perhaps 
provides justification for including patients at their end of their lives in research 
studies. 
The results of all of the outcome measures suggest that the 2-step approach results 
in better pain scores for patients. Those randomised to the 2-step approach spent a 
greater proportion of the first 28 days with a score of <_ 4, were more likely on any 
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day to have recorded a score of <_ 4 and achieved stable pain control (four 
consecutive days with a score of _< 
4) more quickly. These differences were of a 
magnitude that is likely to be clinically meaningful, but were not statistically 
significant probably because of the small numbers in the pilot study. 
Brief pain inventory scores for least, worst, average pains and pain now were also 
better in the 2-step approach and these results were statistically significant. The 
difference for worst pain scores was also clinically significant, with an adjusted 
difference of 2.3 points on a 0-10 scale. 
4.3.8 Adverse events rate 
It was important to compare side effects in the two groups to ensure that improved 
pain control was not achieved at the cost of greater side effects. Overall the 
adverse event rates were low, which was reassuring but meant that it was not 
possible to compare the two approaches. Other studies have confirmed that 
introducing Step III opoids to opioid-naive patients can be done safely. 130-133 
4.3.9 Patient-acceptability of the 2-step approach 
The adverse event rate clearly has an impact on the patient-acceptability of the 
approach and it was therefore promising that these rates were low. However, it is 
likely that a number of patients will have been deterred from entering the study 
because of the negative associations with Step III opioids that were highlighted in 
the interview study. This has implications for recruitment to a definitive study and 
is considered in the discussion of the qualitative study. 
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4.3.10 Comparison with the results from the validation series 
The finding that only three of the patients randomised to the 3-step approach 
during the CRUK funded study remained on a Step II opioid by the end of the 28 
day period is consistent with findings from the validation studies. 48 56 It is difficult 
to compare the primary outcome of this study with the validation series studies 
however, because of the variety of outcomes used in those studies. 
4.3.11 Comparison with the results from other studies 
investigating other approaches 
This study adds to the evidence that alternative approaches which involve the 
earlier introduction of Step III opioids may be superior to the 3-step WHO 
analgesic ladder. Maltoni and colleagues136 used a similar experimental arm to 
ours and found a statistically significant difference in the proportion of time spent 
with a worst pain score of >5 which favoured the 2-step approach. Similarly, in 
their study there was no evidence of an increased risk of side effects in the 2-step 
arm. Marinangeli and colleagues135 reported a statistically significant difference in 
the mean change in pain intensity from baseline, favouring their experimental one- 
step approach as measured by a 0-10 VAS. However, the difference in mean 
change between the two approaches was only 0.68 cm and so the clinical 
relevance of this difference is not known. There was a greater incidence on nausea 
in the experimental approach, but the incidence of vomiting was not different. 
4.3.12 Why might a 2-step approach be superior? 
We had initially considered that a 2-step approach might be superior to the 
traditional 3-step approach for pragmatic reasons. Commencing a low-dose of a 
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Step III opioid as soon as Step I analgesics were no longer effective would mean 
only one change of medication, compared to the two changes to medication that 
are required in the 3-step approach (from the first to second and then second to 
third steps). This will mean that a community patient will need to contact a health 
professional twice. We also hypothesised that a 2-step approach would allow 
easier dose titration to provide pain control and also facilitate the use of escape 
medication since patients would have access to normal-release preparations of a 
Step III opioid as well as regular modified-release preparations. We became aware 
during the study that it was not usual practice to prescribe normal-release 
morphine for patients to use as escape medication in addition to Step II analgesics 
when necessary and in fact, one general practitioner initially refused to prescribe 
this for one of the trial recruits. Thus the 2-step approach meant that recruits 
immediately had access to regular medication and "breakthrough" medication, 
differing from the 3-step approach in usual practice, where patients are prescribed 
only regular Step II analgesics and may not have drugs available for breakthrough 
pain. The results of the interviews suggest it is possible that once the 
psychological barrier of commencing a Step III opioid is overcome, provided the 
initial experience is positive, they are taken more because patients' confidence in 
them will have increased. However, this was not borne out in the trial results, 
where the use of escape medication was less likely in the 2-step approach, but the 
confidence intervals were wide and consistent with both no difference and a 
greater use of escape medication in the 2-step approach. 
The 2-step approach may also be superior because the addition of a Step II opioid 
to non-opioid analgesics does not provide sufficient additional pain relief, as has 
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been suggested by two previous well conducted systematic reviews of the use of 
non-steroidal anti-inflammatory drugs and Step II opioids in the management of 
cancer pain 125 207 
4.3.13 Conclusion 
Thus, in light of the data obtained in this pilot study from both the qualitative and 
quantitative components, from other studies investigating the efficacy of the 
ladder and for pragmatic reasons, it seems a 2-step ladder should be compared to 
the traditional WHO 3-step ladder in a definitive, adequately powered controlled 
clinical trial. 
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4.4 A qualitative study to explore the views of patients 
considering morphine for relief of pain caused by cancer 
The following part of this discussion chapter will address the results of the 
qualitative interviews. I will consider whether the information the interviews have 
given us can be applied to other patients with cancer pain being offered morphine 
or another Step III opioid for the first time i. e the generalisability of the results. 
My role as researcher will also be considered in the light of the findings. The 
results will then be compared to similar studies in the literature and then the 
relevance of each of the themes will be discussed within the context of both the 
pertinent social science and medical literature. I will conclude with what I 
consider to be the implications of the themes generated from the interviews for 
both clinical practice and further research. 
4.4.1 Generalisability 
It is likely the participants in these interviews were a representative group, since 
this was a study nested within a pain management trial and we were recruiting 
patients similar to those seen in clinical practice who were being offered morphine 
for cancer pain relief. I interviewed equal numbers of men and women and the age 
range was 55 - 80 years. I interviewed 12 patients within the 2-step trial and six 
patients who did not enter. Four of the patients not entering the 2-step trial also 
did not wish to be interviewed, but the most common reason for not participating 
in an interview was clinical deterioration. However, the views of all of the 
participants were very similar, irrespective of whether or not they entered the 
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clinical trial. What is not clear from these interviews is whether or not the themes 
generated would have been similar in patients with chronic non-malignant pain. 
However, given the dynamic nature of the themes described previously (Section 
3.4.8), and the way in which the anticipation of death influenced the way 
morphine was seen as a last resort, it seems unlikely the results can be generalised 
to non-cancer populations, or at least to patients with pain due to conditions that 
are not life-threatening. 
4.4.2 Reflexivity 
It is not possible to know absolutely whether or not the strategies described in 
Section 2.4.6 of the methods chapter were successful in mitigating the effects of a 
doctor as researcher, but it seemed to me that these interviews were honest 
accounts of the experience of cancer pain. The participants told me what it was 
like to have pain, how their pain had been dealt with, the different approach they 
encountered when they saw palliative care professionals (including me, but not 
only me) and what being offered morphine meant to them. They told me how 
professionals had influenced their views on morphine (often negatively) and they 
even told me they might have been non-compliant during a clinical trial had they 
been given morphine. It did not feel during the interviews that they were telling 
me what they thought a doctor ought to hear although of course it may be that 
their experiences of pain management were even worse than they described. 
Perhaps for this study, my dual role served well. The interviews raised 
uncomfortable topics but the participants will have known I was used to hearing 
about death and dying and this may have made it easier for them to talk about 
their fears. Indeed, Hoddinott in her review of the opportunities and pitfalls of 
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being both a doctor and qualitative researcher gives examples of how her being a 
doctor facilitated discussion of topics deemed sensitive by the participants. 208 
When discussing reflexivity, Malterud175 suggests that a declaration of beliefs 
should be made at the start of a study. My a priori assumption was that the 
interviews would suggest autonomous individuals needed time to adjust to the 
idea of needing morphine, because of the fears described in the literature. The 
themes generated indicated that these a priori assumptions were wrong. It was 
unlikely therefore that my own views have biased either the interviews themselves 
or the process of analysis. 
4.4.3 Comparisons with existing literature: general findings 
These interviews showed us that for patients with pain caused by cancer, 
morphine is linked with death because of the manner in which they perceive it is 
used (in increasing doses resulting in sedation and shortened life). Those who do 
not consider themselves to be dying might therefore refuse it, in spite of the poor 
pain control they endure as a consequence. Whilst this association is strengthened 
by the anticipation of death that was prominent throughout the interviews, 
professionals themselves were described as the root of fears of morphine, 
particularly by suggesting morphine was life-shortening in some instances. The 
offering of morphine as a choice to patients was also seen as indicating 
professional ambivalence towards it as an option for pain relief. Previous 
experiences of side effects' were important influences for patients, in deciding 
whether or not to accept morphine. Those who told a story of a good outcome 
with either morphine or another Step III opioid spoke of how this helped to alter 
their perceptions of opioids and gave them confidence for the future. These 
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findings are important because they suggest that the fears of tolerance and 
addiction that predominate in the literature are not the most significant for 
patients. They also highlight the extent to which professionals foster fears about 
opioids. After exploring the literature in light of the data gathered, I located 
studies which substantiate the general findings from these interviews. Cohen and 
colleagues209 purposively interviewed 10 patients they considered were 
"masquerading" pain as other symptoms. To the authors, these patients did not 
express their suffering as pain, instead reporting other overwhelming symptoms 
such as fatigue and anorexia, which seemed to respond to pain-relieving 
treatments. The interviews revealed a group of patients who were often unwilling 
to take pain relief medication, because of fear of side effects or lack of knowledge. 
As in my interviews, these patients all expressed an awareness that they were 
dying, but with differing directness. Pain relief was seen as shortening life ("I 
know how hospice is and their treatment. I don't want to think about that because 
I don't want to die just yet. I want to live as long as I can" p. 186-187) and was 
sometimes refused. Schumacher and colleagues210 conducted content analysis of 
transcripts of audio taped nurse-patient discussions during a randomised 
controlled trial of a pain management programme. The discussions involved 11 
patients who consistently took less pain-relief medication than prescribed in spite 
of both uncontrolled pain and receiving coaching about pain control. Whilst the 
audio taped discussions cannot provide the depth my interviews did, they echo 
some of the themes, with fear of opioids stimulated by professionals and concerns 
expressed about previously experienced side effects. They also highlight the 
powerful influence of previous pain management experiences (their so-called 
autobiographies) on subsequent patient pain management behaviour and confirm 
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the need for patients' own stories of pain to be listened to by healthcare 
professionals. 
4.4.4 Comparisons with existing literature: emergent themes 
The four analytical categories derived from our interviews were anticipation of 
dying, morphine as a last resort, the role of the professional and "I haven't got any 
choice" but to commence morphine (or factors influencing the decision to 
commence morphine). 
4.4.4.1 Anticipation of death 
The participants spoke of the link between the presence of pain and thoughts 
about death, with pain a reminder of cancer and mortality. However, they had no 
knowledge of when they might make the transition to the phase of "active dying" 
so death remained probable rather than certain. This is congruent with studies 
already in the literature. Hinton, 211 reports a longitudinal interview study of 
hospice patients examining the process of acceptance of death. His data suggest 
patients and their families are generally more anxious about death when the timing 
of death remains probable rather than certain. Writing from his own personal 
experience, the sociologist and psychoanalyst Ian Craib212 (Mortality 2003) 
describes how his own fear of death was submerged because it was impossible to 
live with it constantly; "the fear that I experienced was not, and is not when it now 
occasionally returns, something which can be faced at full intensity for very long" 
p. 288. Vig, 213 reporting a qualitative study involving 26 terminally ill older men, 
describes how they would question the possibility of disease progression when a 
new symptom developed and that this might cause them to consider whether or 
Ik/ 
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not they had moved to a phase of active dying. Adelbratt and Strang214 also 
describe a similar phenomenon when reporting the results of interviews with 20 
patients with brain tumours. They comment "anxiety that was related to the 
awareness of their terminal disease was easily triggered" p. 502. Trigger 
phenomena in their study were things associated with cancer such as hospital 
smells and headache. 
It is easy to see how pain experienced by people with cancer becomes a trigger for 
anxiety about death. Pain is probably the most feared consequence of cancer31 and 
in his description of modern dying, Field215 emphasises cancer as "the metaphor 
for the feared death" (p. 256) in current British society. This is because of the 
perception of cancer death as untimely, unexpected and that the terminal 
prognosis is often established with relative precision, even if the time of death is 
harder to predict. Another feature of modem dying is the open awareness which 
characterises especially cancer deaths, so individuals with cancer know at some 
point in the future they will enter a dying phase, as in my interviews, but do not 
know when they might die. This is seen as a change from death in earlier periods 
of history e. g. the Middle Ages where the script was shorter and better known i. e. 
death within days from an infectious disease where the clergy and church were 
involved, instead of the doctor. Modem deaths also differ by being more 
individualistic, following the individual's own choices for a "good death", or 
individuals "writing their own script". 216 Whilst this fits with our increasingly 
individualistic society and the current emphasis of palliative care in the United 
Kingdom in promoting patient autonomy, this does however mean that for any 
216 21s individual the script is unknown. Field also proffers another of the 
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characteristics of modern dying as there being no "rites of passage" to signal the 
person's transition to the dying role. 
4.4.4.2 Morphine as a last resort: patients 
In this study, the participants read in the patient information sheet for the 2-step 
trial about a painkiller similar to morphine for their pain. The words they used to 
describe the emotions experienced when being offered morphine were 
"frightened" and "fearful". When this was explored it was clear they were 
interpreting the commencement of morphine as a rite of passage to a dying phase, 
because they believe the dose will be increased until morphine itself becomes the 
cause of death. The role of doctors and nurses in shaping the experience of 
modem dying215 may also explain morphine being seen as a "rite of passage" 
since it will be almost exclusively these professionals who offer morphine to 
patients with cancer pain. That patients with cancer view starting morphine as a 
death sentence is previously documented in the literature but only as comments 
from experts in the field. 124 There have been very few data from patients 
themselves describing this, although associating morphine with a poor disease 
outcome was described briefly in the initial qualitative phase of the development 
of the Pain Opioid Analgesic Belief-Cancer Scale. 119 The equating of morphine 
with a short prognosis was not included in the updated Barriers Questionnaire I1115 
however, and so more recently this has been lost from the literature as 
representing a common fear about opioids and as a reason why they are refused by 
patients. 
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It could be hypothesised that the refusal of morphine represents denial of death; 
some of the participants seemed to state they were attempting to do this; "it's just 
if I take more of this then I'm getting worse.. . and I don't want to get worse". This 
would not explain why some did choose to accept morphine as a painkiller, except 
of course denial of death is not a dichotomous condition, with denial and 
acceptance mutually exclusive states. Weisman 217 talks instead of a "middle 
knowledge", a state of unpredictable shifts between open acknowledgement of 
death and its repudiation. Perhaps what we see in these interviews is an attempt at 
a temporary repudiation of death by patients refusing morphine, such as when 
Gloria states "give me another 10 years and I'll take the morphine if you like". In 
their study examining the use of denial and acceptance as coping strategies by 
hospice patients, Copp and Field218 describe how "denial serves to preserve self- 
esteem-and prevent disintegration and chaos at certain periods of the dying 
process" (p. 126). Perhaps for some of our patients who were anticipating active 
dying because of being offered morphine, a self-protective denial of this 
anticipated death was accomplished by a denial of the necessity of morphine, 
albeit temporarily. 
However, this discussion should not focus solely on the nature of awareness and 
acceptance of death. Whilst these may be pertinent in the context of the use or 
acceptance of morphine by persons with cancer pain, to write at length about 
awareness and acceptance of death would be to ignore the crucial finding from the 
interviews that the offering of morphine was synonymous with active dying to 
patients. The participants associated the use of morphine with dying because of 
the belief that relief of pain was traded for loss of function and hastened death. 
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Further evidence of the perception that pain control required this trade-off was 
found in a study exploring non-professional perceptions of a good death using 
interviews with both patients with cancer and relatives of patients who had died in 
a hospice. 219 Masson describes how pain itself was not an issue; what seemed 
important to the participants was how its treatment impacted on the achievement 
of other goals. One relative described her mother as being "really spaced out" and 
attributed this to morphine. She explained that her father had been "very aware" 
until his death and said this was a manner of death she would choose for herself, 
"even though it's in pain" (p. 204). The hastening of death by increasing doses of 
morphine was not judged to be a wrongdoing by the participants I interviewed. 
Whilst this may have been explained by my small sample, it is supported by the 
results of a focus group study with older people about end-of life preferences 
conducted by Seymour and colleagues220. The general preferences of these older 
people were for "comfort care" as opposed to life prolonging measures and 
morphine was seen as an important factor in providing a good death. Excerpts of 
their transcripts, like mine, demonstrate how the margins between acceptable pain 
relief and hastened death are blurred in laypersons' minds (as they would seem to 
be for some professionals also). Again, the participants in Seymour's study 
deemed the hastening of death by morphine as being acceptable and not the same 
as euthanasia, more of an "easing the passing". Another similarity was that the 
links the participants made to the word morphine were "cancer", "pain" and 
"death" and that it was seen by some as a "last resort for people dying from 
incurable cancer". Although positively viewed as a comfort measure, this also 
meant it was not viewed as a medical intervention for the relief of pain in any 
other setting. It was noted that professionals had reinforced some of these views, 
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with one of Seymour's focus group members recalling how a doctor had told her 
that continuing to give pain-relieving drugs "lessened the resistance". 
It may be that patients face modern death without familiar scripts or role models, 
and this leaves a gap for a "rite of passage" to active dying, such as the 
commencement of morphine, to emerge. In my interviews, I found that 
professionals had enhanced the association of morphine with death and dying. In 
order to address this, we should consider why it might be professionals think and 
then say to relatives that Step III opioids hasten death, all the while "encouraging" 
their use, presumably under the aegis of the doctrine of double effect221 If I am to 
argue that morphine should not be synonymous with death, and if it were not, it 
would be more accepted/used/useful, then we need to examine the evidence that it 
does not cause death. 
4.4.4.3 Morphine as a last resort: professionals 
Professionals have concerns about the hastening of death with morphine because 
of the ability of opioids to cause respiratory depression. When used in acute pain 
or in overdose (such as when taken by drug addicts) or if the patient's clinical 
situation changes unexpectedly (e. g. the development of acute renal failure) 
respiratory depression does occur with opioids and can be life-threatening. 
However, the clinical impression of those working in palliative care is that 
respiratory depression is uncommon in their patient population. 199 222 223 Walsh 
and colleagues222 conducted a small prospective study examining the respiratory 
function of 20 patients receiving in excess of 100mg of morphine daily and could 
not find evidence of respiratory depression. When blood gases did suggest 
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alterations in lung function (many of the patients had co-existing respiratory 
problems such as silicosis and bronchitis) these were not considered to be severe. 
This was supported by a recent Chinese prospective study224 of the use of 
morphine in over 500 patients which showed an incidence of respiratory 
depression of only 0.2%. The absence of respiratory depression when morphine or 
other Step III opioids are used to treat chronic pain is generally explained by the 
tolerance to this side effect which is thought to develop. It is for this reason that 
opioids are not used in euthanasia. 225 Thorns and Sykes226 report further evidence 
to support this theory. They conducted a retrospective analysis of the use of 
opioids in the last week of life in 238 consecutive patients dying in a palliative 
care unit. They showed that patients who received marked opioid dose increments 
at the end of life did not have shorter survival than those who received no 
increases, as would be expected if opioids hastened death by respiratory 
depression. Laboratory evidence also shows that pain stimulates respiration and so 
will attenuate morphine-induced respiratory depression. 227 This has been proven 
in studies with healthy volunteers228 and has been postulated as the mechanism 
that explains case reports of respiratory depression occurring in patients who had 
been receiving stable doses of opioids, following the abolition of their pain by 
other means. In these case reports, successful techniques such as neural blockade 
have alleviated pain, thereby resulting in a loss of the antagonism of the 
respiratory depressant effects of the opioids. 229 230 Thus, the antagonism of the 
respiratory depressant effect by pain and the tolerance that develops to respiratory 
depression in chronic opioid use suggest there is no reason to assume that 
morphine, if used correctly, will shorten life even if dose increments are required. 
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This pharmacological knowledge does not appear to have been translated into 
clinical practice outside of palliative medicine. In a 1997 survey of the attitudes of 
the American Society of Clinical Oncologists about physician assisted suicide and 
euthanasia, 231 a question was asked about the willingness of physicians to use 
escalating doses of morphine, sufficient to cause respiratory depression and end 
life in a patient with poorly-controlled pain. The physicians who would not 
consider increasing doses of morphine for a patient with excruciating pain because 
they thought respiratory depression was a possible outcome, were 0.61 (C. I. 0.48 
to 0.77) times less likely to support euthanasia or physician assisted suicide. The 
authors suggest concerns about euthanasia and physician-assisted suicide inhibit 
the use of opioids by professionals, which results in uncontrolled pain for patients. 
At no time in their paper do they argue against these concerns. Evidence of 
negative attitudes to morphine was also found in a French national survey on 
palliative care232 where 17% of HIV specialists either agreed or strongly agreed 
with the statement "prescribing high-dose morphine to a terminally-ill patient 
should be considered euthanasia" (p. 624). The final sentence in this paper reads 
"Clearer guidelines are also necessary to avoid the confusion between morphine 
analgesia and euthanasia" (p. 626). In an American qualitative study on end-of-life 
decisions, 233 nurses and physicians were asked to comment on an end-of-life 
scenario, within which the use of morphine is postulated to be facilitating death. 
Here the respondents felt that although respiratory depression was not absolute, 
patients receiving high-dose morphine for pain control have a compromised 
sensorium which often leads to hypoventilation and respiratory complications that 
may hasten death. During this study nurses expressed repeated concerns about the 
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high levels of morphine often used to relieve patients' pain, illustrated by the 
following quote from the paper: 
I really struggle with the question of whether I am killing the patient because I am 
turning up his morphine drip and he is going to quit breathing. I can't quite do 
that. (p. 620) 
Reference to inevitable respiratory depression is also found in an article in the 
Journal of Palliative Medicine, 234 an American journal, when Jansen argues for 
involving patients in the decision-making process about pain relief. She advocates 
a scenario in which the physician involves both the patient and the patient's 
chaplain in ethical discussions about increasing doses of opioids, because of the 
risks of hastened death caused by respiratory depression that she argues should be 
communicated to the patient. 
The patients in the interviews talked about the inevitability of increasing doses. In 
an educational paper on end-of-life issues in the Journal of the American Medical 
Association, a medical journal with one of the highest impact factors, a clinical 
scenario involving a Mr B, an 81 year old gentleman with pulmonary fibrosis is 
discussed, using excerpts of conversations with both him and his son . 
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the discussions on treating his disease, the symptomatic treatment of his 
breathlessness is raised and "the promise of gradually escalating (my italics) 
doses of morphine" (p. 2505) suggested for continuing dyspnoea. Another article 
echoing the words participants used in the interviews appeared in the British 
Medical Journal this year236 when two American professors of public health and 
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family medicine described opioids as "a last pharmacological resort" for the 
treatment of osteoarthritis. This is in spite of two systematic reviews providing 
strong evidence that opioids have an overall clinically important benefit of about 
2cm pain relief on a 0-10cm visual analogue scale in osteoarthritis. 198 237 
There is also evidence of the belief that morphine hastens death in the medical 
sociology literature. Timmermans 238 discusses the notion of "death brokering" by 
the medical profession and the concept of the "good death". He describes how 
"hospice workers aggressively treat thirst, bed sores, constipation and pain - even 
if the pain management with morphine might depress breathing (the double 
effect)" (p. 998). 
It is not only in the medical press that beliefs about the use of opioids at the end of 
life are promulgated. Following the publication of a paper by Seale239 about end- 
of-life decisions made by U. K. medical practitioners, the Times correspondent 
Lister, ran an article entitled "Doctors `hasten one third of deaths by using pain 
relief". This was an incorrect interpretation of the Seale paper, in which the figure 
of 33% was given for the percentage of deaths in which the doctors participating 
in the survey considered the alleviation of symptoms had possibly shortened 
patients' lives. This figure therefore included the use of sedatives as well as 
opioids and referred to possible rather than probable or definite shortening of life. 
It is interesting that the literature about respiratory depression caused by morphine 
and the routine use of escalating doses is mainly in the North American medical 
press; the concerns about opioids that once threatened the development of the 
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WHO ladder may still remain and prevent its proper use. However, it would be 
wrong to assume that only North American professionals have negative views 
about morphine. Seale's survey239 showed that U. K. doctors believed the 
alleviation of symptoms possibly hastened death in 33% of dying patients they 
attended. In a subsequent editorial, Forbes and Huxtable240 challenged both the 
methodology of the study and its conclusions. They comment on their experience 
that both clinicians and medical students often believe they are hastening death by 
the use of opioids at the end of life due to respiratory depression, when in fact the 
evidence suggests they are not. This year, in an anonymous personal view in 
support of the assisted dying bill published in Clinical Medicine, the journal of the 
Royal College of Physicians, the author (a doctor) described how his/her mother 
only received "proper terminal care" when she got to the hospice and "a 
morphine infusion ended her lifes241 Is it any wonder that Andy said: "the three 
words that strike the fear of God into your average working class bloke are 
`morphine', `palliative' and `hospice"'? 
It seems that many in both professional and lay circles share the view that the use 
of morphine is precluded until the dying process begins. This is further evidenced 
by the fact that much of the current literature around death and perceptions of a 
good death is consumed by discussions about pain relief . 
213 242 243 In particular, the 
North American literature shows that fear of dying in pain is a significant issue for 
many. 
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4.4.4.4 Lack of concern about addiction and tolerance 
It was interesting to note that when the participants were allowed a "free rein" to 
raise whatever they wished in the interviews, very little was made of addiction and 
tolerance. When addiction was mentioned it was because participants had heard of 
addiction in relation to opioids, but they found it difficult to say what addiction 
would mean to them. Only one participant mentioned tolerance, because he had 
read the patient information leaflet supplied with the bottle of morphine. Even 
then, he spoke of a need to increase the dose rather than the common concept of 
tolerance i. e. "if I use morphine now it will not work later when the pain is 
worse". Other participants talked of inevitable dose escalation but not because of a 
lack of effectiveness of morphine, rather because this was what they had seen 
happen to others. This did not seem to represent anxiety about eventual lack of 
effect of morphine. It is possible that addiction and tolerance have been 
perpetuated through the opioid literature because concerns about them are easier 
or perhaps "safer" to mention in research studies, especially quantitative studies, 
than fears about death and dying. It is also possible that the notion that patients are 
concerned about tolerance and addiction is itself a "myth about morphine". 
4.4.4.5 Side effects 
Another concern raised in my interviews and borne out in the literature was 
patients' fears about side effects. This is supported by a telephone survey 
conducted by Palos and colleagues 244 which also found that prior experience of 
side effects acted as a deterrent to the use of analgesic medication. In this study, 
302 randomly selected adults were asked about prior experience of and knowledge 
about pain and therapy for pain relief and about their willingness to use analgesics 
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for differing levels of pain. The authors found previous experience of side effects 
meant an individual was 1.3 (95% C. I. 1.1 to 1.5) times more likely to be in the 
"conservative cluster" i. e. less willing to take analgesics for pain. The main side 
effects mentioned in our interviews were the neuro-toxic effects of mental 
clouding, sleepiness and hallucinations and these were seen by some as inevitable. 
In fact there is some evidence that being in pain has a more negative effect on 
psychomotor functioning than receiving stable doses of opioids. 245 Klepstad and 
colleagues246 showed cognitive impairment (as measured by objective 
assessments) was not related to patients' self-reports of cognitive impairment and 
sedation, suggesting a more systematic observation of patients' cognitive function 
may be necessary in order to either reassure them that opioids are not associated 
with impaired function or to take appropriate measures if they are. A well 
conducted systematic review of the management of all opioid side effects247 
commented on the poor quality, weak evidence physicians have to guide their 
practice when managing opioid side effects. This lack of available evidence 
suggests side effects have not been considered a research priority in spite of their 
influence on patients' decision-making. If scant attention is paid to side effects or 
they are not managed properly, perhaps because the professionals think they are 
unmanageable, patients will continue to be deterred from using morphine or other 
Step III opioids. 
4.4.4.6 Decision-making (factors influencing the decision to commence) 
There were similarities in our interviews with results of other studies in the non- 
cancer pain literature about the factors that influence patients' decisions to take 
analgesics. Ross and colleagues248 used focus-groups to discuss what strategies 
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older people use to manage pain and found they employed a variety of non- 
pharmacological strategies, seeing medicines as a last resort (no quotations are 
used in the manuscript so it is not known whether this was a phrase used by the 
members of the focus group or an interpretation by the authors). Participants' 
reluctance was in part due to the side effects experienced with analgesics. The 
decision to use a particular strategy was based on the severity of the pain, personal 
experience and self-acquired knowledge (including side effects experienced and 
whether or not a particular strategy had worked in the past). This also fits with a 
synthesis of qualitative studies of lay experiences of medicine taking conducted 
by Pound and colleagues. 249 This review concludes, "there is considerable 
reluctance to take medicines and a preference to minimise medicines intake" 
(p. 151). The authors supported the tendency of the public to "resist" using 
medications (of all kinds) viewing this resistance as a reasonable consequence of 
the adverse drug reactions experienced by many, which they felt had been 
previously marginalized as patient-held "beliefs" about medicines. Home and 
Weinman250 explored the relationship between patients' beliefs about medicines 
and self-reported compliance and found that patients engage in cost-benefit 
analyses when deciding whether or not to use their medications. This could be 
extrapolated to the use of opioids as seen in this study, where one of the factors in 
commencing Step III opioids was the severity of the pain experienced. If the 
perceived benefit for the participants was freedom from pain, then this benefit was 
greater if their pain was severe. The costs perceived by the participants were likely 
to be side effects and perhaps even inevitable death and it may be that it was only 
when pain was "excruciating" that the cost-benefit analysis finally favoured the 
use of Step III opioids. 
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4.4.4.7 The role of the professional 
The participants spoke of the difference in consultation style they experienced 
when they were seen by palliative care professionals who believed their pain, took 
the time to listen to their stories and demonstrated specialist knowledge. They also 
told how other professionals had influenced their decision to commence 
morphine. The impact of the professional on pain management has also been 
demonstrated in other studies. Sherwood and colleagues251 asked a large sample of 
hospitalised patients about satisfaction with pain management using three open- 
ended questions at the end of a questionnaire survey. Patients were more satisfied 
with their pain management if health care providers "affirmed the pain 
experience... used expert knowledge and skills to manage pain and responded with 
caring, timeliness, and attentive presence" (p. 493). The participants in my 
interviews also described language used by professionals that had helped them 
accept morphine or oxycodone and said they thought good explanations of opioids 
were essential. The need for detailed information about opioids, including a 
warning about side effects, was echoed in a focus group study of patients who had 
been using a patient-controlled analgesia device (PCA) containing morphine for 
post-operative pain control. 252 Chumbley and her colleagues designed the study in 
order to develop and evaluate a new patient information leaflet for patients using 
PCA. These patients felt they wanted detailed explanations about morphine, 
especially about side effects, so that if side effects did arise they could seek help. 
They also felt an explanation of the difference between opioids used in a 
controlled manner and as drugs of abuse would have helped. 
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4.4.5 Implications for clinical practice 
4.4.5.1 The role of the palliative care team 
The difficulties of pain management in busy oncology clinics, where the focus of 
care is on disease rather than symptom management, are highlighted in my 
interviews. In the oncology centre where these participants were recruited there is 
no routine measuring of pain scores. However, even in centres that have 
incorporated routine measurement of pain in the outpatient clinic, studies have 
shown pain management does not automatically improve. 253 Reyes-Gibby and 
colleagues254 also demonstrated that patients might report different pain scores in 
different settings. Because of their study design, they were unable to draw definite 
conclusions about possible reasons for this differential reporting, but one 
possibility included patients being unwilling to report pain in places such as 
chemotherapy outpatient clinics, in case this led to treatment being interrupted. 
However, perhaps these findings, along with the stories of sub-optimal pain 
management told in our interviews, should provoke a discussion about the 
involvement of palliative care teams earlier in the patient's disease trajectory. It 
may be that the traditional model of frequent follow-up of patients by palliative 
care teams would not be appropriate, being replaced instead by intermittent 
consultations about pain management. The involvement of palliative care teams 
earlier in the disease trajectory may also help to dispel the fear that the word 
"palliative" invokes in some. Greater education and training of other professionals 
likely to be offering morphine to patients with cancer would also seem crucial to 
improving cancer pain control. 
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4.4.5.2 The role of the professional: offering morphine 
The results of these interviews have implications for the language used by doctors 
when talking to patients about the management of cancer pain, because of the 
effect our words have on patients' decisions about painkillers. Further examples of 
the importance of language are found in the initial wording of the WHO ladder 
with the use of "weak" (Step II) and "strong" (Step III) opioids. Although the 
terminology altered in the 1996 version of the analgesic ladder, the words weak 
and strong have survived in common usage. In their analysis of the consultations 
recorded during a pilot study of a pharmacist as a medication counsellor Chen and 
Britten255 found that perceived potency was important to patients, especially when 
dealing with side effects. If a drug was thought to be strong, but had unwanted 
side effects, then patients would most probably stop it, even if it were effective. It 
seems likely, as shown in my interviews, that language plays a part in decision- 
making about opioids and the use of the term "strong" is not helpful to patients 
when considering morphine or other Step III opioids. These results provide us 
with the evidence we need to educate both students and colleagues in terminology 
that makes Step III opioids less fearful to patients and about the importance of 
professional attitudes to morphine. 
4.4.5.3 The role of the professional: side effects 
The evidence from the literature review in the Introduction (Section 1.5) is that 
professionals believe that side effects from opioids are difficult to treat, or 
inevitable. The paucity of good evidence available about the management of 
opioid-related side effects also suggests that they have not been given priority, in 
spite of the evidence that they have a powerful influence on pain management 
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decisions made by patients. It is clear from the interviews that a negative 
experience of opioids can result in uncontrolled pain not only for that patient, but 
also for those in his/her social circle who may witness the event and later require 
Step III opioids themselves. The management of opioid related side effects must 
be exemplary if they are to be usefully employed in the treatment of cancer pain 
and professionals must be taught about both the monitoring of opioids and the 
consequences of poorly managed side effects. 
4.4.5.4 The use of the doctrine of double effect 
The doctrine of double effect is often employed to support or justify the use of 
opioids at the end of life, 
256 257 in spite of commentaries258 
259 
and evidence226 
suggesting it is not necessary to do so. Fohr258 also argues that it is harmful to do 
so because to invoke the doctrine reinforces negative associations in the minds of 
both professionals and patients. I was interviewing participants at the same time as 
the Assisted Dying Bill was being debated nationally, and the doctrine of double 
effect was mentioned frequently by those against assisted dying, as a means of 
reassuring the public that pain can be controlled at the end of life. It seemed this 
debate was indeed reinforcing the association of morphine with death and dying 
for the study participants. At a recent educational event on ethics aimed at 
palliative care professionals, a scenario involving the possibility of a patient's 
death after the administration of analgesics was introduced in order to stimulate a 
debate about the doctrine of double effect. I would argue that there it is erroneous 
to use opioid analgesics as examples for the principle of the doctrine, because the 
evidence is that opioids do not shorten life and to do so reinforces the 
misconception that they do. 
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4.4.6 Implications for research 
4.4.6.1 The value of qualitative methods 
It is interesting to note that Sela and colleagues260 after conducting a study asking 
patients to rate their pain and then their emotions experienced when in pain on 
seven different visual analogue scales, concluded that pain was not associated 
with fear in patients with cancer. The mean rating of fear was 36.8 (SD 26.4) for 
men and 48.5 (SD 29.8) for women, which was lower than the other emotions 
asked about (frustration, anger, exhaustion, helplessness and hopelessness). The 
correlation coefficients for physical pain and fear were only 0.05 (men) and 0.23 
(women). In the light of these findings, they conclude "Contrary to popular belief, 
it appears that advanced cancer pain does not foster pronounced fear" (p. 30). This 
is contrary to our results also, since the participants spoke of how pain reminded 
them of their disease and their impending death. Perhaps the use of qualitative 
methods is a more sensitive means of eliciting concerns such as fear of death. 
4.4.6.2 Future projects 
We know that knowledge about safe prescribing of opioids is reaching medical 
students when their curriculum allows (Forbes personal communication) but we 
do not know if their attitudes to opioids are altered when they become junior 
doctors on hospital wards and exposed to the attitudes of more experienced 
colleagues. We do not know whether the professional views about opioids 
demonstrated in these interviews belong to mature colleagues, or are in fact more 
widespread and present throughout senior and junior medical and nursing staff. 
The origin of professional concerns about Step III opioids must be investigated if 
we are to change attitudes, particularly if we might suggest their earlier use in 
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cancer pain as part of a 2-step ladder. Increasing regulation of Step III opioids261 
following the Shipman enquiry may lead to further inhibition of their use in 
primary care and this requires investigation. 
4.4.6.3 Conducting a definitive 2-step trial 
Whilst improving recruitment was not the primary aim of the qualitative 
component of the pilot study, we should make use of the findings when 
considering the conduct of the definitive 2-step trial. Other studies have shown 
that in a randomised study the language used and the manner in which treatment 
arms are presented to patients has an influence on recruitment rates. 
262 263 My 
interviews have shown that patients have negative perceptions about morphine 
and other opioids that cannot be ignored when recruiting to a trial involving 
opioids. However, the interviews have also shown that careful use of language e. g. 
low dose and attention to side effects may mitigate against the effect of these 
perceptions. Furthermore, those discussing trials involving opioids with potential 
participants will need to be aware that the offering of morphine will be interpreted 
as a bad prognostic sign. It may be necessary to address this within the patient 
information sheet and certainly during conversations with potential recruits in 
order to maximise recruitment. 
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Chapter 5: Conclusion 
Key conclusions 
" Current approaches to the assessment of cancer pain need to be improved 
9 Current cancer pain control is sub-optimal 
"A trial to compare the 2-step approach versus the 3-step approach is 
feasible and justified 
" Education of professionals about both the application of the ladder 
including the use of adjuvant analgesics and judicious use of opioids is 
required even if no changes are made to the ladder 
" The greatest barrier to the use of opioids in cancer pain is that patients 
associate them with death 
The studies in this thesis have shown that whilst research in palliative care 
involves an often frail patient group, the difficulties this entails can be overcome 
by collaboration with colleagues to maximise recruitment, designing studies to 
minimize the additional burden on the patient and using a combination of methods 
to make maximum use of data obtained. 
The studies have shown that it is likely that cancer pain management can be 
improved, but that we need to listen to patients first, in order to hear from them 
about their expectations and concerns about pain control. The systematic review 
showed, along with others82 83 162 that it is unlikely that the use of an alternative 
Step III opioid to morphine as first choice will have a significant impact on pain 
management. The pain survey showed that according to current research 
definitions, almost 80% of patients had uncontrolled pain, but that the patients 
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themselves when asked did not agree that their pain was poorly controlled. The 2- 
step trial has provided evidence that an approach which omits the second step of 
the current WHO ladder and uses Step III opioids as soon as Step I analgesics are 
no longer effective, may mean improved pain control, although this must be tested 
in a larger randomised controlled trial. However, the interviews showed that if this 
approach is to be adopted, careful language will be required with patients 
themselves, in order to promote earlier use of Step III opioids. 
We must remember that the WHO Ladder was designed to be used worldwide. 
Difficulties in accessing both Step II and Step III opioids remain throughout the 
world (http: //www. eolc-observatory. net/global_analysis/regions_main. htm), both 
because of expense and concerns about diversification. However, it may be that 
the removal of the second step and sole use of Step III opioids would be 
acceptable as a worldwide approach, allowing efforts to improve opioid 
availability to concentrate on making morphine alone more easily available. 
It seems that anecdote is a more powerful teacher than evidence for patients (and 
perhaps also for professionals) as demonstrated by Andy: 
all the information that I've got in my head has come from watching them, 
hearing about them and seeing them dying. 
Earlier introduction of Step III opioids would mean more patients using them 
earlier in their disease trajectory. This may then provide the stories or images of 
people "living" with opioids and perhaps even "living better" with opioids if we 
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can ensure that they are used correctly and side effects are managed properly. The 
consequences of these stories might be to change this quote to 
all the information that I've got in my head has come from watching them, 
hearing about them and seeing them living 
and thus might alter the perception that morphine is synonymous with dying. This, 
along with efforts to minimise the impact of opioid side effects both by studies 
investigating how best to manage them and education of professionals will surely 
have a positive impact on cancer pain control. Perhaps, rather than waiting for 
new approaches to be identified, we should begin to make best use of what we 
have available and consider a commentary in the Lancet from 1995 which stated 
"Morphine is a remarkably effective analgesic, and when used correctly, 
remarkably safe as we1P'. 264 
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l: INTRODUCTION 
It is estimated that over half of all cancer patients suffer needlessly from pain. 
Studies conducted in the United Kingdom and United States, where high levels of expertise as 
available, indicate that fully 25% of patients die with pain. The problem of inadequate 
'control of cancer pain is even greater in the developing countries, where basic analgesic 
drugs are not available to 60-80% of the population. 
Even when the means to control cancer pain are available, they are often not ' effectivel; 
utilized. Administration at adequate doses is avoided even in suffering patients for fear o 
drug addiction and toxicity. A lack of understanding of the basic principles and methods 
already available to relieve pain contributes to the problem. 
The World Health Organization (WHO) Cancer Control Programme has identified three-major 
targets: to prevent cancer; to cure patients detected early; and to promote a good 'qualit; 
of life and death with dignity for the 65% of patients who cannot be cures. 
In 1982 the WHO Executive Board, Advisory Committee on Medical Research and World Healtl 
Assembly endorsed the WHO Cancer Pain Relief Programme, whose objective is to offer pain 
relief to cancer patients through the existing health care system. In October 1982,; a- WHO 
consultation was held in Milan with a core advisory committee of experts in pain treatment. 
A document entitled "WHO Draft Interim Guidelines Handbook On Relief of Cancer Pain", 'was 
prepared. The principle objective of the present study is to field test these guidelines. 
Feasibility, compliance and effectiveness are the main endpoints for the evaluation. 
In 1984, the WHO Collaborating Centre for Cancer Pain Relief was identified in the 
Division of Pain Therapy at the National Cancer Institute of Milan. This centre, in 
conjunction with the WHO Collaborating Centre for Cancer Biostatistics Evaluation at Harvard 
University in Boston, will coordinate the conduct of this study as the central operations 
office for the Field Testing. 
Z. SUMMARY OF THE GUIDELINES 
The guidelines being tested are those-described in the document dated 7 December 1983 
and entitled "WHO Draft Interim Guidelines Handbook on Relief of Cancer Pain". These 
. guidelines propose a therapeutic strategy for the effective use of drugs to treat cancer 
pain. After the assessment of the exact nature of the patient's pain, when specific pain 
relieving procedures (surgical or chemo-radio-hormono therapies) are not indicted or-not 
available, treatment should be started at once with the pain relief drug or drugs'carefully 
selected. Drugs have to be administered at adequate doses at fixed times, by, oral route 
whenever possible. The drugs used for relieving cancer pain can be classified into four 
groups as shown in Table 1. The specific indications for use, recommended doses, and 
potential side effects are given in detail in the guidelines document. 
'The sequence of administration of these dtugs will follow the course and increase-in 
severity of pain with time, starting from nonnarcotic drugs, which represent the first step. 
When the recommended analgesic dosage and frequency fail to relieve pain, the medicatjo 
should be strengthened by a drug of the weak narcotic group. If the weak narcotic and the 
nonnarcotic proves ineffective, a strong narcotic should be used. Especially'in patients 
with bone pain, requiring additional analgesia, aspirin or other antirheumatics may be added 
to the darcotics. Adjuvant drugs should be used together with narcotic and nonnarcotic drugs 
in case of specific indications. The analgesic ladder, which illustrates the basic, principle 
of treatment as defined by the guidelines, is shown in Figure 1. 
THE COMPLETE GUIDELINES DOCUMENT MUST BE CONSULTED PRIOR TO INITIATION OF PAIN TREATMENT 
TO OBTAIN DETAILS OF THE APPROPRIATE REGIMENS TO FOLLOW. 
The following seven points are indicated in the Summary of the Guidelines (page 25): 
1'. ` Cancer pain can and must be treated. 
2. First, take a full history and examination and exclude acute conditions that require 
urgent treatment. 
Drugs will usually provide good relief provided you use the right drug(s), the right 
; II dose(s), and the right frequency of dosage. The drugs must be given regularly by 
the clock and not on demand ("p. r. n. "). 
4. Start the patient on a nonnarcotic drug and adjust the dose to optimum level (see 
Guidelines Table III). If necessary, use an adjuvant drug in addition (Guidelines 
p. '20). 
S. ` If or when this treatment no longer relieves the pain, administer a weak narcotic 
drug (Guidelines p. 10) in addition to the nonnarcotic and together with an adjuvant 
if necessary. 
6, When this no longer relieves the pain, start the patient on strong narcotic therapy 
together, if necessary, with adjuvant drugs and other analgesics (Guidelines p. 20). 
The patient must be supervised as often as possible to ensure that treatment 
continues to match the pain and to exclude side effects and toxic effects. 
Table 1 
A BASIC DRUG LIST 
category Parent drug Alternatives 
1. Nonnarcotic aspirin and other paracetamol (acetominophen) 
antirheumatics 
2. Weak narcotic codeine dextropropoxyphene 







a, Anticonvulsants carbamazepine phenytoin 
be Psychotropics chlorpromazine prochlorperazine 
haloperidol 
diazepam - 
c. Antihistamines hydroxyzine 
d. Antidepressants amitryptiline 
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The Guidelines Field Testing Protocol Study 2 will consist of three phases. 
Phase I involves identifying the participating centres and study coordinators who will 
responsible for local testing of the guidelines. These centre coordinators will complete 
equestionnaire described in Phase II, and submit it to the Collaborating Centre in Milan. 
ecentre coordinator will also instruct local staff in the use of the guidelines document 
d will be 'responsible for monitoring patients and completing data forms for Phase III of 
efield testing trial. 
In phase II, a Participating Centre Questionnaire-will be completed by the study 
rdinator for each participating centre. This questionnaire will request information about 
availability of drugs for pain relief, the use of non-pharmacological methods for pain 
atment, and the personnel resources, facilities, and continuing care networks which are 
ilable. Information about specific drugs to be used at each of the three steps of the 
der willalso be obtained. This information is required to determine current feasibility 
using the WHO Guidelines worldwide. 
7h e evaluation of endpoints in Phase II will provide"a description of the clinical 
tings which make up the sample of centres participating in the Guidelines Testing. It is 
uired to obtain data on the feasibility for each clinic to apply the full guidelines 
cedures. 
Not"all clinics participating in the guidelines testing must have access to all of the 
gs required'for each level of the analgesic ladder. In some clinics where access to 
cotic agents is limited, the ladder may only be feasible to apply up to step two. By 
luating'results of Phase III according to the ability of the individual clinics to 
pletely apply the guidelines we will obtain information about the possible role played by 
delines feasibility. 
In phase III, the guidelines will be applied for the treatment of pain in approximately 
patients per participating centre. Initial, baseline data, 
on the status of the disease and 
severity of the pain will be collected for each patient. The 
*guidelines will be applies 
h monitoring of pain drug treatment and compliance with the; analgesic ladder approach. 
n intensity, pain frequency, treatments, side effects, and use of other modalities will be 
orded. on follow-up forms. "A LASA (linear analogue self-assessment) will also be used to 
sin the patient's evaluation of the extent of relief achieved. The objectives for Phase 
are to determine the level of compliance in delivery of guideline treatment and to 
ermine the effectiveness for reducing pain intensity and-frequency without side effects. 
STUDY SCHEMA 
ise I -' - Identify participating centres and study coordinators. 
se II - Centre questionnaires submitte by participating centres. 
se III - Treat 60 patients on the guidelines approach to determine a) compliance, 
" and b) effectiveness for reducing pain intensity, without side effects. 
The first-10 patients from each centre will be considered pilot patients 
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Follow-up Report Schedule: Weekly for the first two weeks until stabilization of 
the drug regimen, thereafter, at each change in the pain drug treatment, weekly for'twol 
weeks after the change, and once every four weeks if stable. 
6. STUDY OBJECTIVES 
6.1 To determine the feasibility of using the WHO Guidelines in selected participating 
clinics. 
6.2 To test the compliance with the WHO Guidelines approach in selected clinics. 
6.3 To test the effectiveness of the WHO Guidelines in individual patients based on 
measurement of pain reduction with minimal side effects. 
7. METHODS OF APPROACH (PHASE III) ° 
Patients with cancer pain are to be identified and an initial interview form is`to be 
completed. Following a complete history and physical to assess the causes of the, pain, " 
treatment for the pain is started according to the analgesic ladder. Follow-up forms are 
submitted to report on the level of pain and treatment modifications over time.. Specific 
criteria for patient population, starting the ladder, forms submission and follow-up 
schedule, evaluation, and statistical considerations are presented below. 1 
7.1 Patient Population - Patients with cancer pain are eligible for the study. Patient 
who received prior drug treatment for pain are eligible for the study and will begin 
the analgesic ladder at a step which depends on the prior treatment received. 
7.2 Treatment Programme - When appropriate, the initial study treatment should be. at 
Step 1 for at least three days regardless of the initial severity of the pain. Ste! 
1 when delivered according to the guidelines, may be effective even for severe- 
pain. The initial entry step is described in the following table: 
TABLE FOR DETERMINING INITIAL LADDER TREATMENT 
Prior Drug Treatment Status 
No prior drug treatment for pain 
Received prior drug treatment 
for pain but this prior treatment 
was not given according to the 
guidelines (e. g. only occasionally, 
not by the clock, at inadequate 
doses) 
Received prior drug treatment 
for pain which satisfies the 
requirements for Guidelines 
Step 1 
Received prior drug treatment 
for pain which satisfies the 
requirements for Guidelines 
Step 2 or 3 (i. e. regular 
administration of weak or strong 
narcotics) 
Initial Ladder Treatment 
-ý Start on Guidelines Step .1 
for 
. at least three days 
Start on Guidelines Step 1 for at 
least three days 
r 
Start on Guidelines Step 2 for at 
least three days 
Start on Guidelines Step 2 or 
as appropriate 
, 'As 'described in the guidelines document, if pain persists or recurs, modification of the 
tment, including stepping up the ladder, is to be made. 
7.3 Forms Submission and Follow-up Schedule 
A).,. The initial interview form is to be completed at the time of the first patient a.; t interview prior to beginning guidelines treatment. The purpose is to establish 
baseline data on the patient and his/her pain status at the time of starting the 
guidelines. A copy of this form is to be sent to the WHO Collaborating Centre in 
Milan as soon as it is completed to officially register the patient in the study. 
B) Follow-up data are recorded on follow-up forms according to the schedule: 
- Weekly assessements for the first two weeks to monitor stabilization of the 
.;, 
initial ladder regimen. -" 
Every four weeks thereafter as a minimum contact if stable. 
- At the time of change in the pain drug treatment. 
-. ;. Weekly for two weeks after each change to monitor effect, and 
- Every four weeks thereafter. 
_, 




_. 1016 TTTTT " `'" Weekly Every Weekly Every Weekly Every for four for four for four 
two weeks two weeks two weeks 
weeks weeks weeks 
Initial At At 
Form Change Change 
Up' to? 'four follow-up reports can be`matie on each' follow-up form. *, When each form is 
completed, a copy is to be sent to the WHO Collaborating Centre in Milan. 
The critical evaluation of the effectiveness of the guidelines wilLbe based 
upon the' patient's self-assessment"of-pain and the degree of pain relief provides by 
the given treatment. ' A Patient's` Current Self -Assessment"of Pain Form is completed 
by the patient at each follow-up report. The results from this self-assessment are 
then recorded on the follow-up form. 
Application of the guidelines and follow-up of the patients continues until 
death (or until the time of the final analysis of the results). 
7.4 Other Pain Relief Modalities - the use of non-pharmacologic pain relief modalities 
is discouraged during the period of testing of the guidelines. If, however, the use 
of other modalities is felt to be in the best interest of the patient (i. e. 
radiation for bone pain) then these non-pharmacological treatments must be recorded 
on the Follow-up form. If traditional remedies (herbs, spells, etc. ) are also being 
used, these should be noted but will not be grounds for disqualifying a patient. 
ill patients are to be followed until death; those who receive non-guidelines pain 
treatment will have the influence of these interventions accounted for in the 
analysis, but are to continue to have guidelines treatment applied as appropriate. 
STUDY 2 
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7.5 Evaluation - The evaluation of analgesic effectiveness will be bAsed on the. 
patient's self report of pain intensity according to the four-point scale of none; 
slight, moderate, severe. The patient will be asked to specify the number of hour 
of pain, and the number of hours of sleep experienced (per 24 hours average). The, 
simplified measures were adopted so that the field testing could be accomplished i 
a wide diversity of clinical settings. Reduction in the pain intensity report, 
without intolerable side effects is the objective of the programme. 
The experience of pain is subjective, and attempts to objectively quantify pa 
intensity may not adequately reflect the patient's overall impression about the- 
effectiveness of the treatment. How the patient feels about the experience may be 
the most appropriate way to evaluate the programme. A linear analogue 
self-assessment (LASA) will be given to the patient to record how he/she evaluates 
the relief of pain provided by the given treatment '[from "of no value" to "complet 
relief" on a 100 millimetre scale]. Each ladder step will be evaluated by'LASA 
reports, and correlations between the LASA score and "objective" reports, of pain 
intensity and hours will be obtained. 
The duration of effect at each step of the ladder will he evaluated, 
Furthermore, the compliance with respect to providing stronger relief in response 
loss of analgesic effect at the previous level will be ascertained. Thus, it is 
critical that all modifications of pain treatment and the reasons for these 
modifications be recorded on the follow-up form. 
7.6 Statistical Considerations - The objectives of the present study are limited to 
those described earlier: feasibility, compliance, and effectiveness within 
individual patients. No attempt is being made in this protocol to compare the 
guidelines with-current practice, or to determine if introducing the guidelines ha 
an impact on the general quality of life for cancer patients with pain, The latte 
questions will be addressed by other protocols which are being planned.. 
Because the questions of interest in this protocol. are not comparative in 
nature, we will use the concept of acceptable standard error estimates for., 
evaluating extent of compliance to guidelines as a percent of the total cases 
entered. We would like to evaluate n patients per centre so that the standard err' 
of the compliance estimate is no more than . 06. If compliance is around 80X, then 
n-50 patients will satisfy this objective. ", 
In' terms of pain relief, 50 evaluable patients per centre will be sufficientt 
determine if patients on the guidelines experience a noticeable decrease in pain of 
one score or more. Indeed, a shift of one score or more can be detected with 95% 
probability using a two-sided alpha -. 05 Wilcoxon Rank Sum Test based,, on 50 patient 
A pilot study of 10 patients wjil be carried out in each centre. -" The 
Collaborating Centre will contact each participant after this pilot phase to clarii 
guidelines compliance and data cqllection issues which arise. Thus, a total of 61. 
patients entered per centre are recommended for study. 
"i 
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evaluating extent of compliance to guidelines as a percent of the total cases 
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of the compliance estimate is no more than . 06. If compliance 
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determine if patients on the guidelines experience a noticeable decrease in pain of 
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INSTRUCTIONS FOR COMPLETING THE WHO CANCER PAIN RELIEF GUIDELINES FIELD TESTING STUDY FORMS 
The forms packet contains an Initial Interview Form, and three pages to record up to 12 
follow-up reports. Patient's Current Self-Assessment of Pain Forms and additional follow-up 
forms are also provided. 
Complete the first page of the initial interview when a patient with cancer pain ic, _,. identified for the protocol. Submit a copy of the initial Interview Form to the 
Collaborating Centre in Milan immediately to register the patient. Cases should be assigned ` 
numbers sequentially at each hospital. The hospital code and case number will serve to 
identify the patient on future forms. 
- The form should be completed by an adequately instructed nurse. 
- The patient's self-assessment of the level of pain and the degree of relief will be the 
principal items for evaluation. 
- 'The items which should be completed at first visit are on the front page. In the other 
three pages up to 12 follow-ups can be registered. 
- All dates are in day/month/year format. 
FIRST VISIT 
S 
Report the following items: 
Date of first visit (day, month, year), hospital name (with code number), patient's name 
and surname, sequentially determined case number for the patient, age, sex, height, weight, 
type of cancer classified according to organ pathology (i. e. breast; lung, colon-rectum 
etc. ), and how many months since cancer was first diagnosed. 
I PATIENT'S GENERAL CONDITION: indicate with a check (b4 if cancer is primary, 
disseminated or if state is now known. Indicate also if the patient is in terminal phase 
(i. e. prognosis of less than three months survival). Give the ECOG Performance Status Score 
according to the scale given on the pages of codes. State whether the patient is being 
treated as an inpatient or outpatient. 
11 DESCRIPTION OF PAIN: determine how long the patient has had cancer pain, in which part 
of the body the pain is localized, and what the present pain relates to. Using the Patient's 
Current Self-Assessment of Pain ask the patient to specify the mean intensity of pain felt in 
the past 48 hours (as a time-frame). Pain intensity is registered making use of three 
adjectives: slight, moderate and severe. The patient should then be asked the number of 
hours with pain per 24 hours (average), and the number of hours of sleep per 24 hours 
(average). 
III PRESENT DRUG TREATMENT FOR PAIN: report the drug treatment for cancer pain relief 'whic 
the patient is already undergoing. If no 'treatment is being given, check the box labelled 
"no drug treatment". If the patient is being treated pharmacologically, give the tame of the 
drugs, the route (OR - oral route, IV - intravenous, IM - intramuscular, R- rectal), dose 
(mg), schedule and date started. 
IV PAIN DRUG RELATED SIDE EFFECTS: in case the patient has already started pharmacological 
treatments for pain relief, report side effects, if any. If side effects occur, indicate 1 
if intensity is alight; 2 if moderate; or 3 if severe, according to patient's judgement. 
V OTHER PAIN RELIEVING MODALITIES: indicate the types of other treatments for pain relief 
undergone recently (within the past four weeks) by the patient, together with the 
'date when= 
treatment was started. 
STUDY 2 
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INITIAL GUIDELINES TREATMENT: indicate by a check (V which of the four categories to 
ine the initial treatment step apply for this patient. (Note that patients receiving 
ular administration of weak or strong narcotics are not eligible for this field testing 
dy, and, that other patients should start treatment on Step 1 or Step 2 regardless of 
orted pain intensity. ) 
LOW UP REPORTING 
A follow-up report is to be made: 
- Weekly for the first two weeks to monitor stabilization of pain status. 
- At any time the pain drug treatment is modified. 
- Weekly for two weeks after any pain drug treatment modification to monitor the 
ý.: 
"impact-of the modification. 
- `; And at a minimum of every four weeks thereafter for stable patients. 
Each-follow-up report refers to the period between the previous report and the current 
w-uv visit. 
TENT'S CURRENT SELF-ASSESSMENT OF PAIN FORM: 
At each follow-up assessment, the patient is to complete this form to provide an 
uation of pain intensity, hours of pain, hours of sleep, and evaluation of pain relief 
ided by the given treatment. This form may be used at a clinic visit or may be submitted 
mailed) later to the clinic coordinator (registrar). Patients may provide 
-assessments without being required to return to the clinic. 
FORM 
DATE OF FOLLOW-UP REPORT: carefully and accurately enter the date of the evaluation as 
/month year. 
ASK THE PATIENT(using the Self-Assessment Form): how bad is the pain? Mark with a 
k the adjective which the patient uses to best explain the pain intensity felt. Give 
number of hours per 24 hours (average) the patient had pain, and how many hours the 
ent slept per 24 hours (average). Using a measuring ruler 
(in millimetres), determine 
USA PAIN RELIEF SCORE (a number from 0 to 100 millimetres measuring from the left to the 
t) indicated by the placement of the mark (x) by the patient on the LASA scale. 
PAIN DRUG TREATMENT GIVEN SINCE THE PREVIOUS REPORT:, indicate the drugs given, the 
e of administration (OR - oral route, IV - intravenous, IM 
intramuscular, R- rectal), 
dose and schedule. I 
PAIN DRUG MODIFICATION: indicate the reason for any change in pharmacolgical treatment 
due to insufficient analgesic effect, excessive side effects, or other reasons 
(e. g. 
tient's lack of confidence in the drug, too expensive, etc). 
I PAIN DRUG RELATED SIDE EFFECTS: report side effects (I- slight, 2- moderate, 3 
ere) due to-pharmacological treatment for pain relief. 
d- 
OTHER PAIN RELIEVING MODALITIES: indicate any other treatment for pain relief which the 
ent underwent since the previous follow-up report. 
" PATIENT STATUS, indicate if the patient is alive, dead, or lost to follow-up and give 
' date. , his question needs to be completed only once on each follow-up form. An 
-icstion'that the patient has died signals the conclusion of follow-up, so that no more 
h to will be requested. 
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8. COMENTS: enter any comments about the patient's pain and pain treatment course which 
might be helpful for evaluating the compliance and effectiveness of the guidelines for this 
patient. 
DATA SUBMISSION 
Patients are to be followed until death (or until the time when final data analysis for 
the study will begin). The initial interview data form and the follow-up forms containing 
data for 12 follow-tip assessments should be submitted to the Collaborating Centre in Milan as 
soon as they are completed. Patient's Current Self-Assessment of Pain Forms need not be 
submitted, as the data from these forms will be transcribed onto the follow-up forms.. 
Additional follow-up forms, each containing four possible follow-up visit reports, should be 
submitted to Milan when completed. 
PILOT STUDY 
The first 10 patients entered from each participating centre will be reviewed{as a pilot 
study. Patient Self-Assessment Forms should be submitted to Milan for these patients to 
ensure the effectiveness of the methödology. Data for these patients should be submitted 
more frequently to faciliate rapid review and feedback from the Collaborating Centre' in MilaO 
EASTERN COOPERATIVE ONCOLOGY GROUP (ECOG) PERFORMANCE STATUS SCORE 
Score value that the patient is "capable" of performing 
0 Normal Activity. 
1 Symptoms but nearly fully ambulatory. 
2 Some bed time, but needs to be in bed less than 50 per cent of the normal daytime', ' 
3. Needs to be in bed greater than 50 per cent of normal d4ytime. { 
4. Unable to get out of bed. 
OUTLINE OF APPROACH 
Identify Participating Centres 
1and Study Coordinators 
GROUP 2 GROUP 1 
=Those-with Extips ive Those without Extensive 
Previous Exposure to Previous Exposure to 
The Guidelines The Guidelines 
STUDY 1 
Baseline Data on Current Practice. Submit 
Initial Interyiew and Regular follow-up 
data on 30 cancer patients with pain 
STUDY 2 
Introduce Guidelines and Test Feasibility and Effectiveness. 
Submit initial interview and regular follow-up data on` 10 
pilot and 50 study cancer patients with pain treated using 
" the guidelines principle 
STUDY 3 
Outreach Studies V 
To be formulated 
LASA INSTRUCTION EXAMPLE 
PATIENTS CURRENT SELF-ASSESSMENT OF PAIN 
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a Y 
patient's Name: Date: 
a. How bad is the. pain? none 17 
(past 48 hours) 
slight /? Please 
check 
moderate /7 one 
severe /7 
b. How many hours do you have 
pain per 24 hours (average)? hours 
z. How many hours do you sleep 
per 24 hours (average)? hours 
d. Overall, how do you'evaluate the relief of pain provided 
by the given treatment? 
Please put a mark (x) on the scale below to show how you feel* 
No // Complete 
Relief 0 100 Pain 
At All Relief 
"I 
Example: 
No I/ Complete 
Relief 0 100 Pain 
At All 72 Relief 






wnV rAln RLL1Le YYIVLLIKLS VILLD TESTING STUDY I 
INITIAL INTERVIEW FORK 
aa. ry PATIENT, NAME 
.. ACE 
(Years) I1 SEX 
TYPE OF. CANCER Iii 
111, 
PATIENT'S GENERAL CONDITION 
HOSPITAL III 
CASE 19U"ER II 
HEIGHT (c.. ) 1tI WEIGHT NO L1i1 
HOW MANY MONTHS SINCE CANCER WAS DIAGNOSED? ýý south& 
SLATE OF CANCER Cheek ECOG PERFORMANCE STATUS HOSPITALIZATION STATUS thick 
1. primary only 1. in-patient 
2. Dieaeainated rn Terminal patient 2. Out-patient 
3, ,; Not 
known (check if yes) 3. Home case only O 
u DESCRIPTION OF PAIN 
How long has the patient bad the pain? (months 
Whew is the pain! 
pain relates to (check each that applies )t 
CO boo* nerve compression soft-tissue extension 
IM visceral involvement raised intracranial pressure muscle spasm 
ASK THE PATIENT (PATIENT IS 
'CURRENT SELF ASSESSMENT TORM): 




bam' Nov many hours of pain per 24 hours (average)? bouts 
C. Nov . any hours of sleep per 24 hours (average)? I, 1 bouts 
III PRESENT DRUG TREATMENT FOR PAIN - What drug is the patient taking for pain? 
gtack Gregory Generic Hase route dose *schedule 
rQ 
No drug treatment 
'1 Non-narcotics 




E Anticonvulsants --- 
Psychotropics ý- 
0. Antihistamines ---- 
r-I Antidepressants --- 
:, Steroids 
Other ý- 
* Schedule: Specify whether only occassiona ly or less times per week), or frequently; 
as needed, or regularly by the clock.. 
FAIN DRUG RELATED SIDE EFFECTS (If present, give intensity: 0" Done; 1" slight; 2" moderate; 3- severe) 
,; 
TlYusea ýj Bleeding sweating Vertigo ö 
Vomiting Gastralgia Dryouth Others (specify) 
E5 , Drowsiness EZI testlessness "0 
Tremor 
OTHER PAIN RELIEVINC MODALITIES (If yes, specify date and type) 
ask date (dd/m/yy) typo 
Radiation 






INITIAL CUIDELINES TESTING - Indicate the initial guidelines step for this patient (check one which applies) 
po prior drug treatment for pain 
Receiving prior drug treatment for pain. ' but this 
prior treatment was not given according to Guidelines 
(e. g. only occasionally (3 or less times per Week) 
O Received prior drug treatment for pain which 
satisfied the requirements for Guidelines Step 1 
Received prior drug treatment for pain which 
satisfied the requirements for Guidelines step 2 or 3 
.4 
(i. e. regular administration of weak or strong narcotics) 
ýý 
Start on Guidelines stop 1 
for at least 3 days 
start on Guidelines Ste 1 
for at least 3 days 
Start on Guidelines Step 2 
for at least 3 days 
Start of Cuideline" Sceý Pý 2 or 3 , 
ýý, 
as indicated . +'' 
PAIN RELIEF GUIDELINES FIELD TESTING STUDY 2 
tOLLOSJ-UP EVALUATION DATA HOSPITAL 
ý'3 
'f a TE OF FOLLOW-OP REPORT 
! SK THE PATIENT; (Use 
, elf-assessment form) 
ý. Now bad is the pain 
(past 48 bouts)? 
1. low many hours of pain 
per 24 hours (average)? 
C. Nov . any hours of sleep 
per 24 hours (average)? 
4. LISA pain Relief Score 
(0.00ns; 100-complete) 
PAIN DRUG TREAT ENT GIVEN 
SINCE THE PREVIOUS REPORT 
five generic name* 
route JOR. IV, D!. A] . dose and schedule 
Step 1. Non-narcotics 
Step 2: Weak narcotics 







MIN DRUG MODIFICATION 
It pain drug is being 
modified, check nasoo(s)s 
b analgesia ... .... 
Side effects ..... .. 
Other (specify) ". ".. 
CAIN DRUG RELATED SIDE 
LPFECTS. Give intensity 
OT none; 1" slight; 
2" moderate; 3" severe) 
Musen ....... ".. 10miting 
.".... 
Drowsiness ... ..... Ileedins ...... ... 
Cestral=is ... ... . 
lestlessuess .... .. 
Iveatio( . .... ..... 
hyvoutb . ... ..... 
hervor.......... 
1. rtito .... ... .. 
Others (specify) ... .. 
OTHER PAIN RELIEVING 
MODALITIES (If yes, 
specify date and type) 
4diatioo ...... .. 
0ºseatberapy """. ".. surgery . ....... . traditional methods 
Others (specify) 0.... 
, PATIENT STATUS 






































































































































Lost to follw+-up 
STUDY 
PATIENT NAME 
Y! e (ý Dote lost 6l15 11LII L(_J 
Y! s pate of death (I1 "ý i ýýJ 
Ye. 0 ate lost to follow-up l. 11WLII 
d  7Y 
-C0lOttWTt 
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PATIENT'S CURRENT SELF-ASSESSMENT OF PAIN 
Patient's Name: Date: 
a. How bad is the pain 
(past 48 hours) none M 




b. Please put a mark (1) on the scale below to show how bad your worst 




c. How many hours do you have 
. pain per 
24 hours (average)? hours 
d. How many hours do you sleep 
per 24 hours (average)? hours 




no change (I 
worse C] 
f. Please put a mark (ý) on the scale below to show how much relief 
you now feel from your original pain. 
No Complete 
Relief Pain 
at all Relief 
0 100 
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Patient Information Sheet V. 4 27/07/05 
Elk University of 
I BRISTOL 
A Survey of Pain Control in the South West 
We (the Department of Palliative Medicine at the University of 
Bristol) would like you to help us with a research study we are 
carrying out in all palliative care departments in the South West of 
England. Before you decide, it is important for you to understand 
why the research is being done and what it will involve. Please 
take time to read the following information carefully and discuss it 
with others if you wish. Ask us if there is anything that is not clear 
or if you would like more information. Take time to decide whether 
or not you wish to take part. Thank you for reading this. 
What is the purpose of the study? 
We are checking that the pain relief guidelines we currently follow 
are controlling cancer pain adequately in as many patients as 
possible. Previous research studies suggest that 8 out of 10 
people with cancer pain will achieve adequate pain relief with 
these guidelines, but this has never been checked in the United 
Kingdom. 
Why have I been chosen? 
It would be impossible for us to involve everyone with cancer in the 
South West of England in our survey because of the large 
numbers involved. However, we can use a smaller number and still 
get accurate results, by asking a smaller "cross-section" of patients 
to complete the survey. We have decided to try to involve 
everyone seen by a palliative care team professional today. 
Do I have to take part? 
It is up to you to decide whether or not to take part. If you do 
decide to take part you will be given this information sheet to keep 
and be asked to sign a consent form. If you decide to take part you 
are free to withdraw at any time. A decision not to take part or to 
withdraw will not affect your care at any time. We would be grateful 
if we could still record information such as your date of birth and 
diagnosis and level of activity, to ensure that we are not missing an 
important group of people from our survey. 
What do I have to do? } 
If you agree to help us, we will ask you to fill in a questionnaire that 
will not be seen by the doctor or nurse managing your pain (this is 
Patient Information Sheet V. 4 27/07/05 
so that you can be as honest as you wish). This questionnaire 
should be placed in the attached envelope and the envelope then 
sealed. With your permission, they will also fill in a questionnaire 
about your cancer and your pain relief medication. 
Will my taking part in this study be kept confidential? 
We are not collecting your name on the questionnaire. However, 
we are collecting your postcode because this will allow us to see if 
social or financial factors have an impact on pain control. We will 
not use your postcode for any other purpose. It is possible that 
your identity could be revealed from your postcode but we will 
keep all questionnaires in locked filing cabinets and only the 
research team will have access to them. We will keep them for 15 
years and then they will be confidentially destroyed. This is normal 
procedure for research records. 
If you are completing this survey in your own home or in a day- 
care setting, with your permission we will send a letter to your 
general practitioner just to let them know that you have taken part 
in a pain survey. 
What will happen to the results of the research study? 
Once the study is completed, we will use the results to assess our 
current management of cancer pain and in particular to identify 
types of pain which may be more difficult to control. We will try to 
publish the results in a journal read by palliative care 
professionals. We will also send a copy of the results to all the 
centres that participated in the study. 
Who is organising and funding the research? 
This study is being conducted and funded by the Department of 
Palliative Medicine at the University of Bristol. It is one of a series 
of studies that I will submit in order to attain a higher degree 
(Doctor of Medicine). 
Who has reviewed the study? 
The South West Multi-centre Research Ethics Committee has 
approved this study 
Thank you for your help. 
Dr. Colette Reid Department of Palliative Medicine 
Research Fellow University of Bristol 
0117 928 3336 
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Patient Consent Form Version 3 27/07/05 
Centre Number Patient Identification Number for this trial 
33 - 09 
CONSENT FORM 
Title of Project: Cancer Pain Control in the South West 
Name of Researcher: Dr. C Reid, Department of Palliative Medicine, University of Bristol. 
Please initial box 
1. I confirm that I have read and understand the information sheet dated 27/07/05 
(V4) for the above study and have had the opportunity to ask questions. 
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical care 
being affected. 
3.1 agree to take part in the above study. 
Q 
4. I am happy for my palliative care doctor or nurse to fill in a questionnaire 
about my pain relief medication. 
Q 
5. I am happy for my GP to be informed of my participation 
(for patients seen in their own homes). 
Clk University of 
O&SBRISTOL 
6. I do not agree to take part in the above study, but agree to my date of birth, 
diagnosis and level of activity being recorded. F1 
Date Name of Patient 
Name of Person taking consent 




1 for patient; 1 for researcher; 1 to be kept with hospital notes 
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Patient Questionnaire Version 2 10(07/05 
Pain Survey Centre No. I Study No 33 - 09 
Q. 1 How old are you? m Yew 
Q. 2 What is your postcode? 
Q. 3 Are you male Q1 or female 2 
Q. 4 Do you have pain or need painkillers? Yes F1 1 No 
E2 
If you have answered no, there are no more questions. Thank you for your help. 
If you have answered yes, we would like to find out how bad your pain is. 
Q. 5 Please circle the number that best describes your pain right now 
WORST 
No 0123456789 10 pain 
pain imaginable 
Q. 6 Please circle the number that best describes your pain at its worst in the last week 
No WORST 
pain 0123456789 10 pain 
imaginable 
Q. 7 Please circle the number that best describes your pain at its least in the last week 
No WORST 
pain 0123456789 10 pain 
imaginable 
Q. 8 Please circle the number that best describes your pain on average in the last week 
No WORST 
pain 0123456789 10 pain 
imaginable 
Q. 9 Do you also experience temporary flares of pain that are worse than your usual 
pain? 
Yes 0i No I1 2 
Q. 10 If yes, on average, how many times a day do you get these flares? 
0-3 times per day 01 4-6 times per day 02 
7-10 times per day 03 >10 times per day 14 
Q. 11 Do you take pain relief medication for these 
flares? (break-through or rescue doses) Yes Q1 No F 2 
Q. 12 If yes, does it work? Yes Q1 No F-1 2 
Overall, is your pain controlled? Yes Q, No Q2 
Thank you 
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A survey of cancer pain control by South West England palliative care teams 
Instructions for professionals 
1. Please sign the professional's consent form and the site staff signature log at 
the beginning of the study day. 
2. Please sign each patient's consent form. 
3. Please fill in your professional number on all questionnaires. This is a 
combination of your initials and the last two digits of your year of birth. E. g. 
Mary Smith born in 1954 is MS54. 
4. We recommend you fill in your questionnaire as the patient completes theirs. 
There are no patient details on the your professional questionnaire to identify 
which questionnaire belongs to which patient. 
5. For patients seen in day care or community settings, please post a copy of the 
GP letter to the GP. Stamped envelopes are provided for this purpose. 
6. Please make four copies of the signed patient consent form. One should be 
placed in the envelope along with both the patient and professional 
questionnaires, one in Section 10 of the Investigator Site File, one in the 
patient's notes and one copy is to be given to the patient when they are next 
seen. 
7. At the end of the study each large envelope should contain a sealed patient 
questionnaire, the relevant professional questionnaire and a copy of the 
patient's consent form. 
Please do not approach patients about the study if you are concerned it may add to 
their distress. 
It is acceptable for you to help a patient complete their form if there is no-one 
accompanying them who could help. 
THANK YOU for helping us with this pain survey. 
Definitions 
1. Opioid Switch 
This is defined as a change of opioid. A change from morphine to diamorphine in 
a dying patient would be considered a switch and the reason would be "alternative - 
route". -ý However, changing. 
from four-hourly morphine to modified-release 
morphine is a change of formulation and not an opioid switch. 
Professional Questionnaire V2 18/07/05 
Centre No. Professional Patient 
No. No. 33 09 
Q. 1 What is your role? (please tick box) 
Doctor EJ i Nurse 
n2 
Q. 2 In which setting are you seeing this patient? 
Hospice IPU II Outpatient clinic 02 
Day hospice 13 Home 4 
Hospital 05 
Q. 3 Where is this patient's primary tumour(s)? 
Breast 0I Prostate/ Genitourinary 06 
Colorectal 02 Haematological 07 
Lung 13 Mesothelioma 08 
Upper GI 04 Head and neck 09 
Unknown 1° 05 Other 0 10 
Q. 4 What is their ECOG p erformance status? (see 
below) 
ECOG SCALE: 
0= Normal Activity 3= Needs to be in bed >50% of the day but not bedridden 
1= Symptoms, but fully ambulatory 4= Unable to get out of bed 
2= Symptomatic but in bed <50% of the day 
Q. 5 What do you think is the mechanism of their pain(s)? 
I 
Nociceptive QI Neuropathic 
Mixed Q3 Other (e. g. te 
Q. 5a If other please describe 








Professional Questionnaire V2 18/07/05 
Q. 6 Has this patient had radiotherapy for current pain control? Yes Q1 No Q2 
Q. 7 Has this patient had chemotherapy for current pain control? Yes Ili 
QI No Q2 
Q. 8 Has this patient had a nerve block for current pain control? Yes Q1 No Q2 
Q. 9 Has this patient had spinal analgesia for current pain Yes Q1 No Q2 
control? 
Q10. Which of the following is your patient currently using fo r pain control? 
DRUG 24 hour dose Used for breakthrou h pain? 
i i 
Dose 
a) Asp nQ r 1 
b) Paracetamol Q Q1 
c) NSAID Q Q1 
d) COX2 Inhibitor Q, Q1 
e) Codeine Q 
Q 
f) Coproxamol Q1 Qi 
g) Morphine Q1 
Q 
h) Diamorphine Q Qt 
i) Oxycodone Qi Q 
j) Tramadol Q1 Qt 
k) Hydromorphone Q1 Qi Q1 
1) Methadone Q1 Qi 
m) Fentanyl Qi 
Qi 
n) Buprenorphine Q1 
Q 
Q. 11 What is the route of administration of the opioid? 
POQi SCQ2 IVQ3 
Intrathecal Q4 Epidural Q5 Transdermal Q6 
Please tick which drug is used for breakthrough pain. If none used please tick below 
None used II i 
Professional Questionnaire V2 18/07/05 
Q12. Which of the following is your patient currently using for pain control? (Please 
tick appropriate boxes and give total 24 hour regular dose) 
o) Steroid QI Name Dose Eý 
p) Anti-depressant 
Q1 Name Dose 
q) Anti-convulsant QI Name Dose 
E= 
r) Ketamine Q' Dose 
--ý Breakthrough Dose CQ 
s) Bisphosphonates 
Q PO II IV 02 
t) Any other drugs or non-drug Q Please describe 
measure 
Q. 13 Has this patient ever had an opioid switch? 
Yes Q No Q2 
Q. 14 If yes, how many times? 
Q 
Q. 15 What was the prime indication(s)? 
Inadequate analgesia 
Alternative route (e. g. patch) 
Poor adherence 
Q. 16 How long has this pat! 
Less than 24 hours 
Any comments? 
Q1 Inadequate analgesia and side-effects Q2 
Q3 Adequate analgesia but side-effects Q4 
Qs 
ent been known to the PCT? 
Qi<1 week Q2>1 week Q3 
Date Completed 2005 
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20 December 2004 
Dear «Title» «Surname» 
A Survey of Cancer Pain Control by South West England Palliative Care Teams 
I am writing to ask if you would be prepared to participate in a survey of cancer pain 
control in a palliative care population. This survey aims to measure the prevalence of 
cancer pain, but also aims to estimate the effectiveness of the W. H. O. analgesic ladder 
by measuring the prevalence of uncontrolled cancer pain. We are assuming that 
patients being seen by palliative care professionals will have their pain managed 
according to the analgesic ladder. The W. H. O. studies conducted to validate the 
ladder suggested that about 80% of patients can have their pain controlled but this 
figure has not been supported by subsequent pain surveys from the United States and 
France. No similar studies have been carried out in the United Kingdom. The survey 
will also examine factors associated with poor pain control such as the nature of pains 
and breakthrough pain information. 
I would like to conduct the survey from as many palliative care units as possible in the 
South West of England. My aim is to collect data from around 425 patients. 
The survey will be conducted on one day only in a designated week and will involve 
both patients and professionals completing anonymised matched questionnaires. 
These have been kept as brief as possible. I am enclosing a copy of the questionnaires 
and the patient and professional information sheets, to give you an idea of the time 
involved. 
At the moment I am in the process of submitting to the South West MREC but will 
also require R+D approval from each trust involved. In order to collect data from `'. 
patients in community settings when seen by community palliative care nurses, we 
will need to have designated local investigators. (This would involve completing part 
C of the ethics application forms but should not be onerous. ) If you would like to 
participate as a local investigator, or would like further information about the study, 
please return the enclosed reply form with your contact details and the name of your 
trust. I aim to conduct the survey in March or April 2005 and would like to arrange an 
investigators' meeting for later in the year to discuss the study findings. 
This study will contribute to my MD thesis based on the WHO analgesic ladder and 
the management of cancer pain. My supervisor is Professor Geoffrey Hanks at the 
University of Bristol. 
Thank you for your time 
Yours sincerely 
Dr Colette Reid 
Research Fellow 
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NHS Research Ethics Committee 
APPLICATION FORM 
This form should be completed by the Chief Investigator, after reading the Guidance Notes. 
See Glossary for clarification of different terms in the application form. 
Short Title and version number: (maximum 70 characters - this will be inserted as header on all forms) 
Cancer Pain Survey 
Name of NHS Research Ethics Committee to which application for ethical review is being made: 
SWMREC 
Project Reference number from above REC: 05/MRE06121, 
Submission Date: 08/02/2005 
a 
Al. Title of Research 
Full title: A Survey of Cancer Pain Control by South West England Palliative Care Teams 
Key words: Cancer pain palliative care 




Post: Research Fellow in Palliative Medicine 
Qualifications: MBChB, MRCGP 
Organisation: Department of Palliative Medicine, University of Bristol 
Address: Level C, Bristol Haematology and Oncology Centre 
Horfield Road 
BRISTOL 
Post Code: BS2 8ED ' 
E-mail: Colette. reid@bristol. ac. uk 
Telephone: 0117 928 3336 0 
Fax:. 0117 928 3865 .. 0 
A3. Proposed Study Dates and Duration 
Start Date: 01/05/2005 
End Date: 31/05/2005 
Duration: Months: 1; Years: 
NHS REC Application Form - Version 4.0 1 AB/20370/1 
Date: 08102/2005 Reference: 05/MRE06121 Online Form 
A4. Primary purpose of the research: (Tick as appropriate) 
Q Commercial product development and/or licensing 
Q Publicly funded trial or scientific investigation 
Educational qualification 
Q Establishing a databaseldata storage facility 
Q Other 
AS. Tick the box If your research: 
Q Involves testing a medicinal product 
Q Involves investigating a medical device 
Q Involves additional radiation above that required for clinical care 
Q Involves using stored samples of human biological material (e. g. blood, tissue) 
Q Involves taking new samples of human biological material 
Q Involves only patient records or data, with no other direct patient contact 
Q Involves prisoners or others in custodial care 
Q Involves adults unable to consent for themselves through physical or mental incapacity 
Q Has the primary aim of being educational (e. g. a student project, or a project or research necessary for a 
postgraduate degree or diploma) 
A6. Do you consider that this research falls within the category where there is no need to appoint a Principal 
Investigator at each site? 
O Yes 0 No 
If Yes, please justify: 
NHS REC Application Form - Version 4.0 2 AB/20370/1 
Eý; '' Date: 08/02/2005 Reference: 05/MRE06/21 Online Form 
A7. What Is the principal research question/objective? (Must be In language comprehensible to a layperson. ) 
The principal research question is how effective is the World Health Organization (W. H. O. ) analgesic ladder, as utilised by 
specialists in palliative care, in the management of cancer pain. This will be estimated by measuring the prevalence of 
uncontrolled cancer pain in a population of patients referred to specialist palliative care teams. 
AS. What are the secondary research questionslobjectives? (If applicable, must be in language comprehensible to a lay 
person. ) 
To define/identify in a population of patients referred to palliative care teams: 1. The point prevalence of cancer pain 2. The 
proportions of different types of cancer pain 3. Factors associated with poor pain control 4. The proportion of patients who 
need a change of opiold or an anaesthetic procedure and 5. Whether or not patients are receiving pain medication 
appropriate to their pain. 
A9. What Is the scientific justification for the research? What Is the background? Why Is this an area of 
importance? (Must be in language comprehensible to a layperson. ) 
Pain is the most common symptom in patients referred to palliative care services. The W. H. O. analgesic ladder provides the 
framework for the treatment of cancer pain worldwide and was validated at its inception in 1986 by several studies 
coordinated by the W. H. O. These studies suggested that 80% of cancer pain could be controlled by appropriate use of the 
ladder. However two large pain prevalence studies conducted in France and U. S. A. in 1991 suggested that cancer pain 
control remained poor, inspite of widespread adoption of the principles of the ladder. A Scottish audit of cancer pain control 
conducted In 2000 also revealed poor pain control with almost 50% of patients recording a pain score of 4 or greater on a 
0-10 scale. A systematic review of the validation studies, by Jadad and Browman, published in 1995, questioned the quality 
of the evidence supporting the ladder's effectiveness and called for further research. These data together suggest that the 
proportion of patients with unrelieved pain is possibly much higher than we believe. This study is part of a series of studies 
investigating the continuing utility and effectiveness of the ladder. 
A10. Give a brief synopsis/summary of methods and overview of the planned research, Including a brief explanation of 
the theoretical framework which Informs It. It should Include a brief description of how prospective research 
participants and concerned communities (not necessarily geographical) from which they are drawn have been 
consulted over the design and details of the research. 
(Where appropriate a flow chart or diagram should be submitted separately. lt should be clear exactly what will happen to the 
research participant, how many times and In what order). 
This section MM be completed in language comprehensible to the lay person. Do 1`IS2I simply reproduce the protocol. 
This is a cross-sectional study. All patients seen on a single designated day by a doctor or nurse in a palliative care team 
will be asked if they wish to participate, provided they are competent and that in the opinion of the health professional their 
participation will not cause distress. 
Those who are willing to participate will then be asked to complete a questionnaire, (one side of A4) which should not take 
more than 10 minutes to complete. The professional seeing the patient will also be asked to complete a questionnaire about 
that patient's treatment (two sides of A4). The questionnaires will be anonymised, but will have matching numbers to ensure 
paired data is obtained. Patients will be asked to score their pain on a 11 point numerical rating scale. This scale has been 
chosen because of its demonstrated utility in this population and because scores of 5 or greater on this scale have been 
shown to correspond to significant interference with function in patients. 
We wish to obtain a representative group of palliative care patients and so need to recruit from all settings in which palliative 
care patients are seen by a health care professional. This means we will be recruiting from hospital wards and outpatients, 
hospice in-patient units and day centres and also recruiting patients seen by professionals in their own homes. 
, The questionnaires will be piloted in the investigator's institution. Feedback from both patients and professionals after this 
pilot will be used to amend the questionnaire design. 
All. Will any Intervention or procedure, which would normally be considered a part of routine care, be withheld from ? 
the research participants? 
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0 Yes a No 
A12. Will the research participants receive any clinical intervention(s) or procedure(s) including taking samples of human biological material over and above that which would normally be considered a part of routine clinical care? 
0 Yes Q No 
A13. Will the research participant be subject to any non-clinical research-related intervention(s) or procedure(s)? 
(These include interviews, non-clinical observations and use of questionnaires. ) 
(7 Yes O No 
Average Average time Details of additional Intervention or procedure who Additional Intervention number per taken , will undertake it, and what training they have - patient (mins/hours/days) received. - 
The questionnaire will be handed to the patient by the 
Other Questionnaire 1 10 minutes palliative care professional, but will be completed 
independently by the patient where possible. 
A14. Will Individual or group Interviews/questionnaires discuss any topics or Issues that might be sensitive, - 
embarassing or upsetting, or is it possible that criminal or other disclosures requiring action could take place during 
the study (e. g. during Interviews/group discussions, or use of screening tests for drugs)? 
Question A 14 below is not applicable if No is selected in question A 13. 
0Yes G) No 
A15. What is the expected total duration of participation in the study for each participant? 
10 minutes 
A16. What are the potential adverse effects, risks or hazards for research participants either from giving or withholding 
medications, devices, Ionising radiation, or from other interventions (including non-clinical)? 
None 
A17. What is the potential for pain, discomfort, distress, Inconvenience or changes to lifestyle for research 
participants? 
None 
A18. What is the potential for benefit to research participants? 
None 
A19. What is the potential for adverse effects, risks or hazards, pain, discomfort, distress, or inconvenience to the 
researchers themselves? (if any) 
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None 
A20. How will potential participants in the study be (I) Identified, (ii) approached and (iii) recruited? 
Give details for cases and controls separately if appropriate: 
'We will ask that all patients seen as part of routine practice on a designated day will be considered for inclusion in the 
study. However, the decision to approach the patient will be at the discretion of the palliative care professional, to ensure that 
patients who are unable to provide consent or for whom the study may cause uneccessary distress are not approached. 
Potential participants will be given the patient information leaflet to read. In centres where it is feasible, this leaflet will be 
given to patients 24 hours before the designated data collection day. Patients who are willing to participate will then be asked 
for their written consent by the health professional. 
A21. Where research participants will be recruited via advertisement, give specific details. 
.. 
El Not Applicable 
A22. What are the principal Inclusion criteria? (Please justify) 
All patients with cancer seen by a palliative care professional on a single designated day, who are able and willing to 
complete a pain questionnaire in order to calculate the prevalence of unrelieved pain in a representative sample. 
A23. What are the principal exclusion criteria? (Please Justify) 
Patients unable or unwilling to complete a pain questionnaire. 
Patients for whom the palliative care professional feels participation is inappropriate. 
A24. Will the participants be from any of the following groups? (7-Ick as appropriate) 
Q Children under 16 
Q Adults with learning disabilities 
Q Adults who are unconscious or very severely ill 
Adults who have a terminal illness -- 
Q Adults in emergency situations 
Q Adults with mental Illness (particularly if detained under Mental Health Legislation) 
Q Adults suffering from dementia 
Q Prisoners 
[: ]Young Offenders 
Q Adults in Scotland who are unable to consent for themselves 
Q Healthy Volunteers 
Q Those who could be considered to have a particularly dependent relationship with the investigator, e. g. those in care 
homes, medical students 
Q Other vulnerable groups 
Justify their inclusion. 
Pain is the commonest symptom of advanced cancer and causes great anxiety for patients and their families. 
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A25. Will any research participants be recruited who are Involved to existing research or have recently been involved in 
any research prior to recruitment? 
Q Yes 0 No 0 Not Known 
If Yes, give details and Justify their Inclusion. If Not Known. what steps will you take to find out? 
We are investigating the management of cancer pain so it is possible that some participants will have previously been 
involved in cancer treatment trials. However, this study will only require 10 minutes of the participant's time. 
A26. Will Informed consent be obtained from the research participants? 
0 Yes 0 No 
If Yes, give details of who will take consent and how it will be done. Give details of any particular steps to provide information 
(in addition to a written Information sheet) e. g. videos, interactive material. 
If participants are to be recruited from any of the potentially vulnerable groups listed in A24, give details of extra steps taken 
to assure their protection. Describe the arrangements to be made for obtaining consent from a legal representative. 
If consent Is not to be obtained, please explain why not 
The palliative care professional seeing the patient will Inform that patient about the study and invite them to read the Patient 
Information Sheet. Those patients who are willing to participate will be asked for their written consent prior to completing the 
questionnaire. 
A27. Will a signed record of consent be obtained? 
O Yes ONo 
A28. How long will the participant have to decide whether to take part in the research? 
The time available to decide about participating will vary between settings. In in-patient units potential participants will be 
given information 24 hours before the designated data collection day. However, in the community setting, it Is likely that 
participants will have to make a decision about participation within an hour. 
A29. What arrangements have been made for participants who might not adequately understand verbal explanations or 
written Information given In English, or who have special communication needs? (e. g. translation, use of interpreters eta. ) 
We will use hospital translaters where possible and relatives if available. 
A30. What arrangements are in place to ensure participants receive any Information that becomes available during the 
course of the research that may be relevant to their continued participation? 
Not applicable. 
A31. Does this study have or require approval of the Patient Information Advisory Group (PIAG) or other bodies with a 
similar remit? (see Guidance Notes) 
Q Yes 'O No 
(. 'M 
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A32a. Will the research participants' General Practitioner be Informed that they are taking part in the study? 
0 Yes (j) No 
A32b. Will permission be sought from the research participants to Inform their GP before this is done? 
O Yes O No 
If No to either question, explain why not 
It is unlikely that such information will be useful for the General Practitioner. 
A33. Will Individual research participants receive any payments for taking part in this research? 
0 Yes O No 
A34. Will Individual research participants receive reimbursement of expenses or any other Incentives or benefits for 
taking part In this research? 
0 Yes O No 
A35. What arrangements have been made to provide indemnity and/or compensation in the event of a claim by, or on 
behalf of, participants for ngqligent harm? 
I am attaching a letter from the University of Bristol outlining the liability insurance policy for this study 
A36. What arrangements have been made to provide indemnity and/or compensation in the event of a claim by, or on 
behalf of, participants for non-negligent harm? 
None (not applicable) 
A37. How Is It Intended the results of the study will be reported and disseminated? (Tick as appropriate) 
Peer reviewed scientific journals 
Q Internal report 
Q Conference presentation 
Other publication - 
Q Submission to regulatory authorities- 
Access to raw data and right to publish freely by all investigators In study or by Independent Steering Committee on 
behalf of all Investigators 
Q Written feedback to research participants 
Q Presentation to participants or relevant community groups 
Q Other/none e. g. Cochrane Review, University Library 
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A38. How will the results of research be made available to research participants and communities from which they are 
drawn? 
The individual results for each team will be fed back to that team along with the pooled results for the whole group. 
A39. Will the research Involve any of the following activities at any stage (Including Identification of potential research 
participants)? (Tick as appropriate) 
Q Examination of medical records by those outside the NHS, or within the NHS by those who would not normally have 
access 
Q Electronic transfer by magnetic or optical media, e-mail or computer networks 
Q Sharing of data with other organisations 
Q Export of data outside the European Union 
Q Use of personal addresses, postcodes, faxes, e-mails or telephone numbers 
Q Publication of direct quotations from respondents 
Q Publication of data that might allow identification of individuals 
Q Use of audio/visual recording devices 
Q Storage of personal data on any of the following: 
Q Manual files including X-rays 
R NHS computers 
Q Home or other personal computers 
Q University computers 
Q Private company computers 
Q Laptop computers 
Further details: 
We will use the participants' postcodes to examine any associations between pain control and soclo-economic deprivation 
using Townsend Scores. 
Data stored will be password protected on university computers. 
A40. What measures have been put In place to ensure confidentiality of personal data? Give details of whether any 
encryption or other anonymisation procedures have been used and at what stage: 
The questionnaires will be anonymous. Each patient will be assigned a unique study identification number. Each 
professional will have an identification number derived from their initials and year of birth. 
A41. Where will the analysis of the data from the study take place and by whom will it be undertaken? 
Data analysis will take place in the Department of Palliative Medicine at the University of Bristol, by Dr Colette Reid. 
A42. Who will have control of and act as the custodian for the data generated by the study? 
Dr Colette Reid and Professor Geoffrey Hanks. ` 
A43. Who will have access to the data generated by the study? 
fý, 
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The Department of Palliative Medicine at the University of Bristol. 
I A44. For how long will data from the study be stored? 
5 Years Months 
Give details of where they will be stored, who will have access and the custodial arrangements for the data: 
Paper questionnaires will be stored in locked tiling cabinets. The information extracted will be stored in an Access database 
which will be password protected and accessed by the investigators only. 
A45. How has the scientific quality of the research been assessed? (Tick as appropriate) 
Q Independent external review 
Q Review within a company 
Q Review within a multi-centre research group 
Q Internal review (e. g. involving colleagues, academic supervisor) 
Q None external to the investigator 
Q Other, e. g. methodological guidelines 
If you are not In possession of any referees or other scientific critique reports relevant to your proposed study, justify and 
describe the review process and outcome. If review has been undertaken but not seen by the researcher, give the details of 
the body which has undertaken the review: 
A46. Has similar research on this topic been done before? 
0 Yes (D No 
A47. Have all existing sources of evidence, especially systematic reviews, been fully considered? 
9 Yes 0 No 
If Yes, please give details of search strategy used. If No, explain why not 
Using a search strategy of cancer pain and prevalence, previous studies were identified. Whilst these have examined pain 
prevalence, the majority have not measured pain severity or attempted to estimate the efficacy of current pain management. 
In addition, much of this research has been conducted outside of the United Kingdom. No similar published studies have 
been conducted in palliative care settings in the United Kingdom. 
A48. What Is the primary outcome measure for the study? 
The prevalence of uncontrolled cancer pain. (The percentage of patients with pain who record a pain score of >5 on a 0-10, 
numerical rating scale). 
A49. What are the secondary outcome measures? (if any) 
1. Prevalence of cancer pain 2. Use of analgesic medication and other pain treatments 3. Factors associated with pain that is 
difficult to control. 
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A50. How many participants will be recruited? How many of these participants will be in a control group? 
425 
A51. Has the size of the study been Informed by a formal statistical power calculation? 
0Yes ONo 
If Yes, indicate the basis upon which this was done, giving sutlioent hfonnation to allow the replication of the calculation: 
If the true proportion of controlled cancer pain Is 80%, then 250 questionnaires from patients with pain will allow us to 
calculate this with 95% confidence intervals of 75-85%. It is likely that the overall pain prevalence is 65% and so allowing for 
5% missing data and 20% failure to complete by the health professional, we will require 425 (250'1.35'1.05'1.2) patients 
overall. 
A52. Has a statistician given an opinion about the statistical aspects of the research? 
0 Yes 0 No 
If Yes, give the name and contact details: 
Mrs R Greenwood, RDSU, Level 6 King Edward Building. Bristol Royal Infirmary, Marlborough Street, Bristol BS28HW 
If Yes, give a brief summary of advice offered and attach a copy of comments if available: 
Advice given about number of completed questionnaires required and also appropriate statistical tests to use when analysing 
the data. 
A53. Describe the statistical methods and/or other relevant methodological approaches (e. g. for qualitative research) to be used In the analysis of the results. Give details of the methods of randomisation process to be used If applicable: 
We will compare those patients with pain 9¬ceon averageAC scores of <5 with those with pain Moon averageAE scores 
of >5 using T-tests for continuous variables and chi-squared tests for categorical variables. 
We will compare the associations of a numerical rating scale score of >5 for pain a¬ceon averageAE with the answer 
BEceNoäE for the question a¬ceOverall is your pain controlled? AC using chi-squared tests. 
We will investigate correlations between pain scores and age, performance status, and soclo-economic status (using 
Townsend Deprivation scores), by employing a Spearman9ETMs rank correlation coefficient as it Is not thought that age will 
have a normal distribution. 
A54. Where will the research take place? (Thk as appropriate) 
21 UK 
Q Other states in European Union 
Q Other countries in European Economic Area 
Q Other 
Give details: 
All palliative care teams in the South West of England, identified using the Hospice Directory 2004. have been contacted and 
asked if they wish to participate in the study. We have had positive responses from almost all. Each of these teams will be 
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visited by a research nurse prior to the designated data collection day. 
A55. Has this or a similiar application been previously rejected by a Research Ethics Committee In the UK, the 
European Union or the European Economic Area? 
0 Yes ® No 
A56. In how many and what type of host organisations (NHS or other) In the UK Is It Intended the proposed study will 
take place? 
Indicate the type of organisation by ticking the box and give approximate numbers if known: 
Number of 
organisations 
Q Acute teaching NHS Trusts 7 
Q Acute NHS Trusts 8 
Q NHS Community and/or Primary Care Trusts 
Q NHS Trusts providing Mental Healthcare 
Q NHS Care Trusts 
Q Social Care Organisations 
Q Prisons 
Q Independent hospitals 
Q Educational establishments 
Q Independent research units 
Other (give details) 21 
Other: 
We hope to recruit from both Independant hospices and palliative care units and NHS hospices and palliative care units. 
What are the criteria for electively stopping the trial or other research prematurely? 
Not applicable., 
A58. Has funding for research been secured? ` 
... .... ® Yes ONo 
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If Yes, give details of funding organisation(s) and amount secured and duration: 
Organisation: Napp Pharmaceuticals 
Address: Cambridge Science Park 
Milton Road : 
CAMBRIDGE 
Post Code: CB4 0GW 
UK contact: 
Telephone: 01223 424444 Fax: 
E-mail: 
Amount (£): 3684.30 Duration: I Months 
Organisation: The Dr Mortimer and Theresa Sadder Foundation 
Address: 67 Chester Square 
LONDON 




Amount (£): 20990 Duration: 6 Months 
A59. Has the (under of the research agreed to act as sponsor as set out In the Research Governance Framework? 
O Yes 0 No 0 Not Known 
Has the employer of the Chief investigator agreed to act as sponsor of the research? 
Q Yes ONo 0 Not Known 





Organisation: The University of Bristol 
Address: University of Bristol, 
3rd Floor, Senate House, Tyndall Avenue Telephone: 0117 928 8676 
Bristol Fax: 0117 929 8383 
Postcode: BS8 1TH 
E-mail: " gillian. tallents@bristot. ac. uk 
A60. Has any responsibility for the research been delegated to a subcontractor? 
0 Yes ® No 
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A61. Will Individual researchers receive any personal payment over and above normal salary for undertaking this 
research? 
Q Yes 0 No 
A62. Will individual researchers receive any other benefits or incentives for taking part in this research? 
0 Yes () No 
A63. Will the host organisation or the researcher's department(s) or Institution(s) receive any payment or benefits In 
excess of the costs of undertaking the research? 
"O Yes G )No 
A64. Does the Chief Investigator or any other investigator/collaborator have any direct personal Involvement (e. g. 
financial, share-holding, personal relationship etc. ) In the organisation sponsoring or funding the research that may 
give rise to a possible conflict of Interest? 
(7 Yes 0 No 
A65. Other relevant reference numbers If known(give details and version numbers as appropriate): 
Applicant's/organisation's own reference number, e. g. RD(if available): 
Sponsor's/protocol number: 
Funder's reference number: 
International Standard Randomised Controlled Trial Number (ISRCTN): 
European Clinical Trials Database (EudraCT) number: 
Project website: 
A66. Other key Investlgators/collaborators(all grant co-applicants should be listed) 
Title: Professor 
Forename/Initials: Geoffrey Surname: Hanks 
Post: Professor of Palliative Medicine 
Qualifications: DSc BSc MB FRCP FRCPE FFPM 
Organisation: University of Bristol 
Address: Level C 
Bristol Haematology and Oncology Centre Telephone: 0117 928 3336 
Horfield Road, BRISTOL Fax: 0117 928 3865 
Postcode: BS2 8ED 
E-mail: debbie. ashby@bristol. ac. uk 
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A67. If the research Involves a specific Intervention, (e. g. a drug, medical device, dietary manipulation, lifestyle change 
etc. ), what arrangements are being made for continued provision of this for the participant (if appropriate) once the 
research has finished? 
Q Not Applicable 
PART A: SumMary of Ethical Issues 
A68. What do you consider to be the main ethical Issues or problems which may arise with the proposed study and 
what steps will be taken to address these? 
The main ethical issue is that the health professional Inviting a patient to take part in the study will in some cases be the 
patient's usual palliative care professional. We will inform all health professionals that no patient should feel obliged to 
participate and that all patients must understand that not doing so will not affect their care in any way. 
A69. Do you need to add further information about certain questions In Part A? 
This question is not applicable for the online version of COREC form. 
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PART B: Section 7- Declaration ,w 
- The information in this form is accurate to the best of my knowledge and belief and I take full responsibility for it. 
-I undertake to abide by the ethical principals underlying the Declaration of Helsinki and good practice guidelines on the 
proper conduct of research. 
= If the research is approved I undertake to adhere without unagreed deviation to the study protocol, the terms of the full 
application of which the main REC has given a favourable and any conditions set out by the main REC in giving its 
favourable opinion. 
-I undertake to inform the main REC of any changes in the protocol, and to submit annual reports setting out the progress 
of the research. 
-I am aware of my responsibility to be up to date and comply with the requirements of the law and relevant guidelines 
relating to security and confidentiality of patient or other personal data, including the need to register when necessary with 
the appropriate Data Protection Officer. 
-I understand that research records/data may be subject to inspection for audit purposes if required in future. 
-I understand that personal data about me as a researcher in this application will be held by the relevant RECs and their 
operational managers and that this will be managed according to the principles established in the Data Protection Act. 
Signature: . ...................................... 
Date: (dd/mm/yyyy) 
Print Name: 
- 1. Do you need to add further information about certain questions 
In part B? 
This question is not applicable for the online version of COREC form. 
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Name of NHS Research Ethics Committee to which application for ethical review Is being made: 
SWMREC 
Project Reference number from above REC: 05/MRE06/21 
Name of NHS REC responsible for SSA: 
Central and South Bristol Research Ethics Committee. 
SSA reference (for REC office use only): 
Questions Cl, C4, C5, C6, C7, C8 and Cl 3a correspond to questions Al. A2. A65, Al 0, A12, A13 and A29 on main application 
form respectively and will populate automatically: 
Cl. Title of Research (Populated from A1) 
Full title: A Survey of Cancer Pain Control by South West England Palliative Care Teams 
Key words: Cancer pain palliative care 
C2. Who Is the Principal Investigator for this study at this site? 
Title: Dr Forename/lnitials: Colette Surname: Reid 
Post: Research Fellow in Palliative Medicine 
Qualifications: MBChB, MRCGP 
Organisation: Department of Palliative Medicine 
Address: Level C BHOC 
Horfield Road 
BRISTOL 
Post Code: BS2 8ED 
E-mail: Colette. reid@bristol. ac. uk 
Telephone: 0117 928 4591 
Fax: 0117 928 3865 
C3. Indicate the number of trials/projects within the organisation that the local 2 
Principal Investigator has been Involved with In the previous 12 months: 
How many are still current (active or recruiting)? 2 
Give details of other members of the local research team responsible to the local Principal Investigator 
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Position: Clinical Nurse Specialist 
Qualifications: 
Role In the research team: Research Nurse 
Online Form 
C4. Chief Investfgator(Populated from A2) 
Title: Dr Forename/Initials: Colette Surname: Reid 
Post: Research Fellow In Palliative Medicine 
Qualifications: MBChB, MRCGP 
Organisation: Department of Palliative Medicine, University of Bristol 
Address: Level C, Bristol Haematology and Oncology Centre 
Horfield Road 
BRISTOL 
Post Code: BS28ED 
Telephone: 0117 928 3336 
Fax: 0117 928 3865 
i`F 
C5. Other relevant reference numbers If known (Populated from A65) 
Applicants/organisation's own reference number, e. g. RD(if available): 
Sponsor's/protocol number: 
Funder's reference number: 
International Standard Randomized Controlled Trial Number (ISRCTN): ' 
European Clinical Trials Database (EudraCT) Number: 
Project website: 
C6. Give a brief synopsis/summary of methods and overview of the planned research. This should Include a brief 
" description of how prospective research participants and concerned communities (not necessarily geographical) from 
which they are drawn have been consulted over the design and details of the research? 
(Where appropriate a flow chart or diagram should be submitted separately. It should be clear exactly what will happen to the 
research participant, how many times and in what order). (Populated from A10) 
This is a cross-sectional study. All patients seen on a single designated day by a doctor or nurse in a palliative care team a, 
will be asked if they wish to participate, provided they are competent and that in the opinion of the health professional their 
participation will not cause distress. 
Those who are willing to participate will then be asked to complete a questionnaire, (one side of A4) which should not take, 
more than 10 minutes to complete. The professional seeing the patient will also be asked to complete a questionnaire about 
that patient's treatment (two sides of A4). The questionnaires will be anonymised, but will have matching numbers to ensure 
paired data is obtained. Patients will be asked to score their pain on a 11 point numerical rating scale. This scale has been 
chosen because of its demonstrated utility in this population and because scores of 5 or greater on this scale have been 
shown to correspond to significant interference with function in patients. ' 
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Date: 08/02/2005 Reference: 05/MRE06J21 Online Form 
We wish to obtain a representative group of palliative care patients and so need to recruit from all settings In which palliative 
care patients are seen by a health care professional. This means we will be recruiting from hospital wards and outpatients, 
hospice in-patient units and day centres and also recruiting patients seen by professionals in their own homes. 
The questionnaires will be piloted in the investigators institution. Feedback from both patients and professionals after this 
pilot will be used to amend the questionnaire design. 
C7. Will the research participants receive any clinical intervention(s) or procedure(s) Including taking samples of 
human biological material over and above that which would normally be considered a part of routine clinical care? 
(Populated from A 12) 
10 Yes O No 
C8. Will the research participant be subject to any non-clinical research-related Intervention(s) or procedure(s)? 
(These Include interviews, non-clinical observations and use of questionnaires. )(Populated (mm A 13) 
O Yes 0 No 
Average Average time Details of additional Intervention or procedure, who 
Additional Intervention number per taken will undertake It, and what training they have 
patient (mins/hours/days) received. 
The questionnaire will be handed to the patient by the 
Other Questionnaire 1 10 minutes palliative care professional, but will be completed 
independently by the patient where possible. 
C9a. Give the name of the NHS or other organisation with which the PI holds the necessary contract (substantive or 
honorary) to undertake the research at this site: 
United Bristol Healthcare Trust 
C9b. Give the name of the research site for which the PI is responsible. If different from the above. (The site may be a 
whole organisation, an Individual unit, or a consortium): 









C10. Specify the location(s)ldepartment(s) within the NHS or other organisation where the research will take place. 
Patients will be recruited from both in-patient and outpatient settings in the Haematology and Oncology Centre and 
throughout the Bristol Royal Infirmary. 
l1 
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Date: 08/02/2005 Reference: 05/MRE06/21 Online Form 
C11. How many research participants/samples is it anticipated will be recruited/obtained from this organisation in 
total? 
All patients seen by the Hospital Palliative Care Team on a single designated day will be eligible to participate. This will be 
10-20 patients. 
C12a. Give details of who will be responsible for obtaining informed consent locally, their qualifications and relevant 
expertise and training In obtaining consent for research purposes: 
C13a. What arrangements have been made for participants who might not adequately understand verbal explanations 
or written Information given In English, or who have special communication needs? (e. g. translation, use of interpreters 
etc. ) (Populated from A29) 
We will use hospital translaters where possible and relatives if available. 
C13b. What local arrangements have been made to meet these requirements (where applicable)? 
C14. In addition to Informing the GP (if required), what arrangements have been made to Inform those responsible for 
the care of the research participants In the host care organisation of their involvement in the research? 
A copy of the patient's signed consent form and the Professional Information Sheet will be placed In the patient's notes. 
C15. Are the facilities and staffing available locally adequate to perform any necessary procedures or interventions 
required for the study, and to deal with any unforseen consequences of these? (This should include consideration of 
procedures and Interventions In both control and Intervention arms of a study. ) 
O Yes ONo 
If Yes, give the information necessary to justify your answer. If No, indicate what arrangements are being made to deal with 
the situation: 
C16a. Give brief details of a contact point where participants may obtain further information about the study. 
The Department of Palliative Medicine In the Bristol Haematology and Oncology Centre. 
16b. What Is the contact point for potential complaints by research participants? 
16c. Is there a local source where potential participants can obtain Independent Information about being Involved In a 
research study? 
16d. Please specify the headed paper to be used for the participant information sheet? 
The University of bristol headed paper will be used in all centres. 
C17. If any extra support might be required by research participants as a result of their participation, what local 
arrangements are being made to provide this? 
not applicable 
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Date: 08/0212005 Reference: 05/MRE06t21 Online Form 
C18. Do you need to add further information about certain questions In Part C? 
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Date: 08/02/2005 Reference: 05/MRE06/21 Online Form 
PART C: Declaration 
- The information in this form Is accurate to the best of my knowledge and belief and I take full responsibility for it. 
-I undertake to abide by the ethical principles underpinning the Declaration of Helsinki and good practice guidelines on 
current proper conduct or research. 
- If the research Is approved I undertake to adhere without unagreed deviation to the study protocol, the terms of the full 
application of which the main REC has given a favourable and any conditions set out by the main REC in giving its 
favourable opinion. 
-I am aware of my responsibility to be up to date and comply with the requirements of the law and relevant guidelines 
relating to security and confidentiality of patient or other personal data, including the need to register when necessary with 
the appropriate Data Protection Controller. 
-I understand that research records/data may be subject to inspection for audit purposes if required in future. 
-I understand that personal data about me as a researcher in this application will be held by the relevant RECs and their 
operational managers and that this will be managed according to the principles established in the Data Protection Act. 
Signature of the local Principal Investigator " 
Date: (dd/mmlyyyy) 
Print Name: 
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Invitation Letter to Palliative Care Professionals 
Version 2 01/08/2005 
Dear 
Ilk University of 
MM BRISTOL 
A Survey of Cancer Pain Control by South West England 
Palliative Care Teams 
I am writing to invite you to take part in a research project which aims to 
evaluate the prevalence of unrelieved pain in cancer. This is one of a 
series of studies whose aim is to examine the effectiveness of the current 
approach to pain relief in cancer. 
This study is a cross-sectional survey of patients being seen by specialist 
palliative care services in the South West region. I attach an information 
sheet which gives more details of the study and a consent form. If you are 
happy to participate in the study I should be grateful if you would sign the 
consent form and return it in the envelope provided. 
I should emphasise that this is not an audit of your practice. The data are 
anonymised and we will not examine the pain scores or any of the clinical 
data according to which services or area they came from. We are 
interested in the larger picture to see how well our current approach to 
pain relief in cancer actually works in practice. 
This is a timely question and the results will have important implications 
for ensuring that current practice is truly `best' practice. I very much hope 
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Professional Consent Form V2 27/07/05 
Centre Number Professional Identification Number for this trial 
CONSENT FORM 
Title of Project: Cancer Pain Control in the South West 
Name of Researcher: Dr. C Reid, Department of Palliative Medicine, University of Bristol. 
Please initial box 
t. I confirm that I have read and understand the Information Sheet for Health 
Professionals dated 25/04/05 (V3) for the above study and the Invitation Letter 
to Palliative Care Professionals dated 28/06/05 (V2) and have had the opportunity 
to ask questions. 
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason. 
Elk University of 
I BRISTOL 
3.1 agree to take part in the above study. 
Q 
Name of Professional Date 
Name of Person taking consent Date 
(if different from researcher) 
Signature 
Signature 
1 for patient; 1 for researcher; I to be kept with hospital notes 
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South West Multi-centre Research Ethics Committee 
09 May 2005 
Dr Colette Reid 
Research Fellow in Palliative Medicine 
Department of Palliative Medicine, University of Bristol 




Dear Dr Reid 








TQ9 6J E 
Tel: 01803 861947 
Fax: 01803 861914 
Email: swmrec@sw-devon-ha. swest. nhs. uk 
A Survey of Cancer Pain Control by South West England 
Palliative Care Teams 
05/MRE06121 
Version 2 dated 9 February 2005 
Thank you for your letter of 26 April 2005, responding to the Committee's request for 
further information on the above research and submitting revised documentation. 
The further informatiori has been considered on behalf of the Committee by Anne 
Hong and Jane Maxwell. 
Confirmation of ethical opinion 
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for 
the above research on the basis described in the application form, ` protocol and 
supporting documentation as revised. 
However, the Committee has not yet been notified of the outcome of any site-specific 
assessment (SSA) for the'research site(s) taking part in this study., ; The favourable _ 
opinion does not therefore apply to any site at present. I will write to you again as 
soon as one Local Research Ethics Committee has notified the outcome of a SSA.. J.. 
In the meantime no study procedures should be initiated at sites'requiring SSA. 
Conditions of approval 
The favourable opinion is given provided that you comply with the conditions set out 
in the attached document. You are advised to study the conditions carefully. 
'Approved documents 
The final list of documents reviewed and approved by the Committee is as follows: 
Document Type: Version: Dated: Date Received: 
A lication 4.0 10/02/2005 14/02/2005 
Investi ator CV none given 14/02/2005 
Protocol 1 09/02/2005 14/02/2005 
Letter from Sponsor 31/01/2005 14/02/2005 
Peer Review Letters dated 8 14/02/2005 
June, 24 June, 14 
July and 22 July 
2004 
Indemnity letter 31/01/2005 14/02/2005 
Copy of v1 09/02/2005 14/02/2005 
Questionnaire `- 
Letters of Invitation Palliative Care 25/04/2005 27/04/2005 
to Participants Professionals 
v2 
Participant 3 For Health 25/04/2005 27/04/2005 
Information Sheet Professional 
Patient Information v3 25/04/2005 27/04/2005 
Sheet 
Participant Consent v2 22/03/2005 31/03/2005 
Form 
Participant Consent v1 22/03/2005 31/03/2005 
Form Professionals 
Response to 29/03/2005 31/0372005 
Request for Further 
Information 
Response to 26/04/2005 27/04/2005 
Request for Further 
Information 
GP Letter v1 18/03/2005 31/03/2005 T 
Management approval 
The study should not commence at any NHS site until the local Principal Investigator 
has obtained final management approval from the R&D Department for the relevant 
NHS care organisation. 
Membership of the Committee 
The members of the Ethics Committee who were present at the meeting are listed on 
the attached sheet. 
Notification of other bodies 
The Committee Administrator will notify the research sponsor that the study has a 
favourable ethical opinion. 
The Committee Administrator will notify the research sponsor that the study has a 
favourable ethical opinion. 
Statement of compliance 
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees (July 2001) and complies fully with the Standard 
Operating Procedures for Research Ethics Committees in the UK. 
05/MRE06/21 Please quote this number on all correspondence 
With the Committee's best wishes for the success of this project, 
Yours sincerely 
z( v"al 
John Alexander PP 
Chair 
Enclosures: List of names and professions of members who were present at the 
meeting and those who submitted written comments 
Standard approval conditions 
South West Multicentre Research Ethics Committee 
List of Members for the meeting of 10 March 2005 
Dr John Alexander 
Chairman 
Ica * 
Dr Harry Baumer 
®* 
Suzanne Blowey 
Dr Yoav Ben-Shlomo 
MBBS FRCA MRCS LRCP RCOG 
Consultant in Anaesthesia 
BRISTOL 
MB ChB FRCP 
Consultant Paediatrician 
PLYMOUTH 
BSc RGN Nursing FAETC CEd 
Education and Development Nurse 
PLYMOUTH 
BSc (Hons) MBBS MRCPhys MscEpid MFPHM 
Senior Lecturer in Clinical Epidemiology & Hon Consultant 
BRISTOL 
Dr Brian Cooke MB BS LRCP MRCS FFPH 
Consultant in Public Health 
SOUTH WEST PENINSULA STRATEGIC HEALTH 
AUTHORITY 
Mr Christopher Foy MA MSc CStat 
Vice-Chairman Medical Statistician, R&D Support Unit 
GLOUCESTERSHIRE 
Peter Hildrew Lay Member BA MPA 
DEVON 
Dr Anne Hong FRCP FRCR 
Consultant Clinical Oncologist 
EXETER 
Dr Christopher Martyn 
Mrs Jane Maxwell 
Dr Alan Middleton 
MA D Phil FRCP 
Clinical Scientist/Honorary Consultant Neurologist 
SOUTHAMPTON 
MA (CANTAB) PGCE 
Lay Member 
GLOUCESTERSHIRE 
BSc MB ChB M Phil 
General Practitioner 
CORNWALL 
Mrs Eloise Monger BSc (Hons) RGN ENB 100 
Lecturer in Critical Care Nursing 
SOUTHAMPTON 
Mr David Perrott LLB (Exon); BCL (Oxon); Coif (Illinois) 
Lay Member 
EXETER 
Mrs Janet Powell JP MEd FETC 
Lay Member 
SOMERSET 
Prof Alan Preece BSc PhD FIPSM MRCSHC (PE) M Inst RP 
Professor of Medical Physics and Consultant Clinical Scientist 
BRISTOL 
0* 
Dr John Reckless DSc MD FRCP 
Consultant Physician and Honorary Reader in Medicine 
University of Bath 
AVON 
Mrs Sally Tomlin BPharm MBA LLM MRPharmS 
Pharmacist 
SALISBURY 
Barbara Inger- MREC Committee Administrator and secretary to the meeting. 
Annotation: 
Not present at the meeting. 
Submitted written comments to the meeting. 
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Central Öff e for Research Ethics: COmm ttees 
1wiic) 
NOTICE OF SUBSTANTIAL AMENDMENT 
For use in the case of all research other than clinical trials of investigational medicinal products 
(CTIMPs). For substantial amendments to CTIMPs, please use the EU-approved notice of 
amendment form (Annex 2 to ENTR/CTI) at htta: /leudract. emea. eu. int/document. html#guidance. 
To be completed in typescript by the Chief Investigator and submitted to the Research Ethics 
Committee that gave a favourable opinion of the research ("the main REC ). In the case of multi-site 
studies, there is no need to send copies to other RECs unless specifically required by the main REC. 
Further guidance is available in section 5 of our Standard Operating Procedures available at 
www. corec. orq. uk/applicants/help/docs/SOPs. doc. 






Dr Colette Reid 
Level C 
Bristol Haematology and Oncology Centre 
Horfield Road 
Bristol, BS2 8ED 
0117 928 4591 
Colette. reid@bristol. ac. uk 
0117 928 3865 
Full title of study: A Survey of Cancer Pain Control by South 
West England Palliative Care Teams 
Name of main REC: South West MREC 
REC reference number: 05/MRE06/21 
Date study commenced: N/A 
Protocol reference (if applicable), 
current version and date: 
Version 1 
09/02/2005 
Amendment number and date: Amendment 1 26/07/2005 
Notice of amendment (non-CTIMP), version 2.0, May 2004 
) 
_) 
Type of amendment (indicate all that apply In bold) 
(a) Amendment to information previously given on the REC application form 
Yes No 
If yes, please refer to relevant sections of the REC application In the 
'summary of changes' below. 
(b) Amendment to the protocol 
Yes No 
If yes, please submit either the revised protocol with a new version number 
and date, highlighting changes In bold, or a document listing the changes 
and giving both the previous and revised text 
(c) Amendment to the information sheet(s) and consent form(s) for participants, or to any other 
supporting documentation for the study 
Yes No 
If yes, please submit all revised documents with new version numbers and 
dates, highlighting new text In bold 
Summary of changes 
Briefly summarise the main changes proposed in this amendment Explain the purpose of the 
changes and their significance for the study. 
Supporting scientific information should be given (or enclosed separately) where the 
amendment significantly alters the research design or methodology, or could otherwise affect 
the scientific value of the study. 
The changes proposed have resulted from feedback about the questionnaires from both 
patients and professionals. 
After piloting the patient questionnaire in the Bristol Haematology and Oncology Centre, we 
realised that we had to capture more Information about the use of medication for breakthrough 
pain (or flares of pain). We have added two questions to the patient questionnaire in order to 
do this. 
The professional feedback led to the addition of 3 questions and clarification of some of the 
original questions. 
In both cases, the length of the questionnaire has not been significantly altered although the'- 
format of the professional questionnaire has been changed. 
Notice of amendment (non-CT1MP), version 2.0, May 2004 
Any other relevant information 
Applicants may indicate any specific ethical issues relating to the amendment, on which the 
opinion of the REC Is sought. 
i 
List of enclosed documents 
Professional Questionnaire version 1 09/02/05 
Professional Questionnaire version 218/07/05 
Patient Questionnaire version 109/02/05 
Patient Questionnaire version 2 10/07/05 
,,.. , -. 
a 
Declaration 
"I confirm that the information in this form is accurate to the best of my knowledge and I 
take full responsibility for it. 
"I consider that it would be reasonable for the proposed amendment to be implemented. 
Signature of Chief Investigator. 
Print name: ............................:.:........... 
' ... .;;:.. ;°. 
Date of submission: ............................................ ,$;.., 
Notice of amendment (non-CTIMP), version 2.0, May 2004 
Central Office for Research Ethic Committees 
(COREC) 
NOTICE OF SUBSTANTIAL AMENDMENT 
For use in the case of all research other than clinical trials of investigational medicinal products 
(CTIMPs). For substantial amendments to CTIMPs, please use the EU-approved notice of 
amendment form (Annex 2 to ENTR/CT1) at htto: //eudract. emea. eu. int/document. html#guidance. 
To be completed in typescript by the Chief Investigator and submitted to the Research Ethics 
Committee that gave a favourable opinion of the research ('the main RECT. In the case of multi-site 
studies, there is no need to send copies to other RECs unless specifically required by the main REC. 
Further guidance is available in section 5 of our Standard Operating Procedures available at 
oc. www. corec. org. uk/agt)licants/heir)/docs/SOPs. d 







Dr Colette Reid 
Level C 
Bristol Haematology and Oncology Centre 
Horfield Road 
Bristol, BS2 8ED 
0117 928 4591 
Colette. reid@bristol. ac. uk 
0117 928 3865 
Full title of study: A Survey of Cancer Pain Control by South 
West England Palliative Care Teams 
Name of main REC: South West MREC 
REC reference number: 05/MRE06/21 
Date study commenced: N/A 
Protocol reference (if applicable), 
current version and date: 
Version 1 
09/02/2005 
Amendment number and date: Amendment 2 28/07/2005 
Notice of amendment (non-CTIMP), version 2.0, May 2004 
Any other relevant information 
Applicants may indicate any specific ethical issues relating to the amendment, on which the 
opinion of the REC Is sought. 
List of enclosed documents 
Professional Consent Form Version 1 22/03/05 
Professional Consent Form Version 2 27/07/05 
Patient Consent Form Version 2 18/03/05 
Patient Consent Form Version 3 27/07/05 
Patient Information Sheet Version 3 25/04/05 
Patient Information Sheet Version 4 27/07/05 
Declaration 
"I confirm that the Information in this form is accurate to the best of my knowledge and I 
take full responsibility for it. 
consider that it would be reasonable for the proposed amendment to be implemented. 
Signature of Chief Investigator ............... 
Print name: 
M. e'D 
Date of submission: Q,., ,.......... 
s 
Notice of amendment (non-CTIMP), version 2.0, May 2004 
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A Survey of Cancer Pain Control in South West England Palliative 
Care Teams 
Trust R&D number: 1482 
MREC number: 05/MRE06/21 
Sponsor Details Name: University of Bristol 




Telephone: 0117 954 6966 
Principal Investigator details Name: 
Address: 
Telephone: 
Chief Investigator details Name: Dr Colette Reid 
Address: Dept. of Palliative Medicine 





Start date: End date: 
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A survey of cancer pain control by South West England palliative care teams 
Instructions for Principal investigators 
1. Where possible please distribute the patient information sheet to in-patients 
the DAY BEFORE the study, to allow patients 24 hours to decide about 
participating. 
2. Each participating health professional should sign the study personnel page in 
Section 3 of the Investigator Site File. 
3. Each participating health professional should sign a consent form at the start 
of the study day and return it to you. 
4. Please ensure that all professionals understand what is required in their 
questionnaire at the start of the day. A definition of "opioid switch" is given 
on the front of their questionnaire. 
5. You are provided with "patient packs" for the study. Each pack comprises a 
patient consent form, a patient questionnaire with a unique study number, a 
numbered envelope in which to place the patient questionnaire, the 
professional questionnaire with a matching study number, and a large 
envelope with the matching study number. 
6. The ethics committee require that the professional should not see the patient's 
pain scores. Patients should place their completed questionnaires directly into 
the numbered envelope. If a patient requires help with completing the form, 
we would prefer another person e. g. a family member to assist. If this is not 
possible then the professional may assist the patient. 
7. The consent form must be copied four times, with a copy given to the patient, 
and copies placed in the patient's notes, in the large envelope to be returned to 
Bristol and in Section 10 of the Investigator Site File. 
8. The professional questionnaire needs to be completed as the patient completes 
their questionnaire as there will be no details to identify the patient on it. The 
professional questionnaire should then be placed into the large envelope along 
with the consent form and the envelope containing the patient questionnaire. 
9. The GP letter should be sent out to -the relevant general practitioner for 
patients seen in the community or in day care settings. Stamped envelopes are 
provided but you will need to address them. 
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Trial sponsorship and insurance arrangements 
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Mlkýe University of LI BRISTOL 
31 January, 2005 
Our Ref: Insurancelclinical trials/CT 286 Insure confirm 
(Insert details of Ethics Committee) 
Secretary's Office, Senate House, 
Tyndall Avenue, Bristol BS81TH 
Direct line: (0117) 928 7791 
Fax: (0117) 925 1558 
E-mail: Ginny. Hope@bristol. ac. uk 
Katharine McKenzie, BA, DPhil, 
University Secretary 
Ethics Application No: 
Title of Research: A survey of cancer pain control by South West England Palliative care 
teams 
The University holds the following Liability Insurance policies. 
Employer's Liability: Limit of Indemnity: £25M 
Insurer Policy No Renewal Date 
Royal & Sun AUiance GA11188062 1 August 2005 
ACE Europe 42UKA07016 1 August 2005 
Public/Products Liability: Limit of Indemnity: £25M 
Insurer Policy No Renewal Date 
Royal & Sun Alliance GA11188062 1 August 2005 
ACE Europe 46UKC05973 1 August 2005 
The Public Liability insurance includes legal liability for or arising from premises & their contents not 
owned by the University at which we are undertaking work in connection with our business. 
Cover Includes an Indemnity, at our request, to any principal against legal liability in respect of which 
the University would have been entitled to Indemnity if the claim had been made against us. 
Since this research involves a questionnaire only study, the negligible risk of injury to research 
subjects is considered by insurers to be covered under this Public Liability policy, rather than the 
university's Clinical Trials insurance (see below) 
Clinical Trials: Limit of Indemnity: £10M (max any one occurrence & period of insurance & 
costs Inclusive) 
NB Details included for information only 
insurer Policy No Renewal Date 
Royal & Sun Alliance GA00378442 1 August 2005 
1V University of r1r9 BRISTOL 
The Clinical Trials Insurance provides legal liability or non-negligent harm cover (where non- 
negligent harm is required for ABPI indemnified trials). 
All trials are included except those involving: 
1. More than 1500 research subjects 
2. Children under the age of 5 
3. Pregnant research subjects 
4. Conception / contraception 
5. Genetic engineering 
6. Medical products manufactured by the University itself 
7. Trials undertaken outside the UK 
Professional Indemnity: Limit of Indemnity: £10M (maximum any one occurrence and period 
of Insurance) 
Insurer.. Policy Number Renewal Date. 
Royal & Sun Alliance 60K/GA00256621 1 August 2005 
Should there be any further information you require, please contact me. 
Signed 
Mrs V Hope ACII 
Insurance Officer 
Mon Jan 31 16: 13: 57 2005 Conditional Research sponsorship 
Date: Mon, 31 Jan 200515: 21: 24.0000 
From: "Gillian Tallents, RED" <Gillian. Tallents@bristoi. ac. uk> 
Subject: Conditional Research sponsorship 
To: Colette Reid <Colette. Reid@bristol. ac. uk> 
Cc: Avril Stocks <Avrii. Stocks@bristol. ac. uk>, V Hope <Ginny. Hope@bristol. ac. uk> 
Message-ID: <4006125.1107184884@ored-grt. admin. bris. ac. uk> 
To whom it may concern: 
PROVISIONAL AGREEMENT BY THE UNIVERSITY OF BRISTOL TO ACT AS RESEARCH 
SPONSOR. 
Title of Research: A survey of cancer pain control by South West England 
Palliative care teams 
Chief Investigator: Dr Colette Reid 
The University of Bristol hereby confirms that it will, in principle, agree 
to act as the research sponsor for the above project with Dr Colette Reid 
as Chief Investigator. This agreement Is conditional on the following being 
in place before any participant recruitment commences: 
- NHS/Social Care approval from the relevant Research Management Office(s) 
- NHS Ethics approval. 
- Confirmation of the details of any collaborators in the research. 
In order to secure FULL APPROVAL for University of Bristol sponsorship of 
the project, the Chief Investigator needs to send a copy of the above 
approval letter(s) to me as soon as possible. 
Please note that NO SUBJECTS CAN BE RECRUITED TO THE STUDY UNTIL FULL 
APPROVAL HAS BEEN GRANTED BY THE UNIVERSITY OF BRISTOL AS RESEARCH SPONSOR. 
If you have any questions regarding this email or require any further 




esearch Governance Manager university 
of Bristol 
Research & Enterprise Development 
Senate House, Tyndall Avenue, Bristol BS8 ITH 
1'el: +44 (0) 117 954 6966 (ext. 46966) 
Fax: +44 (0) 117 929 8383 
G41ian. Tallents@bristol. ac. uk 
wv . bristol. ac. uk/research 
dis e-mail and any attachment is for authorised use by the intended 
ecipient(s) only. It may contain proprietary material, confidential 
Lformation and/or be subject to legal privilege. It should not be copied, 
iýsclosed to, retained or used by, any other party. If you are not an 
nded recipient then please promptly delete this e-mail and any 
rrachment and all copies and Inform the sender. Thank you. 
Page: 1 
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GP Letter Version 1 18/03/05 
MlVe University of MCI BRISTOL 
Dear Doctor 
A Survey of Cancer Pain Control by South West England 
Palliative Care Teams 
Patient's Name: 
Address: 
I am writing to inform you that this patient took part in a survey of cancer 
pain control today. This study is being conducted by the University of 
Bristol with the help of local palliative care teams. 
He/she was asked to complete a pain questionnaire which may cause 
him/her to have questions about their pain or pain control. I am enclosing 
a copy of the questionnaire for your information. 
Please contact me if you would like further details. 
Yours faithfully 
Dr C Reid 
Research Fellow 
Department of Palliative Medicine 
01 17 928 3336 
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#13 NEOPLASMS*: ME (Explode MeSH term) 
#14 NEOPLASM* 
#15 CANCER* 
#16 (TUMOR* orTUMOUR*) 
#17 ((( #13 or #14) or #15) or #16) 
#18 PAIN*: ME (Explode MeSH term) 
# 19 PAIN* 
#20 (#18 or #19) 
#21 ((# 12 and #17) and #20) 
324 
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versus a three-step approach in the management of cancer-related pain 
Study sponsor application to UBHT 
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United Bristol Healthcare 
NHS Trust 
Statement of Principal Investigator's Responsibilities 
Name I Professor Geoffrey Hanks 
Project Title An open, randomised, parallel group study in patients with cancer pain, to compare a two-step 
analgesic ladder (non-opioid to oxycodone) with conventional management using a three-step 
approach. 
As the Principal In vostlgatorl agree to adhere to the following statements; 
1. The dignity, rights, safety and well being of subjects are given priority at all times. 
2. The study has UBHT Research & Development (R&D) approval prior to commencement 
3.. The study has appropriate Research Ethical Committee (REC) approval prior to commencement. 
4. The Data Protection Officer has been informed of the study. 
5. Where appropriate, permission to conduct the study has been granted by the Caldicott Guardian. 
'-. 6. R&D and necessary REC approval will be gained for all protocol amendments. 
7. In the event that REC and/or R&D approval be withdrawn, the study will be suspended until approval 
Is re-instated. . 
8. Care staff will be adequately Informed of the subjects' participation in this study 
9. The study will be conducted by myself personally and/or members of my research team. 
10. Each member of the research team, including myself, who has direct involvement with research 
subjects and/or person-identifiable data, has a full or honorary UBHT, contract. : '. 
11. Each member of the research team, including myself, is suitably qualified by education, training and 
experience. 
12. Students and new researchers have adequate supervision, support and training. ' 
13. Procedures are in place to ensure collection of high quality, accurate data. 
14.. Data will be processed and stored in accordance with the Data Protection Act 1998 and the'Cäldicott 
Principles.. 
15. Arrangements have been made to comply with the Health and Safety policies of the UBHT, in 
accordance with the Health" and Safety Act 1974. 
Serious Adverse Events will be reported to the REC 'and R&D Management Office. 
17. Arrangements are in place for the management of financial and other resources provided for the 
study, Including the management of any intellectual property arising. 
18. Adequate and accurate records will be maintained and made available for audit as required. " 
19. Reports on the progress and outcomes of the work required by the R&D Management Office will be 
produced on time and to an acceptable standard. 
20 ." The findings from the work will be 
open to critical review and disseminated appropriately. 
21. Suspected research misconduct and/or fraud will be reported through appropriate systems. ' 
22. All members of the research team are informed of their obligations in meeting the 
I commitments. - 
... 
".: ; .: 
,"... 
ý... signature..................., .............. .....: Date2 
L ýý .:.................. 
° .... 
Version 2,27/05/03 
UBHT R&D PROJECT REGISTRATION FORM 
The following form must be completed if your research uses UBIIT patients, staff or facilities and submitted to the relevant research 
leader with a completed ethics form, UBHT Project Costing Form and Statement of Principal Investigator's Responsibilities, to 
receive R&D approval. Guidance for this process can be found on the UBHT R&D web site (http: //www. ubht. nhs. uk/R&D) or from 
the R&D Office on 0117 928 3473. 
Project Information 
Lead researcher details (please Identify the person with overall responsibilty for this project) 
Name: Professor G Hanks Department: Palliative Medicine Email : debbie. ashby@bristol. ac. uk 
Type of Project: (tick as appropriate, more than one option may be selected) 
Student Q Pilot ® Full Q Multicentre 
Please select the category that most accurately describes this research proJect: Cltnlcal Trials 
Project start date (dd/mnyy): 01/09/04 Project end date (dndyy): 31/05/05 Related website address: 
Project title (please give the full project title here as sisplayed on the ethics application) 
0 
An open, randomised, parallel group study in patients with cancer pain, to compare a two-step analgesic ladder (non-opioid to 
oxycodone) with conventional management using a three-step approach. 
ý. ., -- 
Relevance to NHS Research Priorities and Needs 
Explain briefly how the project will address local and or national research priorities. Indicating potential benefits to the NHS: 
This project falls within the scope of the "Improving the Patient Experience" R+D programme because it's aims are to improve 
the management of cancer pain, both by evaluating an alternative approach to the WHO three-step analgesic ladder and by seeking 
to improve the communication between health professionals and patients when discussing choices in pain relief. 
Is this a multidisciplinary project i. e. Involving multiple professional groups? Yes 
Ifyes, please describe the professional groups involved and how they have already or will contribute to this project: 
This project will involve our clinical nurse specialists in the management of the subjects' cancer pain. We will also be collaborating 
with our colleagues in primary care, who will be recruiting to the trial and managing pain togetherwith the clinical nurse, 
specialists and study doctors. 
If this project will be subject to an external review process please Include the name of the reviewing organisation .'- 
This protocol has been reviewed by the Pain sub-group of the Palliative Care Clinical Studies Development Group of the 
C 
NCRI. The planned definitive study is being considered for inclusion in the group's national portfolio of studies. 
all people who will be Involved In at mis site 
Name 
Prof. G. Hanks 
Dr. C. Reid 
Dr. Karen Forbes 




UBHT Contract. Type 
Full Honorary. Unknown 
. 
19 El Ö® 
El 
®QQ 
Dr. Cath Blinman Doctor Q Q; , Mr. James Rice Clinical Nurse Specialist ® Q. .. 
Q. 
Ms. Gaye Senior-Smith Clinical Nurse Specialist 
National Research Register (NRR) 
This project will be submitted for Inclusion !n the I`n'. ycu iuü; caie otherwise by placing a cross In this box.,. 
Li 
If you have put a cross in the box please indicate your reasons e. g. research has security issues, breaks confidentiality agreements 
with commercial sponsors or jeopardises intellectual property rights: 
Intellectual Property Rights 
'4 , Within UBHT Intellectual Property (IP) can be considered to be the outputs of novel research which have significant implications, 
both commercially and to improving patient care, and is eligible for protection to give legal recognition to it's ownership referred to as 
Version 2,27-05-03 
Clinical Director: I confirm that the full implications of this project have been considered and hereby give permission for the research 
to be condu to as described above. 




& Effectiveness Department 
Professor Hanks 
Palliative Medicine 




Research & Effectiveness Department 
Level 1, Old Building 
Bristol Royal Infirmary 
Bristol BS2 8HW 
Tel: (0117) 022 3828 Fax: (0117) 828 3524 
21 July 2004 
ýý. 
Dear Professor Hanks 
Re: ON! 200411772 - An open, randomised, paralleil group study in patients with cancer pain, to 
compare a two-step analgesic ladder with conventional management using a three-step approach 
I am pleased to tell you that the above project has been approved by United Bristol Healthcare NHS 
Trust and can now proceed subject to full approval by the local research ethics committee. 
It is essential that this project be carried out according to Good Clinical Practice and within the 
guidelines of the NHS Research Governance Framework for Health and Social Care (full information 
available on http: //www. doh. gov. uktresearchlyd3/nhsrandd/researchgovemancelgovhome. htm or from 
the R&D Office). You have responsibility for ensuring that all participants sign informed consent and 
that the protocol agreed by the local research ethics committee is adhered to by yourself and any co- 
workers. 
May I also remind you that as Principal Investigator you will be required to provide us with Information 
in regard to monitoring and outcome Information for this project, Including a lay summary upon 
completion of the research. Investigators who fail to provide timely information on projects may 
compromise their ability to obtain Trust approval for future work. 
Congratulations on Initiating this research project. We wish you every success. We are keen to 
support good research at UBHT and are pleased that you have decided to conduct your project here. 
If you need any support or Information please do not hesitate to contact Debbie McPhee, R&D 
Information Administrator on 0117 928 3828 or by email (debbie. mcphee@ubhtswest. nhs. uk). 
Yours sincerely 
ýp ýý 'lý 
Maria Palmer PhD 
Director of Research and Development 
0 
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Safeguard ng puh-'i, - health 
Telephone: 020 7084 2327 
Facsimile: 020 7084 2443 
Medicines and Healthcare products 
Regulatory Agency 
MarketTowers 
I Nine Elms Lane, London SW8 5NQ 
Room 12-242 
Professor G Hanks 
Professor of Palliative Medicine 
Level C 




CTA No. 12893/0001/001 
16 June 2004 
Dear Professor Hanks 
THE MEDICINES FOR HUMAN USE (CLINICAL TRIALS) REGULATIONS 
2004 S. I. 1031 
AUTHORISATION FOR CLINICAL TRIALS INVOLVING GENERAL 
MEDICINAL PRODUCTS 
Product: Coproxamol, Cocodamol, Morphine, Oxycodone 
Protocol Number: 
NOTICE OF ACCEPTANCE 
I am writing to confirm that, under regulation 18(2), the Licensing Authority accepts your 
request to carry out a clinical trial in accordance with your letter received 30 April 2004 
subject to you receiving a favourable opinion from the relevant ethics committee in 
accordance with regulation 15(1). You may therefore carry out the trial as notified, but I 
must remind you of the Authorities powers under regulation 31 to suspend or terminate a 
clinical trial if the conditions set out in regulation 31(1)(a) and (b) are satisfied. 
The authorisation is effective from the date of this letter and may continue under this 
authorisation. In accordance with regulation 27, you must notify the Licensing Authority 
within 90 days of the conclusion of the trial, that it has ended. 
Yours sincerely 
Mrs S Syed 
Clinical Trials Unit 
An Executive Agency of the Department of Health 
ý 
v? ý., c 
www. mhra. gov. uk iv f» IN PEOPLE 
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Annex 2: Notification of Amendment Form A 
. A_ 
ý Lc 
'REQUEST FOR AUTHORISATION OF A SUBSTt ,r .t 04" -rk CLINICAL TRIAL 
ON A MEDICINAL PRODUCT FOR HUMAN USE'-!. JIHORITIES AND FOR 
TIIE OPINION OF THE ETHICS .ý Kim, %-vivI UNITY 
For official use: 
Date of receiving the request: Grounds for non acceptance / negative opinion: 
yes Q no Q 
If es, date: 
Date of start of the procedure in the CA: Authorisation / positive opinion: yes Q no Q 
Date : 
Competent authority/Ethics committee registration number of the trial: 
To be filled in by the applicant: 
This form is common for request for authorisation from the Competent Authority and for the opinion from an 
Ethics Committee. Please indicate the relevant purpose in a box. 
Member State in which the amendment is 
being submitted: 
U. K. 
REQUEST FOR AUTHORISATION TO THE COMPETENT AUTHORITY: Q 
REQUEST FOR OPINION OF THE ETHICS COMMITTEE: 
NOTIFICATION FOR INFORMATION ONLY: 
- to the competent authority 
- to the Ethics committee 
0 
0 
A 1. TRIAL IDENTIFICATION (When the amendment concerns more than one trial, repeat this form as 
necessary. ) 
EudraCT number: 
Full title of the Trial: 
pn open, randomised, parallel group study in patients with cancer pain, to compare a two-step analgesic ladder 
(non-opioid to oxycodone) with conventional management using a three-step approach. 




Date (yyyy-mm-dd : 
2004-09-17 
": 41a. -z 
EUD127 vl-1 
REQUEST FOR AUTHORISATION OF A SUBSTANTIAL AMENDMENT 
A 2. AMENDMENT IDENTIFICATION : 
Amendment to `protocol' 
Sponsor's protocol amendment code number : 
Revised Amendment 2 
Q If checked specify sponsor's amendment 
code number, version and date 
Version Date (yyyy-mm-dd) : 
2001-09-17 
Amendment to `initial request for authorisation' 
Sponsor's request amendment code number : 
Q If checked specify sponsor's amendment 
code number, version and date 
Version Date (yyyy-mm-dd) : 
EUD127 v1.1 
REQUEST FOR AUTHORISATION OF A SUBSTANTIAL AMENDMENT 
B. IDENTIFICATION OF THE SPONSOR RESPONSIBLE FOR THE REQUEST 
B 1. Sponsor 
Organisation: United Bristol Healthcare Trust 
Name of person to contact - 
Name of person to contact 
Name of person to contact - Family name : Palmer 
Street address : 
Town / city : 
Bristol Royal Infirmary, Marlborough Street 
BRISTOL 
postcode: BS2 8HW Country: U. K. 
Telephone number : 0117 928 3473 
Fax number : 10117 928 3524 
e-mail: debbie. mcphee@ubht. swest. as. uk 
B 2. Legal representative' of the sponsor in the Community for the purpose of this trial (if different from the 
sponsor) 
Organisation: 
Given name : Maria 
Middle name : 
Name of person to contact - 
Name of person to contact - 
Name of person to contact - 
Street address : 
Given name : 
Middle name : 
Family name 
Town/city: 
Post code : Country 
Telephone number : 
Fax number : 
e-mail: 
1 as stated in article 19 of Directive 2001/20/EC 
EUD127 v1.1 
REQUEST FOR AUTHORISATION OF A SUBSTANTIAL AMENDMENT 
C. APPLICANT IDENTIFICATION, (please tick the appropriate box) 
C1. Request for the competent authority 
- Sponsor :Q 
- Legal representative of the sponsor 
Q 
- Person or organisation authorised by the sponsor 
to make the application. In that case, complete 













Family name : 
Street address: 






C2. Request for the Ethics Committee M-1 
- Sponsor :Q 
- Legal representative of the sponsor Q 
- Person or organisation authorised by the sponsor 
to make the application. In that case, complete 
below: Q 
In the case of the investigator in charge of the 





Given nnmC ; _ ._ Name of 
person to 
contact 




Family name : 
Street address: 






EUD127 vl. 1 
REQUEST FOR AUTHORISATION OF A SUBSTANTIAL AMENDMENT ...... Page 6 of 8 
D. TYPE OF AMENDMENT (please tick the appropriate box) 
This amendment concerns mainly urgent safety measures already implemented: []yes E] no 
Reasons for the amendment: 
Changes in safety or integrity of trial subjects: Q yes Q no 
Changes in interpretation of scientific documents/ value of the trial: Q yes Q no 
Changes in quality of IMP(s): Q yes Q no 
Changes in conduct or management of the trial: 
Change or addition of site, principal investigator(s), co-ordinating investigator: Q yes ® no 
Change of sponsor, legal representative, applicant Q yes ® no 
Change in transfer of major trial related duties Q yes ® no 
Other change: Q yes Q no 
Other case: Q yes 0 no 
I es, specify: 
Content of the amendment: 
an amendment to information in the application form : 
an amendment to the protocol 
an amendment to other appended documents 
Qyes®no 
yes D no ®yes0no 
Ifyes, specify: 
We have amended the Introductory Letter for Interview so that it refers to the approved PIS version and 
date. We have amended the Participant Information Sheet for Interview to state that it has been reviewed 
Land approved by the South West MREC. 
Other case :0 yes 0 no 
If yes, specify: 
We have removed paragraph 3.1.8 in version 2 of the protocol referring to the compensation arrangements. 
EUD127 v1-1 
REQUEST FOR AUTHORISATION OF A SUBSTANTIAL AMENDMENT 
- Investigator in charge of the application: 
" Coordinating investigator 
(for multicentre trial) : 
" Principal investigator 
(for multicentre trial); Q 
In the case of the Investigator, complete below 
Name: Professor Geoffrey Banks 
Street address: Dept. of Palliative Medicine 
Level C 
Bristol I hematology and 
Oncology Centre 
liorficld Road 
Town /city: BRISTOL 
Post Code: BS2 8130 
Telephone 01 17 928 3336 
number. 
Fax number: 01 17 928 3865 
e-mail: dcbbie. ashby®bristol. ac. uk 
EUD127 v1.1 
REQUEST FOR AUTHORISATION OF A SUBSTANTIAL AMENDMENT 
G: LIST OF THE DOCUMENTS APPENDED TO THE NOTIFICATION FORM : 
Please submit only relevant documents and /or when applicable make clear references to the ones already 
submitted. Make clear references to any changes of separate pages and submit old and new texts. Tick the 
appropriate box(es). 
ED Covering letter stating the type of amendment and the reason(s) 
Q Summary of the proposed amendment 
List of modified documents (identity, version, date) 
If applicable, pages with previous and new wording 
Q Supportive Information 
Q When applicable, revised XML file and copy of initial application form with amended data highlighted 
I. SIGNATURE OF THE APPLICANT IN THE MEMBER STATE : 
I hereby confirm that/ confirm on behalf of the sponsor that: (delete which is not applicable) 
- the above information given on this request is correct 
- the trial will be conducted according to the protocol, national regulation and the principles of good clinical 
practice 
- it is reasonable for the proposed amendment to 
be undertaken. 
APPLICANT of the request for the competent authority APPLICANT of the request for the Ethics Committee 
(as stated in section Cl): (as stated in section C2): 
Date: Date: 
k Za tX ' CF 
Signature: Signature: 
Print Name: Print Name: 
ý. Cw 4-A4r4 
EUD127 v1.1 
REQUEST FOR AUTHORISATION OF A SUBSTANTIAL AMENDMENT 
E. REASON FOR AMENLMLF 1 (one or two sentences) : 
This is a modification of Amendment 2 dated 13 August 2004. We were advised to make the changes 
by the protocol amendment committee. 
F. BRIEF DESCRIPTION OF THE CHANGES : 
EUD127 Al 
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a 
W/o A Iff 
South West Multi-centre Research Ethics Committee 
12 October 2004 
Professor Geoffrey Hanks 
Dept of Palliative Medicine 
Level C 




Dear Professor Hanks 





Tel: 01803 861947 
Fax: 01803 861914 
Email: swmrec@sw-devon-ha. swest. nhs. uk 
Full title of study: An open, randomised, parallel group study in patients with cancer 
pain, to compare a two step analgesic ladder (non-oploid to oxycodone) with 
conventional management using a three step approach. 
Amendment number: Revised Amendment 2 
Amendment date: 17 September 2004' 
REC reference number: MREC/03/6/26 
Protocol number: OXT3203 
The above amendment was reviewed by the Sub-Committee of the Research Ethics 
Committee at the meeting held on 7 October 2004. 
Ethical opinion 
The members of the Committee present gave a favourable ethical opinion of the amendment 
on the basis described in the notice of amendment form and supporting documentation. 
Approved documents 
The documents reviewed and approved at the meeting were: 
"A revised Notice of Amendment form dated 20/9/04 
"aA copy of the current CTA ._".: 
', 
" Copy of a letter from UBHT dated 6 August 2004 
"A revised protocol version 3 dated September 2004 
" PIS for interview version 1 dated September 2004 
Site-specific issues 
It was noted as part of the review that the amendment has no implications for the suitability 
of local investigators, sites or facilities. You are not required to obtain any further site- 
specific assessment, and there is no need to inform Local Research Ethics Committees of 
the amendment. 
SOPs version 1.0 dated February 2004 
SL28 Favourable opinion of amendment (multi-site) 
The Central Office for Research Ethics Committees is responsible for the 
operational management of Multi-centre Research Ethics Committees 
Approval of host organisations 
Local principal investigators or research collaborators should notify their host organisations 
of this amendment and check whether it affects local management approval of the research. 
Membership of the Committee 
The members of the Ethics Committee who were present at the meeting are listed on the 
attached sheet. 
Statement of compliance (from I May 2004) 
This Committee is recognised by the United Kingdom Ethics Committee Authority under the 
Medicines for Human Use (Clinical Trials) Regulations 2004, and is authorised to carry out 
the ethical review of clinical trials of medicinal products. 
The Committee is fully compliant with the Regulations as they relate to ethics committees 
and the conditions and principles of good clinical practice. 
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees (July 2001) and complies fully with the Standard Operating 
Procedures for Research Ethics Committees in the UK 
REC reference number: MREC10316126 Please quote this number on all correspondence 
Yours sincerely 
ý lý, - 
Barbara Inger 
Committee Administrator 
Enclosures List of names and professions of members who were present at the meeting 
and those who submitted written comments 
SOPS version 1.0 dated February 2004 
SL28 Favourable opinion of amendment (multi-site) 
South West Multicentre Research Ethics Committee 
List of Members 
at 
Protocol Amendment Sub-committee meeting on 7 October 2004 
Dr John Alexander MBBS FRCA MRCS LRCP RCOG 
Chairman Consultant in Anaesthesia and Pain Management 
BRISTOL 
Prof Alan Preece BSc PhD FIPSM MRCSHC (PE) M Inst RP 
Professor of Medical Physics and Consultant Clinical Scientist 
BRISTOL 
Mr Christopher Foy MA MSc CStat 
Medical Statistician, R&D Support Unit 
GLOUCESTERSHIRE 
Barbara Inger 
MREC Administrator & Secretary to the Meeting 
Annotation: 
7k Not present at the meeting on 7 October 2004. 
® Submitted written comments to the meeting 
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Potential Recruits: 
Patients with uncontrolled cancer pain only taking 
paracetamol or a non-steroidal anti-inflammatory drug. 
Ad%ice sought from 
patient/relative/carer re pain 
management . 
Telephone call to patient 
and advice given re the 
addition of pm codeine 
Patient seen and advice 
given re the addition of 
pm codeine 
Request permission for research team to contact 
patient. (If in surgery give PIS) 
Phone Dept of Palliative 
Medicine 0117 9284591 
and speak to Colette Reid 
or Tina Quinn 
Patient screened and if 
eligible consent requested 
Patient agrees to 
participate. Proceed 
to randomisation 
Patient randomised to 
experimental group using 2- 
step approach 
Patient randomised to 
control group using 3- 
step approach. 
Prescribe OxyContin MR 5mg BD and 
OxyNorm 5mg 4-6 hrly or as directed. 
(Please prescribe as full packs) 
Oxycodone is a step 3 opioid, please remember 
laxatives and anti-emetics. 
Keep a copy of the handwritten prescription, 
or the computer generated script. (These will 
be required for reimbursement) 
Patient declines to 
participate. Give 
information about 
-qualitative'study. ' ` 
Prescribe either cocodamol 30/500 or 
coproxamol 
Consider laxatives. 
Patients will need Oramorph or Sevredol 
5-10mg for breakthrough pain, but this may 









Key: Consultation. G. P to do Research team to do. 
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Protocol; Page 1 of 2 
Investigator Number Site Number Patient Number Visit Date 
2 
may mönth year 
STUDY ENTRY (DAY 0) 
Brief Pain Inventory (Short Form) 
1. Throughout our lives, most of us have had pain from time to time (such as minor headaches, sprains and 
toothaches). 4 ', " . "f-'. - wzth,, ",,; i *;, 
Have you had pain o her than these everyday'kinds of pain today? (circle one) 
1. YES 2. NO 
2. On the diagram, shade in the areas where you feel pain. Put an X on the area that hurts the most. 
Right 'Ile Left Left Right 
s 011 
3+ 
3. Please rate your pain by circling the one number that best describes your pain at its WORST in the last 24 hours. 






4. Please rate your pain by circling the one number that best describes your pain at its LEAST in the last 24 hours. 
No Pain as bad 
Pain 012.3 ,45,6 789 10 as you can 
- Imagine" 
5. ' Please rate your pain by circling the one number that best describes your pain on the AVERAGE. 
Pain as bad No E 
Paln 01'2345 -- 67 8as you can Imagine -- `# 
6,: Please rate your pain bycircling the one number that tells how much pain you have RIGHT NOW. 
No Pain as bad 
Pain 0123456789 10 as you can 
Imagine 
ALL ALTERATIONS MUST 
BE SIGNED AND DATED 
'"'' Final Version 107 March 2003 
Page 2 of 2 
tI ýý, 
Investigator Number Site Number Patient Number Visit Date 
al-j 
2 L 
ay month year 
STUDY ENTRY (DAY 0) 
Brief Pain Inventory (Short Form) 
7. What treatments or medications are you receiving for your pain? 
" i, ý' '"1ý'. y: 
`, ill ý. ', : +' ý 
is 
. jl 
8. In the last 24 hours, how much relief have pain treatments or medications provided? Please circle the one 
percentage that most shows how much RELIEF you have received. 
Relief 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100° 
C 
Replete 
9. Circle the one number that describes how, during the past 24 hours, pain has interfered with your. 
A. General Activity 






Does not 23456789 10 
Completely 
Interfere Interferes 
C. Walking Ability 
Does not 23456789 10 
Completely 
interfere Interferes 
D. Normal Work (includes both work outside the home and housework) 
Does not 23456789 10 
Completely 
Interfere Interferes 
E. Relations with other people 
Does not Completely 
Interfere 0123456789T 10 Interferes 
F. Sleep 
Does not 123456789 1p 
Completely 
interfere interferes 
G. Enjoyment of life 
Does not 123456789 10 Completely interfere Interferes 
Copyright 1991 Charles S. C1N1and, PhD 
Pain Research Group 




y mon year 
1ALL ALTERATIONS MUTT 
 E SIONED AND DATED 
Final Version 107 March 2003 
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A study to explore attitudes and beliefs influencing the decision to commence 
oploid analgesia in patients with cancer-related pain 
Topic Guide for Interviews 
Introduction 
The researcher will confirm consent 
The researcher will remind the participant that of the aim of the interview is to discuss 
the choice made by the- participant about entering a trial which may or may not have 
been because one of the treatment options was a strong painkiller like morphine. 
The researcher will then ask permission to discuss the participant's illness. 
The participant will be asked tell the researcher about their illness (which will allow 
the researcher to use the appropriate terminology for that individual during the rest of 
the interview). 
Question: e. g. "can you tell me about your illness? " 
Pain History 
The researcher will try to establish what coping mechanisms the participant uses and 
the impact of the pain on the participant. 
Question: e. g. "Can you tell me about your pain? " 
"Can you tell me how your pain affects you? " 
Recollection of the consultation at which opioids were offered 
(This will be the consultation at which the trial was discussed) i 
The researcher will encourage the participant to describe their recollections of this 
consultation and their emotions around this consultation. 
The researcher will explore what the patient understood when the drug name 
oxycodone was mentioned. 
Question: e. g. "I'd like to talk now about the appointment when the trial was 
discussed with you, when the team looking after you explained that an option for your 
pain was a strong painkiller like morphine. Can you tell me how you felt then? " 
"What did you think when the drug name oxycodone was mentioned? " 
Exploration of associations with oxycodone/painkillers like morphine 
The researcher will ask what the participant's opinions are about opioids and possible 
sources of these e. g. media, health professionals, family members. 
Questions: e. g. "what do you think when you hear the drug name morphine? " 
"have you ever discussed using morphine with anyone else? " 
Flexibility of decision to commence or delay oxycodone/painkillers like morphine 
The researcher will try to establish whether decisions about commencing opioid 
painkillers hold firm over a short period of time. 
Question: e. g. "how do you feel about this now? " 
"have you had any more thoughts about your decision? " 
Influence of others on the decision 
If appropriate, the researcher will ask about other people who may have influenced 
the decision e. g. carers, family or professionals. 
Question: e. g. "did you consider anyone else when you made you decision? " 
If appropriate, the researcher may follow on with a question about the effect of the 
second step of the analgesic ladder. There will be flexibility in the words used to 
describe the painkiller, depending on the drug names that the participant has been 
using. 
Question: e. g. "How would you feel if there was no option other than oxycodone for 
your pain? " 
"How would you feel if there was no option other than morphine for your pain? " 
Appendix 27 
A qualitative study to explore the views of patients considering morphine for 
relief of pain caused by cancer 
Patient information sheet 
352 
Participant Information Sheet Interview Pa 
September 2004 Pik University of MCI BRISTOL 
Department of Palliative Medicine 
Bristol Haematology & Oncology Centre 
Horfield Road 
Bristol BS2 8ED 
Fax: +44 (0)117 928 3865 
GW Hanks, DSc (Med), BSo, MB, FRCP, FRCPE, FFPM 
Dear Professor of Palliative Medicine 
Tel: +44 (0)117 928 3336 Email: Debbie. Ashby®bristol. ac. uk 
K Forbes, MB, FRCP 
Choices about pain relief Consultant and Macmillan Senior Lecturer in Palliative Medicine 
Tel: N4 (0)117 928 3507 Email: K. Forbes®b. istol. ac. uk 
(A study to explore attitudes and beliefs influencing the decision to 
commence opioid analgesia in patients with cancer-related pain. ) 
You are being invited to take part in a research study. This letter is to explain 
the study to you, why it is being done and what it will involve. Please take time 
to read this and show it to others if you wish. Please ask if you would like 
more information. Take time to decide whether or not you wish to take part. 
Thank you for reading this. 
What is the purpose, of the study? 
Some people become anxious the first time they are offered morphine (or a 
strong painkiller like morphine) for their pain. Often they decide not to try it. I 
would like to find out more about the reasons why people choose either to 
take or not to take morphine. This is part of a larger study looking at improving 
the management of cancer pain. 
Why have I been chosen? 
I want to talk to people with cancer pain who have recently'been offered 
morphine (or a strong painkiller like morphine). I want to talk to them whether 
or not they have chosen to try it. 
Do I have to take part? 
It is up to you to decide whether or not to take part. If you decide not to take 
part it will not affect your treatment or care in any way. Whatever you decide, I 
would be grateful if you would let me know by returning the enclosed form in 
the pre-paid envelope. However, if I do not receive your form I will assume 
that you do not want to take part. 
What will happen to me if I take part? :.. ",.: k 
I will telephone you to arrange a convenient time and place to meet. This can 
be at your home if you wish. I will explain to you the purpose of the study and 
ask you to sign a consent form. I will then ask you some questions about the 
visit to the doctors when you were offered a strong painkiller like morphine. I 
EJ Chambers, MB, FRCR, FRCP, Honorary Senior Lecturer In Clinical Oncology and Palliative medicine 
J Skye., MB, FRCP. Honorary Senior Lecturer In Palliative Medicine 
J Gilbert, MB, FRCP, Honorary Senior Lecturer in Palliative Medicine 
E Thompson, BA(Oxon), MBBS, MRCP, MFHom, Honorary Senior Lecturer in Palliative Medicine 
O Tanner BSc, MBBS, MRCOP, DOM, Honorary Senior Lecturer in Palliative Medicine 
Participant Information Sheet Interview 
V. 2 September 2004 
will record our conversation using a tape-recorder. Our conversation should 
not last longer than an hour. 
I will ask you for your consent to the storage of the cassettes and the typed 
version of our conversation, called the transcript. These will be stored in a 
locked filing cabinet in a locked office. I will allocate you a study number, so 
your name will not appear on the outside of the cassette, nor will any other 
details about you. 
I will also seek your permission for using anonymised quotes in my report of 
the study and in any scientific papers I may write about the study. You will 
never be identified in anything we write or say about the study. 
After listening to all the conversations I record, it may be that I come to certain 
conclusions about how people decide whether or not to take strong painkillers 
like morphine. If you would like, I will tell you about these conclusions. 
What are the possible risks and disadvantages of taking part? 
will be asking you to think about the thoughts and feelings you had during 
the appointment when your pain control and painkillers were discussed. This 
may have been a difficult appointment for you, so thinking about it again may 
be difficult. After our conversation, if you have questions about your pain 
control, I can help identify a professional, such as your general practitioner, 
for you to talk to. 
Who has approved this study? 
The South West Multi-centre Research Ethics Committee has reviewed and 
approved this study. 
What do I do now? 
Thank you for considering taking part in this study. I would be grateful if you 




Dept. of Palliative Medicine 
Bristol Haematology and Oncology Centre 
0117 928 3336 
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Patient Consent Form Interview V1 June 2004 
Study Number: 
Patient Identification Number for this trial: 
"Choices about pain relief' 
Elk University of MCI BRISTOL 
Department of Palliative Medicine 
Bristol Haematology & Oncology Centre 
Hoffeld Road 
Bristol BS2 8ED 
Fax: +44 (0)117 928 3865 
GW Hanks, DSc (bled), BSc, MB, FRCP, FRCPE, FFPM 
Professor of Palliative Medicine 
Tel: +44 (0)117 928 3336 Email: Debbie. Ashby@bristol. ac. uk 
K Forbes, MB, FRCP 
Consultant and Macmillan Senior Lecturer In Palliative Medicine 
Tel: +44 (0)117 928 3507 Email: K. Forbes®bristol. ac. uk 
(A study to explore attitudes and beliefs influencing the decision to 
commence oplold analgesia in patients with cancer-related pain. ) 
Name of Researcher. Colette Reid Department of Palliative Medicine, Bristol University. 
Please initial box 
ý. I confirm that I have read and understand the information sheet a 
dated ............................ 
(version ............ ) for the above study and have had the opportunity to ask questions. 
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical care 
or legal rights being affected. 
3.1 am happy for the interview to be tape-recorded and then written out. 
4. I am happy for words I used to be quoted in reports or published papers 
written about this study and understand that I will not be identified from 
these quotes. 
5.1 agree to take part in the above study 
Name of Patient Date 
Researcher Date 
(1 for patient; I for researcher; I to be kept with hospital notes) 
EJ Chambers, MB, FRCR, FRCP, Honorary Senior Lecturer In Clinical Oncology and Palliative Medicine 
J Skyes, MB, FRCP, Honorary Senior Lecturer In Palliative Medicine 
J Gilbert, MB, FRCP, Honorary Senior Lecturer in Palliative Medicine 
E Thompson, BA(Oxon), MBBS, MRCP, MFHom, Honorary Senior Lecturer In Palliative Medicine 
Q Tanne, BSc, MBBS, MRCGP, DOM, Honorary Senior Lecturer In Palliative Medicine 
II 
Signature 
Signature 
